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  2Abstract 
The metabolism of the anti-tubercular drug, thiacetazone (TAZ) by human FMOs in vitro and 
the disposition of TAZ in vivo in mice were studied.  Reverse phase chromatography 
confirmed TAZ to be a substrate for human FMO1, FMO2.1 and FMO3 with the formation 
of TAZ-sulphinic acid and TAZ-carbodiimide via a TAZ- sulphenic acid intermediate.  The 
products are the same as those formed by the Mycobacterium tuberculosis enzyme EtaA, the 
enzyme responsible for TAZ activation.  Kinetic studies found FMO2.1 to be significantly 
more efficient at TAZ oxygenation than EtaA, FMO1 and FMO3.  Asians and Europeans do 
not express functional FMO2 in their lungs as a result of a premature stop codon. However 
about 28% of African individuals lack this mutation.  The products of FMO2 are expected to 
be toxic to mammalian cells; therefore individuals expressing FMO2 in their lungs may be at 
higher risk of FMO-dependent TAZ bioactivation.   
Protein variants of FMO3 were analysed for their ability to catalyse TAZ 
oxygenation. Kinetic studies showed that the L360P variant displayed a significantly higher 
catalytic activity towards TAZ than the wild type protein.  The K158/G308 protein was 
inactive towards TAZ, whereas K158 or G308 variants oxygenated TAZ.  These findings 
may reflect the underlying mechanism of TAZ-dependent liver toxicity reported in patients 
taking TAZ as part of treatment for TB.   
Mouse liver and lung microsome experiments indicated that both FMOs and 
cytochromes P450 (CYPs) metabolise TAZ in vitro. FMO contribution was higher in the lung 
than the liver.  Kinetic studies using microsomes from Fmo1 knockout mice show FMO1 to 
be the predominant contributor to TAZ oxygenation in vitro.   
Metabolism of TAZ in liver and lungs of mice in vivo was not observed, however 
TAZ, TAZ-sulphenic acid, TAZ-sulphinic acid and TAZ-carbodiimide were identified in 
kidney. 
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Chapter 1: Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  161.1 Xenobiotic Metabolism 
 
 
Xenobiotic metabolism refers to the biochemical pathways involved in the processing of an 
exogenous substance.  The principle site of xenobiotic metabolism is the liver, but 
biochemical transformations, to a greater or lesser extent occur throughout the body and 
depend on the site of xenobiotic exposure.  Xenobiotic metabolism can be considered in two 
phases.  Phase I metabolism is the stage at which polar groups are either introduced or 
exposed in the xenobiotic.  This step is achieved by oxidation catalysed by Cytochrome P450 
Monooxygenases (CYPs), Flavin Containing Monooxygenases (FMOs), Alcohol and 
Aldehyde Dehydrogenases, Monamine Oxidase or Peroxidases or hydrolysis by Esterases, 
Amidases or Epoxide Hydrolase.    Phase II metabolism refers to the detoxification of 
modified products of Phase I metabolism by conjugation to water-soluble, non reactive 
chemical moieties to facilitate their excretion from the body.  This step is catalysed mainly by 
Transferases e.g. Glutathione S-Transferase, Sulfotransferases or UDP Glucuronyl 
Transferase.   
   After the CYPs, the FMOs are the largest group of enzymes involved in the Phase I 
metabolism of drugs and other xenobiotics and provide the focus for this investigation. 
 
1.2 FMOs  
FMOs (EC 1.14.12.8) are β-Nicotinamide adenine dinucleotide phosphate (reduced) 
(NADPH)-dependant enzymes that catalyse the N-  and  S-oxidation of a wide range of 
compounds.  They contain flavin dinucleotide (FAD) as a prosthetic group and are dependant 
on molecular oxygen for enzyme catalysis.     
 
 
 
  171.2.1 Discovery of FMOs 
In 1960, a study described how rat liver microsomes contained enzymes that catalysed the 
oxygen- and NADPH-dependent oxidation of a number of azo dyes (Miller et al. 1960).  The 
localisation (membrane bound), co-factor requirement (FAD), and activity of this enzyme 
(oxidation) towards xenobiotics was similar to that observed for CYPs which had recently 
been discovered at the time.  Studies with purified pig liver microsomes provided evidence 
that this enzyme was not a CYP.  It was immunologically distinct from the microsomal 
NADPH-dependent NADPH cytochrome P450 reductase and unlike this enzyme, which 
contains FAD and flavin mononucleotide (FMN), FAD was the only prosthetic group found 
in the pig liver oxidase (Masters et al. 1971).  Further studies with purified pig liver 
microsomes, confirmed the dependence of this oxidase enzyme on FAD but not FMN (Pettit 
et al. 1964).  At the time, most of the characterisation of the pig liver enzyme had been done 
using N, N- dimethylaniline as a model substrate and so ‘amine oxidase’ and ‘dimethylaniline 
monooxygenase’ were apt names for this enzyme.  The enzyme was initially classified as a 
mixed function-amine N-oxidase because it consumes two atoms of oxygen per substrate 
where one atom is transferred to the nitrogen of the amine moiety and the other is reduced to 
form one molecule of water.  Further studies with a panel of xenobiotics revealed that the 
enzyme was capable of reacting with a remarkably broad and rather promiscuous range of 
compounds with no common chemical feature (described in section 1.2.3). The name mixed 
function amine oxidase was now too restrictive in describing the reactions catalysed by this 
enzyme.  The enzyme was given the trivial name flavin containing monooxygenase which is 
usually abbreviated to ‘FMO’.   
 
 
 
  181.2.2 FMO Enzyme Mechanism  
The mechanism of FMO enzyme catalysis was determined by extensive kinetic and spectral 
studies by Poulsen and Zeigler in the 1970’s (Poulsen et al. 1979). 
A sequential cycle is observed in FMO enzyme catalysis with the first step being the 
reduction of the prosthetic FAD by NADPH (Fig 1.1).  The reduced form (FADH2) can 
rapidly react with molecular oxygen to generate a hydroperoxyflavin (FAD-OOH) radical.  In 
a mechanism that distinguishes FMOs from all other monooxygenases, the formation of this 
radical does not require binding of the oxygenatable substrate to the active site of the enzyme, 
in fact the hydroperoxyflavin formation occurs before the interaction of substrate and FMO 
(Poulsen et al. 1979).  The enzyme-bound C4a-hydroperoxyflavin is stable from minutes to 
hours at 4˚C and the radical is presumed to be in this state in a cell.   Thus, FMOs have been 
described to be in a ‘cocked gun’ state, ready to attack any substrate bearing a soft 
nucleophile moiety, which has gained access to the active site bearing the hydroperoxyflavin 
radical.  In the presence of a suitable substrate (see next section) FMO transfers one atom of 
molecular oxygen (from the FAD-OOH) to oxygenate the substrate, while the other is 
reduced to form water.   The oxygenated substrate is released immediately and the next and 
rate-limiting step is the release of water.  The last step in the cycle is the release of NADP
+ 
and then the regeneration of FAD-OOH starts again.  It is important to note that substrate 
binding has no effect on the velocity of product formation; that is decided by the rate-limiting 
step (the release of water), despite this, the enzyme displays Michaelis-Menten kinetics 
(Poulsen et al. 1979).      
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Figure 1.1: Major Steps in the Catalytic Cycle of FMO.   
Substrate binding is not required for the cycle to begin.  In the first step, the xenobiotic 
substrate S is oxidised to SO by the enzyme-bound 4a-hydroperoxyflavin (FAD-OOH). SO is 
released immediately and the release of water in step 2 is rate-limiting.  The subsequent steps 
3-5 simply regenerate the FAD-OOH form of the enzyme.  Adapted from Ziegler 2002. 
 
 
 
 
 
  201.2.3 Substrate Specificity 
In general, any compound bearing a soft nucleophile that can gain access to the enzyme-
bound C4a-hydroperoxyflavin site is a potential substrate for an FMO.   The unique 
mechanism of FMOs is theorised to be the basis of the broad range of compounds that are 
substrates for this enzyme.  Substrates include hydrazines (Prough et al. 1981), phosphines 
(Smyser et al. 1985), iodine boron containing compounds (Jones et al. 1986), sulphides 
(Hamman et al. 2000), selenium bearing compounds (Ziegler et al. 1992) and an array of 
amines (Ziegler 2002).   There is evidence of a number of endogenous compounds being 
FMO substrates including methionine (Duescher et al. 1994), cysteamine, cysteine- and 
homocysteine-S-conjugates (Ziegler 1993).     
  Structure-activity studies with purified and microsomal pig liver FMO indicate that 
the overall size and shape of a nucleophilic substrate are major factors limiting access to the 
FMO-bound hydroperoxyflavin radical.               
 
1.2.4 Reactions Catalysed by FMOs: Detoxification vs Bioactivation  
Detoxification refers to the removal of toxic metabolites by the process of oxidation or 
conjugation, i.e. it is a form of xenobiotic metabolism.  Conversely bioactivation is the 
process of metabolism in which a generated metabolite is more toxic or reactive than the 
parent compound. FMOs generally catalyse the former reaction that results in the formation 
of metabolites with reduced pharmacological and toxicological properties.  For instance, the 
neurotoxicant, 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine  (MPTP) is readily N-
oxygenated by FMO to the N-oxide, a non-toxic and easily excretable metabolite (Weisman 
et al. 1985; Cashman et al. 1986).     As with every rule however, there are exceptions.  In the 
case of certain sulphur-containing compounds such as thiocarbamides, FMOs efficiently 
catalyse their bioactivation. 
  21 Thiourea  and  N,N-mono or disubstituted thioureas are amongst the best substrates for 
FMOs (Poulsen et al. 1979; Henderson et al. 2004a; Onderwater et al. 2004; Onderwater et 
al. 2006).  Initial work by Poulsen and Zeigler  using phenylthiourea (Poulsen et al. 1979), 
demonstrated that FMOs catalyse a two-step, sequential oxidation of thiocarbamides to 
generate the sulphinic acid via a sulphenic acid intermediate (Fig 1.2).    The sulphenic acids 
of thiocarbamide compounds are strong electrophiles that are highly susceptible to reduction 
by thiol-containing molecules, such as glutathione (GSH).  The net effect of the non-
enzymatic reduction of sulphenic acid by GSH results in the formation of oxidised GSH 
(GSH disulphide, GSSG) and regeneration of the parent thiocarbamide (Fig. 1.3A).   In the 
presence of glutathione reductase, a futile cycle is established whereby the formation of 
sulphenic acid by the action of FMO is concomitantly linked to the reaction of glutathione 
reductase to regenerate GSH in its reduced form (Fig. 1.3A and B).  Both enzymatic 
pathways are powered by the oxidation of NADPH to NADP
+.   
The glutathione status within a cell (i.e. the disulfide:thiol ratio), if disturbed, can 
affect the activity of numerous enzymes and thus can alter normal cellular function (reviewed 
elsewhere by Kosower et al. 1978).   An increased ratio of GSSG:GSH is an indication of 
oxidative stress and triggers cellular pathways to correct it (reviewed by Kosower et al. 
1978). Studies with rat hepatocytes have determined two mechanisms by which the liver may 
attempt to correct this redox imbalance.  When the amount of GSSG exceeds that of GSH in a 
cell, reductases catalyse the reduction of the oxidised form at the expense of NADPH 
oxidation, but when the rate of GSH oxidation exceeds that of GSSG reduction, excess GSSG 
is excreted in bile.    Livers of rats perfused with thiourea or phenylthiourea led to the efflux 
of GSSG (but not GSH) in the bile of such animals confirming this hypothesis (Krieter et al. 
1984).   N-benzylimidazole a potent CYP inhibitor, had no effect on the  
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Figure 1.2: Oxidation of Thiourea by FMO.  A sequential two-step oxidation of thiourea 
catalysed by FMO generates (1) formamadine sulphenic acid and (2) formamadine sulphinic 
acid.   Adapted from Poulsen et al. 1979. 
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Figure 1.3: Interaction of Glutathione (GSH) with FMO-generated metabolites of 
Thiocarbamide S-oxygenation.   
(A)  Non-enzymatic reduction of formamidine sulphenic acid to the parent thiocarbamide by 
GSH and the formation of GSH disulfide. (B) Enzymatic regeneration of GSH by the 
oxidation of NADPH.  (C) Non-enzymatic reaction of formamadine sulphenic acid and GSH. 
 
 
 
 
 
 
  24amount of GSSG excreted in bile and thus indicated that this monooxygenase was not 
involved in the bioactivation reaction.   The contribution of hydroperoxidase and glutathione 
peroxidase in the bioactivation process was not determined to be significant as selenium-
deficient mice excreted similar amounts of GSSG in bile when compared to mice 
supplemented with selenium (Krieter et al. 1984).   Lack of GSSG efflux in bile after 
administration of mice with the corresponding nitrogen analogue of thiourea and 
phenylthiourea (i.e. urea and phenylurea) was consistent with a model in which a reactive 
sulphur-containing derivative of the thiocarbamide was responsible for the toxicity.  Given 
the substrate specificity of FMO and the formation of sulphenic acid species by this enzyme 
led to a FMO-dependent pathway being implicated in the bioactivation of thiourea and 
phenylthiourea in the liver of rats (Krieter et al. 1984). 
In addition to the exhaustion of GSH in the redox cycling of sulphenic acids, 
depletion of NADPH as a result of the uncontrolled oxidation reactions may lead to the 
depletion of glycogen.   NADPH is largely maintained from the dehydrogenation of glucose-
6-phosphate, a process that occurs as part of the pentose phosphate pathway.  Since glucose-
6-phosphate is derived from glycogenolysis, the need to regenerate NADPH from NADP
+ 
results in the depletion of glycogen (Krieter et al. 1984).  In the liver, thiocarbamide 
bioactivation and GSH:GSSG imbalance may directly contribute to glycogen depletion  as 
glycogenolysis is also stimulated by elevated GSSG levels (Sies et al. 1978).  This has been 
defined as the basis of glycogen depletion observed in liver of rats perfused with 
thiocarbamides (Krieter et al. 1984).   
The reactive SO
- moiety of sulphenic acids can attack the thiol group of GSH directly, 
generating a glutathione-sulphenate adduct and thus further depleting the concentration of 
GSH in a cell (Giri et al. 1970; Krieter et al. 1984) (Fig. 1.3C).   
  25Other than the thiol-group in glutathione, sulphenic acid metabolites can react with 
thiol-containing molecules such as cysteine residues in proteins thus perturbing protein 
function (Decker et al. 1992).     
  The sulphenic acid metabolite of thiourea is implicated in forming DNA adducts 
(Ziegler-Skylakakis et al. 1998).  Furthermore the sulphinic acid of thiourea has been 
demonstrated to initiate DNA repair synthesis, form DNA adducts and cause the formation of 
micronuclei in cultured rat hepatocytes (Ziegler-Skylakakis et al. 1998).   A micronuclei test 
is used to assess DNA damage induced by a compound.  Micronuclei form when a 
chromosome or fragment of a chromosome fails to incorporate into daughter nuclei at the 
time of cell division.       
 
1.3 Human FMOs   
In humans, five FMO genes are known to encode protein (FMO1-5) (Phillips et al. 1995).  
FMOs 1, 2 3 and 4 are found in a cluster with FMO6, a putative pseudogene, at 1q23-4 
(Shephard et al. 1993; Hernandez et al. 2004).  FMO5 is located further away from this 
cluster at 1q21 (McCombie et al. 1996).  A second cluster on chromosome 1 contains five 
FMO  pseudogenes,  FMO7P-FMO11P, which are located within a cluster ~4Mb to the 
centromeric side of the functional FMO gene cluster (Hernandez et al. 2004). 
FMOs 1-5 exhibit 50-59% amino acid identity across mammalian species including 
humans (Lawton et al. 1994).   A primary sequence alignment of the five functionally active 
human FMOs is given in Figure 1.4 and illustrates the highly conserved motifs identified in 
all mammalian FMOs.   Two GXGXXG motifs, known to be important in the binding of the 
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Figure 1.4: A primary sequence alignment of the five functional FMOs in humans.  The 
primary sequence of FMOs 1-5 are aligned.  An asterix denotes conserved identical residues, 
a colon indicates conserved similar residues, and a dot indicates highly similar residues.  The 
‘GXGXXG’ FAD and NADPH binding moieties are boxed in red along with the FMO 
characteristic ‘FATGY’ motif boxed in blue. Primary sequences were aligned using the 
ClustalW2 tool available at http://www.ebi.ac.uk/Tools/clustalw2/index.html. 
  27Adenine dinuceotide phosphate (ADP) moiety in FAD and NADPH are present at positions 
(residues 9-14 and 191-196, respectively) within human FMOs (Fig. 1.4) and other examined 
mammalian FMOs.  The FAD-binding site is contained within a highly conserved motif that 
predicts a βαβ secondary structure, a Rossman fold, known to be important in binding 
dinucleotides (Wierenga et al. 1986).  In addition to this motif, an FMO characteristic motif 
‘FATGY’ has been identified and is present at identical positions within the human FMOs 
(Fig.1.4) and is thought to play a role in N-oxidation. 
 
1.3.1 FMO1 
FMO1, purified from porcine liver microsomes, was the first FMO to be isolated from 
porcine liver microsomes and was named as a mixed function amine oxidase (Ziegler et al. 
1971) (see section 1.2.1).     A cDNA corresponding to the human FMO1 protein was 
identified in 1991 (Dolphin et al. 1991) and was formally named as FMO1 in 1994 (Lawton 
et al. 1994).  The human gene encodes a polypeptide of 532 amino acid residues that has a 
molecular weight of 60,603 Daltons.   
FMO1 is highly expressed in the liver of most adult mammals such as pig, rabbit, rat, 
dog and mouse (Gasser et al. 1990; Lawton et al. 1990; Cherrington et al. 1998; Lattard et al. 
2002; Stevens et al. 2003) but the gene is not expressed in the liver of adult human. Neither 
the mRNA (Phillips et al. 1995; Dolphin et al. 1996) nor protein (Yeung et al. 2000; 
Koukouritaki et al. 2002) of FMO1 is detected in the adult liver. The lack of FMO1 
expression in the adult human liver is thought to be due to the insertion of several long 
interspersed nuclear elements (LINEs), just upstream of the proximal promoter P0 (Shephard 
et al. 2007), which influence the expression in the adult, but not in the foetal liver. FMO1 is 
expressed in foetal liver of humans (Dolphin et al. 1991; Phillips et al. 1995; Dolphin et al. 
  281996; Yeung et al. 2000; Koukouritaki et al. 2002), but its expression is switched off in a 
mechanism linked tightly to birth but not gestational age (Koukouritaki et al. 2002). The  
repression is likely to be due to increased methylation, around the time of birth, of the 
proximal promoter P0 due to the close presence of LINE elements (Shephard et al. 2007) 
FMO1 expression is abundant in the adult human kidney, and the gene is also, to a 
lesser extent, expressed in the small intestine (Yeung et al. 2000), stomach and endocrine 
organs such as the thymus, testis, pancreas, adrenal cortex and thyroid (Hernandez et al. 
2004). FMO1 is also detected in the foetal kidney, but unlike in the liver, expression in this 
tissue increases after birth (Dolphin et al. 1991; Phillips et al. 1995; Dolphin et al. 1996; 
Yeung et al. 2000; Krause et al. 2003). The continued expression of the gene in adult tissues 
such as the kidney is due to the use of tissue-specific, alternative, downstream promoters 
(Shephard et al. 2007). 
  Levels of expression of FMO1 in the kidney (47 ± 9 pmol/mg microsomal protein) 
(Yeung et al. 2000) are not much lower than that observed in the liver for the major hepatic 
CYP isoform, CYP3A4 (96 ± 51 pmol/mg microsomal protein) (Shimada et al. 1994).  In 
kidney, the amount of FMO1 is greater than that of total CYP expression and thus is likely to 
be an important contributor to renal xenobiotic metabolism.   
  FMO1, among all the FMO isoforms has the broadest substrate specificity.  This is an 
attribute of the size and dimension of the access channel through which a substrate gains 
entry to the active site.  The access channel in human FMO1 is estimated to be 5 Å in 
diameter and the active site containing FAD-OOH is at least 5 Å below the surface of the 
channel (Kim et al. 2000).  This is the theorised basis by which FMO1 can oxygenate 
substrates as small as thiourea with the same efficiency as it metabolises large and bulky 
compounds such as tricyclic tertiary amines (Fig. 1.5).     A wide range of xenobiotics and 
foreign compounds are among its substrates including therapeutic drugs, pesticides and 
  29endogenous compounds.  A list of all known substrates of human FMO1 that are of 
therapeutic importance has been listed in Tables 1.1 and 1.2.   
 
1.3.1.1 Inter-Individual Differences in Expression of Human FMO1: Consequences for 
Drug Metabolism 
Human FMO1 is the most conserved gene amongst the FMOs within the gene cluster located 
on 1q23-4.  In a recent study, four non-synonymous single nucleotide polymorphisms (SNPs) 
were identified in the protein coding region of FMO1 in African-American subjects (Furnes 
et al. 2003).  The genetic substitutions (and subsequent amino acid substitution) were 
observed to be g.9614C>G (H97Q), g.23970A>G (I303V), g.23971T>C (I303T) and 
g.27362C>T (R502X) and were estimated to occur at a relatively low frequency of 1-2% in 
this population (Furnes et al. 2003).  Functional studies with heterologously expressed 
protein variants indicated a moderate but distinct substrate-specific difference towards typical 
FMO1 substrates including the hyperthyroidism drug, methimazole, the anti-depressant drug 
imipramine and the pesticide agent fenthion.   An interesting finding was that the truncated 
variant, R502X was capable of oxidising imipramine and fenthion but was inactive towards 
methimazole.     
Recently, studies have reported inter-individual differences in levels of protein 
expression of human FMO1 in the kidney (Yeung et al. 2000; Koukouritaki et al. 2002; 
Krause et al. 2003).  As FMOs are generally not inducible by environmental factors, it is 
plausible to assign such inter-individual differences to genetic variability within promoter and 
regulatory sequences within the gene that ultimately lead to different amount of protein being 
produced.  A single nucleotide substitution, g.-9,536C>A (FMO1*6) was identified in the 
upstream region of exon 0 that happens to be within a Yin Yang 1 (YY1) binding site 
sequence (Hines et al. 2003).  The YY1 site also overlaps binding sequences of other  
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Thiourea  Phenylthiourea   
 
 
Alpha-naphthylthiourea 
Chlorpromazine  Imipramine  Orphenadrine   
 
Figure 1.5: Selected substrates of human FMO1. Chemical structures of xenobiotics are 
given to illustrate the diversity in size and dimension of substrates oxygenated by human 
FMO1.   Phenylthiourea and alpha-naphthylthiourea are thiocarbamides where as Imipramine 
and Chlorpromazine are tricyclic tertiary amines.  Orphenadrine is a methylated derivative of 
diphenylhydramine.  (Figure adapted from (Kim et al. 2000).  
 
 
 
  
 
  31Table 1.1 Nitrogen-containing drugs oxygenated by Human FMO1 
 
Substrate 
Type of Drug or health 
condition 
 
Product  Reference 
Benzydamine 
non-steroidal anti-
inflammatory agent 
(rheumatism) 
N-oxide 
(Lang et al. 2000; 
Rettie et al. 2000) 
Chlorpromazine 
Dopamine D2 antagonist 
(antipsychotic) 
- (Kim et al. 2000) 
Deprenyl 
Monoamine oxidase type B 
inhibitor 
(Parkinsons Disease) 
hydroxylamine  (Szoko et al. 2004) 
Imipramine 
5HT/noradrenaline uptake 
inhibitor (anti-depressant) 
N-oxide (Kim et al. 2000) 
Itopride 
dopamine D2 antagonist 
(gastroprokinetic agent) 
N-oxide 
(Mushiroda et al. 
2000) 
Methamphetamine Psychostimulant  Hydroxylamine  (Szoko et al. 2004) 
N- deacetyl 
ketoconazole* 
anti-fungal agent  N-hydroxy 
(Rodriguez et al. 
2000) 
Olopatadine anti-histamine agent  N-oxide (Kajita  et al.  2002) 
Orphenadrine 
Anti-cholinergic 
(Parkinson’s Disease) 
- (Kim et al. 2000) 
SNI-2011 
muscarinic receptor agonist 
(Sjogren's Syndrome) 
N-oxide (Washio et al. 2001) 
Tamoxifen 
estrogen-receptor modulator 
(Breast Cancer Therapy) 
N-oxide  (Parte et al. 2005) 
Xanomeline 
muscarinic receptor agonist 
(Alzheimer’s disease) 
N-oxide (Ring et al. 1999) 
*Major metabolite of anti-fungal agent ketoconazole.   
-  product not identified 
In many cases, FMO1 is not the only enzyme involved in the metabolism of the drug in vivo.      
This table appears in the review by Phillips, Francois and Shephard (Phillips 2007) 
which is bound into the back of this thesis. 
 
  32Table 1.2: Suphur-containing drugs oxygenated by Human FMO1 
 
 
Substrate  Type of Drug or 
health condition 
 
Product  Reference 
Ethionamide 
 
Antibiotic 
(tuberculosis) 
S-oxide/sulphinic 
acid 
(Henderson et al. 
2008) 
Methimazole Thyroperoxidase 
inhibitor 
(hyperthyroidism) 
S-oxide (Furnes et al. 2004) 
S – methyl 
esonarimod* 
 
cytokine production 
inhibitor 
(rheumatism) 
S-oxide (Ohmi et al. 2003) 
Tazorotenic acid** 
 
Retinoic acid 
receptor modulator 
(acne/psoriasis) 
S-oxide (Attar et al. 2003) 
Thiacetazone 
 
Antibiotic 
(tuberculosis) 
Sulphinic 
acid/carbodiimide 
(Qian et al. 2006) 
 
 
*active metabolite of parent compound esonarimod. 
** active metabolite of parent compound tazarotene. 
In some cases FMO1 is not the only enzyme involved in the metabolism of the drug in vivo. 
 
This table appears in the review by Phillips, Francois and Shephard (Phillips 2007) 
which is bound into the back of this thesis. 
 
 
 
 
 
  33transcription factors, mainly Oct1 and HNF1 (Hines et al. 2003). YY1 is a transcription 
factor which is known to negatively regulate FMO1 expression in rabbit (Luo et al. 2001). 
Transcriptional reporter assays with human FMO1 gene constructs however suggest YY1 to 
be a positive regulator of FMO1 expression, but only in the presence of other yet to be 
identified upstream regulators.  In humans therefore, it is suggested that the disruption of the 
consensus YY1 binding site as a result of the g.-9,536C>A mutation results in the 
downregulation of transcription of FMO1.    This finding has been postulated as the basis of 
inter-individual difference in FMO1 expression levels observed in adult kidney (Hines et al. 
2003).  Analysis of the frequency of the variant allele, FMO1*6 was not found to be 
statistically different among African Americans or Northern European-Americans but was 
found to be prevalent in Hispanic Americans at a significantly higher frequency of 26.9% 
(Hines et al. 2003).  A significantly higher amount of FMO1 in kidney obtained from African 
individuals than Caucasians has been reported.   However, it is noteworthy that the 
comparison made in this study may not be appropriate as kidney biopsies were used for 
African sample analysis while samples from cadavers were analysed for all Caucasians 
(Krause et al. 2003). 
  The genetic variations observed in FMO1 may have consequences for the ability of 
individuals to metabolise therapeutic drugs and other xenobiotics that are substrates for this 
enzyme.  For example, Fmo1  (-/-) mice administered with the anti-depressant drug 
imipramine, display exaggerated pharmacological behavioural responses including tremors 
and body spasms and increased amounts of parent drug in the plasma and kidney (Hernandez 
et al. 2009).  Conversely, higher levels of FMO1 in the kidney may be associated with 
increased renal toxicity as a result of bioactivation of xenobiotics containing sulphur 
moieties.    
 
  341.3.2 FMO2      
In 1984, direct evidence of the existence of multiple forms of FMO was obtained when an 
enzyme from rabbit lung was purified.  The ‘lung’ FMO was distinctly different from the 
‘liver’ FMO (now known as FMO1) in that it had restricted substrate specificity related to 
steric properties, greater thermal stability and displayed a higher pH optimum for enzyme 
activity (Williams et al. 1984; Williams et al. 1985; Nagata et al. 1990; Williams et al. 1990; 
Venkatesh et al. 1992).  This enzyme is now know as FMO2.   
  FMO2 is highly expressed in the lung of mammals including rabbits (Williams et al. 
1984; Tynes et al. 1985; Williams et al. 1985; Lawton et al. 1990; Williams et al. 1990), 
guinea pig (Nikbakht et al. 1992), mouse (Karoly et al. 2001), and rhesus macaque (Yueh et 
al. 1997). FMO2 expression in rabbit has been estimated to represent 10% of total lung 
protein (Williams et al. 1984; Tynes et al. 1985).    The mRNA of FMO2 is the most 
abundant amongst the isoforms in human lung (Zhang et al. 2006) but efforts to isolate and 
purify the protein from this tissue proved unsuccessful (Whetstine et al. 2000).     
  Genotypic analysis revealed that the FMO2 gene, in humans has ethnic-specific 
variation in its base sequence (Dolphin et al. 1998; Whetstine et al. 2000).  All Europeans 
and Asians genotyped to date possess the FMO2*2 allele in which a C>T substitution at 
position 1414 bp  (in the cDNA) replaces a glutamine amino acid residue at position 472 with 
a premature stop codon in the polypeptide (Q472X) (Fig. 1.6) (Dolphin et al. 1998). This 
position corresponds to g.23238C>T (Q472X) of the gene.  A proportion of individuals of 
African descent however, possess an FMO2 gene that encodes a full-length protein (Dolphin 
et al. 1998). This allele is called FMO2*1.  The truncated protein, FMO2.2, when compared 
with FMO2 from rabbit, guinea pig and rhesus macaque lacks 64 amino residues from its 
carboxy terminus.  Analysis of the product of heterologously expressed FMO2.2 cDNA 
revealed that the truncated protein is catalytically inactive (Dolphin et al. 1998).  In the 
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Figure 1.6: The Nonsense Mutation in Human FMO2 is absent in Other Mammalian 
Species: (A) The codon at position 1414 bp (relative to the A of the ATG translation 
initiation codon) in the ancestral gene of human FMO2*1 and mouse and rhesus macaque 
FMO2 is given in blue.  The corresponding codon in human FMO2*2 is boxed in red and the 
position of the nucleotide base substitution is marked with an arrow. (B) Horizontal bars 
represent the polypeptide chains encoded by genes given in part (A).  N and C denote the 
amino- and carboxy- termini respectively.  Alternative grey and white boxes indicate regions 
encoded by exons 1-9.    
 
 
 
 
 
 
  36human lung, the truncated protein is thought to be rapidly degraded because of incorrect 
folding (Dolphin 1998) and this probably explains why attempts to purify FMO2 from human 
lung had been unsuccessful (Whetstine et al. 2000).  In contrast, when the full-length 
FMO2.1 protein is expressed in a heterologous system it is catalytically active (Dolphin et al. 
1998).   
A recent study in which 1800 people, of recent African descent from sub-Saharan 
Africa were genotyped, up to 50% of individuals were found to possess at least one copy of 
the ancestral allele FMO2*1 (Veeramah et al. 2008).  Individuals with one or two FMO2*1 
alleles are thus expected to express the full-length and catalytically functional protein 
(FMO2.1) in the lung (Dolphin et al. 1998; Krueger et al. 2002; Veeramah et al. 2008) (Fig. 
1.6).  The ancestral allele occurs at relatively low frequency in North Africa and its 
distribution in sub-Saharan Africa differs significantly within this region (Fig. 1.7).  The 
FMO2*1 allele has also been observed in 5-7 % of Hispanics of African decent (Whetstine et 
al. 2000). 
  The nonsense mutation g.23238C>T (Q472X) is not present in non-human 
primates such as the chimpanzee (Pan troglodytes) and the gorilla (Gorilla gorilla) and must 
have therefore arisen in the human lineage some time after the divergence of the Homo and 
Pan clades took place some 6 million years ago (Brunet et al. 2002).   
The full length human FMO2 protein contains 535 amino acid residues and has a 
molecular weight of 60, 920 Daltons.  Analysis of microsomes prepared from a lung sample 
obtained from a single individual heterozygous for the FMO2*1  allele detected the 
expression of FMO2.1 protein in this tissue.  The microsomal sample was capable of S-
oxygenating methimazole with a similar catalytic efficiency as that observed for 
heterologously expressed human FMO2.1 (Dolphin et al. 1998; Krueger et al. 2002).  
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Figure 1.7: The Frequency and Distribution of the Human FMO2*1 allele in Africa: Pie 
charts illustrating the prevalence of the human FMO2*1 allele in different parts of Africa.  
Yellow = frequency of individuals possessing at least one allele encoding human FMO2*1, 
blue = individuals homozygous for the human FMO2*2 allele. Figure taken from Veeramah 
et al. 2008. 
 
 
 
 
 
  381.3.2.1 Structure-Function Studies: The Restricted Substrate Specificity of FMO2 
Limited structure-function studies have been carried out with human FMO2.  A kinetic study 
using a panel of phenothiazine derivatives indicated that the oxygenatable moiety of a 
compound bearing large or bulky groups, needed to be a certain distance away from them to 
gain access to the active site (Fig. 1.8) (Krueger et al. 2005).   For instance, FMO2.1 was not 
active towards a phenothiazine derivative with a 3-carbon side chain but was active when the 
side chain increased in length from 3 to 5 or 8 alkyl groups (Fig. 1.8).  A similar study with 
rabbit FMO2 and porcine FMO1 demonstrated how the latter efficiently catalysed the 
oxidation of phenothiazine derivatives with a 3-carbon side chain whereas FMO2 could not 
(Nagata et al. 1990).   Using a panel of thioureas of various sizes, Nagata et al.  demonstrated 
that unlike porcine FMO1, rabbit FMO2 could not catalyse the oxygenation of 1,3-
diphenylthiourea, the largest thiourea tested in this investigation (Nagata et al. 1990).    These 
findings predicted that in addition to the access channel of FMO2 being narrower than that of 
FMO1, the catalytic centre of FMO2 was considerably deeper within the enzyme than FMO1 
(Nagata et al. 1990; Kim et al. 2000).     
 
1.3.2.2 Inter-individual Differences in human FMO2 expression: Consequences for 
Xenobiotic Metabolism  
The principle inter-individual difference in FMO2 expression in humans is the expression of 
functionally active (FMO2.1) or inactive (FMO2.2) protein in the lung.  As detailed in the 
preceding section, the majority of the world’s population does not produce FMO2 in their 
lungs, but a significant proportion of sub-Saharan Africans do.  The amount of FMO2.1 
expressed in the lung of individuals possessing the ancestral gene has been estimated to be 
around 8.8 pmol/mg microsomal protein which is comparable if not greater than most CYPs 
expressed in this tissue (Krueger et al. 2002; Henderson et al. 2004b). 
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Figure 1.8: Human FMO2.1 substrate specificity towards phenothiazines.  Activity of 
FMO2.1 towards phenothiazine with tertiary amine substituents of differing lengths.  3PTZ, 
5PTZ and 8PTZ represent phenothiazine derivaties with 3, 5 or 8 carbon alkyl side chains 
respectively. Adapted and revised from Krueger et al. 2005.   
 
 
 
 
 
 
 
  40It is therefore plausible to assume that individuals expressing FMO2.1 will have altered 
metabolism of drugs and xenobiotics in the lungs.   This raises an important question of 
whether such individuals are more or less predisposed to FMO-dependent toxicity of 
xenobiotics, whether the activity of this enzyme will affect the efficacy of a drug or whether 
these individuals may be at a genetic advantage with regard to protection from exogenous 
toxicants. 
  To date, limited studies have investigated the contribution of FMO2.1 in drug 
metabolism, probably because of the apparent lack of this isoform in human lung.  The recent 
discovery that a significant proportion of individuals carry the FMO2*1 allele has however 
generated interest in the toxicological consequences of xenobiotic metabolism by this 
enzyme.   
  Heterologously expressed human FMO2.1 is capable of catalysing the S-oxygenation 
of a wide range of thiourea-containing compounds including phenylthiourea, alpha-
naphthylthiourea and ethylenethiourea (Henderson et al. 2004a).  Thiourea containing 
compounds are used extensively in industry and to a certain extent are used in household 
products.  Thiourea is an industrial chemical with a number of uses, it is used extensively in 
the manufacture of flame retardant resins and is the main component of liquids used to clean 
items made of silver.  Recently, the interest in thiourea-containing drugs has risen since the 
development of Trovirdine, an N-substituted thiocarbamide as a potent HIV-1 non-
nucleoside, reverse transcriptase inhibitor (Cantrell et al. 1996; Onderwater et al.  2004).     
Alpha-naphthylthiourea (ANTU) is used extensively as a rodenticide.  The product of the 
FMO-mediated oxygenation of thioureas, the sulphinic acid metabolite, is generated via a 
sulphenic acid intermediate that is more toxic than the parent compound.  As detailed in 
section 1.2.4, the intermediate metabolite is capable of redox cycling in the presence of 
glutathione and glutathione reductase which is hypothesised to result in oxidative stress.   
  41Other than reacting with glutathione, the sulphenic acid metabolite can react with sulphhydrl 
groups including cysteine residues of other proteins.  This is the mechanism by which the 
FMO-dependent S-oxygenation of phenylthiourea (PTU) was shown to inhibit the activity of 
CYP1A1 (Onderwater et al. 1999) in rat hepatocytes.    In rats, ANTU is toxic to the lungs 
causing severe pulmonary edema and vascular injury which has been demonstrated to be 
FMO-dependent (Boyd et al. 1976; Lee et al. 1980; Scott 1990).  Since ANTU is sold in a 
powdered form, inhalation of ANTU particles is likely to be toxic to individuals expressing 
FMO2.1 in the lungs.    
  Recent studies have demonstrated the activity of human FMO2.1 towards pesticides 
such as phorate and disulfoton (Henderson et al. 2004b).  Phorate and disulfoton are 
thioether-containing organophosphate insecticides used extensively in agriculture.  They are 
broad-spectrum insecticides used to protect crops such as corn, potatoes, cotton and grain, 
including wheat. Exposure to these compounds occurs both in occupational settings and to 
the public in general.  In the occupational setting, the primary route of exposure is inhalation 
and dermal, whereas in the general population it is inhalation, diet and dermal (Brokopp et al. 
1981).  As inhalation is a major route of exposure, extensive pulmonary metabolism of such 
compounds is expected.  The role of CYPs in organophosphate metabolism is well 
documented.  As with other organophosphates, CYPs can catalyse the desulphuration to yield 
the corresponding oxon, a toxic metabolite and potent inhibitor of acetylcholinesterase 
(Kulkarni 1984).  CYPs can also catalyse the formation of the S-oxide and further oxidise this 
metabolite to generate a sulphone (Kulkarni et al. 1984).  In addition to the toxic oxon, the 
sulphone metabolite of organophosphate pesticides is also a acetylcholinesterase inhibitor 
(Levi et al. 1988).  Human FMO2.1-dependent sulphoxidation of phorate and disulfuton 
generates the S-oxide, a typical detoxification product and does not catalyse the second 
oxidation reaction to the sulphone (Henderson et al. 2004b).  With the higher FMO:P450 
  42ratio in the lungs and the high catalytic activity displayed by FMO2.1 towards these 
compounds, plus the lack of production of toxic oxons and sulphone metabolites (generated 
by CYP oxidation), suggests that individuals expressing FMO2.1 in the lung are protected 
from bioactivated species of such exogenous compounds. Conversely one may argue that the 
extensive formation of the S-oxide by FMO2.1 in the lungs may provide a source for the 
CYPs to catalyse the secondary oxidation reaction of this metabolite to give more of the toxic 
sulphone species.      
    With respect to altered drug metabolism in the lung, anti-tubercular drugs are of 
particular concern.  Thiacetazone and Ethionamide are prodrugs that require metabolic 
activation by Mycobacterium tuberculosis to exert an anti-microbial effect (Baulard et al. 
2000; DeBarber et al. 2000; Vannelli et al. 2002; Qian et al. 2006; Dover et al. 2007).  A 
detailed description of these drugs and their activation will be given in section 1.4.2.   
Thiacetazone and Ethionamide are thiocarbamide-containing compounds and thus are 
expected to be FMO substrates.  Human FMO1 and FMO3 are capable of catalysing the S-
oxygenation of thiacetazone to form the sulphinic acid and carbodiimide derivatives of this 
drug (Qian et al. 2006).  Although an intermediate was not identified, a sulphenic acid 
metabolite is postulated to be the precursor of the observed products. In vitro studies have 
demonstrated that the metabolites of this reaction lead to the depletion of glutathione and thus 
it represents a bioactivation.  Whether or not FMO2.1 can catalyse this reaction is still to be 
determined and provides the focus of experiments described in this thesis.  Given that 
tuberculosis is a major problem in a world region where the frequency of the FMO2*1 allele 
is considerably high, raises the question of whether individuals given this drug as part of 
chemotherapy will be at a greater risk of drug toxicity.  It also poses the question of whether 
the ‘use’ of thiacetazone by FMO2.1 in the lung may affect drug efficacy.  It is tempting to 
assume that thiacetazone will be a substrate for FMO2.1 as FMO1 and FMO3 are capable of 
  43 
 
 
 
A 
 
 
B 
 
 
 
Figure 1.8A: Chemical Structures of Second-line Antibiotics: (A) Thiacetazone and (B) 
Ethionamide.  
 
 
 
 
 
 
 
  44its S-oxygenation, but caution must be exercised when extrapolating substrate specificities 
among FMO isoforms.  As detailed in the preceding section, FMO2 has the most restricted 
substrate specificity when compared to both FMO1 and FMO3.  Marked differences in 
substrate oxygenation between isoforms is a result of the dimension of the channel that gives 
access to the active site of the enzyme and has been described in section 1.3.2.1.  
 
1.3.3 FMO3 
A cDNA for human FMO3 was identified in 1992 (Lomri et al. 1992) and it encoded a 
polypeptide of 532 amino acid residues with a molecular weight of 60, 047 Daltons. 
  FMO3 is the major FMO isoform present in the adult human liver (Phillips et al. 
1995; Dolphin et al. 1996).  FMO3 mRNA has also been detected in the lung, kidney, adrenal 
medulla and cortex, pancreas, thyroid, gut and brain (Hernandez et al. 2004).  Low levels of 
FMO3 are detected in embryonic liver cells but not in the foetus. Currently, the mechanisms 
and factors required for the expression of FMO3 in the embryo, silencing through foetal 
development and reactivation after birth are not known.  After birth the onset of FMO3 
expression in the liver occurs in three distinct phases between 3 weeks and 10 months of age, 
10 months and 11 years and between 11 and 18 years of age (Koukouritaki et al. 2002).   
Unlike the regulation of human FMO1 in the foetal liver which is tightly linked to birth but 
irrespective of gestational age, the onset of FMO3 gene expression after birth is less defined.  
Birth is necessary but not sufficient for expression of FMO3 in the adult liver and some 
individuals show no expression of this protein up until 10 months of age (Koukouritaki et al. 
2002).   
  In terms of substrate specificity, FMO3 is an intermediate between FMO1 and FMO2.  
It can metabolise substrates which are excluded from the active site of FMO2 (such as 
secondary amines, (Cashman et al. 1999)) but cannot catalyse the oxidation of bulkier 
  45compounds such as imipramine which are good substrates for FMO1 (Kim et al.  2000).   
Given the relatively broad substrate specificity of this enzyme and its expression in the liver, 
FMO3 is considered the most important FMO isoform in hepatic drug metabolism in humans.  
Compounds of therapeutic importance metabolised by FMO3 are given in Tables 1.3 and 1.4.   
  Unlike other FMO isoforms, an endogenous role for FMO3 in humans is established.  
The bacterial break-down product of dietary choline in the gut is trimethylamine (TMA), a 
compound with an extremely strong, fish-like odour.  In the liver, FMO3 catalyses the N-
oxygenation of TMA to its N-oxide, a metabolite with no detectable offensive odour.  TMA 
N-oxide is excreted from the body via the urine and sweat.  Impairment of this detoxification 
reaction results in the rare but serious condition of Trimethylaminuria, which will be 
described below.     
 
1.3.3.1 Genetic Variants of human FMO3 
Human FMO3 is the most polymorphic among the FMO genes with more than 40 SNPs 
identified across the entire length of this gene (reviewed elsewhere by Phillips 2007 and 
Phillips et al. 2008).  These variations, many in the form of single nucleotide substitutions, 
may have consequences for the ability of individuals to metabolise therapeutic drugs and 
other xenobiotics that are substrates for this enzyme.   
 
1.3.3.2 FMO3 Variants and Trimethylaminurea  
Some of the documented SNPs identified in FMO3 are rare (occurring at a frequency of <1% 
in a population) and result in the total loss of FMO3 catalytic activity.  A list of these 
mutations has been given elsewhere (for a review see Phillips 2007).  Such polymorphisms 
 
 
 
 
  46Table 1.3: Nitrogen-containing drugs oxygenated by Human FMO3 
 
Substrate 
Type of Drug Or Health 
Condition 
Products Reference 
Amphetamine 
dopamine transporter 
ligand (antipsychotic) 
hydroxylamine 
(Cashman et al. 1999; 
Szoko et al. 2004) 
Benzydamine 
non-steroidal anti-
inflammatory 
(rheumatism) 
N-oxide 
(Lang et al. 2000; Stormer 
2000) 
Clozapine antipsychotic agent  N-oxide  (Tugnait et al. 1999) 
5,6-Dimethylxanthenone 
4-acetic acid (DMXAA) 
antitumour agent  Hydroxylamine  (Zhou et al. 2002) 
Deprenyl 
monoamine oxidase type 
B inhibitor 
(Parkinson’s Disease) 
Hydroxylamine (Szoko et al. 2004) 
Itopride 
Dopamine D2 antagonist 
(gastroprokinetic agent) 
N-oxide  (Mushiroda et al. 2000) 
K11777 
Cysteine protease 
inhibitor 
(Agent against 
Trypanosoma Cruzi) 
N-oxide  (Jacobsen et al. 2000) 
Methamphetamine psychostimulant  Hydroxylamine 
(Cashman et al. 1999; 
Szoko et al. 2004) 
N-deacetyl ketokanozole*  anti-fungal agent  N-hydroxy/nitrone  (Rodriguez et al. 2000) 
 
 
 
 
 
 
 
 
  47Table 1.3: Nitrogen-containing drugs oxygenated by Human FMO3 (continued) 
 
Substrate 
Type of Drug Or Health 
Condition 
Products Reference 
Nicotine Stimulant  Trans N-oxide (Park et al. 1993) 
Olapatadine anti-histamine agent  N-oxide  (Kajita et al.  2002) 
Pyrazolacridine Anti-tumour  agent N- oxide  (Reid et al. 2004) 
Ranitidine 
Anti-histamine 
(stomach ulcers/Zollinger 
Ellison syndrome) 
N-oxide  (Chung et al. 2000) 
S16020 
(Olavicine Derivative) 
anti-tumour agent  N- oxide 
(Pichard-Garcia et al. 
2004) 
Tamoxifen 
estrogen-receptor modulator 
(Breast Cancer Therapy) 
N- oxide  (Mani et al. 1993) 
Xanomeline 
muscarinic receptor agonist 
(Alzheimer’s disease) 
N- oxide  (Ring et al. 1999) 
 
*Major metabolite of anti-fungal agent ketoconazole.   
In some cases FMO3 is not the only enzyme involved in the metabolism of the drug in vivo. 
This table appears in the review by Phillips, Francois and Shephard (Phillips 2007) 
which is bound into the back of this thesis. 
 
 
  48Table 1.4: Suphur-containing drugs oxygenated by Human FMO3 
 
Substrate 
Type of Drug Or Health 
Condition 
Products Reference 
Ethionamide antibiotic  (tuberculosis)  S-oxide/sulphinic acid 
(Henderson et al. 
2008) 
MK-0767 methyl sulfide 
peroxisome proliferator 
receptor activator 
(diabetic) 
S-oxide  (Karanam et al. 2004) 
Ranitidine 
Anti-histamine 
(stomach ulcers/Zollinger 
Ellison syndrome) 
S-oxide  (Chung et al. 2000) 
S - methyl esonarimod * 
cytokine production 
inhibitor 
(rheumatism) 
S-oxide  (Ohmi et al. 2003) 
Sulindac Sulphide** 
Non-steroidal anti-
inflammatory agent  
(Colorectal Cancer) 
S-oxide  (Hamman et al. 2000) 
Tazarotenic Acid*** 
Retinoic acid receptor 
modulator 
(acne/psoriasis) 
S-oxide  (Attar et al. 2003) 
Thiacetazone antibiotic  (tuberculosis)  sulphinic acid /carbodiimide  (Qian et al. 2006) 
*active metabolite of parent compound esonarimod. 
** active metabolite of parent compound sulindac. 
*** active metabolite of parent compound tazarotene. 
In some cases FMO3 is not the only enzyme involved in the metabolism of the drug in vivo.  
This table appears in the review by Phillips, Francois and Shephard (Phillips 2007) 
which is bound into the back of this thesis. 
  49are causative of Trimethylaminuria (TMAU) or ‘Fish-odour syndrome’, a condition in which 
individuals have a body odour similar to that of rotten fish.   In the absence of functional 
FMO3 in the liver, trimethylamine derived from the diet or from the reduction of dietary 
precursors such as choline, accumulates within the body and is then excreted in its raw, 
odorous form in the bodily fluids.   The smell of rotten fish thus emanates from a patient’s 
urine, sweat and breath.  Affected individuals have >40% unmetabolised TMA in their urine 
compared to 0-9% in unaffected individuals (Cashman et al. 2003).    More than the 
physiological effects, the psychological and social consequences of this condition are 
important.   Patients affected by this condition generally have trouble integrating into society 
because they are often perceived by others as being unhygienic.  In some cases individuals 
are known to have taken their own lives as a means of escape from their condition (Todd 
1979).    
The first described clinical report of TMAU was in 1970 (Humbert et al. 1970) but it 
is not the first TMAU-like reference on record.  Shakespeare’s The Tempest describes a 
character, Caliban of which was written:‘‘What have we here? A man or a fish? Dead or 
alive? A fish: he smells like a fish; a very ancient and fish-like smell’’ (Man Burrows 1975).  
The earliest reference is thought to be in a Hindu folklore, contained in the Indian epic, 
Mahabharata dating back to nearly 1400 BC, Satyavata, a young women condemned to 
solitary life as a ferry women was cast from society because she smelt of ‘‘rotten fish’’ (New 
York Times 2005).        
TMAU patients display altered metabolism of therapeutic drugs that are substrates for 
FMO3. For instance, the non-steroidal anti-inflammatory drug Benzydamine (BZD) is 
metabolised to its N-oxide by FMO3 in the liver and a measure of the BZD N-oxide: BZD 
ratio in the serum and urine is considered as an index for FMO3 activity in vivo (Stormer 
2000).  In a recent study, TMAU patients were administered BZD and monitored for the 
  50amount of metabolised and unmetabolised drug in their urine and serum (Mayatepek et al. 
2004).  The ratio of BZD N-oxide: BZD displayed by TMAU patients was considerably 
lower from that observed for control subjects.  This study was the first to demonstrate the 
effect of FMO3-defiency on drug metabolism.  The study did not however, determine the 
clinical implications of the altered metabolism of BDZ.    
 
1.3.3.3 Inter-individual Differences and the Impact on Drug Metabolism     
During the course of study on the genetic causes of TMAU, numerous SNPs were identified 
in  FMO3 which affected the catalytic activity of the enzyme but were not causative of 
TMAU (Table 1.5).  The polymorphisms are relatively common (ranging from 2-50% 
depending on the population sampled) and thus are of particular interest as they may alter the 
metabolism of therapeutic drugs in the general population.  For instance, an individual with a 
polymorphism in FMO3 that causes a reduction in oxidation activity (e.g. D132H or E158K) 
may be considered a poor or ‘‘slow’’ metaboliser of FMO3 substrates and therefore may have 
heightened risk of overdose.  Conversely an individual possessing a variant FMO3 with 
increased catalytic activity (e.g. L360P) may be considered as a ‘‘rapid’’ metaboliser of a 
drug.  This may lead to lower efficacy of a drug metabolised by FMO3 and ineffective dose 
prescription due to more rapid drug clearance.    
  The E158K amino acid variant of FMO3 is the product of a G>A substitution at 
position g.15167 in exon 4.  g.15167 (E158K) is by far the most common polymorphism 
occurring at a frequency of 45-50% in African Americans, 42% in Caucasian Americans and 
in 19% of Asians (Dolphin et al. 1997; Park et al. 2002; Koukouritaki et al. 2005; Hao et al. 
2006; Hao et al. 2007; Koukouritaki et al. 2007).  Individuals homozygous for this 
polymorphism display similar TMA: TMA N-oxide ratio to individuals with the reference  
 
  51Table 1.5: Polymorphic Variants of FMO3 not causative for TMAU 
Variant exon 
Amino Acid 
Change 
Functional Consequence  Reference 
g.72G>T 2  E24D  Limited 
(Koukouritaki et al. 
2005) 
g.11177C>A 3  V58I  Reduced  (Kubota et al. 2002) 
g.15089G>C 4  N61K*  reduced  or  abolished 
(Koukouritaki et al. 
2005) 
g.15167G>A 4  N61S  S-oxygenation only  (Dolphin et al. 2000) 
g.15475G>T  5 D132H substrate-dependant  decrease 
(Furnes et al. 2003; 
Lattard et al. 2003) 
g.15550C>T 5  E158K 
moderate, substrate-dependent 
decrease 
(Brunelle et al. 1997) 
g.18281G>A 6  G180V  no  effect  (Dolphin et al. 1997) 
g.18290A>G 6  R205C      moderate  decrease  (Fujieda et al. 2003) 
g.21350T>C 7  V257M 
no effect or limited substrate-
dependent decrease 
(Treacy et al. 1998) 
g.21443A>G 7  M260  n.d.  (Shimizu et al. 2007) 
g.21599T>C 7  V277A  n.d.  (Cashman  2002) 
g.21604G>C 7  E308G 
moderate substrate-dependent 
decrease 
(Treacy et al. 1998; 
Lattard et al. 2003) 
g.23613G>T 8  L360P  increased  activity 
(Furnes et al. 2003; 
Lattard et al. 2003) 
g.24642G>A 9  E362Q  n.d.  (Cashman  2002) 
g.24691G>C 9  K416N  Limited 
(Koukouritaki et al. 
2005) 
g.24642G>A 9  I486M  n.d.  (Cashman  2002) 
g.24691G>C 9  G503R  n.d.  (Furnes et al. 2003) 
*Likely to be causative for TMAU. 
n.d. – Not determined.  Coordinates are based on assigning the ‘A’ of the ATG translation 
initiation codon as +1 
This table appears in the review by Phillips, Francois and Shephard (Phillips 2007) 
which is bound into the back of this thesis. 
  52genotype (Zschocke et al. 1999).  The finding is indicative of this amino acid variant having a 
similar catalytic efficiency to the wild type protein.       
g.21443A>G (E308G) is a relatively common polymorphism occurring at a frequency 
of 18% in Asians, 20% in Caucasian-Americans and in 5% of African-Americans (Treacy et 
al. 1998; Park et al. 2002; Koukouritaki et al. 2005; Hao et al. 2006; Hao et al. 2007; 
Koukouritaki et al. 2007).  Linkage analysis confirmed g.15167 (E158K) and g.21443A>G 
(E308G) polymorphisms to be linked in 4% of individuals from a German population 
(Zschocke et al. 2000).  In this study, individuals homozygous for both variants in cis (on the 
same allele) were reported to display a mild TMAU phenotype, as confirmed from TMA: 
TMA N-oxide ratios.   Interestingly, individuals who had one E158K or E308G variant allele 
and one E158K variant allele showed little difference between urinary metabolic ratio of 
TMA: TMA N -oxide (0.0084) and individuals with the reference genotype (0.0056).  This 
data suggested, for the first time, that the occurrence of E158K and E308G in cis has more 
effect on catalytic function than a genotype of E158K or E308G and E158K alone (Zschocke 
et al. 2000).    Studies with African-American subjects suggested that a haplotype containing 
E158K and E308G in cis occurred at a frequency of around 5% (Koukouritaki et al. 2007). 
 The  in vivo consequence of the polymorphism g.21599T>C (L360P) is still to be 
determined, but it is the only polymorphic variant to result in an enzyme with higher catalytic 
activity (Furnes et al. 2003; Lattard et al. 2003).  The polymorphism has been estimated to 
occur at a frequency of around 2% in African-Americans and genotypic analysis to date 
infers the variant to be specific to this ethnic population.    
Inter-individual differences of 10- to 20-fold in the amount of hepatic FMO3 protein 
have been reported (Overby et al. 1997; Koukouritaki et al. 2002).   FMOs are generally 
considered not to be inducible by environmental factors and therefore such variation must be 
due to genetic factors.  SNPs discovered in the 5’-flanking region of the FMO3 gene are 
  53implicated in the observed inter-individual differences in levels of FMO3 protein expression 
in the liver.  In vitro analysis of such SNPs illustrates their effect on FMO3 transcription, in 
some cases effectively silencing it, and in others increasing it as much as 8-fold 
(Koukouritaki et al. 2002).     
  
1.3.4 FMO4 
FMO4 is 558 amino acid residues long.  Other members of the FMO family, with the 
exception of FMO2.2, contain between 532 and 535 residues (Phillips et al.  1995).   
Sequence comparisons reveal that the additional residues in FMO4 are contained in a single 
block located at the C-terminus of the polypeptide (Dolphin et al. 1992).  It has been 
suggested that the additional amino acid residues may have arisen as a result of a single point 
mutation in the termination codon of the ancestral FMO4 gene.   
  The mRNA of FMO4 is expressed constitutively at low levels in the liver, kidney and 
lung of the adult human (Dolphin et al. 1992; Dolphin et al. 2000; Hernandez et al. 2004; 
Zhang et al. 2006).  The protein encoded by this gene is still to be detected in human tissue. 
  Evidence of FMO4 contribution to xenobiotic metabolism is limited. In fact, very 
little is known of this FMO in general.  The probable reason is the difficulty encountered in 
expressing this FMO isoform in a heterologous system (Itagaki et al. 1996).           
 
1.3.5 FMO5 
A cDNA encoding human FMO5 was isolated in 1995 (Overby et al. 1995; Phillips et al. 
1995) and consists of a polypeptide of 533 amino acid residues and of molecular weight 60, 
255 Dalton.  FMO5 is expressed in many foetal and adult tissues, but in humans its main site 
of expression is adult liver although it is not expressed in the same amounts as FMO3 
(Janmohamed et al. 2001; Hernandez et al. 2004; Zhang et al. 2006).  
  54FMO5 is regarded as the ‘‘black sheep’’ of the FMO family with respect to gene 
expression, gene regulation and substrate specificity.  Despite this, it is classified as an FMO 
because of its sequence similarity to other members of this family.   
The FMO5 gene is not part of the FMO gene cluster on human chromosome 1q24.3 
but is located ~26Mb closer to the centromere at 1q21.1 (Hernandez et al. 2004).  FMO5 is 
thought to be the ancestral FMO gene (Hernandez et al. 2004).     Currently, FMO5 is the 
only human FMO demonstrated to be under hormonal regulation (Miller et al. 1997). 
FMO5 shows little or no activity towards classic FMO substrates such as methimazole 
(FMO1, FMO2 and FMO3), imipramine (FMO1) and thioureas (FMO1, FMO2 and FMO3) 
(Overby et al. 1995; Henderson et al. 2004a; Onderwater et al. 2004; Hernandez et al. 2009) 
but efficiently catalyses the N-oxygenation of short chain aliphatic primary amines like n-
octylamine, that are not utilized by other human FMOs.   FMO5 is capable of oxidising 
thioethers with proximal carboxy groups, like the drug Esonarimod, a reaction not catalysed 
by FMO1 or FMO3 (Ohmi et al. 2003). 
  Sequencing studies performed on human FMO5 from individuals of African-
American descent suggest it is the most conserved isoform of the FMO family (Furnes et al. 
2003).   
Despite its expression in the adult human liver, FMO5 is not thought to play a 
significant role in drug metabolism as a result of its limited substrate specificity.   FMO5 
may, however be important in an endogenous metabolic pathway, yet to be identified. 
    
 
 
 
 
 
 
 
  55Table 1.6: Summary of Tissue-specific FMO expression in Man 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Human FMO  Major site of expression  Reference 
FMO1 Kidney  Koukouritaki et al. 2002 
FMO2 Lung*  Krueger et al. 2002 
FMO3 Liver  Phillips et al.  1995, 
Koukouritaki et al. 2002 
FMO4 Not  determined  - 
FMO5 Liver  Janmohammed et al. 2001 
 
*Absent in the majority of the human population, see section 1.3.2 for details. 
 
 
 
 
 
 
    
 
 
 
 
 
 
 
 
 
 
  561.4 Tuberculosis  
Tuberculosis (TB) is an infectious disease caused by the opportunistic bacterium, 
Mycobacterium tuberculosis.  TB is a severe infection of the lung that can disseminate to 
other parts of the body such as the lymph nodes, the spine and the central nervous system.  
The symptoms of pulmonary TB include persistent coughing with blood appearing in sputum, 
chest pains, weight loss, intermittent fever and night sweats.    
 
1.4.1 Transmission and Pathogenesis    
Transmission of the disease occurs when an infected individual expels Mycobacteria in the 
form of aerosols in the air when they cough, sneeze, spit or laugh.   The bacteria once inhaled 
in the lungs of an uninfected person lodge in the distal airways of the alveoli and are engulfed 
by alveolar macrophages.   At this stage the pathogen has one of several fates.  In the 
majority (>90%) of cases, Mycobacterium ‘hides’ within macrophages and evades the 
primary innate immune response by interfering with intracellular signalling pathways in the 
macrophage by mechanisms that are currently poorly understood.   The pathogen in this state, 
is non-replicating and initiates a latent infection.  This sub-clinical, asymptomatic infection 
can last for years and in the majority of cases never re-activates.  Re-activation or ‘post-
primary’ infection occurs in 5-10 % of individuals and its onset is accelerated in an 
immunocompromised host.      In the remainder of l0% of cases, Mycobacterium starts to 
replicate and the onset of a primary infection develops. 
 
1.4.2 TB Incidence, Prevalence and Mortality 
One third of the world’s population is infected with TB.  The World Health Organisation 
(WHO) Report 2009 estimated 9.2 million new cases of TB worldwide in 2007, of which 
31% were in Africa (WHO 2009).   Among the 9.2 million cases, 0.5 million were caused by 
  57multi-drug resistant strains of Mycobacterium tuberculosis (MDR-TB) and  5 % of the 
incident cases were estimated to be HIV-positive.  There was an estimated 13.7 million 
prevalent cases worldwide in 2007 and this estimate is slightly higher than that reported for 
the previous year (13.4 million in 2006).  The number of deaths caused by TB in HIV-
negative patients was estimated to be 1.32 million in 2007 and there was an additional 0.48 
million TB deaths in HIV-positive cases. In absolute terms, the total number of TB cases is 
on the rise and the WHO statistics highlight that TB is still a major global health problem.   If 
controls are not imposed, an estimated 1 billion people will be infected by 2020, over 125 
million will get sick and more than 30 million will die from this disease (Ghiladi et al. 2005).          
          
1.4.3 Genus Mycobacterium and Disease 
Mycobacterium is a genus of Actinobacteria given its own family name, Mycobacteriacea.  
Several species belonging to this genus are pathogenic and known to cause serious disease in 
mammals.  Mycobacterium tuberculosis is the primary causative agent of TB in humans.   
Other pathogenic species of Mycobacteria have been isolated in man; albeit rare they include 
Mycobacterium Microti, Mycobacterium africanum and Mycobacterium canettii (Miltgen et 
al. 2002; Cadmus et al. 2009; Frank et al. 2009). 
  
1.4.3.1 Mycobacterium tuberculosis (M.tuberculosis)  
M. tuberculosis is an aerobic, non-motile, polytrophic organism that grows in straight or 
curved rod-like structures (bacillus).  The bacterium has a remarkably slow rate of growth 
with a doubling time of around 20-30 hours (cf. E.coli which can divide every 20 mins under 
optimum conditions).  M. tuberculosis is classified as Gram-positive bacteria as it has one 
phospholipid outer membrane.  Despite this feature, the bacteria stains weakly upon Gram-
staining and in some cases will not stain at all.   The inability to retain Gram stain is because 
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the stain to encounter this barrier.  Instead, an acid-fast or Ziehl-Neelsen stain can be 
employed to identify M. tuberculosis in bacterial cultures.  
  The cell wall of M. tuberculosis and species belonging to the Mycobacterium genus in 
general have a unique and complex cell wall structure that is considered one of the attributes 
of making this organism one of the most successful pathogens of mankind.  The cell wall 
consists of an inner and outer layer that surrounds the plasma membrane of the organism.  
The outer layer compartment consists of lipids and proteins.  Linked to the lipid moiety are 
polysaccharides including lipoarabinomannan (LAMs), lipomannan and sulpholipids.  This 
layer is the soluble component of the cell wall and contains receptors that interact with the 
host immune system.  The inner layer consists of peptidoglycans (PG), arabinogalactan (AG) 
and mycolic acids (MA) covalently linked to form a complex known as the MA-AG-PG 
complex that extends from the plasma membrane towards the outer layer, starting with PG 
and ending with MA.  This complex is insoluble and impermeable and is referred to as the 
essential core of the cell wall.  This component is the target of several antibiotics and will be 
described later.                 
              
1.4.4 Anti-tuberculosis chemotherapy 
There are five main aims of chemotherapy 
a.  Cure of the patient  
b.  Prevention of death from active disease or its late effects 
c.  Avoidance of relapse or re-current disease 
d.  Prevention of spread of drug-resistant organisms 
e.  Protection of the community from infection 
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are generally prescribed in combination as monotherapy can lead to drug resistance.    A two-
tier system is established in TB chemotherapy and consists of first-line and second-line 
antibiotics.  First-line antibiotics; isoniazid (INH), rifampicin (RIF), pyrazinamide (PZA), 
and streptomycin (SM) are predominantly bactericidal in action.  Thiacetazone (TAZ), 
ethionamide (ETA) and ethambutol (EMB) are second-line antibiotics and are predominantly 
bacteriostatic.  First-line antibiotics are generally more expensive and display higher drug 
efficacy, second-line drugs on the other hand are cheaper but have higher levels of toxicity 
and are less effective at treating TB.  Among all the current TB drugs, TAZ is the cheapest 
antibiotic available.  The WHO recommends Directly Observed Therapy (DOTs) that 
consists of the following drug regimen for treatment of active TB infection: 6 months therapy 
consisting of initial 2 month phase of treatment with four drugs; INH, RIF, PZA and EMB 
followed by a continuation phase with INH and RIF for another 4 months (WHO 2009 ).  All 
of these drugs are expensive and are ineffective in treating TB in areas of high incidence of 
multi-drug resistant TB (MDR-TB).  In developing countries, the cost of these drugs is too 
much to afford and more second-line drugs are substituted for first-line antibiotics.  For 
instance drug regimens in Sudan, Nigeria, Ghana, Senegal and some parts of South America 
administer the following course of treatment: 4 months intensive chemotherapy with INH, 
RIF, PZA, EMB followed by 3 months of TAZ and INH (Lawn et al. 1999; Mame Thierno et 
al. 2001; Dosumu 2002; Keus et al. 2003).   Poverty-stricken areas of Africa and certain parts 
of India however can ill afford this relatively cheap combination and thus resort to a 
preparation of INH and TAZ (Thiazina) course of treatment which lasts for 18 months, 
despite it being less effective and causing potentially life-threatening side effects (Nunn et al. 
1992).   The side effects of this drug have been presumed to be from the TAZ component of 
this preparation (Anonymous 1963; Aquinas 1968; Volek et al. 1970; Hussain et al. 1973; 
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et al. 1991; Kole 1991; Nunn et al. 1991; Ipuge et al. 1995).   
  INH is the most potent bactericidal antibiotic amongst the essential drugs and is most 
effective towards metabolically active and continuously growing bacteria. RIF is a good 
bactericidal agent towards growing bacteria but is also effective at targeting semi-dormant 
bacteria.  Thus RIF is a good sterilising agent that will kill Mycobacteria capable of surviving 
the action of INH.    PZA, like RIF is a good sterilising agent of Mycobacteria, especially 
those that grow in an acidic environment.  SM has less bactericidal action but nevertheless is 
effective. 
  It is envisaged that tubercle bacilli in lesions within an infected host consist of sub-
populations that display differences in metabolic status.  These are ‘‘(a) those that are 
metabolically active, continuously growing bacteria that are killed by the action of INH (but 
in the case of INH resistance are killed by RIF and SM), (b) semi-dormant bacteria that 
undergo spurts of metabolism which are killed by RIF, (c) those that are of low metabolic 
activity and reside in acid pH environment which are killed by PZA and (d) those that are 
‘dormant’ which are not killed by any current TB drug’’ (Zhang 2005).    
  
1.4.5 Mechanisms of Drug Action  
The action of drugs can be categorised in the following groups, inhibitors of cell wall 
synthesis (INH, TAZ, ETA, EMB), inhibitors of nucleic acid synthesis (RIF), inhibitors of 
protein synthesis (SM) and drugs that inhibit or deplete membrane energy (PZA).  It is 
beyond the scope of this report to detail the mechanism of each drug, for a detailed insight 
into the mode of drug action/activation see review by (Zhang 2005).  A brief description will 
be provided here. 
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Inhibitors of cell wall synthesis target components within the lipid rich inner and outer layer 
that surrounds the cell wall, thereby weakening the cell scaffold that is crucial to bacterium 
survival.    INH is a pro-drug that is activated by M. tuberculosis catalase-peroxidase enzyme, 
KatG ((Zhang et al. 1992), Johnson and Schultz 1994) to generate a range of toxic oxygen 
species.  The active species of this activation, the isonicotinic acyl radical, reacts with NAD 
to form an INH-NAD adduct that inhibits the enzyme InhA (Rozwarski et al. 1999).  The 
enoyl-acyl carrier protein reductase, InhA is part of the Fatty Acid Synthase type II (FAS II) 
complex that is responsible for the synthesis and elongation of mycolic acids.   The primary 
target of INH is thus mycolic acid biosynthesis (Winder et al. 1970).  Mutations in KatG and 
in InhA confer resistance to INH treatment (Banerjee et al. 1994). 
  EMB interferes with the production of arabinogalactan, an important polysaccharide 
component of the essential core of the cell wall.  EMB inhibits the polymerisation of the 
arabinin moiety of arabinogalactan and LAMs thus weakening the scaffold of the 
mycobacterial cell wall (Zhang 2005).  The exact details of EMB action or activation are still 
poorly understood but aribinosyl transferase, an enzyme involved in arabinogalactan 
synthesis has been postulated as the target of this drug. 
  ETA and TAZ also target cell wall biosynthesis and this will be described in detail in 
section 1.4.6 and 1.4.7 respectively. 
 
Inhibitors of nucleic acid synthesis  
RIF is a broad spectrum, rifamycin B derivative that inhibits RNA synthesis in bacteria.  RIF 
inhibits the synthesis of RNA by binding to the β-subunit of bacterial DNA-dependent RNA 
polymerase (DDRP) thus inhibiting the transcription of RNA and subsequent translation to 
protein (Zhang 2005).  The beta subunit of DDRP is the translational product of the rpoB 
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2005). 
   
Inhibitors of Protein Synthesis 
SM is an aminoglycoside that inhibits translation of bacterial mRNA. It does so by binding to 
specific components associated with the bacterial ribosome that is composed of a large (50S) 
and a small (30S) subunit.  Studies have identified that SM binds to the 16S rRNA 
component of 30S and also to the S12 protein that is associated with this complex (Spotts et 
al. 1961).   16S rRNA and S12 are encoded by the rrs and rpsl genes respectively and 
mutations in these genes are known to cause resistance to SM action (Garvin et al. 1974). 
 
Inhibition and Depletion of Membrane Energy 
PZA, a structural analogue of nicotinamide, is a prodrug that requires conversion to its active 
form pyrazinoic acid (POA) by the pZase/nicotinamidase enzyme (Scorpio et al. 1996).  The 
drug has no activity against Mycobacteria growing at normal culture conditions near neutral 
pH, but is effective in killing bacilli at lower pH (Tarshis et al. 1953).  Acid pH facilitates the 
formation of uncharged protonated POA that permeates through the membrane easily, this 
results in the accumulation of POA and the decrease in membrane potential in M. 
tuberculosis (Zhang et al. 1999; Zhang et al. 2003).  Protons flow into the cell and this 
subsequently causes the collapse of the proton-motive force and affects membrane transport 
(Zhang et al. 2003).   
    The pZase/nicotinamidase enzyme is encoded by the pncA gene in M. tuberculosis.  
Mutations in pncA are considered the major mechanism of resistance to this drug (Scorpio et 
al. 1996; Scorpio et al. 1997).  
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Ethionamide (2-ethylpyradine-4-carbothioamide, ETA) is a second-line antibiotic developed 
by the Lederle Research Laboratories in 1956 (Liebermann D 1956).  The drug has been used 
in the developing world and in the United States to either treat the mycobacterium or reduce 
the risk of resistance to first-line antibiotics.   
  ETA is a structural analogue of INH (Fig. 1.9).  It was observed that mutations in the 
promoter and coding region of InhA, which encodes the enzyme that is the cellular target for 
INH (InhA) conferred resistance to ETA treatment (Banerjee et al. 1994).  This gave the 
impression that ETA and INH have common modes of activation, but it was hard to explain 
why clinical isolates of M. tuberculosis that were resistant to INH treatment were still 
susceptible to ETA and vice versa.  The lack of cross-resistance suggested that KatG, the 
catalase peroxidase responsible for INH activation was probably not involved in the 
conversion of ETA. In 2000, two independent laboratories identified an FAD-containing 
monooxygenase as the activator of ETA, this enzyme was named Ethionamide-Activating 
enzyme usually abbreviated to EtaA (also known as EthA) (Baulard et al. 2000; DeBarber et 
al. 2000). Clinical isolates containing mutations in the gene encoding EtaA are resistant to 
ETA action and an activation step for ETA activity is thus necessary for it to exert an anti-
tubercular effect.   Heterologous expression of the enzyme in E.coli confirmed this enzyme to 
catalyse the oxidation of this drug (Vannelli et al. 2002).  EtaA will be described in section 
1.4.8.   
     In vitro studies claim that EtaA catalyses the sequential oxidation of ETA to form 
the  S-oxide (ETA-SO) and 2-ethyl-4-amidopyridine (ETA-amide) (Vannelli et al.  2002).   
Since the anti-tubercular activity of ETA-amide and ETA-SO is comparable to that exhibited 
by the parent compound, it is unlikely that these metabolites represent the activated species of 
this drug.    Although not identified, an intermediate precursor of ETA-amide has been  
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Figure 1.9: Chemical Structures of Isoniazid (INH) and Ethionamide (ETA) 
 
 
 
 
 
 
 
 
 
  65postulated to be the reactive species of ETA oxidation and is predicted to be a sulphinic acid 
metabolite (Vannelli et al. 2002).   In an independent study, the in vivo metabolism of ETA in 
M.tuberculosis was investigated and in addition to ETA-SO and ETA-amide, the 
corresponding nitrile, acid and alcohol derivatives of ETA were observed (DeBarber et al. 
2000).  Both studies employed extraction methods prior to MS analyses and some argue that 
these products may result from spontaneous chemical modification/oxidation rather than an 
enzymatic reaction as none of these compounds display anti-microbial activity (Hanoulle et 
al. 2006).  To establish the product(s) of EtaA catalysed oxidation, one study employed high 
resolution magic angle spinning-NMR to determine the metabolism and identify the active 
species of this drug in living M.smegmatis (Hanoulle et al. 2006).  The study investigated the 
metabolism of ETA in the growth medium and within the cells in real time.  The study 
demonstrated that the concentration of ETA in the growth medium decreased over time and 
was coupled to the formation of two metabolites.  NMR analysis confirmed these as ETA-SO 
and ETA-alcohol.  Analysis of the intracellular distribution of this drug however did not 
identify ETA, ETA-alcohol or ETA-amide.  This suggests that upon activation of ETA, the 
products are rapidly expelled from the cell.  Furthermore, the accumulation of an aromatic 
ETA derivative was observed within the cell and its formation correlated to the loss of ETA 
in the growth medium. This metabolite, ETA* is considered to be the active product of EtaA 
catalysed oxidation, the nature of this species however, is still to be determined but is 
postulated as the sulphinic acid of ETA (Hanoulle et al. 2006).   Given that ETA, ETA-SO, 
and ETA-alcohol were only observed in the growth medium and that ETA* accumulated over 
time within the cell indicates that ETA activation is coupled to a complex molecular sorting 
of metabolites and to a selective accumulation of a specific species.  (Vannelli et al. 2002; 
Hanoulle et al. 2006). 
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established.  The cellular target of ETA is the enoyl acyl carrier protein reductase, InhA 
(Larsen et al. 2002).  This enzyme is involved in the final step of the Fatty Acid Synthase 
complex reactions.  The actual mechanism by which ETA or its active metabolite inhibit this 
enzyme is still to be established.  
  Given that InhA is the cellular target of ETA, it is reasonable to assume that the drug 
will affect lipid metabolism in Mycobacteria.  ETA causes the cessation of alpha-, keto and 
methoxy-mycolate methyl ester synthesis; these lipids are sub-types of mycolic acids that are 
essential components of the Mycobacterium cell wall.   Thus impairment in their biogenesis 
is likely to weaken the cell scaffold and make Mycobacteria more susceptible to host immune 
attacks (Dover et al. 2007). More details regarding the role of mycolic acids will be provided 
in the next section.   
 
1.4.7 Thiacetazone  
Thiacetazone (p-acetylaminobenzaldehyde thiosemicarbazone, TAZ) is a member of the 
thiosemicarbazone family of drugs that were developed in the late 1940s by Farbenfabriken 
Bayer in Germany (Behnisch et al. 1950).  The therapeutic importance of TAZ was 
investigated by Domagk (Domagk 1950) when the drug was used to treat some 10, 000 
patients in Germany as a single agent in treatment for TB (Mertens et al. 1950).  As was the 
norm of the time, these trials were uncontrolled and details referring to drug efficacy, 
tolerance and safety were not documented but two American observers concluded that TAZ 
appeared to have ‘‘anti-tuberculous activity of the same order of magnitude as p-
aminosalicyclic acid; and a potential toxicity somewhat like the arsenics used to treat 
syphilis’’ (Hinshaw et al. 1950; Nunn et al. 1993).  The drug has not been used in the United 
States or in Europe (outside Germany) because of the discovery of INH and SM, drugs that 
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costs of obtaining first-line antibiotics and the long duration of drug regimens means that 
poorer countries can ill afford them.  This has led to the use of TAZ as either monotherapy or 
in conjunction with other drugs in areas of Africa, India and South America (Narang ; 
Anonymous 1963; Fox et al. 1974; Neill et al. 1990; Nunn et al. 1992; Nunn et al. 1993; 
Lawn et al. 1999; Mame Thierno et al. 2001).   
  The main role of TAZ in current drug regimens is to prevent the emergence of 
Mycobacteria that are resistant to first line drugs such as INH and RIF.  Despite TAZ being a 
bacteriostatic drug with poor sterilising activity (Heifets et al. 1990), recent interest in this 
drug has arisen since it has not been used in the developed world.  This means that M. 
tuberculosis strains resistant to drugs prescribed in industrialised countries are likely to be 
susceptible to TAZ treatment. For example, a recent report described the treatment of an 
individual suffering from chronic TB infection in Japan whose sputum smeared positive for 
TB during and after extensive chemotherapy with INH, RIF and PZA (Wada et al. 2007). 
Drug susceptibility tests confirmed the individual to suffer from a multi-drug resistant strain 
of M. tuberculosis. TAZ was included in the regimen as a ‘last resort’ and after four months 
of therapy, the individual’s sputum smeared negative for the first time since the onset of 
infection. 3 years after the termination of TAZ therapy in a follow-up, the patient displayed 
negative sputum smears and no signs of relapse were observed (Wada et al. 2007).  This 
finding is valuable as the level of multi-drug resistant M. tuberculosis, i.e. strains resistant to 
INH and RIF are on the rise and pose a major obstacle in the successful treatment of this 
disease.  Furthermore, statistics regarding X-MDR TB, (that is individuals infected with 
bacterial strains resistant to INH and RIF and at least three of the six second line drugs) 
confirm its rise in industrialised parts of the world (WHO 2009 ).  A major problem regarding 
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observed in regimens containing this drug. 
  The first controlled clinical trial of TAZ chemotherapy was conducted in East Africa 
in which 51 patients with active TB infections were administered 150 mg of TAZ daily 
(Anonymous 1960).  During this study, severe skin rashes were observed in about 20% of 
patients and a single case of Steven’s Johnson syndrome was reported.  Stevens-Johnson 
syndrome is a life threatening disease in which cell death causes the epidermis to separate 
from the dermis and is usually described as ‘skin falling off’. Since this study, numerous 
reports of dermatological reactions including Stevens-Johnson syndrome and Lyell disease, 
inflicted by TAZ usage have been documented (Harland 1962; Ferguson et al. 1971; Hussain 
et al. 1973; Bedi et al. 1974; Sahi et al. 1974; Purohit et al. 1976; Strobel et al. 1979; Naraqi 
et al. 1980; Strobel et al. 1980; Anonymous 1981; Gupta et al. 1983; Mullick et al. 1986; 
Fegan et al. 1991; Fegan et al. 1991; Nunn et al. 1991; Chintu et al. 1993; Kelly et al. 1994; 
Ipuge et al. 1995; GOTHI 1998 ; Lawn et al. 1999; Dieng et al. 2001; Mame Thierno et al. 
2001).     Stevens-Johnson syndrome is more common in HIV-positive patients than HIV-
negative patients that take TAZ as part of TB treatment (Colebunders 1989; Colebunders et 
al. 1989; Elliott et al. 1990; Elliott et al. 1996) and work in Uganda specifically implicated 
TAZ as the responsible drug (Eriki et al. 1991).  Therefore TAZ is strongly contraindicated in 
patients that are HIV-positive.   Reports of adverse skin reactions have been made in smaller 
district programmes in India, Kenya, Tanzania and Senegal whereby cutaneous rashes are 
reported as common (Shane et al. 1951; Ipuge et al. 1995; GOTHI 1998 ; Mame Thierno et 
al. 2001). A common complaint of patients given this drug is of gastrointestinal disturbances 
such as nausea and vomiting (Shane et al. 1951; Teklu 1976; GOTHI 1998 ; Mame Thierno 
et al. 2001) this is a potential problem with regard to drug compliance as chemotherapy may 
last for up to 24 months with this drug.   Liver function tests performed, such as thymol 
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incidence of liver toxicity (Hinshaw et al. 1950; Shane et al. 1951; Anonymous 1963).   
Jaundice has also been reported in around 4% of individuals in India given TAZ as 
chemotherapy (Narang ; Sharda et al. 1976; Gupta et al. 1977).  Jaundice was frequently 
reported in patients on TAZ containing regimens in controlled studies conducted in Africa, 
Singapore and Hong Kong (Anonymous 1963; Aquinas 1968; Anonymous 1971). These 
findings are hard to interpret for two reasons; TAZ is usually administered as a preparation 
with INH (Thiazina) or as multi-drug therapy with other first- and second-line antibiotics and 
thus it cannot be assumed that TAZ is responsible for inducing hepatotoxicity, secondly 
disseminated TB infections of the liver may also lead to hepatic dysfunction. To complicate 
the interpretation further, contradictory findings have been reported about the role of INH in 
potentiating TAZ-induced toxicity in individuals being given Thiazina or regimens in which 
the drugs are prescribed together.  One case study of 13 British TB patients reported liver 
toxicity and liver damage in individuals prescribed INH and TAZ but not in those prescribed 
TAZ as monotherapy (Pines 1964). This would indicate a role of INH in liver toxicity rather 
than TAZ.  Though uncommon, INH-induced hepatotoxicity has been reported and in part 
has been associated to one’s acetylator status (Rubin 1952, Reynolds 1962, Bahrs 1963, 
Pande 1996, Huang 2002, Possuelo 2008, Bozok Centintas 2008).    A study in Zimbabwe 
however, observed hepatotoxicity in patients given TAZ, INH, PZA and SM but not in drug 
regimens in which TAZ was omitted, the study also noted that adverse-drug reactions showed 
no correlation to INH acetylator status (Neill et al. 1990).   Although a role of INH cannot be 
ruled out entirely, it is generally accepted that TAZ is the main contributor of liver toxicity 
and liver damage (Anonymous 1963; Aquinas 1968; Axton 1971; Sharda et al. 1976; Gupta 
et al. 1977; Coetzee 1980). 
  70  Details regarding the metabolism and potential mechanism of toxicity of TAZ are 
poorly documented, probably because the development of this drug before the advent of 
clinical trials and drug licensing and also owing to the lack of TAZ used in the United States.  
The drug is administered orally in a tablet form and is likely to be well absorbed; hepatic 
metabolism is thus expected to be important, though bioavailability data is not available. UV-
spectral and HPLC analysis of human urine and faecal samples suggest that 15-20% of the 
drug is excreted unchanged (Ellard et al. 1974; Jenner 1983; Jenner et al. 1984).  Spectral 
analysis observed p-aminobenzaldehyde thiosemicarbazone and p-acetylaminobenzoic acid 
in urine (Ellard et al. 1974) but these metabolites were not identified in later work using 
HPLC (Jenner 1983; Jenner et al. 1984).  The latter method detected two unidentified 
metabolites, although in small quantities in urine (Jenner 1983; Jenner et al. 1984).      
The mode of action of TAZ in killing M. tuberculosis has recently been investigated.  
TAZ, like other TB drugs is a pro-drug that requires metabolic activation by an enzyme 
specific to Mycobacteria.  The enzyme necessary (but not sufficient) to activate TAZ is the 
bacterial FMO, EtaA (Baulard et al. 2000; DeBarber et al. 2000; Qian et al. 2006; Dover et 
al. 2007; Alahari et al. 2009).  In the presence of NADPH and molecular oxygen, EtaA 
catalyses the oxidation of TAZ to generate two major metabolites; TAZ-sulphinic acid and 
TAZ-carbodiimide (Qian et al. 2006).  Experiments with chemical oxidants such as H2O2 
and the desulphuration agent cuprous chloride (CuCl), demonstrate that TAZ-sulphinic acid 
and TAZ-carbodiimide are not products of sequential oxidation, i.e. the carbodiimide is not 
formed by desulphuration of the sulphinic acid, but instead both products are formed by 
independent enzymatic reactions of TAZ probably through an unidentified intermediate.   
Given that sulphinic acids can be generated by the oxidation of sulphenic acids and the fact 
that EtaA is a monooxygenase, the authors of this study postulated a TAZ-sulphenic acid 
metabolite as the intermediate precursor for both products (Fig. 1.10) (Qian et al. 2006). 
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Figure 1.10: EtaA Catalyses the Two-Step Oxidation of TAZ.  Chemical structures of 
oxidative products generated by the oxygen- and NADPH-dependant oxidation of TAZ by 
EtaA.  The structure of the postulated sulphenic acid intermediate is given in brackets (Qian 
et al. 2006).   
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EtaA (Alahari et al. 2009).   This implies that in addition to EtaA, other activators of TAZ are 
present. The Mycobacterial methyltransferase Mma4 is necessary in the activation of TAZ, 
though currently it is unclear how this enzyme interacts with EtaA and whether the enzymes 
share a common target (Alahari et al. 2009).   Although the mode of TAZ action has recently 
been established, the drug metabolite responsible for inhibiting the growth of M. tuberculosis 
is still unknown.  
TAZ is an inhibitor of cell wall mycolic acid biogenesis (Alahari et al. 2007; Dover et 
al. 2007; Alahari et al. 2009).  Mycolic acids are mixtures of alpha, methoxy- and keto-
mycolic acid methyl esters that are branched, long chain fatty acids representing the key 
components of the hydrophobic cell wall.  These lipids provide several protective features 
including resistance to oxidative injury, low permeability to antibiotics and the ability to 
persist within the host (Daffe et al. 1998; Dubnau et al. 2000; Glickman et al. 2000).   
Synthesis of alpha- and keto-mycolic acid methyl esters occurs through a coordinated 
pathway involving oxidation, methylation and cis or trans-cyclopropanation that is catalysed 
by cyclopropane mycolic acid synthases (CMASs). In a recent study, the effect of TAZ on 
wild type and TAZ-hypersensitive strains of M. bovis were studied to elucidate the 
mechanism by which this drug impairs cell wall biogenesis (Dover et al. 2007).  TAZ inhibits 
the formation of all sub-types of mycolates and results in the accumulation of alpha- and 
keto-mycolate precursors.  These lipids, when analysed by NMR and MS, lack the 
cyclopropane ring moiety and imply that the cellular target of TAZ may be enzymes that 
catalyse this step (Alahari et al. 2007).  The cellular target of TAZ has thus been identified as 
the S-adenosyl methionine (SAM)-dependant methyltransferases, Mma2, Mma4 and PcaA 
(Alahari et al. 2007).  The actual mechanism by which TAZ or its reactive metabolite inhibits 
the function of such enzymes is still unclear. It is noteworthy that although the action of ETA 
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unsaturated mycolates, this implies ETA and TAZ inhibit mycolic acid biogenesis by 
different mechanisms.  Furthermore, TAZ does not inhibit the function of enzymes involved 
in the FAS II synthase pathway i.e. InhA, KasA, KasB, MabA or mtFabH and further 
suggests that TAZ and ETA although activated by the same enzyme have different cellular 
targets (Dover et al. 2007).     
    
1.4.8 Ethionamide-Activating Enzyme (EtaA): A bacterial FMO 
In 2000, two independent studies identified a gene Rv3854c (EtaA) in the M. tuberculosis 
genome that encoded a protein responsible for ETA activation (Baulard et al. 2000; DeBarber 
et al. 2000).  The protein was accordingly named Ethionamide-Activating enzyme and is 
usually abbreviated to EtaA or EthA.   
Characterisation of EtaA revealed that it was 488 amino acid residues in length and 
was membrane associated (Vannelli et al. 2002).  UV-spectral analysis of EtaA yielded a 
spectrum displaying absorbance maxima at 365 nm and 440 nm suggesting the presence of a 
flavin containing prosthetic group (Vannelli et al. 2002).  Extraction of the flavin species 
identified FAD and not FMN as the prosthetic group in this enzyme.  The enzyme 
demonstrated dependence on molecular oxygen and NADPH.  EtaA is inactive under 
anaerobic conditions and NADH can not be substituted for NADPH.  The size, prosthetic 
group, dependence on oxygen and NADPH and enzyme localisation of EtaA are consistent 
with it being a flavin-containing monooxygenase (Vannelli et al. 2002).  A primary sequence 
alignment of EtaA and human FMO1, 2.1 and 3 is given in Figure 1.11 and demonstrates that 
the bacterial enzyme contains the characteristic ‘GXGXXG/A’ consensus sequence that is 
important in binding dinucleotides in eukaryotic FMOs.  As described in the preceding 
section, EtaA catalyses the S-oxidation of TAZ  
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Figure 1.11: A primary sequence alignment of EtaA and human FMOs involved in drug 
metabolism.  The primary sequence of EtaA and FMO1, 2.1 and 3 are aligned.  An asterix 
denotes conserved identical residues, a colon indicates conserved similar residues, and a dot 
indicates highly similar residues.  The ‘GXGXXG/A’ FAD and NADPH binding moieties are 
boxed in red. Primary sequences were aligned using the ClustalW2 tool available at 
http://www.ebi.ac.uk/Tools/clustalw2/index.html.   
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oxidation of TAZ to TAZ-sulphinic acid and carbodiimide the same products identified for 
EtaA (Qian et al. 2006). This finding suggests that upon administration of TAZ to humans, 
oxidation of TAZ by eukaryotic monooxygenases may result in the production of potentially 
toxic metabolites and/or the inactivation of the drug leading to reduced drug efficacy.  It is 
therefore crucial to determine the role of mammalian monooxygenases in the activation of 
TAZ and other thiocarbamide drugs and this provides the focus of this investigation.   
EtaA is under the transcriptional control of a regulatory protein that is encoded by the 
gene, Rv3855.  In vitro studies demonstrate that over-expression of Rv3855 generates ETA 
resistance. The protein encoded by this gene displays homology to members of the TetR 
family of transcriptional repressors and thus is thought to be a negative repressor of EtaA 
expression and has been designated as EtaR.  Supporting this finding is the observation that 
chromosomal inactivation of Rv3855 in M. bovis results in the hyper-sensitivity of 
Mycobacteria to ETA and TAZ (Baulard et al. 2000; Dover et al. 2007).  Not only do these 
findings confirm the regulation of EtaA  by EtaR but also confirm EtaA as the enzyme 
responsible for activating ETA and TAZ.   Clinical isolates resistant to TAZ and ETA are 
also resistant to thiocarlide (a second-line antibiotic) treatment.   It thus appears that EtaA 
may be a common activator for thiocarbamide containing drugs (Dover et al. 2007).   
  
 
 
 
 
 
 
  761.5 Pharmacogenetics 
Pharmacogenetics is the discipline that studies the influence of genetic variation on drug 
response.  The field has generated recent interest owing to the fact that around 100,000 deaths 
occur in the United States every year because of adverse-drug reactions exhibited by patients 
on medication (Lazarou 1998; Abbott 2003).   
The first observation of genetic variation on drug response was in the 1950s for 
suxamethonium chloride, a muscle relaxant administered during general anaesthesia (Kalow 
1952; Evans et al. 1953; Kalow 1961 reviewed by Gardiner et al. 2006).   Doctors observed 
that upon drug administration, some patients remained paralysed for longer than others and 
some suffered from life-threatening respiratory arrest (Abbott 2003; Kalow 2004).  It was 
later established that homozygousity for mutations on the butyrlcholinesterase gene led to 
this phenomena (Kalow 1957; Jensen et al. 1995).  Cholinesterase is the enzyme that 
hydrolyses the drug to an inactive metabolite and in the event when this process is impaired, 
the resultant accumulation of succinylcholine results in the prolonged paralysis of muscles 
including those that are involved in breathing (Jensen et al. 1995; Yen et al. 2003 and 
reviewed by Lee 2009).   
     Of particular interest to pharmacogenetic studies are families of drug metabolising 
enzymes, in particular the cytochrome P450s (CYPs).  It is estimated that more than 80% of 
serious adverse drug reactions are the consequence of polymorphic variants of CYPs (Abbott 
2003).  Though it is beyond the scope of this section to describe in detail the polymorphic 
nature of CYPs, a few examples of altered drug metabolism by CYP variation will briefly be 
described here.  For an extensive review see Gardiner et al. 2006.   
  Codeine, a pain killer commonly given to post-operative patients to manage pain is 
ineffective in about 10% of individuals.  The drug is oxidised to morphine by CYP2D6, but 
in people possessing polymorphic variants of this enzyme, the drug is ineffective and patients 
  77do not get any pain relief (reviewed by Lotsch et al. 2009 and Thorn et al. 2009).  CYP2D6 is 
in fact the most polymorphic of CYP genes and genetic variations result in individuals being 
rapid, normal or slow metabolisers of drugs that are substrates for this enzyme (reviewed in 
(Gardiner et al. 2006)).   Therapeutics metabolised by CYP2D6 for which a pharmacogenetic 
link has been established include the anti-hypertensive agent debrisoquine (Tucker et al. 
1977; Wolf et al. 1992), the anti-depressant nortriptyline (Dalen et al. 1998; Dalen et al. 
2003) and the anti-angina drug perhexilline (reviewed by Ashrafian et al. 2007). 
    The anti-coagulant Warfarin is metabolised by CYP2C9.  Variant alleles that reduce 
the enzymes capacity to clear this drug, such as CYP2C9*2 and CYP2C9*2 cause Warfarin 
hypersensitivity that can lead to life-threatening bleeding and a higher risk of stroke (Rettie et 
al. 1994; Haining et al. 1996).  Allelic variants of CYP2C8 have been implicated in altered 
oxidation of the mitotic inhibitor paclitaxel (Dai et al. 2001; Bahadur et al. 2002).   
The ultimate goal of pharmacogenetic research is a healthcare service that would 
consider the genetic profile of a patient so that therapeutics can be tailored to maximise drug 
efficacy and minimise adverse drug reactions.  No matter how beneficial the concept of 
‘personalised medicine’ may sound it is unlikely to happen in the foreseeable future given the 
complex nature of drug metabolism that usually involves the inter-play of several enzymes 
and not to mention the cost and time involved in mass biochemical and genetic testing.  Even 
if it is viable in affluent parts of the industrialised world, it may be unethical to broaden the 
gap between the rich and poor in terms of healthcare. At this moment, it is feasible to 
consider using genomic data to avoid prescribing certain drugs to people that may be 
predisposed to an adverse drug reaction. Whether pharmacogenetic information will be used 
in such a way is still to be seen.  Experiments described in this thesis attempt to elucidate the 
basic biochemistry behind the metabolism of anti-tubercular drugs by polymorphic variants 
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exhibited by these drugs in so many TB patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  791.6 AIMS 
The aims of this investigation were as follows. 
•  To establish whether TAZ and ETA were substrates for human FMO2.1 and  to 
identify the products of this reaction.  To compare the products of TAZ oxidation by 
human FMO2.1 to those generated by EtaA-, FMO1- and FMO3- catalysed reactions.  
To determine the kinetic parameters of the reaction of human FMO2.1 and TAZ 
through the development of a spectroscopic assay. To compare the kinetic constants 
obtained for  FMO2.1 to those of human FMO1, FMO3 and EtaA. 
•  To determine the catalytic consequences of human FMO3 variation, particularly 
focussing on polymorphisms that increase or abolish catalytic activity and those that 
are prevalent in Africa.   Kinetic performance of FMO3 variants was assessed using 
an established enzyme assay for a typical FMO substrate and the novel spectroscopic 
assay for TAZ. 
•  To attempt to understand the relative contribution of FMOs and CYPs to TAZ 
metabolism in vitro by using microsomal samples isolated from mouse lung and liver.   
Microsomes isolated from wild type and FMO knockout mouse lines were employed 
to determine the role of individual FMO isoforms to TAZ metabolism.   
•  To attempt to gain an understanding of the in vivo metabolism and disposition of TAZ 
by FMOs using a mouse model.     
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Chapter 2: Materials and Methods 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                                      
2.1 Chemicals 
 
  81All chemicals, except tissue culture material, where purchased from Sigma-Aldrich (St. 
and, CA, USA) and were of cell culture grade.  Plastic ware for cell culture 
PLC 
C 
.2.1 Spodoptera frugiperda, (Sf9) Cells 
•  SF-900 Serum-Free Media (Media/SFM) (Invitrogen): Stored at 4˚C in the dark. 
tored at 4˚C.  
l Bovine Serum (FBS), (Invitrogen): Stored at -20˚C and thawed on ice before 
ese stocks contained 10% Fetal Bovine Serum (FBS) (Invitrogen). Maintaining 
ells in serum has been reported to make cell cultures prone to contamination and also results 
Louis, MO, USA) unless stated otherwise.  Tissue culture materials were purchased from 
vitrogen (Carlsb In
was purchased from VWR International (West Chester, PA, USA).  Materials used for H
and LC-MS were purchased from Fisher Scientific (Hampton, NH, USA) and were of HPL
grade. 
 
2.2 Cell Culture Conditions 
 
2
Solutions: 
•  Gentamicin, tissue culture grade: S
•  Feta
use. 
 
Frozen stocks of Sf9 cells were previously prepared in the laboratory and stored in liquid 
nitrogen.  Th
c
in higher costs.   The cells were therefore adapted to grow in serum-free conditions.  Cells 
were also adapted to grow in suspension cultures as higher levels of protein expression can be 
achieved in this way.  A frozen Sf9 cell aliquot was removed from liquid nitrogen and rapidly 
thawed by rubbing the tube repeatedly between two hands.  As soon as the cells started to 
thaw the contents of the tube were poured into a T25 attachment flask (Nunc™ VWR, UK) 
containing 5mL of pre-warmed SF-900 serum-free media and 10 µg/mL gentamicin.  The 
  82cells were allowed to attach to the surface of the flask in a nonhumified incubator (Innova™ 
4230, New Brunswick Scientific, USA) at 27˚C and were inspected after 1 hour.  After 1 
hour the cells had attached to the surface, this was observed by viewing the flask under a light 
microscope and gently moving the flask from side to side.   Cells which have attached remain 
stationary whereas unattached cells ‘float’ in the medium.  The cells were incubated at 27˚C 
until they reached confluence.  This took approximately 48 hours.  At this point the cells were 
seeded.  To seed the cells, medium from the flask was removed and replaced with 5mL of 
fresh media containing gentamicin.  The flask was then firmly hit against the palm of the 
hand three times to dislodge cells from the surface. 2.5 mL of culture was transferred into a 
new T25 flask containing 2.5 mL of media, gentamicin and 10% FBS.  This culture was 
maintained in serum and was used as a ‘stock’ while cells where adapted to suspension 
cultures. The remainder 2.5 mL of the original culture was transferred into a 125 mL shaking 
flask (sterile, disposable Erlenmeyer flask (VWR Intl.), containing 23 mL of SF-900 serum-
free media and 10 µg/mL gentamicin.  To start off, cells were shaken at 110 rpm.  Cells were 
counted every 24 hours to assess cell viability at the rotational speed.  If cell death was 
apparent then the speed of shaking was reduced by 5 rpm until cells reached a mid-log phase 
(2x10
6 cells/mL).  It was found that at this initial stage, slower rates of shaking (<110 rpm) 
led to cell death, as did a rate over 115 rpm.  If these cell batches reached cell densities of 
2x10
6 cell/mL, they were re-seeded to a density of 8x10
5cell/mL and shaken at 115 rpm.  Cell 
batches were monitored in this way until they had adapted to grow at 125 rpm.  This speed is 
the optimum speed given in the supplier’s instructions (Invitrogen).  The cells took a total of 
5 weeks to adapt to the new conditions. 
       
Sf9 cells adapted to serum-free and suspension cultures were maintained in SF-900 serum-
free media containing 10 µg/mL gentamicin in suspension cultures.    Cells were seeded at a 
  83density of 2x10
6  to 5x10
5 cell/mL every 2-3 days in 25 mL or 50 mL suspension cultures in 
•  Dulbecco’s Phosphate - Buffered Saline (D-PBS) 
ain 
L of D-PBS, 100 µL of Trypan blue 
 a 1.5mL microfuge tube.  100µL of this sample was 
en mounted onto a hemocytometer (VWR, Intl.) and viewed under a light microscope.  
) = (Final cell density / No. of viable cells x10
6) X Final Volume 
 a batch has <98% viability it is not used for transfection or infection with baculovirus.   
were counted every 2-3 days.   
sterile 125 mL or 250 mL Erlenmeyer flasks respectively. Cultures were grown in a 
nonhumified incubator at 27ºC and at 125 rpm shaking.    
 
2.2.2 Cell Counting and Seeding 
Solutions:  
•  0.4%  (w/v) Trypan Blue St
 
To count the cells, a 1 in 10 dilution was prepared.  900 µ
stain and 100 µL of cells were mixed in
th
Cells within the grid of the cytometer were counted.  In the presence of the stain, viable cells 
appear round and have a bright silver–white outline.  Dead cells appear blue and usually have 
lost their characteristic round shape.  Only viable cells (i.e. white and round) are counted.  In 
this way, the stain allows one to assess the viability of cell cultures.  Using equation 1, the 
volume of cells required for seeding is calculated and cultures made up to the final volume 
(25 mL or 50 mL) with SFM containing gentamicin.  Media was incubated at 27˚C for 30 
minutes before use. 
 
Equation 1: 
Volume of cells (mL
If
Cell batches 
 
  842.2.3 Culture of Bacteria 
Solutions 
•  Luria-Bertani Agar medium (LB – Agar) (Q-Biogene Inc., USA). Formulation/L: 10g 
t Extract B, 10g NaCl, 15g Agar-B.  Tablets were dissolved in 
ed water and autoclaved.   
lution was prepared by weighing out the appropriate 
 
ghing out the appropriate 
te 
.   The solution was allowed to cool until it could be held by the hand comfortably 
ut not long enough for the agar to set.  At this point the appropriate antibiotics were added 
Tryptone – B, 5g Yeas
deionis
•  Luria-Bertani Medium (formulation/L: 10g bactotryptone, 5g yeast extract, 5 g NaCl).  
Forty tablets were dissolved in 1 L of deionised water and autoclaved. 
•  Ampicillin: A 50 mg/mL stock so
amount of solid ampicillin and dissolving it in deionised water. 
•  Tetracycline: A 50 mg/mL stock solution was prepared by weighing out the appropriate
amount of solid tetracycline and dissolving it in ethanol. Aliquots were stored at -20˚C. 
•  Gentamicin: A 10 mg/mL stock solution was prepared by wei
amount of solid gentamicin and dissolving it in water. Aliquots were stored at -20˚C. 
•  Kanamycin: A 50 mg/mL stock solution was prepared by weighing out the appropria
amount of solid kanamycin and dissolving it in water.  Solution aliquots were stored at -
20˚C. 
 
Forty tablets of LB-Agar were dissolved in 1 litre of deionised water and autoclaved on the 
day of use
b
and the solution gently swirled by the wrist.  Approximately 30 mL of medium was poured 
into 82 mm Petri dishes or till they were half full.   
The agar was allowed to set at room temperature.  The plates were briefly kept at 37˚C and 
then stored at 4˚C.   
  85Bacteria was streaked on to plates and incubated at 37˚C overnight.  The following 
day, a singly colony was picked and inoculated into 5mL of LB-medium containing the 
approp
irus Expression system (Invitrogen) 
 expression of a 
ene in insect cells by producing recombinant baculovirus.  The system provides a faster 
riate antibiotics.  Cultures were grown for 6-8 hours or overnight with shaking at a 
rotational speed of 250 rpm.   
 
2.3 Bac-to-Bac®  Baculov
 
The Bac-to-Bac® Baculovirus Expression system (Invitrogen) allows high
g
route to recombinant protein expression compared to traditional baculovirus methods as a 
homologous recombination event takes place in E.coli rather than in insect cell.  The system 
uses a pFastBac™ plasmid which encodes an insect cell- specific promoter (i.e. a polyhedrin 
promoter) for high expression in insect cells.  The main features of the plasmid include 
multiple cloning sites to facilitate cloning and an SV40 poly-A sequence to promote 
transcription termination and polyadenalation of the mRNA transcript in insect cells.  The 
plasmid also contains sites to which the bacterial Tn7 transposon (provided by a helper 
plasmid) can attach and allow transposition in bacmid DNA (a baculovirus vector).   The 
presence of a gentamicin resistance gene in pFastBac™ allows for the selection of 
recombinant  E.coli DH10Bac™ cells (these cells provide the bacmid DNA).  Upon 
transformation of competent E.coli DH10Bac™ cells with pFastBac™, a homologous 
recombination event takes place between the mini-T7 element from the pFastBac™ plasmid 
and the mini–attTn7 site in the bacmid.   Successful transposition results in the disruption of 
the lacZα  gene in the bacmid, so E.coli  colonies containing recombinant bacmid appear 
white and non-recombinants appear blue when grown in the presence of a gratuitous inducer 
(Isopropyl-β-D-thiogalactopyranoside) and a chromogenic substrate (i.e. X-Gal).   
  86Recombinant bacmid is used to transfect insect cells which will produce budding virus 
(baculovirus) harbouring the gene of interest.  This virus is used to infect insect cells which 
will express the recombinant protein.  A schematic diagram outlining the main steps is shown 
in Figure 2.1. 
 
2.3.1 Generation of Recombinant Bacmid DNA 
uman FMO1 cDNA was previously cloned into pFastBac™ 1 and maintained in E.coli 
 containing human FMO1 cDNA was 
mid DNA 
olutions: 
iniprep Kit (Qiagen, Hilden, 
seA 
tralisation Buffer 
H
DH5α™ glycerol stocks.  Recombinant bacmid
prepared from this stage as follows. 
 
2.3.1.1 Small Scale Isolation of plas
S
The following solutions were obtained from the QIAprep m
Germany): 
•  P1 – Re-suspension Buffer : 50mM Tris-Cl (pH 8), 10mM EDTA, 100 µg/mL 
RNa
•  P2 – Lysis Buffer: 200 mM NaOH, 1% (w/v) SDS 
•  N3 – Neu
•  PE -  Wash Buffer 
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Figure 2.1: Generation of recombinant baculovirus using the Bac-to-Bac 
expression system.  Taken from Bac-to-Bac®  Baculovirus Expression System 
User’s Manual
  88LB-agar plates were prepared containing ampicillin at a final concentration of 50 
µg/mL as described in section 2.2.3. Glycerol stocks previously prepared in the 
laboratory had been stored at -80˚C and it is important that during their use the 
glycerol sample does not thaw as the bacteria will die as a result of the rapid 
temperature change.    An agar plate was streaked with bacteria from the glycerol 
stock and incubated at 37˚C overnight.  The glycerol stock sample was returned to -
80˚C before it had thawed.  The following day, a single colony was picked and used 
to inoculate 5 mL of LB-medium containing ampicillin at a final concentration of 50 
µg/mL.  The culture was grown for 6-8 hours as described in section 2.2.3. 
Plasmid DNA was isolated from the bacterial culture using the QIAprep 
Miniprep Kit (QIAGEN) and was performed as described in the QIAprep Miniprep 
Kit handbook.  Briefly, 1.5 mL of bacterial culture in mid-log phase was transferred 
into a 1.5 mL microfuge tube and centrifuged for 5 minutes at 13, 000g at 4˚C using a 
bench top microcentrifuge (Eppendorf).  The following steps were carried out at room 
temperature.  The bacterial pellet was re-suspended in 250 µL Buffer P1 by pipetting 
up and down until no clumps were visible.  250 µL of Buffer P2 was added to the 
tube.  The solution was mixed by inverting the tube several times and until the 
solution had turned a homogenous blue.  350 µL Buffer N3 was added drop wise and 
mixed thoroughly by inverting the tube several times to avoid localised precipitation.  
This was done until the solution had turned white.  The sample was centrifuged at 
13,000g for 10 min.  The supernatant from this stage was applied to the QIAprep spin 
column using a pipette (and avoiding the pellet) and centrifuged (30 s).  The flow 
through was discarded.   The column was washed again using 0.75 mL of Buffer PE 
by centrifuging for 30 s and discarding the flow through.   The column was 
centrifuged again for 1 min at high speed to remove any residue of Buffer PE.  The 
  89QIAprep column was placed in a fresh 1.5 mL microfuge tube and 50µL of sterile 
deionised water added to the centre of the column.  The column was allowed to stand 
for 1 min and plasmid eluted by centrifugation for 1 min at high speed.  Isolated 
plasmid DNA was stored at 4˚C until further use. 
 
2.3.1.2 Quantification of Isolated plasmid DNA 
Plasmid DNA was quantified using a Nanodrop Spectrophotometer 1000 (Nanodrop).  
1µL of deionised water was applied to the platform to calibrate the machine and to 
make a ‘blank’ measurement.  The platform was wiped clean and 1µL of isolated 
plasmid DNA sample was applied to the platform.  The absorbance of the samples 
was measured at 260 nm.        
Presence of the plasmid was confirmed by running the DNA sample on a 1% 
(w/v) agarose gel. 
 
2.3.1.3 Agarose Gel Electrophoresis of DNA 
Solutions 
•  10X Tris-Borate-EDTA Buffer (TBE): 0.89 M Tris-base, 0.09 M Boric acid, 
20 mM EDTA (pH 8) 
•  6X loading buffer: 0.25% bromophenol blue, 0.25% xylene cyanol, 30% (v/v) 
glycerol. 
•  Ethidium Bromide (EtBr): 10 mg/mL stock solution (Fisher Scientific, UK) 
 
For a 1% (w/v) agarose gel, 1g of agarose was dissolved in 100 mL of 1X TBE by 
heating the solution in a microwave oven for 2 min or until the solution was clear.  
2µL of Ethidium bromide was added to the solution once it had cooled but before the 
  90agarose had started to set.  The agarose was poured into a gel mould and an 
appropriate comb was positioned into place.  The gel was allowed to set for at least 1 
hour. Once the gel had set, the gel mould was positioned into an electrophoresis tank 
and submerged in 1xTBE. The comb was removed and 10µL of HyperLadder 1 
(Bioline Ltd, UK) was loaded into a well as a molecular weight marker.  Sample DNA 
was mixed with 1X loading dye and loaded into the wells.  The gel was run at 100 
volts to separate the DNA.  After electrophoresis the gel was viewed and 
photographed using a UV transilluminator (Syngene, GeneSnap). 
 
2.3.1.4 Transformation of Competent E.coli DH10Bac™ and the Blue-White 
Assay 
 Solutions 
•  1M Isopropyl-β-D-thiogalactopyranoside (IPTG) (Invitrogen): prepared fresh on 
the day in water and filter-sterilised. 
•  2% (w/v) 5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside (X-Gal) prepared 
fresh on the day in dimethyl sulfoxide (DMSO) and stored in the dark.  
•  SOC Medium provided with MAX Efficiency® DH10Bac™ competent cells 
(Invitrogen) 
 
A 50 µL aliquot of competent MAX Efficiency® DH10Bac™ cells (Invitrogen) was 
removed from -80ºC and thawed on ice.  The cells were transformed with 100 ng of 
plasmid by heat shock treatment for 45 s using a water bath set at 42˚C. 900µL of 
SOC medium was added to the transformed cells and incubated at 37˚C for four hours 
in a shaking water bath. During this time, agar plates containing gentamicin, 
tetracycline and kanamicin at a final concentration of 7 µg/mL, 10 µg/mL and 50 
  91µg/mL respectively were prepared as described in section 2.2.3. 50 µL X-Gal 
(0.02µg) and 10µL IPTG (10µmol) were spread on to these plates and allowed to dry.  
Serial dilutions of the transformed cell culture were prepared (10
-1, 10
-2, 10
-3 10
-4) and 
spread onto the agar plates and incubated for 24 hours at 37˚C.  The following day the 
plates where transferred to 4˚C for a further 24 hours to enhance the colour of the blue 
colonies.  Three white colonies and one blue colony were picked and inoculated into 5 
mL of LB medium containing 7 µg/mL gentamicin, 10 µg/mL tetracycline and 50 
µg/mL kanamycin as described in section 2.2.3.  Bacmid DNA was isolated from 
these cultures.    
 
2.3.1.5 Isolation of recombinant Bacmid DNA 
Solutions: 
•  Propan-2-ol 
•  Ethanol (70%, (v/v)) 
The following solutions were provided with the QIAprep miniprep Kit (Qiagen): 
•  P1 – Re-suspension Buffer : 50 mM Tris–Cl (pH 8) , 10 mM EDTA, 100 
µg/mL RNase A. 
•  P2 – Lysis Buffer: 200 mM NaOH, (1%) SDS. 
•  P3 – Neutralisation Buffer: 3M potassium acetate (pH 8). 
 
Human FMO2.1 and FMO3 
E.coli DH10Bac™ cells containing recombinant bacmid were previously prepared in 
the laboratory and maintained in glycerol stocks.   E.coli DH10Bac™ cells containing 
either human FMO2.1 or FMO3 cDNA were streaked on to agar plates containing 7 
µg/mL gentamicin, 10 µg/mL tetracycline and 50 µg/mL kanamicin and incubated at 
  9237ºC overnight as described in section 2.2.3.  A single colony was used to inoculate 5 
mL of LB medium containing 7 µg/mL gentamicin, 10 µg/mL tetracycline and 50 
µg/mL kanamycin overnight at 37ºC with shaking.     The following day, recombinant 
bacmid was isolated.   
 
Human FMO1, FMO2.1 and FMO3 
Bacmid DNA was isolated using the method of alkaline lysis as described by 
(Janmohamed et al. 2006).  Briefly,  1.5 mL of bacterial culture growing in mid-log 
phase in the presence of antibiotics was transferred into a 1.5 mL microfuge tube and 
centrifuged at 14,000g for 10 min at 4ºC in a bench top microcentrifuge (Eppendorf, 
Germany).  The pellet was re-suspended in 300µL Buffer P1 by pipetting up and 
down.  300µL of Buffer P2 was added to the tube and mixed by inverting the tube.  
The mixture was allowed to stand at room temperature for 5 minutes.  Buffer P3 was 
slowly added to the tube, mixed gently and centrifuged at 14, 000g for 10 min at room 
temperature.  The supernatant was transferred into a 2mL microfuge tube and 800µL 
of propan-2-ol was added.  The tube was inverted several times and placed on ice for 
10 min, then centrifuged at 14, 000g at room temperature.  The supernatant was 
removed and 500µL of 70% (v/v) ethanol was added to the pellet.  The tube was 
inverted several times to wash the pellet and centrifuged at 14, 000g for 15 min at 
room temperature.  The supernatant was removed, initially by decanting the liquid and 
then using a glass Pasteur pipette to remove all the ethanol, which can reduce 
transfection efficiency.  The pellet was air dried for 10 min.  The DNA was dissolved 
in 50µL of sterile deionised water.   The tube was gently tapped to dissolve the DNA - 
vortexing at this stage would cause the DNA to shear.  Bacmid DNA was stored at -
20ºC. 
  932.3.1.6 Polymerase Chain Reaction (PCR) (Standard)  
All standard PCR reactions were carried out using a Genius PCR machine (Techne 
Ltd., UK).   
Solutions 
•  BIO-X-ACT™ Short DNA Polymerase (4U/ μL) (Bioline Ltd, UK) 
•  OptiBuffer™ (10x Reaction buffer): 10 mM Tris-Cl (pH8.3), 15 mM MgCl2 , 
500 mM KCl (Bioline Ltd, UK) 
•  dNTP mix (10 mM) (Bioline Ltd, UK) 
•  50 mM Magnesium Chloride (Bioline Ltd, UK) 
•  Forward and Reverse Primers 
 
PCR consisted of; 10 ng template DNA, 0.2 mM dNTP mix, 1.5 mM MgCl2 and 0.5 
μM reverse and forward primers.  The reaction volume was made up to 50 µL with 
sterile water.  Four units of BIO-X-ACT™ Short DNA Polymerase were added to the 
reaction.  Amplification parameters are shown in Figure 2A for BIO-X-ACT™ 
polymerase catalysed PCR.  The annealing temperature depends on the melting 
temperature (Tm) of the primers which are to be used.  The Tm and annealing 
temperature were calculated using formulae given in Figure 2B.  Primer sequences 
have been given in Table 1 of Appendix 1.  PCR products were electrophoresed on a 
1% (w/v) agarose gel and viewed as described in section 2.3.1.3.   
 
 
 
 
 
  94 (A) 
PCR Conditions 
Initial Denaturation    95 ˚C    2 min             1 Cycle 
Denaturation      95  ˚C   30  sec 
Annealing      55  ˚C                30 sec            40 Cycles 
Extension      72  ˚C   30  sec 
Final Extension    72 ˚C           5 min             1 Cycle     
 
 
(B) 
 
 
Tm = 69.3 + (0.41 x (%G+C)) – 650/length (nt) 
 
Tm1 + Tm2 
            2  -6  Annealing temperature = 
 
 
Figure 2.2: (A) General PCR programme for BIO-X-ACT™.   (B) Formulae for 
determining the Tm and annealing temperatures.   
 
 
 
 
 
 
 
 
 
 
 
 
  95Human FMO1 
A PCR was carried out to confirm the presence of human FMO1 cDNA insert in the 
recombinant bacmid DNA using M13 forward and reverse primers as described 
above.  M13 sequences are present in the regions flanking the site of pFastBac™ 1  
transposition (i.e. the cDNA insert site) in the bacmid. 
 
2.3.1.7 Preparation of Glycerol Stocks 
Solution: 
•  Glycerol. 
 
For long term storage of E.coli transformed with recombinant bacmid DNA, glycerol 
stocks were prepared.  1mL of bacterial culture (grown overnight at 37˚C with 
shaking) was mixed with 100 µL of glycerol in a 1.5 mL microfuge tube.  The 
contents were inverted several times to mix the solutions thoroughly and immediately 
stored at -80˚C.  
     
2.4 Generation of Recombinant Baculovirus 
Solutions: 
•  SF-900 Serum-Free Media (SFM / media) 
•  Tissue culture grade gentamicin 
•  CELLFECTIN® Reagent   
 
Transfection was carried out essentially as described by (Janmohamed et al. 2006).  
Briefly, Sf9 cells in mid-log phase (2x10
6 cell/mL) were seeded at a density of 9x10
5 
cell/mL in 2 mL of media containing gentamicin into a 35-mm dish.  It is important 
  96that cell cultures with a viability of >98% are used for this stage; otherwise 
transfection efficiency is reduced.  The cells were allowed to attach to the dish by 
incubating the dish at 27ºC for 1 hour.  During this time the transfection mixture was 
prepared which consists of solution A and B.  Solution A: 5µL of miniprep bacmid 
DNA and 100 µL SFM without gentamicin.  Solution B: 6µL CELLFECTIN® 
Reagent (Invitrogen) and 100 µL SFM without gentamicin.  The CELLFECTIN® 
reagent tube was inverted several times before use as lipids can settle to the bottom of 
the tube.  Solutions A and B were combined and incubated for 30 min at room 
temperature.  Media was removed from the attached cells by gently tilting the dish to 
one side and pipetting the media away from the dish without touching the surface.  
The cells were washed once in the same way with media without gentamicin.  Media 
(788 µL) without gentamicin was added to the mix of solution A and B to give a final 
volume of 1mL.  This transfection mixture was gently pipetted over the attached cells.  
The dish was placed on a bed of tissues dampened with sterile water in an airtight 
container.  This humidified container was incubated at 27ºC for 5 h.  The transfection 
mixture was then removed and replaced with 2 mL of media containing gentamicin.  
The cells were incubated for a further 72 h at 27ºC in a fresh humidified box.    The 
virus (in the supernatant) was harvested by transferring the medium in the dish into a 
tube (Falcon) and centrifuged at 100g for 10 min at 4ºC.  The virus is present in the 
supernatant and was filter-sterilised using a 0.22 micron filter into a fresh tube.  The 
virus was stored at 4ºC in the dark.   
           
2.4.1 Amplification of Baculovirus 
Virus harvested from the transfection stage is of low titre and needs to be amplified. 
Virus was amplified as described by (Janmohamed et al. 2006).    50µL of the 
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density of 2x10
6 cell/mL.  Cells were infected for 72 hours at 27ºC in shaking.  The 
cell culture was then transferred into a sterile tube (Falcon) and centrifuged for 10 min 
at 4000 rpm at 4ºC.  The supernatant represents the amplified high titre virus.  The 
supernatant was filter-sterilised into a fresh tube and stored at 4˚C in the dark.   Insect 
cell microsomes were prepared from the cell pellet and analysed for FMO expression.   
 
2.5 Expression & Analysis of Recombinant Protein in Sf9 Cells    
 
2.5.1 Baculovirus Infection of Sf9 cells 
The amount of virus required for optimum FMO expression was investigated using a 
range of volumes of amplified virus.  To begin with, 100, 250 and 500µL of virus 
were used to infect 50 mL of insect cell cultures which were at a cell density of 2x10
6 
cell/mL for 72 or 96 hours.  Expression and catalytic activity was then analysed from 
microsomes prepared from these cells using western blotting and the methimazole 
assay. 
 
2.5.2 Insect cell Microsome Preparation 
Solution: 
•  HEPES Buffer: 10 mM HEPES (Sodium salt) (pH 7.4), 0.154 M KCl, 0.1 mM 
EDTA (pH 8), 20% (v/v) glycerol.  
   
Microsomes were prepared as described by (Janmohamed et al. 2006) with slight 
modification. Sf9 cells were transferred into a tube (50 mL Falcon) and centrifuged at 
4000 rpm for 10 min at 4ºC (Eppendorf, Rotor 5810 R).  The cell pellet was re-
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by pipetting up and down.  The cells were lysed by sonification; three 12 s bursts with 
5 s pauses in between each burst were found to cause sufficient cell lysis and 
minimum protein degradation.  Cells were placed on ice during the sonification 
process.  The homogenate was centrifuged at 1000g for 10 min at 4ºC.  The 
supernatant obtained from the previous step was transferred into pre-chilled 
ultracentrifuge tubes and centrifuged at 50,000 rpm for 1 h at 4ºC in a Beckman 
Coulter Optima Max Ultracentrifuge (Fullerton, CA, USA) (rotor TLA-110K). The 
pellet was re-suspended in chilled HEPES buffer using a glass hand held homogeniser 
on ice to give a total protein concentration of around 5 µg/µL and the total protein 
concentration was determined by the assay of Lowry (see next section). The 
microsomes were aliquoted into 500µL samples in 1.5mL microfuge tubes to avoid 
freeze-thawing large volumes as this leads to loss of activity.  Samples were 
immediately stored at -80ºC. 
 
2.5.3 Determination of Total Protein Concentration 
Protein concentration was determined by the assay of Lowry (Lowry et al. 1951) 
using the Bio-Rad  DC
 Protein Assay Kit (Bio-Rad Laboratories, Inc., Hercules, CA, 
USA).
 
Solutions: 
•  Bovine Serum Albumin (BSA) (Bio-Rad) :  Pre-weighed BSA was dissolved 
in  20 mL of sterile deionised water and gave a total concentration of 1.47 
mg/mL  
The following solutions were obtained from Bio-Rad DC Protein Assay Kit 
•  Reagent A 
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The assay was carried out as described in the Bio-Rad Protein Assay Kit hand book 
with slight modification.  Briefly, 6 BSA standard concentrations ranging from 0 – 
147 mg/mL were prepared in HEPES buffer.  2µL and 5µL of experimental protein 
sample were dissolved in HEPES buffer to give a final volume of 100µL.  Each assay 
was carried out in duplicate. 0.5 mL of Solution A was added to each standard and 
sample tube.  These were mixed by vortexing and 4 mL of solution B was then added 
to each tube and the samples mixed immediately (by vortexing).  The tubes were 
allowed to stand for 20 min.  1 mL of each standard and sample were transferred into 
plastic cuvettes and their absorbance was measured at 595 nm using a GeneQuant 
spectrophotometer.  The spectrophotometer deduced the protein concentration of 
standards and sample and this was recorded.   
     
2.5.4 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-
PAGE) Analysis 
Solutions: 
•  Protogel Solution: 30% (w/v) acrylamide, 0.8% (w/v) bisacrylamide (National 
Diagnostics). 
•  10% (w/v) Ammonium persulfate (APS): The appropriate amount of solid 
APS was weighed out and dissolved in deionised water on the day of use. 
•  Resolving buffer: 1.5 M Tris-HCl (pH 8.4), 0.4% (w/v) SDS.  pH adjusted 
with HCl. 
•  Stacking buffer: 0.5 M Tris-HCl (pH 6.8), 0.4% (w/v) SDS. pH adjusted with 
HCl. 
•  TEMED (Bio-Rad). 
  100•  NuPAGE LDS Loading Dye (Invitrogen). 
•  SDS Running Buffer: 0.025 M Tris-base, 0.192 M Glycine, 01% (w/v) SDS 
prepared on the day of use. 
•  β-Mercaptoethanol. 
•  Coomassie Blue Stain: 0.1% (w/v) Coomassie Brilliant Blue Dye, 40% (v/v) 
methanol, 10% Acetic acid.  The solution was filtered through 3MM 
Whatmann paper before use and stored at room temperature. 
•  Destain: 30% (v/v) methanol, 10% (v/v) acetic acid, 60% (v/v) deionised 
water. 
 
25 mL of a 10% resolving gel was prepared with the following materials; 8.33 mL 
Protogel, 6.25 mL resolving buffer, 0.25 mL APS and 10.14 mL deionised water.  
This solution was mixed thoroughly and the gel running mould was set up and 
tested for leaks using water.  Only then was 25 µL of TEMED added to the 
solution, which was mixed and immediately pipetted into the gel mould.  The 
solution was overlaid with propan-2-ol to ensure a flat surface.  The resolving gel 
was allowed to set for at least 2 hours.  10 mL of a 3% stacking gel was prepared 
with the following materials; 1 mL Protogel, 2.5 mL stacking buffer, 100 µL APS 
and 6.40 mL of deionised water.  Once the resolving gel had set, the propan-2-ol 
was washed away by tilting the gel mould slightly to one side.  Water was used to 
wash out any residual propan-2-ol.  10 µL of TEMED was then added to the 
stacking gel mixture and immediately pipetted into the gel mould over the 
resolving gel.  A comb of an appropriate size was positioned to place immediately 
and the gel was allowed to set for at least one hour.  Protein samples were mixed 
with up to 4µL of NuPAGE loading dye and were boiled for 5 min at 95˚C.   
  101β-Mercaptoethanol was added to the sample to give a final concentration of 20% 
(v/v) and samples were centrifuged for 1 min . The gel mould was placed into the 
electrophoresis tank and SDS-running buffer was poured over this so that the 
electrodes were submersed in buffer.  The comb was then removed.  20µL of 
molecular weight marker (See-Blue 2, Invitrogen) was loaded into the well and so 
were the samples.  The gel was electrophoresed with SDS-Running buffer at 25 
mA until proteins had stacked upon the resolving gel and then run at 35 mA till 
the samples had resolved – i.e. till the bands had travelled to the bottom of the 
resolving gel.  The gel was immersed in Coomassie staining solution for at least 
24 hours.  The stain was removed by replacing the staining solution with destain.  
Fresh destain solution was applied until protein bands were clearly visible.  Using 
the geneSNAP tool, the gel was photographed (Syngene).   
 
2.5.5 Western Blot Analysis 
Solutions: 
•  Transfer/Blotting Buffer: 192 mM Glycine, 25 mM Tris, 20% (v/v) methanol.  
The transfer/blotting buffer was prepared fresh. 
•  5X TBS: 100 mM Tris-Cl (pH 7.5), 2.5 M NaCl.  The pH was adjusted with 
HCl. 
•  1X TTBS: 1X TBS, 0.1% (v/v) Tween 20.  A 100 µL of Tween 20 was used 
for every 100mL of 1x TBS. 
•  I-Block Solution: 0.2% (w/v) I-Block (TROPIX Inc., USA) in 100mL 1X 
TBS.  The solution was heated in a microwave oven to melt the solid.  The 
solution was cooled to room temperature before 100µL of Tween 20 was 
added.   
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dilution made up in I-Block solution and were stored at -20˚C.  Primary 
antibody solution used to detect human FMO1, FMO2.1 and FMO3 were goat 
anti-(rabbit FMO1), goat anti-(rabbit FMO2) or goat anti-(rabbit FMO3) 
serum respectively.  Primary antibodies were a kind gift from Dr. R. Philpot.    
•  Secondary Antibody Solution: anti-goat IgG (whole molecule) antibody- 
Alkaline Phosphatase conjugate (Sigma-Aldrich) was used as a 1 in 30, 000 
dilution and dissolved in I-Block solution.  This was prepared on the day of 
use. 
 
The following solutions were obtained with the AP Conjugate Kit (Bio-Rad) 
•  25X Alkaline Phosphatase (AP) Colour Development Solution.  This 
solution is stored at 4˚C. 
•  Reagent A: stored at -20˚C. 
•  Reagent B: stored at -20˚C. 
 
2.5.6.1 Protein Transfer 
Proteins from SDS-PAGE gels were transferred onto a supported nitrocellulose 
0.45µM membrane (BDH) using a TRANS-BLOT Cell (Bio-Rad).    Once protein 
samples had been electrophoresed, the gel mould was dissembled and the approximate 
size (length and width) of the gel was estimated. 4 sheets of 3MM Whatman filter 
paper and 1 sheet of blotting membrane were cut to size. Filter papers and blotting 
pads were soaked in transfer buffer before use. The gel was ‘sandwiched’ between 
filter paper and blotting membrane as shown in Figure 3.  It is important not to move 
the gel once it has come in contact with the membrane, as transfer of protein may 
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running a pipette gently over the gel.  The ‘sandwich’ was placed within a blotting 
cassette and loaded into the transfer cell. The cell was filled with transfer buffer and 
run overnight at 100 mA.  The next day the voltage was turned up to 200 mA for 2 
hours.  
    
Blotting Membrane 
Blotting Pad 
Gel 
Filter Paper 
Filter Paper 
Blotting Pad 
Figure 2.3: ‘Sandwich’ arrangement of the gel during transfer 
 
2.5.6.2 Antigen Detection 
Antigen detection was carried out by a series of incubations and washes as described 
below.  All incubations were carried out at room temperature and on shaking. Blotting 
membrane was washed in I-Block Solution for 1 h and the solution was discarded 
after use.  Primary antibody solution was poured over the membrane and incubated 
for 1 h, this solution can be re-used.  The membrane was washed for 5 min with 1X 
TTBS, three times. The solution was discarded.  A 1 h incubation with secondary 
antibody solution was carried out and the solution was discarded. The membrane was 
washed three times in 1X TTBS for 5 min and once in 1x TBS.  The solution was 
discarded. 
 
2.5.6.3 Development of Western Blot 
An Alkaline Phosphatase Conjugate Kit (Bio-Rad) detection method was used to 
detect the presence of antigen.  1X AP Colour Development solution was prepared 
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were used for every 100 mL of 1X AP solution.  This mixture was poured over the 
membrane and observed for the appearance bands.  As soon as bands started to 
develop the reaction was quenched by replacing the colour detection mixture with 
deionised water – this will prohibit the blotting membrane to overdevelop.   The blot 
was scanned (Epson Scanner, Epson, Naguna, Japan).               
 
2.6 Quantification of Recombinant FMO in Insect Cell Microsomes 
 
2.6.1 Quantitative Western Blotting 
Various amounts of authentic rabbit FMO1, FMO2 or human FMO3 of known 
amounts were loaded along side Sf 9 insect cell membranes containing heterologously 
expressed FMO of unknown concentrations as described in section 2.5.6.  SDS-PAGE 
was performed as described in section 2.5.4 and a Western blot was performed on 
these gels as described in section 2.5.5.  The developed Western blot was scanned at a 
resolution of 1200 dpi and the image was saved in TIFF format.  The amount of FMO 
in the recombinant insect membranes was quantified by scanning densitometry using 
Image Gauge software, version 4.2.1 (Science Lab, FujiFilm, Tokyo, Japan) and by 
comparison with a standard curve of standard FMO vs band intensity.     Values 
determined for FMO quantity were obtained from samples tested in quadruplicate 
from two independent Western blots.  As authentic standards of FMO1 and FMO2 
were from rabbit and authentic FMO3 was from human, relative abundance of FMOs 
was analysed by SDS-PAGE analysis to ensure that there was no difference in 
antigenicity.  The amount of FMO in insect cell microsomes was measured by 
comparison of intensity of Coomassie blue stained protein bands of authentic FMO.   
  1052.7 HPLC and LC-MS Analysis of FMO Catalysed Reactions  
 
2.7.1.1 Incubations with Thiacetazone (TAZ) 
Solutions: 
•  100 mM TAZ: TAZ was dissolved in dimethyl sulphoxide (DMSO)  
•  Assay buffer: 100 mM potassium phosphate buffer, pH 7.5 contained:  
•  100 U/ mL Catalase: prepared by weighing the appropriate amount of solid 
Catalase powder in the appropriate amount of sterile filtered water to give a 
working stock concentration of 40 U/mL.  The solution was stored at -20˚C 
and re-used. 
•  100 U/mL Superoxide dismutase (SOD): prepared by weighing the appropriate 
amount of solid SOD in the appropriate amount of sterile filtered water to give 
a working stock concentration of 40 U/mL. The solution was stored at -20˚C 
and re-used. 
•  0.1 mg/mL Bovine serum albumin (BSA): prepared by weighing the 
appropriate amount of solid SOD in the appropriate amount of sterile filtered 
water. The solution was stored at -20˚C and re-used. 
•  NADPH regenerating system consisting of: 2 U/mL of glucose-6-phosphate 
dehydrogenase, 1 mM NADP
+ and 2.5 mM glucose-6-phosphate.  Working 
solutions were prepared for each component in sterile filtered water and stored 
at -20˚C.  
  
Incubations of TAZ and FMO were performed as described by (Qian et al. 2006) but 
with modifications.  The assay buffer was prepared to give a reaction volume of 1 mL.  
Assay buffer was incubated at 37 ˚C for 10 min to allow the formation of NADPH 
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µM to the assay buffer and mixed.  Reactions were initiated by adding Sf9 insect cell 
microsomes containing heterologously expressed human FMO1, FMO2.1 or FMO3 
(at a final concentration of 500 nM) or purified EtaA (1 µM final concentration).  
Reactions were incubated at 37 ˚C for 90 min and quenched by addition of an equal 
volume of ice-cold acetonitrile (CH3CN).  Mixtures were centrifuged at 10,000g for 5 
min at 4 ˚C and analysed by reverse phase HPLC as described below. 
 
2.7.1.2 Incubations with Ethionamide (ETA) 
Sf9 insect cell microsomes containing heterologously expressed human FMO2.1 were 
incubated with ETA (final concentration 100 µM) for 60 min in assay buffer as 
described for TAZ.  Reactions were analysed by Liquid Chromatography- Mass 
Spectroscopy (LC MS) as described below. 
 
2.7.2 Reverse Phase HPLC analysis  
HPLC analysis was done as described previously (Qian et al. 2006).  The supernatants 
were diluted to a final concentration of 5% CH3CN and then analysed by HPLC on a 
Hewlett Packard II instrument (Hewlett-Packard Company, CA, USA) equipped with 
a photodiode array detector and a reverse-phase C18 column (Waters, 3.5 µm particle 
size, 4.6 mm i.d x 150mm, Symmetry) employing two buffers: A, H2O and 0.1% 
formic acid (FA); and B, CH3CN  and 0.1% FA.  The solvent flow rate was 0.2 
mL/min and the eluent was spectrophotometrically monitored using two bandwidths 
[330 +/- 60 nm and 260 +/- 4 nm]. The column was eluted from 0 to 25 min with a 
linear gradient from 5 to 20% buffer B. For spectral analysis of metabolites eluent 
peaks were ‘monitored’ between 200 and 500 nm. 20 µL of sample was injected.     
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Samples for LC-MS analysis were prepared as described for HPLC.  LC-MS was 
carried out as described previously (Qian et al. 2006).  Briefly, LC-MS analysis of 
TAZ metabolites was performed on a Waters Micromass ZQ coupled to a Waters 
Alliance HPLC system (Waters Corporation, MA, USA).  The system was equipped 
with a 2695 separations module, a Waters 2487 Dual λ Absorbance detector and a 
reverse phase C18 column (Waters, 3.5 µm particle size, 4.6 mm i.d x 150mm, 
Symmetry).  The reverse-phase column was eluted with a flow rate of 0.2 mL/min 
(buffer A, H2O and 0.1% FA; and buffer B, CH3CN and 0.1% FA) with the following 
protocol: 0 - 16 min, 5-30% buffer B (linear gradient).  The eluent was monitored at 
310 nm.  The eluent was monitored at 280 and 320 nm.  The mass spectrometer 
settings were as described previously (Qian et al. 2006). The mass spectrometer 
settings were as follows: mode, ES
+, capillary voltage, 3.5 kv, cone voltage, 25 v, 
desolvation temperature, 250 ˚C.  
  LC-MS analysis of ETA metabolites produced by FMO2.1 was 
performed as described above, with the following modifications.  The column was 
eluted at a flow rate of 0.2 mL/min (buffer A, H2O and 0.1% FA ; and B, CH3CN and 
0.1% FA with the following protocol: 0-15 min with 1% buffer B (isocratic).   The 
eluent was monitored at 350 nm.  
 
2.8 FMO Assays 
 
2.8.1 Methimazole Assay of FMO activity (Dixit et al. 1984) 
Methimazole oxidation by human FMOs was monitored spectrophotometrically using 
a dual beam spectrophotometer (Varian Cary 100, Varian Inc., CA, USA).  The assay 
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nitrobenzoic acid) (DTNB) initially react to form nitro-5-thiobenzoate (TNB), a 
yellow compound which absorbs light in the visible range.  In the presence of 
NADPH and molecular oxygen, FMOs catalyse the oxidation of methimazole to 
methimazole S-oxide, this will oxidise TNB to a colourless compound (Dixit et al. 
1984). The rate of colour change from yellow to colourless is monitored 
spectrophotometrically at 412 nm and is proportional to the rate of methimazole 
oxidation by FMO.    
 
Solutions: 
Assay Buffers 
•  Human FMO1 and 3: 0.1 M Tris-Cl (pH 8.4), 1 mM EDTA 
Buffer was prepared on the day of use.  The pH was adjusted to 8.4 using 
concentrated HCl.  Prior to use, the buffer was aerated for 30 min by placing 
the bottle in a shaking water bath set to 37 ˚C . 
 
•  Human FMO2.1: 0.1 M Tricine (pH 9.5), 1 mM EDTA. 
Buffer was prepared on the day of use.  The pH was adjusted to 9.5 using 5 M 
NaOH. Prior to use, the buffer was aerated for 30 min by placing the bottle in 
a shaking water bath set to 37 ˚C . 
 
Methimazole 
•  200 mM Methimazole:  Stock solution was prepared fresh by adding the 
appropriate amount of solid methimazole to the assay buffer.   
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appropriate amount of solid methimazole to the assay buffer   
 
NADPH  
•  20 mM NADPH reduced (sodium salt):  Stock solution was prepared fresh by 
adding the appropriate amount of solid NADPH to chilled assay buffer and 
stored on ice. 
•  NADPH regenerating system: 
•  2 U/mL Glucose-6-Phosphate Dehydrogenase  
•  3.0 mM Glucose-6-Phosphate   
•  0.375 mM NADP
+   
All components where prepared on the day in the appropriate assay buffer which 
was chilled before use. 
 
•  4 mM Dithiothreitol (DTT):  DTT solution was prepared fresh by adding the 
appropriate amount of solid DTT to assay buffer. 
 
•  12 mM 5, 5-Dithio-bis (2-nitrobenzoic acid) (DTNB): Prepared fresh by 
adding the appropriate amount of solid DTNB to 100% ethanol. 
 
Assay 
Reactions were carried out in a final volume of 1 mL and at 37ºC.  The final 
concentrations of DTNB and DTT were 0.06 µM and 0.02 mM respectively.    Two 
identical ‘blank’ cuvettes were prepared with the following components, 5 µL 
NADPH or 25µL of glucose-6-phosphate, 25µL of NADP+, 7.5µL of glucose-6-
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DTNB and 15-70 µL of human FMO expressing microsomes (no more than 1 mg/mL 
total protein) in assay buffer to give a total volume of 1 mL.  The contents were mixed 
by inverting the cuvettes.  Cuvettes were placed in cell 1 or cell 7 of a Varian Cary 
100 dual beam spectrophotometer and a blank measurement was taken.  Using the 
Kinetics application, the spectrophotometer was set to blank correction mode.   
Methimazole was added at the appropriate concentration to the sample cuvette and the 
equivalent volume of assay buffer was added to the reference cuvette.  The rate of 
decrease in optical density at 412 nm was monitored after one minute for 4 minutes.   
  Kinetic studies were performed on triplicate preparations of enzymes at 
concentrations of methimazole ranging from 10-2000 µM for human FMO1 and 
FMO3 and 200-6000 µM for human FMO2.1.  Steady-state parameters, Vmax, KM 
and kcat were determined as described in section 2.8.3.1. 
 
2.8.2 TAZ Oxygenation by Human FMOs and EtaA 
 
2.8.2.1 Development of a UV-Spectroscopic Assay to monitor the rate of TAZ 
oxygenation 
Solutions:  
•  Assay Buffer: 0.1 M Tris-Cl (pH 8.4). Buffer was prepared on the day of use.  
The pH was adjusted to 8.4 using concentrated HCl.  Prior to use, the buffer 
was aerated for 30 min by placing the bottle in a water bath set to 37 ˚C with 
shaking. 
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(DMSO). Serial dilutions of TAZ were prepared from the 20 mM stock and in 
DMSO. 
 
Two quartz cuvettes containing 999 µL of assay buffer were placed in cell 1 and cell 7 
of a Varian Cary 100 dual-beam spectrophotometer (Varian Inc., USA). Using the 
Varian Scan application, the spectrophotometer was set to blank correction mode.  1 
µL of TAZ (in DMSO) was added to the cuvette in cell 7 (sample cuvette) and 1 µL 
of DMSO to the cuvette in cell 1 (reference).  The final organic solvent concentration 
in each cuvette was held at 0.1% (v/v). Using the Varian Scan application, samples 
were scanned from 200 to 500 nm over a range of TAZ concentrations between 1 and 
20 µM. These measurements were done in triplicate using three independently 
prepared stock solutions of TAZ (20 mM) that were diluted accordingly in DMSO. 
The absorbance of TAZ, measured at its λmax (328 nm) was plotted against 
concentration. The molar extinction coefficient of TAZ in 0.1% DMSO was 
determined from the gradient of this graph and the Beer-Lambert equation (equation 
2).  
  
Molar Extinction Co-efficient (ε)     =        A 
                                                     ℓ.C      
         E q u a t i o n   2  
Where, 
 A = Absorbance of a given solution at a particular wavelength 
 C = concentration of the solution  
 ℓ = the distance light has to travel through a solution 
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2.8.2.2 UV-Spectrophotometric Assay to Monitor FMO-dependent TAZ 
oxidation 
Solutions:  
Assay Buffers: 
•  Human FMO1 and 3:  0.1 M Tris-Cl (pH 8.4), 1 mM EDTA. Buffer was 
prepared on the day of use.  The pH was adjusted to 8.4 using concentrated 
HCl.  The buffer was placed in a water bath set to 37 ˚C. Prior to use, the 
buffer was aerated for 30 min by placing the bottle in a shaking water bath set 
to 37 ˚C.  
•  Human FMO2 and EtaA: 0.1 M tricine (pH 9.5), 1 mM EDTA.  Buffer was 
prepared on the day of use.  The pH was adjusted to 9.5 using 5M NaOH.  The 
buffer was placed in a water bath set to 37 ˚C.  Prior to use, the buffer was 
aerated for 30 min by placing the bottle in a shaking water bath set to 37 ˚C. 
•  20 mM NADPH: prepared fresh by adding the appropriate amount of solid 
NADPH to assay buffer.  The solution was stored on ice. 
•  20 mM TAZ: solution was prepared fresh by adding the appropriate amount of 
solid TAZ to in dimethyl sulphoxide (DMSO). Serial dilutions ogf TAZ were 
prepared from the 20 mM stock solution in DMSO.  TAZ solutions were kept 
at room temperature. 
 
Assay 
TAZ oxidation by human FMO or EtaA was measured by monitoring the rate of 
decrease in TAZ absorbance at 328 nm using a dual beam spectrophotometer (Varian 
Cary 100).  The spectrophotometer was set to blank correction mode and the Peltier 
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following components; 100 µM NADPH, insect cell microsomes containing 
heterologously expressed human FMO1 (320 nM), FMO2.1 (5 nM), FMO3 (230 nM), 
purified ETA (1 µM) or the equivalent amount of uninfected Sf9 cell microsomes in 
the appropriate assay buffer (see next section) to give a final reaction volume of 1 mL.  
The contents of the cuvettes were mixed thoroughly and placed in cell 1 (reference) or 
cell 7 (sample) of the spectrophotometer and a ‘blank’ measurement was made.  The 
samples were allowed to equilibriate at 37˚C for 1 min. 1 µL of TAZ from an 
appropriate stock solution was added to the sample cuvette and 1 µL of DMSO was 
added to the blank cuvette.   The contents were mixed by inverting the cuvette and the 
cuvettes were immediately replaced to their respective cells.  The rate of decrease in 
optical density at 328 nm was monitored after one minute for 4 minutes.   
 
2.8.2.2.1 Determining pH dependence of FMO and EtaA activity 
The pH optimum for human FMOs and ETA was determined using the following 
reaction buffers:  
•  0.1 mM potassium phosphate (pH 7.5), 1 mM EDTA 
•  0.1 M Tris-HCl (pH 8.5), 1mM EDTA  
•  0.1 M Tricine-OH (pH 9.5), 1 mM EDTA. 
 
Buffers were prepared fresh on the day and were aerated for 30 min at 37 ˚C in a 
shaking water bath before use. Optimum pH for enzymes was determined using 
the UV-spectroscopic assay detailed in the preceding section using TAZ at a final 
concentration of 10 µM. 
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2.8.3 Kinetic Studies of TAZ oxygenation using a UV-spectroscopic Assay 
 
Kinetic studies were performed on triplicate preparations of enzymes at 
concentrations of TAZ ranging from 1 to 20 µM.  The final organic solvent 
concentration was held at 0.1% (v/v).  Assays were carried out in triplicate on each 
enzyme preparation as described in section 2.7.2 in the optimum pH buffer for each 
enzyme: pH 8.5 for FMO1 and FMO3 and 9.5 for FMO2.1 and EtaA.   
 
2.8.3.1 Determination of Steady-State Kinetic Parameters 
Enzyme velocity was converted from absorbance min
-1 to µmol L
-1 min
-1 using the 
Molar extinction co-efficient of TAZ (determined to be 38,300 ± 2,320 M
-1 cm
-1) or 
TNB (13,600 M
-1  cm
-1).  Steady-state kinetic parameters, Vmax and KM  were 
estimated by non-linear regression using the Enzyme Kinetics module (v.1.3) of the 
SigmaPlot (v 10.0) program (Systat Software Inc., CA, USA).  Non-linear regression 
has been chosen to determine kinetic parameters as it is superior to methods which 
transform Michaelis-Menten equation in a linear fashion.    Linearity of data was 
confirmed by Hanes-Woolf (Hanes 1932) linear transformations of the Michaelis-
Menten equation using the Enzyme Kinetics module. Turnover number (kcat) was 
determined using the following equation.   
 
kcat = Vmax / [E] 
         E q u a t i o n   3  
Where Vmax is the maximal enzyme velocity of enzyme catalysis and [E] is the final 
enzyme concentration in the reaction. 
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2.8.4 Kinetic Studies of TAZ oxygenation using HPLC analysis  
Sf9 cell microsomes containing heterologously expressed human FMO2.1 were 
incubated in 0.1 M Tricine-OH (pH 9.5), 1 mM EDTA, 0.1 mM NADPH and TAZ 
(concentrations ranged from 1 - 50µM in DMSO). A duplicate set of samples was 
prepared but without the addition of enzyme. The final organic solvent concentration 
was held at 0.1% (v/v). Mixtures were incubated at 37 ˚C for 5 min and reactions 
were quenched with an equal volume of ice-cold CH3CN. ETA was added as an 
internal standard at a final concentration of 100 µM (in DMSO) and mixtures were 
prepared for HPLC analysis as described above.  A standard curve was generated by 
plotting the ratio of the integrated HPLC peak areas of TAZ and ETA (from the 
sample set without added enzyme), against the range of TAZ concentrations used. The 
ratio of the integrated HPLC peak areas of TAZ and ETA, in the sample set with 
added enzyme, was calculated and the amount of unmetabolised TAZ determined 
from the standard curve. This value was subtracted from the input concentration of 
TAZ to calculate the amount of TAZ metabolized by the enzyme. Vmax, KM and kcat 
were determined as described in section 2.8.3.1. 
 
2.9 Generation of human FMO3 Amino Acid Variant cDNAs 
Human FMO3 cDNAs containing the desired mutations were previously prepared in 
the laboratory as described elsewhere (Allerston et al. 2009). Each human FMO3 
cDNA variant was cloned in pET21b and transformed into E.coli DH5α™ and 
maintained as glycerol stocks.  This section describes the sub-cloning of FMO3 
cDNA from pET21b into pFastBac1™ for subsequent expression in Sf9 cells.  For 
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referred to as ‘human FMO3’.  
 E.coli DH5α™ cells containing FMO3-pET21b plasmid DNA were streaked 
on to agar plates containing 50 µg/mL ampicillin and incubated at 37ºC overnight as 
described in section 2.2.3.  A single colony was used to inoculate 5 mL of LB-
medium containing 50 µg/mL ampicillin. The culture was incubated overnight at 37ºC 
with shaking.  The following day, plasmid was isolated from 3 mL of bacterial culture 
using the QIAprep Miniprep Kit (QIAGEN) as described in section 2.3.1.1.  Plasmid 
DNA was quantified as described in section 2.3.1.2.   
pFastBac1™ was purchased from Invitrogen and was at a concentration of 1.3 
µg/µL. 
 
2.9.1  BamHI and HindIII Restriction Digest of human FMO3-pET21b and 
pFastBac1™ 
Solutions: 
•  10X NEBUFFER 2 (New England Biolabs, MA, USA)  
•  100X Bovine Serum Albumin (BSA) (New England Biolabs, MA,USA) 
•  Sterile water 
 
BamHI and HindIII were used to excise FMO3 cDNA from pET21b.  1 µg of plasmid 
DNA was digested at 37ºC overnight with 5 U of BamHI and 5 U of HindIII, in a 
solution containing 1X NEBuffer 2, 1X BSA and sterile water according to NEB 
instructions.  pFastBac1™ was also digested with BamHI and HindIII to produce 
complementary DNA sequences or ‘sticky ends’ to the DNA sequence of digested 
FMO3 cDNA.      
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2.9.2 Gel Extraction of DNA 
Solutions:  
•  SYBR® Green 100,000X Concentrate (Invitrogen)  
•  Propan-2- ol  
•  Sterile Water 
 
The following solutions were obtained from the QIAquick Gel Extraction Kit 
(Qiagen) 
•  Buffer QG 
•  Buffer PE 
 
After digestion of pET21b, human FMO3 cDNA was isolated using the QIAquick gel 
Extraction kit (QIAGEN).  Samples prepared as described in section 2.9.1 were 
separated on a 1% agarose gel as described in section 2.3.1.3 with the exception that 1 
µL of SYBR® Green was added to molten agarose instead of ethidium bromide.  This 
allowed DNA to be visualised using a light box with an orange filter rather than 
exposing it to UV.  Using the molecular weight marker as a guide, FMO3 cDNA was 
excised from the gel using a scalpel.  The piece of agarose was weighed and placed in 
a 1.5 mL microfuge tube.  Three volumes of Buffer QG was added to one volume of 
agarose (1 volume =100 µL of agarose or 100 mg) and incubated at 50˚C for 10 min 
or until the agarose had completely dissolved.  The following steps were carried out at 
room temperature.  One ‘gel’ volume of propan -2-ol was added and the tube was 
inverted.  A QIAquick spin column was placed in a 2 mL collection tube and 800 µL 
of sample was applied to the column.  Samples were centrifuged at 13,000g for 1 min 
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the same collection tube.  0.5 mL of Buffer QG was added to the column to remove 
traces of agarose.  The column was centrifuged for 1 min at 13,000g and the flow 
through was discarded.  The column was washed by adding 0.75 mL of Buffer PE, the 
sample was centrifuged for 1 min and the flow through was discarded.  The column 
was centrifuged for an additional 1 min to ensure all residual ethanol from Buffer PE 
was removed.  For the elution step, the column was placed into a fresh 1.5 mL 
microfuge tube and 30 µL of sterile water was applied to the column.  The column 
was allowed to stand for 1 min and then centrifuged for 1 min at 13,000g.  For short 
term storage, human FMO3 cDNA was kept at 4˚C.           
  
2.9.3 DNA Ligation 
Solutions: 
The following solutions were provided with the Quick Stick Ligase Kit (Bioline Ltd, 
UK). 
•  4X QS Buffer 
•  Sterile water 
 
DNA Ligation was carried out using the Quick Stick Ligase Kit (Bioline Ltd, UK) 
Human FMO3 cDNA isolated in the previous section was ligated to pFastBac1™.  
Prior to this step, pFastBac1™was digested with BamHI and HindIII as described in 
section 2.9.1 and a 1 in 100 dilution was prepared.  For each ligation reaction, two 
tubes were set up: Vector Only (digested pFastBac1™) and Vector plus Insert 
(digested pFastBac1™and digested FMO3 cDNA).  Vector only tubes contained: 1 
µL of digested pFastBac1™, 1 µL of Quick Stick Ligase enzyme, 5 µL of 4X QS 
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tubes contained: 1 µL of digested pFastbac1, 1 µL of Quick Stick Ligase enzyme, 5 
µL of 4X QS buffer (which was vortexed before use) and 13 µL of digested human 
FMO3 cDNA.  The tubes were incubated overnight at 16˚C.   
 
2.9.4 Tranformation of E.coli OneShot™ TOP10 competent cells with Ligation 
Products    
In order to confirm that the ligation reaction between human FMO3 cDNA and 
pFastBac1™ was successful, E.coli OneShot™ TOP10 chemically competent cells 
Invitrogen) were transformed with the ligation reaction mixtures.  A 50 µL vial of 
OneShot™ cells was used per ligation.  OneShot™ cells were thawed by gently 
rubbing the vial in the hands and as soon as thawing was observed, the samples were 
placed on ice and 1 µL of ligation reaction mixture was added.  The contents were 
mixed by gently tapping and inverting the vial as pipetting can reduce transformation 
efficiency.  The vials were incubated on ice for 30 min.  Vials were incubated for 
exactly 30 sec at 42˚C using a heat block.  The vials were then placed on ice. 250 µL 
of pre-warmed SOC solution was added to each vial.  Samples were incubated with 
shaking in a heat block for exactly 1 hr at 37˚C.  During this time, agar plates 
containing ampicilin (prepared as described in section 2.2.3) were placed in a 37˚C 
incubator to warm up.  50 µL of transformed cells from each vial were spread on an 
agar plate, the plates were inverted and incubated at 37˚C overnight.   Colonies were 
counted the following day and the ratio of colonies formed from ‘Vector only’ and 
‘Vector plus Insert’ vials was noted.  5 colonies were picked from each Vector plus 
Insert plate and 1 colony from Vector only plates.      Each colony was inoculated into 
5mL of LB-medium containing 50 µg/ mL of ampicillin.  Cultures were grown for 6-8 
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DNA was isolated using the QIAprep Miniprep kit (QIAGEN) as described in section 
2.3.1.1.   
  
2.9.5 Analysis to Confirm Successful ligation of human FMO3 cDNA and 
pFastBac1™ 
10 µL of plasmid DNA was digested with BamHI and HindIII as described in section 
2.9.1.  Digested products were run on a 1% agarose gel as described in section 2.3.1.3.  
If ligation was successful, two DNA bands were expected to be observed, 
representing pFastBac1™ (4.8kb) and human FMO3 cDNA (~2kb).  In order to 
confirm that the vector was indeed pFastBac1™ (and not the original vector, 
pET21b), a restriction enzyme was chosen which could differentiate between the two 
plasmids.  Bgl II was used as it has two restriction sites in pFastBac1™ but only one 
in pET21b.    Reactions contained 5 µL of plasmid DNA, 1 µL of Bgl II (NEB, 
England), NEBuffer 3 (NEB, England) and 3 µL of water.  Samples were incubated 
for 2 hours at 37˚C.  Digested products were visualised by agarose gel electrophoresis 
as described in section 2.3.1.3.         
 
2.9.6 DNA Sequencing 
DNA sequencing was performed by Eurofins-MWG Biotech (Germany) using the 
‘value read’ service.  The service required 1 µg of plasmid DNA per sequencing 
reaction.  Sequences were analysed by comparison to the wild type human FMO3.  
DNA was sequenced in both forward and reverse orientations using primers annealing 
to sequences in the pFastBac1™ vector, these primers were available at MWG-
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DNA are given in appendix 1. 
 
The remainder of the method is the same as that described for human FMO1, FMO2.1 
and FMO3.  E.coli DH10Bac™ cells were transformed with human FMO3 cDNA as 
described in section 2.3.1.4 and the resulting bacmid DNA was isolated as described 
in section 2.3.1.5.  Generation of baculovirus containing human FMO3 DNA was 
done as described in section 2.4.  Expression of recombinant human wild-type FMO3 
protein and FMO3 amino acid variants was carried out as described in section 2.5.    
Quantitation of FMO3 in insect cell microsomal membranes was done as described in 
section 2.6 using human FMO3 containing insect cell microsomes of known FMO3 
amounts as a standard.     
 
2.9.7 Assays of Variant human FMO3 Activity 
Activity of FMO3 amino acid variants was determined towards methimazole and 
TAZ. 
 
2.9.7.1 Methimazole Assay of FMO3 Amino Acid Variant activity  
Kinetic studies on human FMO3 amino acid variants and methimazole were 
performed at pH 8.4 and essentially as described in section 2.8.1. NADPH was 
supplied to the reaction using a 20 mM NADPH solution prepared in assay buffer.  
200-500 pmol of FMO3 protein was used in the assay depending on the variant. 
Methimazole was tested at concentrations ranging from 10-1000 µM on batches of 
microsomes isolated from three independent infections of Sf9 cells.   Steady-state 
kinetic parameters were determined from assays performed in triplicate for each 
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obtained for wild type FMO3.  Statistical significance was assessed using an unpaired, 
two-tailed t-test performed using the Microsoft Excel application of Microsoft Office 
2003.  
 
2.9.7.2 TAZ Assay of FMO3 amino Acid Variant activity  
Kinetic studies on human FMO3 amino acid variants and TAZ were performed at pH 
8.4 and essentially as described in section 2.8.2.2. 200-500 pmol of FMO3 protein 
was used in the assay depending on the variant. NADPH was supplied to the reaction 
using a 20 mM NADPH solution prepared in assay buffer.   TAZ was tested at 
concentrations ranging from 1-20 µM on batches of microsomes isolated from three 
independent infections of Sf9 cells.  Steady-state kinetic parameters were determined 
from assays performed in triplicate for each FMO3 protein (as described in section in 
2.8.3.1) and were compared to those obtained for wild type FMO3.  Statistical 
significance was assessed using an unpaired, two-tailed t-test performed using the 
Microsoft Excel application of Microsoft Office 2003.  
 
2.10 Isolation and Preparation of Mouse Tissue Microsomes 
Age-matched male and female wild-type C57BL/6 and knockout mice back-crossed 
for eight generations onto the C57BL/6 line were used in this investigation. The 
construction of the Fmo1 (-/-), Fmo2  (-/-)  Fmo4  (-/-) knockout mouse has been 
described (Hernandez et al 2009). The production of the Fmo5 (-/-) knockout line has 
not yet been published but preliminary data on its construction can be found in the Ph 
D thesis of A. Melloni and in (Hernandez et al. 2006). 
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2.10.1 Dissection 
Liver and lungs were obtained from 8-10-week old C57BL/6 mice, Fmo1 (-/-), Fmo2 
(-/-) Fmo4 (-/-) mice and Fmo5 (-/-) mice as described in this section. Mice had access 
to food and water ad libitum and were housed with appropriate animal husbandry 
facilities. 
 
Solutions: 
•  70% Ethanol 
•  Buffer A: 0.1 M Tris-Acetate (pH 7.4), 0.1 M KCl, 1 mM EDTA.  Buffer was 
prepared the day before dissection was to take place and stored at 4˚C. 
 
On the morning of the procedure, dissection equipment was ensured to be clean and 
was wiped with 70% ethanol.  Mice were sacrificed in the morning between 9 and 11 
am by carbon dioxide asphyxiation.  For this, the asphyxiation chamber was first 
placed on its side to allow any residual CO2 to be removed and then returned to its 
upright position.   Mice (no more than 4 at a time) were placed in the box and the CO2 
concentration was slowly increased to avoid stress to the animals.  After 10 min, mice 
were taken out of the box and their feet were pinched to observe pedal reflex.  If no 
response was observed, the abdomen was swabbed with 70% ethanol and opened 
through a U-shaped incision.  The intestines were moved to one side of the torso and 
the liver was excised.  The liver was weighed and submerged in three times the 
volume of chilled Buffer A that was placed on ice. The abdomen was inspected to 
ensure that all three lobes of the liver were excised.  To excise the lungs, the 
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that the entire lung was obtained.  Lungs were weighed and submerged in three times 
the volume of chilled Buffer A.  The tissues were minced in this buffer using scissors. 
The steps described in the next section were performed immediately.          
 
2.10.2 Isolation of Mouse Tissue Microsomes 
Solution: 
•  Storage Buffer: 10 mM potassium phosphate (pH7.5), 1 mM EDTA, 20% 
Glycerol.  Buffer was prepared a day before dissection and stored at 4˚C. 
 
Minced tissues from the preceding section were homogenised using a motor powered 
hand held homogeniser (Citenco, Park Products Ltd, England).  The mortar was 
chilled before transferring minced tissue samples to it and it was kept on ice during 
the procedure at all times. Tissues were homogenised at speed 7 until the tissue was 
completely resuspended. The homogenate was then transferred to a chilled centrifuge 
tube and centrifuged at 10,000g for 10 min at 4˚C.   The supernatant from this step 
was centrifuged at 105,000g for 90 min at 4˚C to give a pale yellow pellet.  The pellet 
obtained from this step is a crude preparation of smooth and rough endoplasmic 
reticulum membranes.  The pellet was immediately placed on ice and resuspended in 
Storage buffer using a glass-glass hand held homogeniser. The desired final 
concentration of the suspended microsomes was about 10-25 µg/µL. Microsomes 
were frozen at -80˚C in 500 µL aliquots  to avoid freeze-thawing of large volumes as 
this leads to reduced activity.    Microsomal protein concentration was determined by 
the method of Lowry as described in section 2.5.3.   
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2.10.3 Kinetic Studies of TAZ Metabolism by Mouse Tissue Microsomes 
2.10.3.1 TAZ metabolism by Mouse Lung and Liver Microsomes 
Solution 
•  Assay Buffer: 100 mM potassium phosphate (pH 7.5), 1 mM EDTA.  Buffer 
was made on the day from a pre-made 1M potassium phosphate solution 
(pH7.5) that was stored at 4˚C.  The buffer was aerated for 30 min in a 37˚C 
water bath with shaking. 
•  NADPH regenerating system: 
•  2 U/mL Glucose-6-Phosphate Dehydrogenase (7.5 µL was used in 
a 1 mL reaction)  
•  3.0 mM Glucose-6-Phosphate (25 µL was used in a 1 mL reaction)    
•  0.375 mM NADP
+ (25 µL was used in a 1 mL reaction) 
All components where prepared on the day in the appropriate assay buffer which 
was chilled before use. 
 
The rate of TAZ metabolism by mouse liver and lung microsomes was determined 
essentially as described in section 2.8.2.2 but using TAZ at a final concentration of 10 
µM and using an NADPH regenerating system.  The relative contribution of FMOs 
and CYPs was to be determined by this method and so reactions were performed at 
pH 7.5 because a) this resembles physiological pH and b) because CYP function is 
inhibited in alkaline conditions.  NADPH was supplied through an NADPH 
regenerating system for which the components are described above. 500 µg of 
microsomal protein was used in the reaction and enzyme velocity was converted from 
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-1 to µmol L
-1 min
-1 using the Molar extinction co-efficient of TAZ 
(determined to be 38,300 ± 2,320 M
-1 cm
-1).  Michaelis-Menten plots (initial enzyme 
velocity vs concentration of substrate) were plotted for microsomal samples isolated 
from liver and lung from female mice.   
The rate of TAZ metabolism obtained for liver and lung microsomal samples 
was compared between mouse lines and to results obtained for enzyme inhibition 
studies (see following section). Statistical significance was assessed using an unpaired 
two-tailed t-test when results were compared between samples (same test condition, 
different samples), when results were compared within a sample (i.e. different test 
conditions, one sample) a paired two-tailed t-test was employed.      
 
2.10.4 Control Experiments used to Assess Activity of Mouse Tissue Microsomes 
It was necessary to check that the microsomes displayed activity towards control 
substrates of the FMOs and CYPs to ensure that they had not become inactivated 
during the isolation procedure.  FMO activity was assessed using the assay of 
methimazole and CYP activity was assessed by monitoring the rate of cytochrome c 
reduction by NADPH-dependent cytochrome P450 reductase.   
 
2.10.4.1 Methimazole Oxidation by Mouse Tissue microsomes 
To ensure that FMOs were not inactivated during the isolation procedure their 
capacity to oxidise methimazole was assessed.   
The rate of methimazole oxidation by mouse liver and lung microsomes was 
determined essentially as described in section 2.8.1.  Reactions were performed in pH 
8.4 and NADPH was supplied through a NADPH regenerating system. 50-200µg of 
microsomal protein was used in the reaction depending on the tissue from which the 
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min
-1 to µmol L
-1 min
-1 using the Molar extinction co-efficient of TNB (13,600 M
-1 
cm
-1).  Though kinetic parameters were not calculated for microsomes because of the 
shortage of sample, the relative rate of TNB oxidation was used as a measure of FMO 
activity.   
 
2.10.4.2 Activity of NADPH Cytochrome P450 Reductase in Mouse Liver 
Microsomes 
Although CYPs are relatively robust enzymes that are stable at room temperature and 
can withstand incubations of up to several minutes at 45-50˚C, it was necessary to 
ensure that they were active during the experiment.  NADPH cytochrome P450 
reductase is an enzyme that is necessary for the activity of CYPs and the activity of 
this enzyme was used as an assessment of CYP activity.  Details regarding its function 
will be given in section 3.3.  It is appreciated that factors other than CRP activity may 
affect CYP activity; however these are uncommon under the conditions used in this 
experiment.   
  
Solutions: 
•  Assay Buffer: 100 mM potassium phosphate buffer (pH 7.5) prepared on the 
day from a pre-made 1M potassium solution that was stored on ice. 
•  0.2 mM Cytochrome c: Stock solution was prepared by weighing the 
appropriate amount of solid Cytochrome c from Saccharomyces cerevisiae and 
adding it to assay buffer. 
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adding the appropriate amount of solid NADPH to chilled assay buffer and 
was stored on ice. 
The rate of cytcochrome c reduction by CRP was measured spectrophotometrically at 
25˚C as described by Omura and Takesue (Omura et al. 1970).   Two identical ‘blank’ 
cuvettes were prepared with the following components; 200 µg of microsomes 
isolated from mouse lung or liver and cytochrome c at a final concentration of 0.2 
µM.  The cuvettes were capped and inverted to mix the contents before placing them 
in cell 1 (reference) or cell 7 (sample) of a Varian Cary 100 dual beam 
spectrophotometer.  The Peltier module was set to 25˚C.  Using the Kinetics 
application, the spectrophotometer was set to blank correction mode and a blank 
measurement was taken.  Reactions were initiated by the addition of 100 µM 
NADPH.  The increase in optical density at 550 nm was measured for 10 min.    
  
2.10.5 Inhibition Studies on Mouse Tissue Microsomes. 
In this section the rate of TAZ metabolism was determined for microsomes that have 
been treated to inhibit FMO activity or CYP activity.  Sections 2.10.5.1 through 
2.10.5.3 describe how FMOs and CYPs were inactivated.   Samples were then 
assessed for their ability to metabolise 10 µM TAZ as described in section 2.10.3.1  
 
2.10.5.1 Competitive Inhibition of FMO activity 
Solutions: 
•  Assay Buffer: 100 mM potassium phosphate (pH 7.5), 1 mM EDTA.  Buffer 
was made on the day from a pre-made 1M potassium phosphate solution (pH 
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bath with shaking 
•  200 mM Methimazole:  Stock solution was prepared fresh by adding the 
appropriate amount of solid methimazole to assay buffer.   
FMO activity was inhibited by pre-incubating mouse tissue microsomes with 
methimazole, a probe substrate of the FMOs that acts as a competitive inhibitor.  The 
concentration of methimazole chosen in this experiment was determined by reviewing 
literature of the saturating concentration of methimazole. 
Tubes (prepared in duplicate) containing 500 µg microsomal protein, 1 mM 
methimazole and NADPH regenerating components were incubated at 37˚C for 2 
min.   The contents of the tubes were transferred to two quartz cuvettes where one 
would be treated with TAZ and the other would serve as a blank in the assay.  The 
rate of TAZ metabolism after FMO inhibition was measured as described in section 
2.8.2.2.  Assays were carried out in triplicate on two batches of mouse tissue 
microsomal samples and statistical significance was assessed as described in section 
2.10.4. 
 
2.10.5.2 Heat Inactivation of FMO Activity 
FMOs are heat labile and can be inactivated by short durations of heat treatment at 45-
50˚C in the absence of NADPH (Rawden et al. 2000; Stormer 2000; Virkel et al. 
2006; Siddens et al. 2008).   
Tubes (prepared in duplicate) containing 500 µg microsomal protein in assay 
buffer (to give a final volume of 942 µL) were incubated at 45˚C for 5 min.   After 
heat treatment, tubes were returned to ice for one min and components of the NADPH 
regenerating system were added. Tubes were inverted to ensure adequate mixing.  The 
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treated with TAZ and the other would serve as a blank in the assay.  The rate of TAZ 
metabolism after FMO inhibition was measured as described in section 2.8.2.2. 
Assays were carried out in triplicate on two batches of mouse tissue microsomal 
samples and statistical significance was assessed as described in section 2.10.4. 
 
2.10.5.3 Inhibition of CYP Inactivity 
NADPH-dependent Cytochrome P450 Reductase (CRP) anti-serum was employed to 
abolish the activity of CYPs in the microsomal samples.   
The amount of CRP-anti-serum was optimised as follows: tubes (prepared in 
duplicate) containing 500 µg microsomal protein in assay buffer and increasing 
volumes of CRP-anti-serum or control non-immune serum (0-50 µL) were incubated 
on ice for 15 min. The components of the NADPH regenerating system were applied 
to these tubes and these were inverted to mix the contents.  The contents of the tubes 
were transferred to two quartz cuvettes where one would be treated with TAZ and the 
other would serve as a blank in the assay.  The rate of TAZ metabolism after CYP 
inhibition was measured as described in section 2.8.2.2. Assays were carried out in 
triplicate on two batches of mouse tissue microsomal samples and statistical 
significance was assessed as described in section 2.10.4.
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chapter 3: Results and Discussion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 3.1 Analysis of the Reaction between Human FMO2.1 and the Anti-
Tubercular Drugs Thiacetazone and Ethionamide.  
 
The work described in this section has been published.  
Francois, A.A., Nishida, C.R., Ortiz de Montellano, P.R., Phillips, I.R., Shephard, 
E.A. (2009) Human Flavin-Containing Monooxygenase 2.1 Catalyzes Oxygenation of 
the Antitubercular Drugs Thiacetazone and Ethionamide.  Drug Metabolism and 
Disposition.  37(1):178-186.  
 
Introduction 
This section describes the reaction between human FMO2.1 and the anti-tubercular 
drugs Thiacetazone (TAZ) and Ethionamide (ETA).  Metabolites generated for TAZ 
by FMO2.1 were compared to those formed by the action of human FMO1, FMO3 
and the Mycobacterial FMO, EtaA.  Kinetic parameters describing the reaction 
between FMO2.1 and TAZ were determined using a novel UV-spectroscopy assay.  
Kinetic parameters for human FMO1, FMO3 and EtaA were also determined for 
comparison.     
     
Results 
Protein Expression 
Human FMO1, FMO2.1 and FMO3 were heterologously expressed in Sf9 insect cell 
membranes as described in sections 2.3-2.5. Insect cell microsomes, which represent 
membranes of the endoplasmic reticulum in suspension, were prepared as described in 
section 2.5.2.  
Figure 3.1.1 shows photographs of polyacrylamide gels obtained from SDS-
PAGE analysis of Sf9 insect cell microsomes containing heterologously expressed 
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Figure 3.1.1: SDS-PAGE gel illustrating the expression of human FMO1, 
FMO2.1 and FMO3 expressed in Sf9 insect cell microsomes. Lane 1: Molecular 
weight marker, lane 2 microsomes prepared from non-infected Sf9  insect cells 
(negative control) and Sf9 insect cell microsomes containing heterologously expressed 
human FMO1 (A), FMO2.1 (B) and FMO3 (C). 
 
 
 
 
 
 
 
 
 
  134human FMO1, FMO2.1 or FMO3.  The amount of FMO expressed in microsomes 
was determined by generating a standard curve from authentic FMO standards as 
described in section 2.6.1. Figure 3.1.2 illustrates an example of a quantitative 
Western blot and a calibration curve generated to quantify human FMO1 in insect cell 
microsomes.          
 
Catalytic Oxidation of TAZ by human FMO2.1      
Reactions analysed by reverse phase HPLC and liquid chromatography-mass 
spectroscopy (LC-MS) were prepared as described in section 2.7.  
Incubation of TAZ  with Sf9 insect cell microsomes containing heterologously 
expressed human FMO2.1, in the presence of NADPH, resulted in the formation of 
three major metabolites with reverse-phase retention times of 7.5 min (M1), 11.4 min 
(M2) and 14.6 min (M3) (Fig. 3.1.3).  No products were observed when TAZ was 
incubated with microsomes isolated from non-infected Sf9 cells or when NADPH was 
omitted (results not shown).  UV spectral analysis of the metabolites (Fig. 3.1.4) 
showed that M1 had a maximal absorption peak at 325 nm and a smaller peak at 
approximately 230 nm. M2 had a similar spectrum, with peaks at 320 and 220 nm. 
The absorption spectrum of M3 exhibited a main peak at 295 nm and a secondary 
peak at 220 nm.   
To identify the three metabolites, M1, M2, and M3, formed from TAZ by the 
action of human FMO2.1, were analysed by LC-MS.  The mass spectrum of M1 had a 
molecular ion [M + H]
+ at
 m/z 269.07, with fragment ions at m/z 205.14 and 163.12 
(Fig. 3.1.5A). The mass of the molecular ion of M1 is 32 atomic mass units more than 
that of the molecular ion of TAZ (237), suggesting a structure in which TAZ has 
incorporated two oxygen atoms (Fig. 3.1.5A) and hence supports identification of the  
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Figure 3.1.2: Quantification of FMO1 amounts in insect cell microsomes.   The 
amount of total FMO1 expressed in microsomal samples was determined as described 
in section 2.6. (A) Quantitative Western blot illustrating bands of known amounts of 
FMO1 standard microsomes and FMO1 expressing insect cell microsome sample and 
(B) a calibration curve generated from the intensities of the standard bands (r
2
  = 
0.9981).                   
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Figure 3.1.3. Metabolites of TAZ generated by human FMO2.1 catalysed 
oxidation.  UV-HPLC chromatogram of M1 (7.6 min), M2 (11.4 min) and M3 (14.5 
min) generated from incubations of TAZ with Sf9 insect cell microsomes containing 
heterologously expressed human FMO2.1 and NADPH.  Reactions were carried out at 
pH9.5 for 90 min at 37 °C 
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Figure 3.1.4: UV-Absorption spectra of TAZ metabolites generated by human 
FMO2.1 catalysed oxidation.  UV-absorption spectra of the products produced by 
FMO2.1 metabolism of TAZ. Dotted line, M1; solid line M2; and dashed line, M3. 
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Figure 3.1.5. Mass spectra of TAZ metabolites generated from human FMO2.1 
catalysed oxidation. Mass spectra and structures of the products from incubations of 
TAZ with Sf9 insect cell microsomes containing heterologously expressed human 
FMO2.1 and NADPH at pH 9.5 for 90 min at 37 °C. (A) M1,  identified as the 
sulphinic acid, has a molecular ion [M + H]+  m/z 269.07, with fragment ions at m/z 
205.14 and 163.12. (B) M2, identified as the sulphenic acid, has a molecular ion [M + 
H]
 + at m/z 253, with fragment ion peaks at m/z 235 and 193 and (C) M3, identified as 
the carbodiimide, has a molecular ion [M + H]+ ) m/z 203.13 with a fragment ion at 
m/z 161.11. 
  139metabolite as the sulphinic acid derivative.  The mass spectrum of M2  had a 
molecular ion [M + H]
 + at m/z 253, with fragment ions at m/z 235 and 193 (Fig. 
3.1.5A).  The mass of the molecular ion of M2 is in accord with a structure in which 
TAZ has incorporated a single oxygen atom, and thus supports identification of M2 as 
the monooxygenated, sulphenic acid derivative. The metabolite M3 has a molecular 
ion [M + H]
+ at m/z 203.13, which suggests that it is the carbodiimide generated by 
elimination from M2 of the oxidized sulfur atom (Fig. 3.1.5C). Previously synthesized 
authentic standards of TAZ-sulphinic acid and TAZ-carbodiimide (Qian et al. 2006) 
were used to confirm the identity of M1 and M3.  UV-HPLC chromatograms and UV 
spectra generated from authentic standards of TAZ-sulphinic acid and TAZ-
carbodiimide are given in Figure 3.1.6.  Comparison of their HPLC elution times (Fig. 
3.1.6), UV spectra (Fig. 3.1.7) and MS spectra (Qian et al. 2006) with those of the 
synthetic standards unambiguously identified the metabolites M1  and  M3  as the 
sulphinic acid and carbodiimide derivatives of TAZ, respectively. 
  The same three metabolites (the sulphinic acid,  sulphenic acid and 
carbodiimide derivatives) were also produced when TAZ was incubated with purified 
EtaA or with Sf9 cell microsomes containing heterologously expressed human FMO1 
or FMO3 (Fig 3.1.8). Previous work identified M1 and M3 as products formed by the 
action of these enzymes on TAZ(Qian et al. 2006). Although the sulphenic acid 
derivative (M2) was not detected, it was postulated as an intermediate in the enzyme-
catalyzed metabolism of TAZ (Qian et al. 2006). To confirm this, incubations of TAZ 
with heterologously expressed human FMO2.1 were quenched at different time points 
(Fig. 3.1.9).  It is clear from the results that formation and accumulation of M2 
precedes that of M1 and M3, indicating that M2 is an intermediate in the formation of 
the latter two metabolites.   
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Figure 3.1.6. UV-HPLC Chromatograms of TAZ metabolite standards. Reverse 
phase chromatograms obtained for (A) TAZ-sulphinic acid (7.6 min) and (B) TAZ-
carbodiimide standard (14.5 min).     
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Figure 3.1.7: UV-spectra of TAZ metabolite standards.   TAZ-sulphinic acid 
standard (top) gives a major peak at 325 nm and a smaller peak at approximately 220 
nm. (Bottom) TAZ-carbodiimide standard gives a major peak at 295 and 220 nm.       
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Figure 3.1.8: Metabolites of TAZ generated by human FMO1, FMO3 and EtaA 
catalysed oxidation.   UV-HPLC chromatogram of TAZ-sulphinic acid (7.6 min), 
TAZ-sulphenic acid (11.4 min) and TAZ-carbodiimide (14.5 min) generated from 
incubations of TAZ with Sf9 insect cell microsomes containing heterologously 
expressed (A) human FMO1 (B) human FMO3 and (C) EtaA and NADPH in pH 8.4 
(for FMO1 and FMO3) or 7.5 (EtaA) for 90 min at 37 °C.   
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Figure 3.1.9: Time Course Experiment of TAZ oxidation by human FMO2.1.  
UV-HPLC chromatograms of the products from incubations of TAZ with Sf9 insect 
cell microsomes containing heterologously expressed human FMO2.1 and NADPH at 
pH 9.5 and 37 °C for 0 min (A) 10 min (B) or 20 min (C).  
 
 
 
 
 
 
 
  144Catalytic oxidation of ETA by human FMO2.1. 
ETA and FMO2.1 reactions were analysed by liquid chromatography-mass 
spectroscopy (LC-MS) as described in section 2.7.  
Incubation of ETA with Sf9 microsomes containing heterologously expressed 
human FMO2.1, in the presence of NADPH, resulted in the formation of a major 
product, P1, with LC retention time of 6.2 min (Fig. 3.1.10A). The mass spectrum of 
P1 had a molecular ion [M + H]
+  at m/z 183, with fragment ions at m/z 151 and 133 
(Fig. 3.1.10B). The mass of the molecular ion of P1 is 16 atomic mass units more than 
that of the molecular ion of ETA (166), suggesting a structure in which ETA has 
incorporated one oxygen atom (Fig. 3.1.10B).  This supports identification of P1 as 
the S-oxide of ETA. The mass spectrum of P1 is identical to that of authentic ETA S-
oxide (Vannelli et al. 2002), therefore unambiguously identifying this metabolite as 
the S-oxide of ETA.  A mass spectrum of the broad peak with a LC retention time of 
approx. 3 min (Fig. 3.1.10A) could not be obtained. 
 
Development of a spectrophotometric assay of TAZ oxidation. 
Although, reverse phase HPLC was used to identify metabolites generated by FMOs, 
access to this method was not always available.  For this reason a UV-spectroscopy 
based enzyme assay was developed to determine the kinetic parameters of TAZ and 
FMOs.   
An assay was developed to monitor the rate of decrease in TAZ 
spectrophotometrically as a measure of its oxygenation by FMOs (described in section 
2.8.2.1).  First, the UV properties of TAZ were investigated.  A UV absorption  
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Figure 3.1.10. LC-MS analysis of ETA metabolites generated by human FMO2.1 
catalysed oxidation. (A) LC chromatogram (350 nm) of the products from incubation 
of ETA, Sf9 insect cell microsomes containing heterologously expressed human 
FMO2.1 and NADPH in pH 7.5 for 60 min at 37 °C.  (B) The mass spectrum and 
structure of the product P1.  P1  has a molecular ion [M + H]
+  at  m/z  183, with 
fragment ion peaks at m/z 151 and 133.   
 
 
 
 
  146spectrum of TAZ revealed an absorption maximum at 328 nm and a smaller peak at 
approximately 220 nm (Fig. 3.1.11). The absorbance of TAZ at 328 nm was linear 
between 1 and 20 μM (Fig. 3.1.12) and at this wavelength the molar extinction 
coefficient of TAZ in 0.1% DMSO was determined as 38,300 ± 2,320 M
-1cm
-1.  
Incubation of TAZ, in the presence of NADPH, with Sf9 cell microsomes 
containing heterologously expressed human FMO1, FMO2.1 or FMO3, or with 
purified EtaA, resulted in a decrease in TAZ absorbance at 328 nm that was linear 
over time (Fig. 3.1.13A and B) and with respect to enzyme concentration (data not 
shown). No decrease in TAZ absorbance was observed in the absence of EtaA or 
human FMOs, or when microsomes prepared from non-infected Sf9 cells were used 
(Fig. 3.1.14).  Omission of NADPH from reaction mixes containing heterologously 
expressed human FMOs resulted in a very small (<1% of that observed in the 
presence of NADPH) and short-lived (<2 min.) decrease in TAZ absorbance (Fig. 
3.1.15). This is due to the presence of endogenous NADPH in the insect cell 
microsomes. This spectrophotometric assay was used to determine the pH optima and 
kinetic parameters of enzyme-catalyzed oxidation of TAZ. 
 
 Effect of pH on TAZ oxidation catalyzed by human FMOs and EtaA.  
FMO1, FMO2.1 and FMO3 display different pH optima for enzymatic activity 
(Krueger et al. 2002; Qian et al. 2006; Siddens et al. 2008). The dependence of FMO 
activity on pH with respect to TAZ oxidation was measured spectrophotometrically as 
described in section 2.7.2.1.1.   
The activity of EtaA and heterologously expressed human FMO1, FMO2.1 
and FMO3 towards TAZ was assessed in buffers of pH 7.5, 8.5 or 9.5.  All enzymes 
displayed activity towards TAZ throughout the tested range.  Each FMO however, 
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Figure 3.1.11: UV-spectra of TAZ.  TAZ in DMSO gives a major peak at 328 nm 
and a smaller peak at approximately 220 nm as measured using a UV-
spectrophotometer.  
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Figure 3.1.12: Linear absorbance of TAZ .  The absorbance of TAZ at 328 nm was 
determined over a range of concentrations. The molar extinction coefficient for TAZ 
was calculated using the gradient of the straight line (r2 = 0.996). 
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Figure 3.1.13A: Human FMO2.1- and NADPH-dependent decrease in TAZ 
absorbance at 328 nm is linear.  TAZ (20 µM) was incubated with insect cell 
microsomes containing heterologously expressed human FMO2.1, NADPH at pH 9.5 
and 37 °C.  Rate of TAZ oxidation was determined from 1-5 minutes.  
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328 nm   
 
 
Figure 3.1.13B:  Human FMO2.1- and NADPH-dependent decrease in TAZ 
absorbance at 328 nm over time. 
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Figure 3.1.14: UV-spectra at 328 nm in the presence of non-infected insect cell 
microsomes and NADPH.   No decrease in TAZ absorbance was observed in the 
presence of non-infected insect cell microsomes and NADPH at pH 9.5 at 37 °C.  The 
change in absorbance during the first minute represents scattering.    
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Figure 3.1.15: Human FMO2.1-dependent decrease in TAZ absorbance in the 
absence of NADPH at 328 nm.  TAZ (20 µM) was incubated with insect cell 
microsomes containing heterologously expressed human FMO2.1 in the absence of 
NADPH at pH 9.5 and 37 °C.   
 
 
 
 
 
 
 
  153had a particular pattern of pH-dependent activity.  The pH optimum for the oxidation 
of TAZ was 8.5 for human FMO1 and FMO3, and 9.5 for human FMO2.1 and EtaA 
(Fig. 3.1.16).  
 
Assessing FMO catalytic capacity using methimazole as a control substrate. 
Human FMOs were first tested for catalytic activity towards methimazole to ensure 
that the Sf9 insect cell microsomes were of good quality.  Kinetic parameters were 
determined for FMO1-, FMO2.1- and FMO3-catalyzed oxygenation of methimazole, 
a probe substrate of the FMOs.   The rate of methimazole S-oxygenation was 
monitored spectrophotometrically by monitoring the rate of decrease of 5-thio-2-
nitrobenzoic acid (TNB) at 412 nm.  Steady state kinetic parameters were determined 
for human FMOs using the non-linear regression application of the Kinetics module 
(v.3.1) of SigmaPlot (v.10) 
KM  values obtained for FMO1, FMO2.1 and FMO3 were in good agreement 
with previously published data (Dolphin et al. 1998; Krueger et al. 2002; Furnes et al. 
2004) (Table 3.1.1).  This confirms microsomes containing heterologously expressed 
FMO1, FMO2.1 or FMO3 were suitable for determining the kinetic parameters for 
TAZ.  
 
Kinetics of TAZ oxidation by human FMOs and EtaA. 
The kinetics of TAZ oxidation catalyzed by EtaA or by heterologously expressed 
human FMO1, FMO2.1 or FMO3 were evaluated by determining the initial rates of 
TAZ oxidation, measured spectrophotometrically, over a range of TAZ concentrations 
(Fig. 3.1.17 and data not shown) as described in section 2.8.2.2.  Assays were 
performed at the optimum pH for each enzyme (see above).   Steady state kinetic 
  154parameters were determined for human FMOs and EtaA using the non linear 
regression application of the Kinetics module (v.3.1) of Sigmaplot (v.10).  
Human FMOs and EtaA displayed hyperbolic Michaelis-Menten relationship 
between enzyme activity and TAZ concentration.  Michaelis-Menten and Hanes-
Woolf plots obtained for human FMO catalysed TAZ oxygenation is given in Figure 
3.1.17.   
TAZ was an excellent substrate for the human FMOs and EtaA (Table 3.1.2).  
The KM values for TAZ oxidation catalyzed by human FMO1, FMO2.1, FMO3 and 
EtaA are in the low micromolar range and very similar to each other (Table 3.1.2). 
The  kcat of the FMO2.1-catalyzed reaction is much higher than that of reactions 
catalyzed by human FMO1, FMO3 or EtaA (Table 3.1.2). Consequently, kcat/KM (the 
specificity constant) for TAZ is much higher for human FMO2.1 than for the other 
three enzymes (Table 3.1.2).  
Kinetic analysis of the reaction between human FMO2.1 and TAZ was 
evaluated by reverse phase HPLC in order to validate the UV-spectroscopy assay.    
ETA was used as an internal standard. The kinetic analysis methodology using HPLC 
is detailed in section 2.8.4.   A standard curve corresponding to the ratio of the 
integrated HPLC peak of TAZ and ETA plotted against TAZ concentration was used 
to determine the amount of unmetabolised TAZ in the reaction (Fig. 3.1.18). Table 
3.1.3 summarises the kinetic parameters for human FMO2.1 and TAZ determined by 
the HPLC and UV methods. There was no statistical difference observed in KM or 
kcat values determined from the use of an HPLC- or the UV-based assay, thus 
validating the UV spectrophotometric method (p>0.05). 
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Figure 3.1.16. Effect of pH on the rate of TAZ oxygenation by purified EtaA or 
Sf9 insect cell microsomes containing heterologously expressed human FMO1, 
FMO2.1 or FMO3.  The decrease in TAZ over time was measured at 328 nm in the 
presence of NADPH in buffers at pH 7.5, 8.5 or 9.5.  
 
 
 
  156Table 3.1.1: Kinetic Parameters of enzyme catalysed oxidation of Methimazole.   
 
 
Enzyme  KM 
(µM) 
kcat 
(min
-1) 
kcat/ KM 
(min
-1M
-1) (x10
4) 
FMO1  8.08 ± 2.35  2.27 ± 0.30  28.1 ± 7.95 
FMO2.1  575 ± 60.02  31.5 ± 2.11  5.48 
 ± 0.68 
FMO3  29 ± 4.06  2.60 ± 0.38  8.97
 ± 1.81 
 
 
The S-oxygenation of methimazole by human FMOs was determined as described in 
section 2.8.1.  KM (µM), kcat (min
-1), kcat / KM (min
-1 / M
-1) are reported as mean ± 
standard error obtained from enzyme assays performed in triplicate on microsomes 
isolated from a single infection of Sf9 cells. 
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Figure 3.1.17A: Non-linear regression and linear transformation of the 
Michaelis-Menten equation for  human FMO1 catalysed TAZ oxidation  (A) 
Michaelis-Menten curve of TAZ oxygenation catalysed by Sf9 insect cell microsomes 
containing heterologously expressed human FMO1 in the presence of NADPH and a 
buffer at pH 8.5. (B) Linear transformation of Michaelis-Menten data using Hanes-
Woolf regression.       
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Figure 3.1.17B: Non-linear regression and linear transformation of the 
Michaelis-Menten equation for  human FMO2.1 catalysed TAZ oxidation (A) 
Michaelis-Menten curve of TAZ oxygenation catalysed by Sf9 insect cell microsomes 
containing heterologously expressed human FMO2.1 in the presence of NADPH and 
a buffer at pH 9.5. (B) Linear transformation of Michaelis-Menten data using Hanes-
Woolf regression.       
  159 
Figure 3.1.17C: Non-linear regression and linear transformation of the 
Michaelis-Menten equation for  human FMO3 catalysed TAZ oxidation  (A) 
Michaelis-Menten curve of TAZ oxygenation catalysed by Sf9 insect cell microsomes 
containing heterologously expressed human FMO3 in the presence of NADPH and a 
buffer at pH 8.5. (B) Linear transformation of Michaelis-Menten data using Hanes-
Woolf regression.     
 
  160Table 3.1.2: Kinetic Parameters of enzyme catalysed oxidation of Thiacetazone. 
 
Enzyme 
 
KM 
(µM) 
kcat 
(min
-1) 
kcat/ KM 
(min
-1M
-1) (x10
5) 
FMO1  6.30 ± 0.80  5.08 ± 0.46  7.9 
 ± 1.99 
FMO2  5.80 ± 0.55  80.10 ± 4.42  142  ± 18.30 
FMO3  7.01 ± 0.53  1.37 ± 0.20  1.96 ± 0.39 
EtaA  9.05 ± 0.57  3.02  ± 0.30  3.2  ± 0.81 
 
The S-oxygenation of TAZ by human FMOs and EtaA is described in section 2.7.2.2.  
KM (µM), kcat (min
-1), kcat / KM (min
-1 / M
-1)  are reported as mean ± standard error 
obtained from enzyme assays performed in triplicate on microsomes isolated from 
three independent infections of Sf9 cells or from a single batch of purified EtaA.     
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Figure 3.1.18: Standard curve representing the ratio of integrated peak area of 
TAZ and ETA plotted against TAZ concentration.  The standard curve was used to 
determine the amount of unmetabolised TAZ after incubation with human FMO2.1 
and NADPH.   
 
 
 
 
 
  162Table 3.1.3: Comparison of kinetic parameters of human FMO2.1 catalysed TAZ 
oxidation determined by HPLC and UV-spectroscopy. 
 
 
Method KM 
(µM) 
kcat 
(min
-1) 
UV-Spectroscopic Assay  5.80 ± 0.55  80.10 ± 4.42 
HPLC Assay  5.90 ± 0.52  71.47 ± 6.80 
 
The S-oxygenation of TAZ by human FMO2.1 is described in section 2.8.3 and 2.8.4.  
Kinetic parameters determined by a UV-spectroscopy based assay and by reverse 
phase HPLC (KM (µM)  and  kcat ( min
-1)  are reported as mean ± standard error 
obtained from enzyme assays performed in triplicate on microsomes isolated from a 
single infection of Sf9 cells.     
 
 
 
 
 
 
 
  163In summary, this section has established TAZ to be an excellent substrate for human 
FMO2.1 and identifies the products of this reaction to be TAZ-sulphinic acid, TAZ-
carbodiimide formed from a common intermediate precursor, a sulphenic acid of 
TAZ.  Kinetic studies confirm this enzyme to be catalytically more efficient at this 
reaction than is the bacterial FMO, EtaA or human FMO1 or 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  164Discussion-Analysis of the reaction between human FMO2.1 and the Anti-
tubercular drugs Thiacetazone and Ethionamide.  
 
Thiacetazone (TAZ) and Ethionamide (ETA) are second-line antibiotics prescribed in 
the treatment of pulmonary tuberculosis. TAZ and ETA are pro-drugs which require 
metabolic activation by the mycobacterial enzyme EtaA, to exert a cytotoxic effect.     
The aim of this section was to establish whether anti-tubercular drugs, 
thiacetazone (TAZ) and ethionamide (ETA) are substrates for human FMO2.1 and 
whether this enzyme catalysed the same reaction as the Mycobacterial FMO, EtaA. 
Experiments carried out in this investigation have shown human FMO2.1 to be 
capable of catalysing the S-oxygenation of TAZ.  The metabolites generated, the 
sulphinic acid, sulphenic acid and carbodiimide of TAZ are the same as those 
identified for EtaA, FMO1 and FMO3 in this investigation.  Although, a previous 
study had identified the sulphinic acid and carbodiimide as the products of EtaA, 
FMO1 and FMO3 catalysed oxidation, a sulphenic acid intermediate was postulated 
to be the precursor of these metabolites (Qian et al. 2006).  Experiments carried out as 
part of this investigation have for the first time, identified the intermediate as the 
sulphenic acid of TAZ. 
Human FMO2.1 catalysed the oxidation of ETA to generate the corresponding 
S-oxide.  Though the S-oxide has been identified as the product of EtaA oxidation 
(DeBarber et al. 2000; Vannelli et al. 2002; Hanoulle et al. 2006), these studies also 
identify the corresponding amide and nitrile of ETA.  According to our results, human 
FMO2.1 does not generate these products and this finding is supported by others 
(Henderson et al. 2008).  Given that S-oxides are generally pharmacologically less 
toxic than the parent compound, it can be presumed that individuals prescribed ETA 
and who express FMO2.1 in the lung will not be at a higher risk of drug toxicity.  
  165Conversely, given that FMO2.1 can oxidise ETA, the inactivation of the drug before it 
reaches  Mycobacteria  may result in reduced drug efficacy.  This suggests that 
individuals expressing this enzyme are at a genetic disadvantage with regard to ETA 
metabolism.      
 Analyses of kinetic parameters indicate FMO2.1 to be more efficient at TAZ 
oxygenation than EtaA, human FMO1 and FMO3 as a measure of the specificity 
constant (kcat/KM).   KM determined for the enzymes was similar indicative of them 
having similar affinities for this substrate.  The high value of the specificity constant 
of FMO2.1 was therefore a result of a higher kcat rather than a lower KM.  Although 
kinetic parameters were determined at optimum pH for each enzyme, human FMO2.1 
was still the most effective at TAZ oxygenation at a more physiological pH, pH 7.5 
(Fig 3.1.16)  .    
  The catalytic cycle of FMOs described in section 1.2.2 illustrates how the rate-
limiting step in an FMO-catalysed reaction is not the binding of a substrate.  In a 
mechanism unique to FMOs, the enzyme is ‘ready’ to oxygenate a substrate before it 
(the substrate) has bound.  Tight binding between enzyme and substrate is therefore 
not required but a single point of contact with the active site (the 4a-peroxyflavin 
intermediate) is sufficient for the substrate to be oxidised.  The rate-limiting step is 
therefore the release of one molecule of water and the subsequent recycling of FAD to 
peroxyflavin after the oxygenation of the substrate.   This implies that a given FMO 
would have similar kcat values for all of its oxidisable substrates.  Comparison of kcat 
values obtained for TAZ and methimazole for FMO1, FMO2.1 or FMO3 respectively 
are in the same order of magnitude and conform to this expectation (Table 3.1.1 and 
3.1.2).  Comparison of kcat values determined for human FMO2.1 towards thiourea 
and ethylene-thiourea (Henderson et al. 2004) are similar to that obtained for TAZ in 
  166this investigation.  Similarly the relatively low kcat values determined for human 
FMO1 and FMO3 are comparable to those obtained for the oxygenation of a panel of 
thioureas by these enzymes (Onderwater et al. 2006).  The high kcat value obtained 
for human FMO2.1 in this section implies that the enzyme is more efficient at 
catalysing the rate-limiting step than is FMO1 or FMO3.   The high KM and high kcat 
determined for the reaction between methimazole and human FMO2.1 (Table 3.1.1) is 
comparable to that observed for purified and heterologously expressed rabbit FMO2 
and this substrate (Lawton et al. 1991).   
FMOs generally catalyse the detoxification of xenobiotics.  The prototypic 
product of FMO reactions is the non-toxic and non-reactive N- and S-oxide.   But 
thiourea compounds undergo FMO-dependent bioactivation in which the metabolites 
generated are more toxic than the parent compound (Smith et al. 2002; Henderson et 
al. 2004; Onderwater et al. 2004; Onderwater et al. 2006) .  Sulphenic acids of 
thioureas (generated by FMO oxygenation) are electrophiles that can react reversibly 
with glutathione (GSH) an important anti-oxidant in a mammalian cell (Ziegler-
Skylakakis et al. 1998; Henderson et al. 2004).   The sulphenic acid of TAZ can react 
with GSH to give rise to TAZ and to oxidised GSH (GSSG) (Qian et al. 2006).   In 
the presence of GSH reductase, a concurrent cycle may establish with the net effect 
being the depletion of GSH in a cell, and regeneration of the parent compound 
subsequently leading to oxidative stress and cell toxicity (Fig. 3.1.19) (Krieter et al. 
1984; Henderson et al. 2004; Onderwater et al. 2004).  Sulphenic acid metabolites can 
react covalently with other thiol-containing molecules like cysteine residues in 
proteins (Decker et al. 1992).  This can perturb the function of proteins and enzymes 
directly and is likely to be detrimental for cellular functions.  TAZ-carbodiimide can  
  167Figure 3.1.19: Diagram depicting TAZ metabolites generated by the oxidation of FMO and the interaction with glutathione (GSH).  
Adapted and revised from Qian et al. 2006. 
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form covalent bonds with GSH thus reducing the amount of an anti-oxidant in a cell 
(Qian et al. 2006).  Human FMO1, FMO2.1 and FMO3 are therefore able to catalyse 
the oxygenation of TAZ to give rise to metabolites which are known to be toxic to a 
mammalian cell. 
Given that human FMO1, FMO2.1 and FMO3 catalyse the bioactivation of 
TAZ may explain the basis of the adverse drug reactions observed in patients 
prescribed with this drug (Harland 1962; Aquinas 1968; Axton 1971; Hussain et al. 
1973; Bedi et al. 1974; Anonymous 1981; Gupta et al. 1983; Fegan et al. 1991; 
Brown 1992; Ipuge et al. 1995; Lawn et al. 1999; Dieng et al. 2001).  The role of 
FMOs in the in vivo bioactivation of TAZ is supported by the fact that TAZ-related 
adverse reactions are observed in tissues in which FMOs are expressed: 
hepatotoxicity, FMO3 in the liver (Dolphin et al. 1996; Hernandez et al. 2004); 
gastrointestinal problems, FMO1 in the small intestine (Yeung et al. 2000); and skin 
rashes, FMO1 and FMO3 in skin (Janmohamed et al. 2001).  TAZ is not prescribed to 
patients who suffer from human immunodeficiency virus (HIV) as adverse clinical 
effects are exasperated.    The underlying mechanism of this cytotoxicity is not known 
but the severity of TAZ-induced toxicity correlates to the level of immunosupression 
(Nunn et al. 1992).  It is noteworthy that immunocompromised individuals display 
impairment in glutathione homeostasis and deficiency of glutathione is established in 
patients with HIV (Eck et al. 1989; Staal et al. 1992a; Staal et al. 1992b; Staal et al. 
1992c).  Given that glutathione mediates a detoxification process by reducing 
sulphenic acids of thiourea-containing compounds, it is speculated that the 
pronounced adverse affects in HIV patients may be due to the accelerated cellular 
toxicity induced by the accumulation of TAZ-sulphenic acid in the absence of 
glutathione.           In humans, FMO1 and FMO3 are expressed in the kidney and liver 
respectively and may contribute to TAZ activation in extra-pulmonary tissues.  Inter-
individual and inter-racial differences are reported for expression in FMOs.  The 
expression of FMO1 is significantly higher in the kidney of African-Americans than 
in Caucasians (Krause et al. 2003).  Significant variations in the amount of FMO1 
expressed in the kidney is reported within individuals and is suggested to be a result 
of upstream promoter variants identified in the FMO1 gene (Hines et al. 2003).   
Genetic polymorphisms in the human FMO3 gene result in protein variants with 
altered catalytic activity (reviewed by Phillips et al.  2007 and Phillips et al. 2008) 
one of which, L360P has increased activity (Lattard et al. 2003). Amino acid variants 
of human FMO3 are implicated in the altered metabolism and therapeutic outcome of 
certain drugs (Stormer 2000; Hisamuddin et al. 2004; Mayatepek et al. 2004; 
Hisamuddin et al. 2005).  Genetic polymorphisms in upstream promoter regions that 
affect transcription of FMO3 have been identified (Koukouritaki et al. 2005; 
Koukouritaki et al. 2007).  This suggests that some people may metabolise TAZ more 
in the liver and kidney than in others.    The result of this inter-individual difference 
may affect the amount of unmetabolised TAZ reaching the lung and thus 
Mycobacteria.   
In humans, the expression of FMO2 is ethnic-dependent (Dolphin et al. 1998; 
Whetstine et al. 2000).  All Europeans and Asians genotyped to date possess the 
FMO2*2 allele in which a C>T substitution at position 1414bp replaces a glutamine 
amino acid residue with a premature stop codon (Dolphin et al. 1998).  The resulting 
protein, FMO2.2, is catalytically inactive and is not detected in human lung (Dolphin 
et al. 1998).  In sub-Saharan Africa, up to 50% of individuals possess at least one 
copy of the ancestral allele (FMO2*1) and are expected to express catalytically 
  170functional protein (FMO2.1) in the lung (Dolphin et al. 1998; Krueger et al. 2002; 
Veeramah et al. 2008).  The in vitro bioactivation of TAZ catalysed by FMO2.1 
observed in this investigation suggests that individuals expressing this enzyme in the 
lung are likely to be predisposed to TAZ-related toxicity in this tissue.  The reaction 
between TAZ and FMO2.1 in the lung represents a non-specific activation of this 
drug and will consequently lead to less TAZ being activated by EtaA in 
Mycobacteria.  The net effect of the reaction is the production of reactive metabolites 
in lung and the decrease in TAZ efficacy.    
Given the high frequency of the ancestral form of FMO2 (FMO2.1) in a region 
where TB is a major problem, may have implications on the toxicity and efficacy of 
TAZ and ETA.      
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Introduction 
This section describes kinetic studies undertaken on amino acid variants of human 
FMO3.  Variant FMO3 proteins were assayed for TAZ oxygenation activity to assess 
whether individuals possessing these variants may have altered metabolism of TAZ in 
the liver and the skin.   
Work in this chapter has focused on SNPs which are highly prevalent or 
unique to the African population.  This is because TAZ is only administered in certain 
parts of Africa due to lack of resources. SNPs which are likely to have a significant 
impact on the proteins ability to oxygenate TAZ are also investigated, even though 
they may not be highly prevalent in the African population.     The African population 
has also been chosen as an average of  28% of Sub-Saharan Africans are found to 
express a functionally active form of FMO2 (FMO2.1) (Dolphin et al. 1998; Krueger 
et al. 2002; Veeramah et al. 2008).   The remainder of the world’s population have 
acquired a polymorphism, which introduces a premature stop codon and thus do not 
produce functional FMO2 (Dolphin et al. 1998; Whetstine et al. 2000; Veeramah et 
al. 2008), this aspect will be discussed later.    
The four FMO3 SNPs to be investigated in this chapter are shown in Table 
3.2.1. 
 
Results – Kinetic Parameters of FMO3 Amino Acid Variants  
FMO3 cDNA constructs containing the desired genetic substitutions were previously 
prepared in the laborotary for bacterial expression (Allerston et al. 2009).  Sub 
cloning of these constructs to produce baculovirus for expression in insect cells is 
described in chapter 2.9.  Both strands of each cDNA were sequenced in order to  
  172Table 3.2.1: Genetic polymorphisms of Human FMO3 investigated in this report. 
 
 
 
GENETIC 
SUBSTITUTION 
AMINO ACID 
SUBSTITUTION 
AND POSITION 
SOURCE SNP  ID 
g.15167G>A E158K 
(Brunelle et al. 1997; 
Dolphin et al. 1997; 
Treacy et al. 1998; 
Zschocke et al. 1999; 
Furnes et al. 2003) 
rs2266782 
 
g.21443A>G 
 
E308G 
(Treacy et al. 1998; 
Zschocke et al. 1999) 
 
rs2266780 
g.15167G>A, 
g.21443A>G 
E158K/E308G 
(Furnes et al. 2003; 
Allerston et al. 2007) 
 
rs2266782 
rs2266780 
g.21599T>C L360P 
(Furnes et al. 2003; 
Lattard et al. 2003) 
rs28363581 
 
Genetic and amino acid substitutions are given for FMO3 polymorphic variants 
studied in this section.   Publications which identified the polymorphism or 
characterised the functional effect have been given.  SNP id references are provided.    
 
 
 
 
 
  173confirm the presence of the SNP and to ensure that other mutations were not 
introduced during the cloning procedure.  The original cDNA for FMO3 which has 
been used in this section and in section 3.1 encodes methionine at position 486 
(Dolphin et al. 1997).  Subsequent studies have found isoleucine to be more common 
at this position and thus the methionine residue has been reported as a polymorphism 
(Cashman 2002). Prior to this knowledge, constructs had been prepared on the 
methionine and isoleucine background.   No population frequency data is available on 
these SNPs and there are no reports of catalytic differences between the I486 and 
M486 proteins.  In this chapter the catalytic activities of heterologously expressed 
FMO3 I486 and M486 have also been compared.  Henceforth, FMO3 M486 will be 
referred to as wild type (M486) and FMO3 I486 as wild type (I486).  Figure 3.2.1 
illustrates whether a SNP has been constructed on the I486 background or on the 
M486 background.  Amino acid variants G308 and P360 will be compared to wild 
type (M486) whereas K158 and K158 / G308 will be compared to wild type (I486).        
  The FMO3 variants, K158, G308, K158/G308, P360 and wild type (I486) and 
(M486) have been investigated by expressing each variant FMO3 protein using the 
baculovirus/insect cell system.   Insect cell microsomal membranes were isolated and 
characterised for their ability to oxygenate TAZ.  This was done using the UV 
spectroscopic assay described in section 3.1.   Previous reports have characterised the 
effects of these SNPs towards methimazole, a probe substrate of the FMOs and 
therefore, the activity of the variant FMO3 proteins towards methimazole was also 
tested.          
 
 
 
  174 
Positions of genetic and amino acid substitutions are shown above.  Exons are numbered.  G308 (B) and P360 (C) polymorphic variants were 
constructed on the M486 background (A), whereas K158 (E) and K158/G308 (F) were on the I486 background (D).
Figure 3.2.1: Polymorphic Variants of Human FMO3 investigated in this Chapter 
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Methimazole S-Oxygenation by human FMO3 Amino Acid Variants  
All protein variants were first tested for catalytic activity towards methimazole to 
ensure that the insect cell microsomes were of good quality.  The rate of methimazole 
S-oxygenation was monitored spectrophotometrically by monitoring the rate of 
decrease of 5-thio-2-nitrobenzoic acid (TNB) at 412 nm. Methimazole assays were 
performed in triplicate on batches of microsomes isolated from three independent 
infections of Sf9 cells.  Steady state kinetic parameters, KM and Vmax were 
determined for wild type and variant FMO3 proteins using the non-linear regression 
application of the Kinetics module (v.3.1) of SigmaPlot (v.10).   Turnover number 
was calculated using Vmax values and enzyme concentration as described in chapter 
2.9.8.2.  The findings are summarised in Table 3.2.2 and 3.2.3. 
  All variant proteins catalysed methimazole S-oxygenation and a hyperbolic 
Michaelis-Menten relationship was observed between methimazole concentration and 
the initial rate of TNB disappearance.   
Wild type (M486) (Fig. 3.2.1A) S-oxygenated methimazole with a turnover 
number (kcat) and Michaelis constant (KM) of 2.95 ± 0.25 min
-1 and 31.45 ± 2.05 µM 
respectively.  These finding are in agreement with previously published data (Dolphin 
et al. 1997) (Table 3.2.2).  Table 3.2.2 summarises kinetic data for FMO3 G308 (Fig. 
3.2.1B) and FMO3 P360 (Fig. 3.2.1C) in comparison to wild type (M486) (Fig 
3.2.1A).  FMO3 G308 catalysed methimazole oxygenation with a kcat of 2.03 ± 0.83 
min
-1 and a KM  of 49.50 ± 5.45 µM.  This represents a 30% decrease in the turnover 
number of FMO3 G308 when compared to that of wild type (M486) (p<0.05). The 
KM  of FMO3 G308 is observed to be higher than that of wild type (M486) but this 
difference was not statistically significant (p>0.05).  Although direct comparison to 
published data is not possible (as published work refers to this SNP expressed on the I486 background), the general effect of this SNP is in agreement with published data.  
Lattard and co-workers report a ~25% decrease in catalytic activity and a 2.4-fold 
increase in KM, similar to findings in this study (Lattard et al. 2003).  Kinetic analysis 
of FMO3 P360 showed this protein to be significantly more efficient at methimazole 
oxygenation than wild type (M486) (p<0.05) with a kcat of 35.45 ± 3.50 min
-1.  The 
turnover number for this variant is 4 -fold greater than that found for wild type 
(M486). There was no significant difference however, in the KM  values determined 
for the two proteins (p>0.05).  This trend is in good agreement with work in previous 
publications in which a 4-fold increase in Vmax was observed (Lattard et al. 2003).     
Table 3 summarises kinetic data for FMO3 K158 (Fig 3.2.1E) and FMO3 
K158/G308 (Fig 3.2.1F) in comparison to wild-type (I486) (Fig 3.2.1C).   Wild type 
(I486) catalysed methimazole oxygenation and displayed a kcat of 6.26 ± 1.55 min
-1 
and a KM of 24.50 ± 1.70 µM.  These kinetic parameters are within a similar range to 
those already published (Lattard et al. 2003; Koukouritaki et al. 2007).  kcat and KM  
values for FMO3 K158 catalysed methimazole oxygenation was found to be 7.25 ± 
2.91 min
-1 and 39.40 ± 2.41 µM respectively.  No significant difference was observed 
in the turnover number between FMO3 K158 and wild type (I486) (p>0.05). This 
data supports previous findings (Lattard et al. 2003).  The double mutant, K158 / 
G308 had significantly reduced activity compared to that of wild type (I486).  The 
double mutant catalysed methimazole S-oxygenation with a kcat  of 0.60 ± 0.09 min 
-1 
and a KM  of  570 ± 26 µM.  These kinetic parameters are significantly different from 
those determined for wild type I486.  The trend is in agreement with previously 
published data, whereby the double mutant has diminished activity compared to that 
of wild type FMO3, and the single variants K158 and G308.  The KM of methimazole  
 
 
  177Table 3.2.2: Methimazole S-oxygenation by human FMO3 (M486) and FMO3 
amino acid variants 
 
 
 
 
 
FMO3 Variant  KM  
(µM) 
kcat  
(min
-1) 
kcat / KM 
(min
-1 M
-1) (x10
4) 
Relative Activity 
(%) 
 
Wild type (M486) 
 
31.45 ± 2.05 
 
2.95 ± 0.25 
 
9.2 ± 2.10 
 
100% 
 
FMO3 G308 
 
49.50 ± 5.45 
 
2.03 ± 0.83 
 
4.10 ± 0.67 
 
45%* 
 
FMO3 P360 
 
35.45 ± 3.50 
 
12.20 ± 3.45 
 
34.5 ± 0.21 
 
375%* 
 
The  S-oxygenation of methimazole by human FMO3 variants was determined as 
described in section 2.9.8.1.  KM  (µM), kcat ( min
-1), kcat / KM ( min
-1 / M
-1) are 
reported as mean ± standard error obtained from enzyme assays performed in 
triplicate on microsomes isolated from three independent infections of Sf9  cells.  
Relative catalytic activity compared to that of wild type FMO3 is displayed (%). 
 
*p<0.05 compared to the result of obtained for wild type (M486) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  178Table 3.2.3: Methimazole S-oxygenation by human FMO3 (I486) and FMO3 
amino acid variants 
 
 
 
 
FMO3 Variant  KM  
(µM) 
kcat  
(min
-1) 
kcat / KM 
(min
-1 M
-1) (x10
5) 
Relative Activity 
(100%) 
 
Wild type (I486) 
 
24.50 ± 1.70 
 
6.26 ± 1.55 
 
2.56 ± 0.66 
 
100% 
 
FMO3 K158 
 
39.4 ± 2.6 
 
7.25 ± 2.91 
 
1.85 ± 0.78 
 
70% 
 
FMO3 K158 / G308 
 
570 ± 26 
 
0.66 ± 0.04 
 
0.12 ± 0.08 
 
5%** 
 
The S-oxygenation of methimazole by human FMO3 variants is described in section 
2.9.8.1.  KM (µM), kcat (min
-1), kcat / KM (min
-1 / M
-1)  are reported as mean ± 
standard error obtained from enzyme assays performed in triplicate on microsomes 
isolated from three independent infections of Sf9 cells.  Relative catalytic activity 
compared to that of wild type FMO3 is displayed (%). 
**p<0.005 compared to the result of obtained for wild type (I486) 
 
 
 
 
 
 
 
  179was found to be several orders of magnitude higher than that reported by Lattard and 
co-workers (Lattard et al. 2003).  This group also report a higher Vmax  for the 
reaction than was observed in this investigation.   However, overall catalytic 
efficiency of K158/G308 determined in this chapter (as kcat  /KM) and by Lattard et 
al. (as Vmax / KM) are very similar (5% and 9% of wild type FMO3 activity 
respectively).   
 
TAZ S-Oxygenation by human FMO3 Amino Acid Variants  
Rate of TAZ oxygenation catalysed by FMO3 protein variants was assessed by 
monitoring the rate of decrease in TAZ at 328 nm (described in chapter 2.9.8.2).  TAZ 
assays were performed in triplicate on batches of microsomes isolated from three 
independent infections of Sf 9 cells.  Steady state kinetic parameters, KM and Vmax 
were determined for wild type and variant FMO3 proteins using the non linear 
regression application of the Kinetics module (v.3.1) of SigmaPlot (v.10).   Turnover 
number was calculated using Vmax values and enzyme concentration as described in 
chapter 2.9.8.2.  These findings are summarised in Table 3.2.4 and 3.2.5. 
FMO3 wild type (M486) (Fig.3.2.1A), FMO3 G308 (Fig 3.2.1B) and FMO3 
P360 (Fig 3.2.1C) were capable of TAZ oxygenation.  Analysis of Michaelis-Menten 
plots confirmed a hyperbolic relationship between enzyme activity and initial rates of 
TAZ disappearance (Fig. 3.2.2 A-C).   
  The reaction between TAZ and FMO3 wild type (M486) was found to have a 
kcat and KM   of 1.47 ± 0.37 min
-1 and 8.2 ± 0.70 µM respectively.  This data is in 
good agreement with kinetic parameters determined in section 3.1.  FMO3 G308 
catalysed TAZ oxygenation with an observed kcat of 0.35 ± 0.09 min
-1 and a KM of 
14.40 ± 3.52.  
  180Table 3.2.4: S-oxygenation of TAZ by Human FMO3 (M486) and FMO3 amino 
acid variants 
 
 
 
FMO3 Variant  KM  
(µM) 
kcat  
(min
-1) 
kcat / KM 
(min
-1 M
-1) (x10
5) 
Relative Activity 
(%) 
 
Wild type (M486) 
 
8.2 ± 0.70 
 
1.47 ± 0.37 
 
1.80 ± 0.34 
 
100% 
 
 
FMO3 G308 
 
14.40 ± 3.52 
 
0.35 ± 0.09 
 
0.24 ± 0.13 
 
14%** 
 
FMO3 P360 
 
8.53 ± 0.83 
 
4.05 ± 0.57 
 
4.75 ± 0.81 
 
263%* 
 
The S-oxygenation of TAZ by human FMO3 variants is described in section 2.9.8.2.  
KM (µM), kcat (min
-1), kcat / KM (min
-1 / M
-1)  are reported as mean ± standard error 
obtained from enzyme assays performed in triplicate on microsomes isolated from 
three independent infections of Sf9 cells.  Relative catalytic activity compared to that 
of wild type FMO3 is displayed (%). 
 
 
*p<0.05 compared to the result of obtained for wild type (M486) 
**p<0.005 compared to the result of obtained for wild type (M486) 
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Table 3.2.5: S- oxygenation of TAZ by Human FMO3 (I486) and FMO3 amino 
acid variants 
 
 
FMO3 Variant  KM 
(µM) 
kcat 
(min
-1) 
kcat / KM 
(min
-1 M
-1)(x10
5) 
Relative Activity 
(%) 
 
Wild type (I486) 
 
10.80 ± 1.33 
 
1.70 ± 0.25 
 
1.57 ± 0.30 
 
100% 
 
FMO3 K158  
 
8.80 ± 0.57 
 
1.87 ± 0.19 
 
 
 
2.12 ± 0.26 
 
135% 
 
FMO3 KI58 / G308 
 
N.D 
 
N.D 
 
 
N.D 
 
N.D 
 
 
The S-oxygenation of TAZ by human FMO3 variants is described in section 2.9.8.2.    
KM (µM), kcat (min
-1), kcat / KM (min
-1 / M
-1)  are reported as mean ± standard error 
obtained from enzyme assays performed in triplicate on microsomes isolated from 
three independent infections of Sf9 cells.  Relative catalytic activity compared to that 
of wild type FMO3 is displayed (%). 
 
N.D: Enzyme activity was not detected. 
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Figure 3.2.2A: Non-linear regression and linear transformation of the Michaelis-
Menten equation for FMO3 wild type (M486) catalysed TAZ oxidation  (A) 
Michaelis-Menten curve of TAZ oxygenation catalysed by Sf9 insect cell microsomes 
containing heterologously expressed FMO3 wild type (M486) in the presence of 
NADPH and a buffer at pH 8.4. (B) Linear transformation of Michaelis-Menten data 
using Hanes-Woolf regression.       
  183Figure 3.2.2B: Non-linear regression and linear transformation of the Michaelis-
Menten equation for FMO3 G308 catalysed TAZ oxidation (A) Michaelis-Menten 
curve of TAZ oxygenation catalysed by Sf9 insect cell microsomes containing 
heterologously expressed FMO3 G308 in the presence of NADPH and a buffer at pH 
8.4. (B) Linear transformation of Michaelis-Menten data using Hanes-Woolf 
regression.       
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Figure 3.2.2C: Non-linear regression and linear transformation of the Michaelis-
Menten equation for FMO3 P360 catalysed TAZ oxidation (A) Michaelis-Menten 
curve of TAZ oxygenation catalysed by Sf9 insect cell microsomes containing 
heterologously expressed FMO3 P360 in the presence of NADPH and a buffer at pH 
8.4. (B) Linear transformation of Michaelis-Menten data using Hanes-Woolf 
regression.       
 
  185Compared to wild type (M486), this variant shows a significant decrease in TAZ 
oxygenation activity.  The kcat / KM of this reaction is approximately 85% lower than 
that of wild type (M486) (p<0.005).  A small increase in the KM  of the reaction 
between FMO3 G308 and TAZ was observed when compared to that of wild type 
(M486) and TAZ, however this is not of statistical significance (p>0.05).  These 
findings suggest that individuals expressing FMO3 G308 in the liver may metabolise 
TAZ at a much lower rate than those who possess the wild type form.  Analysis of 
FMO3 P360 found this enzyme to be significantly more efficient at TAZ oxygenation 
than wild type (M486) (p< 0.05).  The kcat of the FMO3 P360 catalysed reaction was 
found to be 4.05 ± 0.57 min
-1, 2.7-fold greater than that observed for wild type 
(M486).  No significant difference was observed in the KM  of TAZ and FMO3 P360 
(8.53 ± 0.83 µM) compared to that of wild type (M486) and TAZ (p>0.05).   These 
findings suggest that individuals possessing this variant in the liver are likely to 
metabolise TAZ much faster than those who possess the wild type form. 
FMO3 wild type (I486) (Fig.3.2.1D) and FMO3 K158 (Fig 3.2.1E) were 
capable of TAZ oxygenation. Analysis of Michaelis-Menten plots confirmed a 
hyperbolic relationship between enzyme activity and initial rates of TAZ 
disappearance (Fig. 3.2.3A and B).  No TAZ oxygenation activity was observed for 
the K158/G308 variant of FMO3.    
kcat values for wild type (I486) and FMO3 K158 catalysed TAZ oxygenation 
were determined as 1.70 ± 0.25 and 1.87 ± 0.19 min
-1 respectively (see Fig. 3.2.1 D 
and E).  KM values for wild type (I486) and FMO3 K158 towards TAZ were found to 
be 10.80 ± 1.33 and 8.80 ± 0.57 µM respectively (Table 3.2.5).  kcat and KM values 
for FMO3 K158 were not statistically different to those determined for wild type 
(I486) (Table 3.2.5).  This suggests that individuals expressing this variant in the liver  
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Figure 3.2.3A: Non-linear regression and linear transformation of the Michaelis-
Menten equation for FMO3 wild type (I486) catalysed TAZ oxidation  (A) 
Michaelis-Menten curve of TAZ oxygenation catalysed by Sf9 insect cell microsomes 
containing heterologously expressed FMO3 wild type (I486) in the presence of pH 
NADPH and a buffer at pH 8.4. (B) Linear transformation of Michaelis-Menten data 
using Hanes-Woolf regression.       
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Figure 3.2.3B: Non-linear regression and linear transformation of the Michaelis-
Menten equation for FMO3 K158 catalysed TAZ oxidation (A) Michaelis-Menten 
curve of TAZ oxygenation catalysed by Sf9 insect cell microsomes containing 
heterologously expressed FMO3 K158 in the presence of NADPH and a buffer at 8.4. 
(B) Linear transformation of Michaelis-Menten data using Hanes-Woolf regression. 
 
 
       
  188are likely to metabolise TAZ at similar rates to those possessing the wild type form.  
No activity was detected for FMO3 K158 /G308 towards TAZ at the tested TAZ 
concentrations (Table 3.2.5). This suggests that the double mutant is either, not 
capable of TAZ oxygenation, or that the reaction has a significantly higher Michaelis 
constant for TAZ. 
 
Finally, kinetic parameters obtained for TAZ and methimazole S-oxygenation 
catalysed by wild type M486 and I486 were compared.  Table 3.2.6 summarises 
kinetic data determined for FMO3 wild type (M486) and wild type (I486) with 
methimazole.    
Data shows a significant difference in kcat values between wild type (M486) 
and wild type (I486) (p<0.005).  Wild type (I486) is approximately twice as efficient 
at methimazole oxidation as wild type (M486).  No significant difference in KM  
values was observed between the two proteins (p>0.05).  In terms of TAZ 
oxygenation, wild type (486M) catalysed this reaction with a kcat of 1.47 ± 0.37 min
-
1, whereas a kcat  of 1.70 ± 0.25 min
-1  was observed for wild type (I486) (Table 
3.2.7). Therefore no significant difference was found in the rate of TAZ oxygenation 
by wild type (M486) and wild type (I486) (p>0.05).  These findings suggest that the 
M486 mutation is reducing its catalytic efficiency in a substrate-specific manner.    It 
is therefore important for this mutation to be addressed in future work in this field.       
  
HapMap Frequency Analysis of human FMO2 and FMO3 Variations 
Tables 3.2.4 - 6 illustrate how single nucleotide polymorphisms in the FMO3 gene 
can result in the alteration of enzyme activity towards a given substrate.  This may a 
  189affect the metabolism of a therapeutic drug and furthermore have an impact on the 
outcome of such a compound in vivo.   In the second part of this section, analysis of 
HapMap was undertaken to establish whether individuals possessing the ‘rapid’ 
variant of FMO3 might also possess the ancestral allele encoding the functional 
FMO2.1 protein.  The reason why this is deemed important is because functional 
FMO2.1 is expressed only in a proportion of sub-Saharan African and Hispanic 
individuals and the enzyme, as demonstrated in section 3.1, is capable of oxidising 
TAZ to metabolites that are expected to be detrimental to a cell.   Therefore 
individuals expressing this protein in the lung and FMO3 P360 in the liver may be at 
higher risk of adverse drug reactions.   
HapMap is an international collaboration that catalogues genetic differences 
and similarities in humans of different ethnic populations.  This allows one to 
investigate variations in several genes in a given individual.    Table 3.2.8 depicts 
information derived from HapMap on individuals from three African populations who 
possess at least one copy of g.21599T>C (L360P) SNP in FMO3.  Table 3.2.8 also 
identifies which variant of FMO2 these individuals possess. 
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Table 3.2.6: S-oxygenation of methimazole by Human FMO3 (M486) and FMO3 
(I486) 
 
 
FMO3 Variant  KM  
(µM) 
kcat  
(min
-1) 
kcat / KM 
(min
-1 M
-1) (x10
5) 
 
Wild type (M486) 
 
 
 
31.45 ± 2.05 
 
 
2.95 ± 0.25 
 
 
9.2 ± 2.10 
 
Wild type (I486) 
 
 
 
24.50 ± 1.70 
 
 
6.26 ± 1.55** 
 
 
2.56 ± 0.66 
The S-oxygenation of methimazole by human FMO3 (M486) and (I486) is described 
in section 2.9.8.1.  KM (µM), kcat (min
-1), kcat / KM (min
-1 / M
-1)  are reported as 
mean ± standard error obtained from enzyme assays performed in triplicate on 
microsomes isolated from three independent infections of Sf9 cells. 
 
**p<0.005 compared to the result obtained for wild type (M486) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  191Table 3.2.7: S- oxygenation of TAZ by Human FMO3 (M486) and FMO3 (I486) 
 
 
 
 
The S-oxygenation of TAZ by human FMO3 variants is described in section 2.9.8.2.  
KM (µM), kcat (min
-1), kcat / KM (min
-1 / M
-1) are reported as mean ± standard error 
obtained from enzyme assays performed in triplicate on microsomes isolated from 
three independent infections of Sf9 cells. 
FMO3 Variant  KM  
(µM) 
kcat  
(min
-1) 
kcat / KM 
(min
-1 M
-1) (x10
5) 
 
Wild type (M486) 
 
 
8.2 ± 0.70 
 
1.47 ± 0.37 
 
1.80 ± 0.34 
 
Wild type (I486) 
 
 
10.80 ± 1.33 
 
1.70 ± 0.25 
 
1.57 ± 0.30 
 
 
 
 
 
 
 
 
 
 
 
 
 
  192Table 3.2.8: Data extracted from HapMap for FMO3 g.21599T>C (FMO3 
360Pro/Leu) and FMO2 g.23238C/T (FMO2-472Gln/STOP). 
 
 
 
HapMap Chromosome 
Identifier No. 
 
FMO3 g.21599T>C 
(FMO3 360Pro/Leu) 
 
 
FMO2  g.23238C>T 
FMO2 – 472Gln/STOP 
 
Population 
NA20340_c1 
NA20340_c2 
 
 
C  (360Leu) 
T   (360Pro) 
T   472 STOP 
          C   472 Gln 
ASW 
 
NA19438_c1 
NA19438_c2 
 
T   (360Pro) 
C  (360Leu) 
T     472 STOP 
T     472 STOP 
LKW 
 
NA19182_c1 
NA19182_c2 
T   (360Pro) 
C   (360Leu) 
T     472 STOP 
T     472 STOP 
YRI 
 
NA18855_c1 
NA18855_c2 
T   (360Pro) 
C   (360Leu) 
T     472 STOP 
T     472 STOP 
YRI 
NA19093_NA19092_c1 
NA19093_NA19092_c2 
C   (360Leu) 
T   (360Pro) 
 
 
T     472 STOP 
NO DATA 
AVAILABLE 
YRI 
 
 
 (HapMap Genome Browser (Phase 3 - genotypes, frequencies & LD, 
www.hapmap.org).  ASW = African ancestry in Southwest USA (population sampled: 
82 individuals). YRI = Yoruba in Ibadan, Nigeria (population sampled: 256 
individuals). LKW = Luhya in Webuye, Kenya (population sampled: 268 
individuals). 
 
 
  193Given that the g.21599T>C (L360P) polymorphisms encodes a protein with 
higher catalytic activity, it is of particular interest to assess the frequency at which it 
occurs in cis with FMO2 g.23238C (Q472, FMO2.1).  Such individuals will express 
functional FMO2 in their lungs and a rapid metaboliser of TAZ in the liver.  Analysis 
of the African data set on HapMap identifies one individual (out of a sample of 82), of 
African-American descent to be heterozygous for g.21599T>C (L360P) and FMO2 
g.23238C (Q472).  Given the small sample size (82 individuals) and the fact that 
L360P is a rare polymorphism it is of no surprise that only one individual was 
identified.  Nevertheless, this finding is of importance as it confirms that the two 
polymorphisms can and do occur together.  Allelic frequencies cannot be calculated 
from data obtained from one individual and so we have considered frequency data of 
g.21599T>C (L360P) and FMO2 g.23238C (Q472) that have been published by 
studies employing larger samples. The number of individuals estimated to possess at 
least one copy of the ancestral allele of FMO2.1 is 28% in African-Americans 
(Dolphin 1998, Whetstine 2000).  The frequency of individuals heterozygous for the 
g.21599T>C (L360P) polymorphism has been determined as 2% in an African-
American population (Furnes and Schlenk 2003).   Thus assuming that the variations 
assort independently, the frequency at which they occur in cis can be estimated by 
multiplying the individual frequencies.  By doing so, it is estimated that 0.56% of 
African-American individuals will encode FMO3 P360 and FMO2.1 in their liver and 
lungs respectively.  Given that the population of African-Americans is approximately 
36 million, the number of individuals possessing at least one copy of these 
polymosphisms in cis is estimated to be around 20,000.  Though not a considerably 
high number, it must be noted that this figure may be in the order of several million in 
  194sub-Saharan Africa (where these individuals have originally come from) since the 
population of this area is in excess of 800 million.      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  195Discussion – Kinetic Parameters of FMO3 Amino Acid Variants 
 
 
The impact of pharmacogenetics on anti-tubercular drug metabolism has been 
established.   Isoniazid (INH), an anti-tubercular prescribed since the 1950’s is a pro-
drug that requires metabolic activation by the Mycobacterial catalase-peroxidase 
KatG to generate an irreversible inhibitor of the FAS II enzyme, InhA(Zhang et al. 
1992; Banerjee et al. 1994).  Variant alleles of human arylamine N-acetyltransferase 
2 are implicated in the altered metabolism of Isoniazid.   The drug undergoes 
acetylation in the liver by arylamine N-acetyltransferase 2 (NAT2) and this process 
represents the inactivation of the drug (reviewed in (Preziosi 2007)).    The human 
population can be divided into ‘rapid’, ‘moderate’ and ‘slow’ acetylators depending 
on which variant allele of NAT2 they possess(Parkin et al. 1997; Singh et al. 2009).  
‘Slow’ acetylators have slower rates of INH acetylation in the liver and are more 
likely to develop neuropathy and hepatotoxicity as a result of the accumulation of 
toxic intermediates of INH than those who are ‘rapid’ acetylators (Ellard et al. 1976; 
Timbrell et al. 1977; Ellard et al. 1981; Possuelo et al. 2008). 
  Thiacetazone (TAZ) was once a widely prescribed drug against tuberculosis in 
Africa, Asia, South America and Germany (Anonymous 1963; Anonymous 1968; 
Heffernan 1968; Anonymous 1971; Mame Thierno, On et al. 2001).  But numerous 
reports of TAZ-induced dermatological reactions and hepatotoxicity led to this drug 
being discontinued in the industrialised world (Narang ; Harland 1962; Aquinas 1968; 
Axton 1971; Hussain et al. 1973; Bedi et al. 1974; Gupta et al. 1977; Fegan et al. 
1991; Fegan et al. 1991; Chintu et al. 1993; Ipuge et al. 1995; GOTHI 1998 ; Dieng et 
al. 2001; Mame Thierno et al. 2001). Severe cutaneous rashes including Stevens-
Johnson syndrome have frequently been reported for patients taking TAZ and early 
studies on this drug have shown ethnic-dependent side effects (Miller et al. 1966).  
  196Despite the availability of more effective and ‘safer’ antibiotics, certain parts of 
Africa still receive TAZ as part of treatment for TB because of the lack of resources 
(Lawn et al. 1999; (Keus et al. 2003).  To date the underlying cause of the observed 
adverse reactions has not been explained.  It has been suggested that the toxicity may 
be driven by the parent compound, by a reactive metabolite, impairment in 
detoxification processes or by any combination of these factors (Park et al. 1990). 
  In humans the major FMO involved in hepatic drug metabolism is FMO3. 
Expression of FMO3 while largely restricted to the liver in humans is expressed in the 
skin in amounts comparable to other Phase I metabolising enzymes such as CYPs 
2A6, 2B6 and 3A4 (Janmohamed et al. 2001).  FMO3 is encoded from a highly 
polymorphic gene and several polymorphisms give rise to amino acid variants with 
altered catalytic capacity (reviewed in (Phillips et al. 2008)).  This section of the 
thesis describes five amino acid variants of human FMO3 and their capacity to 
catalyse TAZ oxygenation.  It is important to assess the catalytic activity of 
commonly occurring amino acid variants of FMO3 towards TAZ oxygenation given 
that the in vitro reaction between FMO3 and TAZ represents one of bioactivation as it 
generates metabolites that represent chemically reactive species (discussed in section 
3.1).  It is expected that the catalytic efficiency of an FMO3 variant will dictate the 
amount of reactive products produced (discussed in section 3.1). 
    The most common polymorphism  g.15167G>A (E158K) has an allelic 
frequency ranging from 19-50% depending on the population sampled (Dolphin, 
Riley et al. 1997; Park, Chung et al. 1999; Zschocke, Kohlmueller et al. 1999; 
Cashman and Zhang 2002; Park, Kang et al. 2002; Lattard, Zhang et al. 2003; 
Koukouritaki, Poch et al. 2005; Hao, Sun et al. 2007).  In African-Americans, the 
frequency ranges from 45-50% and is the most common FMO3 polymorphism found 
  197in this ethnic group (Dolphin et al. 1997; Lattard et al. 2003; Hao et al. 2007).   
Heterozygotes for this polymorphism showed no significant decrease in TMA N-
oxidation as judged by the excretion of free TMA in urine (Zschocke et al. 1999).  In 
vitro studies by other groups have also shown the lack of significant effect of E158K 
amino acid substitution on FMO3 catalysis towards several substrates (Lattard et al. 
2003; Zhang et al. 2003; Koukouritaki et al. 2005; Shimizu et al. 2007).   This finding 
is confirmed in this investigation where no significant difference was observed in the 
E158K protein ability to catalyse S-oxygenation of TAZ and methimazole.  This 
suggests that individuals possessing only this polymorphism of FMO3 are not likely 
to metabolise TAZ less efficiently than those possessing the wild type enzyme. 
    A relatively common polymorphism g.21443A>G (E308G) has an allelic 
frequency of 5-26% depending on the population sampled (Akerman et al. 1999; Park 
et al. 1999; Cashman et al. 2001; Dolan et al. 2005; Koukouritaki et al. 2005; Hao et 
al. 2007). The E308G mutation, unlike E158K, is less prevalent in African- 
Americans, occurring in approximately 5% of individuals (Koukouritaki et al. 2007).   
In vivo studies have shown the variant to have little consequence catalytically to 
FMO3 efficiency (Sachse et al. 1999; Lambert et al. 2001).  Kinetic data determined 
for heterologously expressed G308 have shown moderate but substrate specific effects 
of this mutation on enzyme catalysis (Stormer 2000; Lattard et al. 2003).   In this 
investigation we observe a significant decrease in enzyme efficiency.  In the case of 
methimazole S-oxygenation, a decrease of 55% was observed (Table 3.2.2) (P<0.05). 
In the case of TAZ oxygenation, the E308G variant retained just 20% of the wild type 
FMO3 capacity (p<0.005) as a measure of kcat /KM.    This finding supports previous 
reports that G308 displays substrate-specific catalytic efficiency.   In terms of TAZ 
metabolism, individuals expressing the G308 variant are likely to metabolise TAZ at a 
  198slower rate in the tissues that normally express FMO3, the liver and skin, compared to 
those who possess wild type FMO3. This may be beneficial for individuals receiving 
TAZ as chemotherapy.   The advantages of possessing a ‘slower’ enzyme are 
discussed below. 
  The two polymorphisms g.15167G>A (E158K) and g.21443A>G (E308G) 
occur in cis at an allelic frequency ranging from 1-16% depending on the population 
sampled (Cashman et al. 2001; Hao et al. 2007; Koukouritaki et al. 2007).  In 
African- Americans, a small proportion (~1 %) of individuals possess a haplotype in 
which g.15167G>A (E158K) and g.21443A>G (E308G) exist in cis (Allerston et al. 
2007; Koukouritaki et al. 2007).  The K158/G308 double variant when found in cis 
has previously been shown to reduce FMO3 activity by around 50% in vivo (as 
measured by the amount of free TMA excreted in urine samples compared to control 
subjects) (Akerman et al. 1999; Akerman et al. 1999; Zschocke et al. 1999; Zschocke 
et al. 2000).  Another in vivo study investigating the metabolism of the H2-receptor 
antagonist ranitidine, showed less ranitidine N-oxide, compared to control subjects, in 
the urine of individuals possessing the K158/G308 variant (Park et al. 2002). The 
activity of in vitro expressed K158/G308 shows a dramatic reduction in catalytic 
activity when compared to either the K158 or G308 single variants (Park et al. 2002; 
Lattard et al. 2003).  The kinetic data presented in this investigation supports these 
findings.  The double variant displayed a significant reduction in enzyme efficiency, 
retaining just 5% of FMO3 activity towards the S-oxygenation of methimazole (as a 
measure of kcat/KM) (p<0.005).  TAZ oxygenation catalysed by this variant was not 
observed at the tested TAZ concentrations.  This may indicate that the enzyme has 
lost the ability to oxygenate TAZ as an effect of the amino acid substitutions, or that 
the variant has a considerably higher Michaelis constant for this substrate.  The 
  199finding that the double variant has reduced activity towards TAZ and methimazole is 
of concern to FMO3-substrate metabolism with particular reference to substrates of 
therapeutic importance.  FMO3-substrate metabolism shown to be affected by the 
reduction of in catalytic efficiency of the K158/G308 variant occurring in cis includes 
the H2-receptor antagonist ranitidine (Park et al. 2002) and the non-narcotic, non-
steroidal anti-inflammatory drug, sulindac (Hamman et al. 2000; Hisamuddin et al. 
2004; Hisamuddin et al. 2005).  In the latter case, a less active FMO3 enzyme has 
been shown to be beneficial.  The K158/G308 double variant is implicated in having a 
protective effect on the development of polyps in familial adenomatous polyposis 
patients who received sulindac as part of primary chemoprevention.  The prodrug 
sulindac, is converted by gut bacteria to the active metabolite sulindac sulphide.   
FMO3 inactivates the drug by converting it to sulindac sulphoxide.  The beneficial 
outcome for a patient with an FMO3 protein with reduced enzyme activity is 
presumed to be the result of the reduced ability of this enzyme to inactivate the drug 
and thus leading to prolonged exposure to the active form of sulindac, sulindac 
sulphide (Hisamuddin et al. 2004; Hisamuddin et al. 2005).  The K158/G308 variant 
protein therefore has the potential to affect the efficacy of a given therapeutic agent.  
In the case of TAZ, the double variant K158/G308 and the single variant FMO3 G308 
(described above) may both be advantageous to those receiving TAZ as part of TB 
treatment. Mycobacterial infections are treated when TAZ is activated by the bacterial 
FMO, EtaA (Qian et al. 2006; Alahari et al. 2007).  This results in cell death.  The 
reaction of FMO3 and TAZ in vivo would therefore represent a ‘non-specific’ TAZ-
activation event that would not just give rise to chemically reactive species in a 
mammalian cell (which we wish not to harm) but would also reduce the amount of 
pro-drug reaching the Mycobacteria at the site of infection.  This scenario is likely to 
  200not only reduce the efficacy of the drug but also to produce harmful side effects in the 
patient. So an individual who possesses an FMO3 variant which is catalytically 
inefficient may be at a lower risk of TAZ bioactivation in the liver and skin and is 
likely also to have increased drug delivery to the site of infection and thus increase 
and prolong the exposure of the Mycobacteria to TAZ. 
  A rare polymorphism, g.21599T>C (L360P), is observed at an allelic 
frequency of about 2% in African-American populations (Furnes et al. 2003; Lattard 
et al. 2003).  The polymorphism is thought to be unique to this ethnic group as it has 
not been identified in Caucasians and Asians (Furnes et al. 2003; Lattard et al. 2003).  
In vitro studies of heterologously expressed protein have shown that FMO3 P360 is 
the only known variant of FMO3 to display an increased catalytic efficiency to 
substrates.  The substrates investigated were methimazole, TMA and 10-(N,  N-
dimethylaminopentyl)-2-(trifluoromethyl) phenothiazine (5-DPT) (Lattard et al. 
2003).  This variant has therefore both increased N- and S-oxygenation activity. In the 
studies we undertook, the P360 variant showed significantly higher catalytic 
efficiencies towards both TAZ and methimazole when compared to wild type FMO3 
(p<0.05).   No data has been published on the in vivo consequence of this 
polymorphism for drug metabolism.  With respect to TAZ metabolism, we speculate 
that individuals expressing the P360 variant may be at higher risk of mediating TAZ 
activation in the liver and skin for reasons described above.  The formation of 
chemically reactive and oxidising metabolites (described in section 3.1) and depletion 
of TAZ may be detrimental to individuals possessing this variant. 
  The functional effects of the g.24642G>A (M486) polymorphism have been 
investigated.  The allelic frequency of this polymorphism is yet to be determined.  
Kinetic data obtained as part of this investigation has shown this variant to have 
  201significantly reduced catalytic efficiency towards methimazole (but not to TAZ) when 
compared to wild type FMO3 (I486), as a measure of the turnover number (p<0.05).  
This finding supports previously described data regarding the substrate-specific 
effects of certain amino acid substitutions on FMO3 activity.                     
  In this section, the effect of five polymorphic variants on FMO3 enzyme 
catalysis has been discussed, with particular reference to methimazole and TAZ.   
Work in this section has focussed on functional effects of genetic polymorphisms 
identified in the coding region of the human FMO3 gene and discussed how they 
might influence the metabolism of an anti-tubercular in vivo.  However, it must be 
noted that genetic variations in upstream sequences (promoter and enhancer) of the 
gene have not been analysed.  It is possible than an individual expressing a ‘slow’ 
variant of FMO3 like G308 or K158/G308 may have additional polymorphisms in the 
promoter region of this gene, whereby the expression of the protein is upregulated. 
The production of more ‘slow enzyme’ would therefore be expected to have a 
compensatory effect.  Promoter variations have been identified by Koukouritaki and 
co-workers and are shown to vary within ethnic groups(Koukouritaki et al. 2005; 
Koukouritaki et al. 2007).  Interestingly the group reported an inferred frequency of 
5.6% of African-American individuals to possess a haplotype which encodes a high 
activity promoter and at least one of the g.15167G>A (E158K) and/or g.21443A>G 
(E308G) polymorphisms.  Haplotype analysis has not been reported for the 
g.21599T>C (L360P) polymorphism, it is yet to be seen whether an upstream 
polymorphism will mask or exacerbate the functional effects of this variant.   
  In the second part of this section, an attempt was made to estimate the 
frequency of individuals that possess the g.21599T>C (L360P) and the g.23238C 
(Q472) alleles in cis.  Though just a rough estimate, it was determined that more than 
  20220,000 Africans in America and in excess of 4 million people in sub-Saharan Africa 
may express FMO2.1 and FMO3 P360 in their lungs (FMO2.1), liver and skin 
(FMO3).  This may have implications regarding the metabolism of TAZ and other 
xenobiotic compounds that are substrates for these enzymes.      
  Although, to elucidate the cause(s) or mechanism of TAZ-induced toxicity are 
beyond the scope of this investigation, this section has described significant catalytic 
differences in commonly found variants of human FMO3 which may be involved in 
the inter-individual difference observed for the response towards TAZ treatment.     
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  2033.3 Metabolism of Thiacetazone by Mouse Tissue Microsomes 
 
 
Introduction 
Sections 3.1 and 3.2 described the in vitro metabolism of TAZ by heterologously 
expressed human FMOs in microsomes prepared from insect cells.   In this section, 
microsomes prepared from mouse tissue have been used to investigate the relative 
contribution of the flavin containing monooxygenases (FMOs) and cytochrome P450s 
(CYPs) to TAZ metabolism.  
Microsomes prepared from tissue are fragments of membranes of the 
endoplasmic reticulum in suspension, they reflect (among other things) the tissue-
specific expression of Phase I drug metabolising enzymes.  This makes them an 
invaluable tool to investigate the contribution of such enzymes in the metabolism of a 
given substrate in vitro.   A UV spectroscopy assay (described in section 3.1 and 
2.8.2.2) was used to analyse the rate of TAZ metabolism catalysed by microsomes 
isolated from mouse liver and lung.  Mouse liver was investigated for its capacity to 
metabolise TAZ as the first site of metabolism of an orally administered drug is 
thought to be the liver.   The lung was analysed as this is thought to be the site of 
activation of TAZ (by Mycobacterium tuberculosis)  in the case of pulmonary 
tuberculosis.     
The expression of FMOs is known to be sex- and tissue-specific, the key sex-
difference in mice is the absence of FMO3 expression in the liver of adult males (Falls 
et al. 1995; Falls et al. 1997).  FMO3 continues to be expressed in adult, male lung 
(Janmohamed et al. 2004).  Lung and liver microsomes from male and female mice 
were therefore analysed.   Microsomes from liver and lung were prepared from three 
mouse lines; wild type (C57BL/6 mice), Fmo1 (-/-), 2 (-/-), 4(-/-) line and an Fmo 5(-
  204/-) line.  Each of the Fmo knockout lines was produced by back-cross breeding onto 
the C57BL/6 line for 8 generations.  Preparation of microsomes from the three mouse 
lines allowed the investigation of the relative contribution of different members of the 
FMO family of enzymes to TAZ metabolism to be analysed.  
 
Results  
Metabolism of TAZ by Liver Microsomes 
Liver microsomes were prepared from wild type C57BL/6 mice, Fmo1 (-/-), 2 (-/-), 4 
(-/-) and Fmo 5 (-/-) mouse line as described in section 2.10.1.  The rate of TAZ 
metabolism catalysed by mouse liver microsomes was monitored 
spectrophotometrically and is described in section 2.10.2.  Data represent mean ± 
standard deviation obtained from two independent isolations of microsomes.  All 
assays were carried out in triplicate on each batch of microsomes. 
Figures 3.3.1-3 represent Michaelis-Menten plots (Vo versus [TAZ]) obtained 
for female liver microsomes prepared from the three mouse lines.  Liver microsomes 
from all three mouse lines catalysed TAZ metabolism and showed a hyperbolic 
Michaelis-Menten relationship between initial rate of enzyme activity and substrate 
concentration.   
There are five FMO proteins to consider in the mouse. Studies on FMO 
expression in mouse tissues have reported FMO1, FMO3 and FMO5 to be highly 
expressed in female liver whereas FMO2 and FMO4 are not expressed (Falls et al. 
1995; Janmohamed et al. 2004).  Therefore in the case of wild type liver microsomes, 
TAZ metabolism could be due to FMO1, FMO3 or FMO5 (Fig. 3.3.1). Experiments 
shown in Fig. 3.3.2 implicate FMO1 in TAZ metabolism as there is a marked decrease  
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Figure 3.3.1: νo versus [TAZ] plot for TAZ metabolism catalysed by wild type 
female mouse liver microsomes.  The rate of TAZ metabolism by wild type female 
mouse liver microsomes was determined as described in section 2.10.2.  Data are 
mean ± standard deviation obtained from assays carried out in triplicate.   
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Figure 3.3.2: νo versus [TAZ] plot catalysed by wild type and Fmo1 (-/-), 2 (-/-), 4 
(-/-) female mouse liver microsomes.   The rate of TAZ metabolism by wild type and 
Fmo1 (-/-), 2 (-/-), 4(-/-) female mouse liver microsomes was determined as described 
in section 2.10.2.  Data are mean ± standard deviation obtained from assays carried 
out in triplicate.   
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Figure 3.3.3: νo versus [TAZ] plot catalysed by wild type, Fmo1 (-/-), 2 (-/-), 4(-/-) 
and Fmo5 (-/-) female mouse liver microsomes.   The rate of TAZ metabolism by 
wild type, Fmo1 (-/-), 2 (-/-), 4(-/-) and Fmo5 (-/-)   female mouse liver microsomes 
was determined as described in section 2.10.2.  Data are mean ± standard deviation 
from assays carried out in triplicate.   
 
 
 
 
 
 
  208in TAZ metabolism by microsomes isolated from the mouse line that has the Fmo1 
gene deleted.   In contrast, microsomes isolated from the Fmo 5 (-/-) line showed 
similar metabolism to that of wild type microsomes (Fig 3.3.3).  FMO5 therefore does 
not contribute to hepatic TAZ metabolism.  To establish whether these differences 
were significant, rates of TAZ metabolism were analysed at saturating TAZ 
concentrations.  Figure 3.3.4 illustrates a significant decrease in TAZ metabolism by 
microsomes isolated from liver of the Fmo1  (-/-), Fmo2 (-/-), Fmo 4 (-/-)  line 
compared to wild type liver microsomes(P<0.005).   There is no significant 
difference, however between wild type and Fmo 5 (-/-) liver microsomes (P>0.05).  
FMO3 is expressed in liver microsomes from all three mouse line and its contribution 
needs to be addressed.  In the liver of a mouse, FMO3 is expressed in a sex-specific 
manner whereby its expression is ‘turned off’ in males as a result of high testosterone 
levels (Falls et al. 1995; Falls et al. 1997).   In order to distinguish between the 
contribution of FMO1 and FMO3 to the rate of TAZ metabolism, microsomes from 
male liver were prepared.  As shown in Figure 3.3.5 there is no significant difference 
between male and female liver microsomes isolated from wild-type mice, indicative 
that FMO3 is unlikely to contribute to the activity shown by female liver microsomes 
(Fig. 3.3.1-4).  Comparison between male, wild-type and Fmo5 (-/-) liver microsomes, 
shows no significant difference in TAZ metabolism (Fig. 3.3.5) indicating that FMO5 
is unlikely to contribute to this reaction.  A small decrease in TAZ metabolism is 
observed in male Fmo 1 (-/-), 2 (-/-), 4 (-/-) liver microsomes when compared to male 
wild-type liver, however this difference is not statistically significant (p>0.05) (Fig. 
3.3.5).  Compared to female Fmo 1 (-/-), 2 (-/-), 4 (-/-) liver microsomes, male 
microsomes from the same mouse line showed a significant increase in TAZ  
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Figure 3.3.4: Rate of TAZ metabolism observed for female mouse liver 
microsomes.  The rate of TAZ metabolism catalysed by liver microsomes prepared 
from female wild type, Fmo1 (-/-), 2 (-/-), 4 (-/-) and Fmo5 (-/-) mice was determined 
as described in section 2.10.2.  Data are mean ± standard deviation obtained from two 
independent experiments.  Enzyme assays were carried out in triplicate.   
 
**p<0.005 compared to the result obtained from wild type female liver microsomes. 
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Figure 3.3.5: Rate of TAZ metabolism observed for female and male mouse liver 
microsomes.  The rate of TAZ metabolism catalysed by liver microsomes prepared 
from female and male wild type, Fmo1 (-/-), 2 (-/-), 4 (-/-) and Fmo5 (-/-) mice was 
determined as described in section 2.10.2.  Data are mean ± standard deviation 
obtained from two independent experiments.  Enzyme assays were carried out in 
triplicate.   
 
*p<0.05 compared to the result obtained from female Fmo1 (-/-), 2 (-/-), 4 (-/-) liver 
microsomes. 
 
 
 
 
 
 
 
 
  211metabolism (p<0.005).  These findings suggest the contribution of FMOs to TAZ 
metabolism in male mice may be less than in female mice.    
Although FMO contribution to TAZ metabolism has been confirmed, it was 
important to assess whether FMOs are responsible for all of the TAZ metabolism 
observed in the liver. The relative amount of FMO contribution to TAZ metabolism 
was tested by using methods to distinguish between FMO and CYP activity. 
 
Assessing FMO Contribution to TAZ Metabolism in Mouse Liver 
Methimazole is used as a probe substrate and as a competitive inhibitor for FMO 
activity (Dixit et al. 1984; Chung et al. 1997; Rawden et al. 2000; Stormer 2000; 
Virkel et al. 2006).  By acting as a competitive inhibitor, methimazole can be used to 
inhibit FMO-dependent TAZ metabolism. Figure 3.3.6 shows the effect of pre-
incubation of female mouse liver microsomes with methimazole before the addition of 
TAZ.  In the presence of methimazole, a significant decrease in TAZ metabolism is 
observed in the wild type (p<0.005) and Fmo5  (-/-) (p<0.05) female liver 
microsomes, with a reduction of 48% and 35% in enzyme activity respectively. This 
confirms that FMOs contribute to TAZ metabolism.  In the Fmo 1 (-/-), 2 (-/-), 4 (-/-) 
female liver microsomes, however, there is no significant difference between 
methimazole treated and untreated samples (p>0.05). Given that there was no 
significant decrease in TAZ metabolism in microsomes in which the Fmo1 gene had 
been deleted further supports the role of FMO1 in the metabolism of this drug.  In 
male, microsomal liver samples, a decrease in TAZ metabolism activity was observed 
for wild type, Fmo1 (-/-), Fmo2 (-/-), Fmo4 (-/-), and Fmo5 (-/-) knockout lines in the 
presence of methimazole (Fig. 3.3.7), however this was only significant for wild-type  
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Figure 3.3.6: The effect of pre-treatment of female mouse liver microsomes with 
methimazole on the rate of TAZ metabolism. Pre-treatment of liver microsomes 
with methimazole is described in section 2.10.3.1. The rate of TAZ metabolism 
catalysed by liver microsomes prepared from female and male wild type, Fmo1 (-/-), 2 
(-/-), 4 (-/-) and Fmo5 (-/-) mice was determined as described in section 2.10.2.   Data 
are mean ± standard deviation obtained from two independent experiments.  Enzyme 
assays were carried out in triplicate.   
 
*p<0.05  compared to the result obtained from untreated Fmo5 (-/-) female liver 
microsomes. 
*p<0.005  compared to the result obtained from untreated female wild type liver 
microsomes.  
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Figure 3.3.7: The effect of pre-treatment of male mouse liver microsomes with 
methimazole on the rate of TAZ metabolism. Pre-treatment of liver microsomes 
with methimazole is described in section 2.10.3.1. The rate of TAZ metabolism 
catalysed by liver microsomes prepared from male wild type, Fmo1 (-/-), 2 (-/-), 4 (-/-
) and Fmo5 (-/-) mice was determined as described in section 2.10.2.   Data are mean 
± standard deviation obtained from two independent experiments.  Enzyme assays 
were carried out in triplicate.   
 
*p<0.05  compared to the result obtained from untreated wild type male liver 
microsomes. 
 
 
 
 
 
 
 
 
 
  214microsomes (p<0.05) and not for the Fmo knockout lines.  This may indicate a lesser 
contribution of FMOs to TAZ metabolism in male mice.  
Although the use of methimazole as a measure of FMO contribution is 
accepted, methimazole is not a substrate for FMO5 and therefore will not affect its 
activity towards TAZ (Cherrington et al. 1998).  Some reports also claim that 
methimazole may inhibit the activity of certain CYP isoenzymes (Guo et al. 1991).  
To gain more of an understanding of FMO contribution to TAZ metabolism, liver 
microsomes were pre-heated to inactivate FMOs.  Unlike CYPs, FMOs are relatively 
heat labile and this property has been exploited to distinguish between FMO and CYP 
activity in vitro    (Rawden et al. 2000; Stormer 2000; Virkel et al. 2006).  Figure 
3.3.8 illustrates the effects of heat inactivation on TAZ metabolism activity for female 
liver microsomes.  There is a significant reduction in activity for wild type (p<0.005) 
and Fmo5 (-/-) (p<0.05) female liver microsomes, but not for microsomes isolated 
from livers of Fmo1 (-/-), 2 (-/-), 4(-/-) mice (p>0.05).  A 42% and 36% decrease in 
activity is seen for wild type and Fmo5  (-/-) female liver microsomal samples 
respectively.  For male liver microsomes, there was no significant difference in TAZ 
metabolism by liver microsomes isolated from wild type, Fmo1 (-/-), 2 (-/-), 4(-/-) or 
Fmo5 (-/-) mouse lines after heat treatment (p>0.05) (Fig. 3.3.9).  The reduction in 
activity in wild type male liver microsomes observed after methimazole treatment 
(Fig. 3.3.7) may therefore indicate the inhibition of a CYP rather than an FMO.     
These findings suggest a sex-specific difference in TAZ metabolism in liver of a 
mouse.  To ensure that FMO activity had fully diminished after heat inactivation, 
samples were tested for activity towards methimazole (see section 2.10.3.1) before 
and after heating. No TNB oxidation was observed after heat treatment (data not 
shown) indicating that FMOs were no longer active.  
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Figure 3.3.8: The effect of pre-heat treatment of female liver microsomes on TAZ 
metabolism.  Heat inactivation of FMOs in liver microsomes is described in section 
2.10.3.2.  The rate of TAZ metabolism catalysed by liver microsomes prepared from 
female wild type, Fmo1 (-/-), 2 (-/-), 4 (-/-) and Fmo5 (-/-) mice was determined as 
described in section 2.10.2.   Data are mean ± standard deviation obtained from two 
independent experiments.  Enzyme assays were carried out in triplicate.   
 
*p<0.05  compared to the result obtained from untreated Fmo5 (-/-) female liver 
microsomes. 
**p<0.005 compared to the result obtained from untreated wild type female liver 
microsomes. 
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Figure 3.3.9: The effect of pre-heat treatment of male liver microsomes on TAZ 
metabolism.  Heat inactivation of FMOs in liver microsomes is described in section 
2.10.3.2. The rate of TAZ metabolism catalysed by liver microsomes prepared from 
male wild type, Fmo1 (-/-), 2 (-/-), 4 (-/-) and Fmo5 (-/-) mice was determined as 
described in section 2.10.2.   Data are mean ± standard deviation obtained from two 
independent experiments.  Enzyme assays were carried out in triplicate.   
 
 
 
 
 
 
 
 
  217As TAZ metabolism was not completely abolished by methimazole treatment 
or heat inactivation, it indicates that another enzyme or group of enzymes are 
involved in the metabolism of TAZ.    
 
Assessing CYP Contribution in Liver Microsomes to TAZ Metabolism 
The relative contribution of CYPs was investigated using an antibody specific to 
NADPH-dependent Cytochrome P450 reductase.   This antibody will inactivate all 
liver microsomal CYP activity regardless of the CYP form.  NADPH-dependent 
Cytochrome P450 reductase (CRP) are FAD and FMN containing enzymes which 
transfer electrons to CYPs.  By inhibiting CRP, CYPs can no longer function as there 
is no electron donor from which they can accept an electron (as a result of the absence 
of reduced cytochrome P450 reductase).  Therefore the use of an antibody against 
CRP is a useful tool to investigate the relative contribution of CYP to a given 
substrate in vitro. The amount of NADPH-dependent Cytochrome P450 Reductase 
antiserum was optimised by testing increasing volumes of antiserum on rates of TAZ 
metabolism catalysed by microsomal samples until no further change in the rate of 
TAZ metabolism was observed (see section 2.10.3.4).    Non-immune sera was used 
to approximate the amount of non-specific inhibition.   Non-specific inhibition of 
TAZ metabolism was found to be ~20%.  The actual amount of inhibition by 
NADPH-dependent Cytochrome P450 Reductase antiserum was corrected for the 
non-specific inhibition (see section 2.10.3.4).   Figure 3.3.10 shows the effect of CYP 
inactivation on the rate of TAZ metabolism in isolated female liver microsomes.  CYP 
inactivation caused a significant decrease in TAZ metabolism by the wild type and 
two Fmo knockout mouse lines.   A 44%, 63% and 52% decrease in  
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Figure 3.3.10: The effect of Anti-NADPH-dependent Cytochrome P450 reductase 
serum on TAZ metabolism by female liver microsomes.  Inactivation of P450s in 
liver microsomes is described in section 2.10.3.4.  The rate of TAZ metabolism 
catalysed by liver microsomes prepared from female wild type, Fmo1 (-/-), 2 (-/-), 4 (-
/-) and Fmo5 (-/-) mice was determined as described in section 2.10.2.   Data are mean 
± standard deviation obtained from two independent experiments.  Enzyme assays 
were carried out in triplicate.   
  
 
* p<0.05 compared to the result obtained from untreated female Fmo1 (-/-),2 (-/-),4 (-
/-) liver microsomes. 
** p<0.005 compared to the result obtained from untreated female wild type or Fmo5 
(-/-) female liver microsomes respectively.    
 
 
 
 
 
  219TAZ metabolism was observed for microsomes from wild type (p<0.005), Fmo1 (-/-), 
2(-/-), 4(-/-), (p<0.05) and Fmo5 (-/-)  mice (p<0.005)  respectively.   In males, 
inactivation of CYPs caused a significant decrease in TAZ metabolism by liver 
microsomes isolated from all three mouse lines.  Wild type, Fmo1 (-/-), 2 (-/-), 4(-/-) 
and Fmo5 (-/-) microsomes had a reduction of 61%, 64% and 75% respectively (Fig. 
3.3.11). This confirms that CYPs, as well as FMOs contribute towards the metabolism 
of TAZ by mouse liver microsomes.   
Figure 3.3.12 summarises the results obtained after heat inactivation (FMO 
inactivation) or after anti-CRP incubation (CYP inactivation) in male and female wild 
type liver microsomes.  The reduction in TAZ metabolism after FMO or CYP 
inactivation in female samples was 42% and 44% respectively whereas in male liver 
microsomes CYP inactivation led to a 61% decrease in enzyme activity but no 
significant difference was observed after FMO inactivation.  When FMO and CYPs 
were both inactivated (heat inactivation and anti-CRP incubation) the effect was 
additive.  In the case of female liver microsomes inactivation of FMO and CYPs 
resulted in an insignificant amount of enzyme activity being observed but in the male 
microsomal samples, approximately 23% of TAZ metabolism was still present (data 
not shown).           
 
Data reported here suggests that FMO and CYPs are involved to similar degrees in the 
metabolism of TAZ in liver microsomes of female wild type mice, but not in liver 
microsomes of male mice.   In male liver microsomal samples (of wild type mice), 
data suggests a CYP-mediated enzymatic reaction as the major pathway and the 
possibility of a third, unidentified enzyme or group of enzymes to contribute as well.  
Analysis of data from the two knockout lines implicates FMO1 as the major FMO  
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Figure 3.3.11: The effect of Anti-NADPH-dependent Cytochrome P450 reductase 
serum on TAZ metabolism by male liver microsomes. Inactivation of P450s in 
liver microsomes is described in section 2.10.3.4. The rate of TAZ metabolism 
catalysed by liver microsomes prepared from male wild type, Fmo1 (-/-), 2 (-/-), 4  
(-/-) and Fmo5 (-/-) mice was determined as described in section 2.10.2.   Data are 
mean ± standard deviation obtained from two independent experiments.  Enzyme 
assays were carried out in triplicate.   
  
 
*  p<0.05  compared to the result obtained from untreated male wild type liver 
microsomes. 
** p<0.005 compared to the result obtained from untreated male Fmo1 (-/-), 2 (-/-), 4 
(-/-) or Fmo5 (-/-) female liver microsomes respectively.    
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Figure 3.3.12: Comparison of the effects of pre-heat treatment and Anti-
NADPH-dependent Cytochrome P450 reductase serum incubation on the rate of 
TAZ metabolism by male and female liver microsomes.  Pre-heat treatment and 
incubation with NADPH-dependent cytochrome P450-Reducatse antibody of liver 
microsomes is described in section 2.10.3. The rate of TAZ metabolism catalysed by 
liver microsomes prepared from male and female wild type, Fmo1 (-/-), 2 (-/-), 4 (-/-) 
and Fmo5 (-/-) mice was determined as described in section 2.10.2.   Data are mean ± 
standard deviation obtained from two independent experiments.  Enzyme assays were 
carried out in triplicate.   
 
*p<0.05 compared to the result obtained from untreated male liver microsomes. 
**p<0.005 compared to the result obtained from untreated female liver microsomes. 
 
 
 
  222isoform to be involved in TAZ metabolism by female liver microsomes but not by 
male liver microsomes. 
 
TAZ Metabolism by Lung Microsomes 
 
Lung microsomes were prepared from wild type (C57BL/6 mice), Fmo1 (-/-), 2 (-/-), 
4 (-/-) and an Fmo 5 (-/-) mouse line as described in section 2.10.1.  The rate of TAZ 
metabolism catalysed by mouse liver microsomes was monitored 
spectrophotometrically and is described in section 2.10.2.2.  Data represent mean ± 
standard deviation obtained from two independent microsomal isolations.  All assays 
were carried out in triplicate on each batch of microsomes. 
Figure 3.3.13 represents Michaelis-Menten plots (νo versus [TAZ]) obtained 
for female lung microsomes prepared from the three mouse lines.  Lung microsomes 
prepared from wild type and Fmo5 (-/-) mice catalysed TAZ metabolism and showed 
a hyperbolic Michaelis-Menten relationship between initial rate of enzyme activity 
and substrate concentration.  Microsomes prepared from Fmo1 (-/-), 2 (-/-), 4 (-/-) 
mouse lung however were not found to metabolise TAZ, suggesting that one or all of 
the three genes deleted (Fmo1, 2 or 4) are important in TAZ metabolism in the lung.  
To test whether the lack of activity towards TAZ is because of the absence of FMO 
protein or because the lung microsomal samples were inactivated during isolation, a 
control experiment was carried out.  In the control experiment the activity of 
NADPH-dependent Cytochrome P450 reductase was measured using the substrate 
cytochrome c.  The methimazole assay was not used because mouse lung have low 
amounts of FMO3, therefore in the absence of FMO1, FMO2 and FMO4, little or no 
activity towards this substrate would be expected.  The activity of NADPH-dependent  
  223 
 
0
0.5
1
1.5
2
2.5
3
02468 1 0 1 2
TAZ (μΜ)
T
A
Z
 
O
X
Y
G
E
N
A
T
I
O
N
 
(
n
m
o
l
 
L
-
1
/
 
m
i
n
/
μ
g
 
p
r
o
t
e
i
n
)
Wild Type
Fmo1 (-/-), Fmo2 (-/-), Fmo4 (-/-)
Fmo5 (-/-)
 
Figure 3.3.13: νo versus [TAZ] plot for TAZ metabolism catalysed by female 
mouse lung microsomes.   The rate of TAZ metabolism catalysed by wild type 
female mouse lung microsomes was determined as described in section 2.10.2.  Data 
are mean ± standard deviation from assays carried out in triplicate.   
 
 
 
 
 
 
 
  224NADPH-dependent Cytochrome P450 reductase was assayed by measuring the initial 
rate of cytochrome c reduction [Omura et al. 1970].  Figure 3.3.14 shows the activity 
of lung microsomes isolated from female Fmo1 (-/-), 2(-/-), 4(-/-) and female wild 
type mice.  The rate of cytochrome c reduction by Fmo1  (-/-), 2(-/-), 4(-/-)  lung 
microsomes is similar to that catalysed by wild type microsomes and therefore shows 
that the microsomes from the knockout line are active.   
Wild type and Fmo5  (-/-)  lung microsomes showed Michaelis-Menten 
behaviour over the tested TAZ concentrations (Fig. 3.3.13).  At saturating TAZ 
concentrations, lung microsomes from female and male wild type and Fmo5 (-/-) mice 
showed a significant difference in TAZ metabolism (p<0.05) (Fig. 3.3.15).  Female 
lung microsomal samples from both mouse lines were more efficient at TAZ 
metabolism than were microsomes from male lung samples (Fig. 3.3.15).  There was 
no significant difference in TAZ metabolism between female wild type and female 
Fmo5  (-/-)  lung microsomes (Fig. 3.3.15) indicating that FMO5 is unlikely to be 
contributing to TAZ metabolism in female lung microsomes.  In males however, lung 
microsomal samples from Fmo5 (-/-) mice showed a significant decrease in TAZ 
metabolism compared to the wild type microsomes (p<0.005)  (Fig. 3.3.15).  The 
results indicate a sex-dependent difference in mouse lung towards TAZ and also 
indicate a role for FMO5 in male lung microsomes.   A possible explanation for the 
observed activity in the Fmo5 (-/-) microsomal samples may be that the lack of FMO5 
in lung leads to an up-regulation of another FMO or CYP to compensate for the role 
FMO5 would normally play in the lung.    
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A  B 
 
 
Figure 3.3.14: The reduction of cytochrome c catalysed by wild type and Fmo1  
(-/-),  2  (-/-),  4  (-/-) lung microsomes.  The rate of cytochrome c reduction was 
monitored as described in section 2.10.4. The change in absorbance signal at 550 nm 
representing the reduction of cytochrome c by lung microsomes prepared from wild 
type female (A) and Fmo 1 (-/-), Fmo2 (-/-), Fmo4 (-/-) female mice (B) are shown. 
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Figure 3.3.15: Rate of TAZ metabolism observed for female and male mouse 
lung microsomes. The rate of TAZ metabolism catalysed by lung microsomes 
prepared from female and male wild type and Fmo5 (-/-) mice was determined as 
described in section 2.10.2.  Data are mean ± standard deviation obtained from two 
independent experiments.  Enzyme assays were carried out in triplicate.   
 
**p<0.05 compared to the result obtained from female wild type or Fmo5 (-/-) lung 
microsomes respectively. 
 
 
 
 
 
 
 
  227Assessing FMO Contribution to TAZ Metabolism in Mouse Lung Microsomes 
Methimazole was used as a competitive inhibitor to determine the contribution of 
FMOs to TAZ metabolism as described above.  Female lung microsomes showed a 
significant difference in TAZ metabolism after treatment with methimazole; a 63 and 
65% decrease in activity was observed for wild type and Fmo5  (-/-)  microsomes 
respectively (Fig. 3.3.16).   For male lung microsomes treated with methimazole; a 
32% and 47%  decrease in activity in TAZ metabolism was observed for wild type 
(p<0.005) and Fmo5  (-/-)  (p<0.05)  lung microsomes respectively (Fig. 3.3.17).   
These findings suggest that although FMOs are contributing to TAZ metabolism in 
the lung, FMO contribution is higher in the female microsomes than the male 
microsomes of this organ. This is supported by experiments shown in Figure 3.3.15 
where female lung microsomal samples are observed to be more efficient at TAZ 
metabolism than male lung microsomes.  The role of FMO5 is not confirmed by these 
findings (shown in Fig. 3.3.17).  FMO5, unlike other members of the FMO family, 
does not metabolise methimazole, therefore, if one assumes the difference in TAZ 
metabolism between male wild type and male FMO5 (-/-) microsomes (shown in Fig. 
3.3.16) is because of the absence of FMO5, then methimazole treatment should have 
no effect on the rate of TAZ metabolism catalysed by Fmo5 (-/-) lung microsomes. 
Figure 3.3.17 shows, however a significant decrease in TAZ metabolism in male 
FMO5 (-/-) lung microsomes compared to TAZ ‘only’ treated Fmo5 (-/-) microsomes 
(p<0.05).  This suggests that FMO5 is unlikely to influence TAZ metabolism in the 
male lung microsomes.      Following heat inactivation of the FMOs, a significant 
difference in TAZ metabolism was observed for female lung microsomes (Fig. 
3.3.18).  Compared to unheated lung microsomes; heating caused a reduction in TAZ 
metabolism of 61% and 68% by wild type and Fmo5 (-/-) female lung microsomes  
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Figure 3.3.16: The effect of pre-treatment with methimazole on the rate of TAZ 
metabolism by female mouse lung microsomes.  Pre-treatment of lung microsomes 
with methimazole is described in section 2.10.3.1. The rate of TAZ metabolism 
catalysed by lung microsomes prepared from female wild type and Fmo5 (-/-) mice 
was determined as described in section 2.10.2.   Data are mean ± standard deviation 
obtained from two independent experiments.  Enzyme assays were carried out in 
triplicate.   
* *
 
*p<0.05 compared to the result obtained from untreated female wild type or Fmo5  
(-/-) lung microsomes respectively. 
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Figure 3.3.17: The effect of pre-treatment with methimazole on the rate of TAZ 
metabolism by male mouse lung microsomes.  Pre-treatment of lung microsomes 
with methimazole is described in section 2.10.3.1. The rate of TAZ metabolism 
catalysed by lung microsomes prepared from male wild type and Fmo5 (-/-) mice was 
determined as described in section 2.10.2.   Data are mean ± standard deviation 
obtained from two independent experiments.  Enzyme assays were carried out in 
triplicate.   
 
*p<0.05 compared to the result obtained from untreated male wild type or Fmo5 (-/-) 
lung microsomes respectively. 
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Figure 3.3.18: The effect of pre-heat treatment on TAZ metabolism observed by 
lung microsomes.  Heat inactivation of FMOs in lung microsomes is described in 
section 2.10.3.2. The rate of TAZ metabolism catalysed by lung microsomes prepared 
from female wild type and Fmo5 (-/-) mice was determined as described in section 
2.10.2.   Data are mean ± standard deviation obtained from two independent 
experiments.  Enzyme assays were carried out in triplicate.   
 
*p<0.05 compared to the result obtained from untreated female wild type or Fmo5  
(-/-) lung microsomes respectively.  
 
 
 
 
 
  
 
 
 
  231This data is in agreement with findings from methimazole treated microsomes.  Heat 
inactivation of FMOs in male lung microsomes caused a significant decrease in TAZ 
metabolism by wild type lung microsomes (p<0.05) but not however, for Fmo5 (-/-) 
lung microsomes (Fig. 3.3.19).  This indicates that FMO contribution is less in the 
lung microsomes of the male Fmo5 (-/-) mouse line.     
 
Assessing CYP Contribution to TAZ Metabolism in Mouse Lung Microsomes 
As described earlier, anti-sera to NADPH-dependent Cytochrome P450 Reductase is a 
tool which can be used to inactivate CYP activity.  Here it has been used to deduce 
the relative contribution of CYPs to TAZ metabolism in mouse lung microsomes. 
Non- specific inhibition of TAZ metabolism by serum addition was found to be 
~20%.   
The effects of pre-incubating microsomes with NADPH-dependent 
Cytochrome P450 Reductase  antibody shows that in both male and female lung 
samples a significant decrease in TAZ metabolism had occurred (p<0.05) (Fig. 3.3.20 
and 3.3.21).  For female lung microsomes there was a 31 and 57% reduction in 
activity for wild type and Fmo5 (-/-) mouse lines respectively and in males a 34 and 
31% decrease in activity of wild type and Fmo5  (-/-)  lungs respectively.  These 
findings confirm that CYPs contribute to the metabolism of TAZ in mouse lung 
microsomes.      
 
Figure 3.3.22 summarises the results obtained after heat inactivation (FMO 
inactivation) or after anti-CRP incubation (CYP inactivation) in male and female wild 
type lung microsomes.  The reduction in TAZ metabolism after FMO or CYP 
inactivation in female samples was 63% and 31% respectively whereas in male liver  
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Figure 3.3.19: The effect of pre-heat treatment on TAZ metabolism by male lung 
microsomes.  Heat inactivation of FMOs in lung microsomes is described in section 
2.10.3.2. The rate of TAZ metabolism catalysed by lung microsomes prepared from 
male wild type and Fmo5 (-/-) mice was determined as described in section 2.10.2.   
Data are mean ± standard deviation obtained from two independent experiments.   
Enzyme assays were carried out in triplicate.   
 
*p<0.05  compared to the result obtained from untreated male wild type  lung 
microsomes. 
 
 
 
 
 
 
 
 
  233microsomes FMO and CYP inactivation led to a 32% and 34% decrease in enzyme 
activity respectively.  When FMO and CYPs were both inactivated (heat inactivation 
and anti-CRP incubation) the effect was additive.  In the case of female liver 
microsomes inactivation of FMO and CYPs resulted in an insignificant amount of 
enzyme activity being observed but in the male microsomal samples, approximately 
25% of TAZ metabolism was still present (data not shown). Data reported here 
suggests that FMO is the major enzymatic pathway involved in the metabolism of 
TAZ in the lung microsomes of female wild type mice, but not in lung microsomes of 
male mice.   In male lung microsomal samples (of wild type mice) the contribution of 
FMOs and CYPs is similar, the sum of FMO and CYP contribution however does not 
equal the total amount of TAZ metabolism observed in this tissue.  This may indicate 
a role of another enzyme in the metabolism of TAZ in male lung microsomes of mice.  
The relative contribution of FMO1 and FMO2 to TAZ metabolism could not be 
deduced, mainly because methimazole is a substrate for both isoforms.  A probe 
substrate for FMO1 could have been imipramine (Kim et al. 2000; Hernandez et al. 
2004), however this compound is also a substrate for some CYPs.  Further studies are 
required to elucidate the relative contribution of FMO1 and FMO2 to TAZ 
metabolism in vitro  
 
Comparison between Liver and Lung Microsomes With Respect to TAZ 
Metabolism 
Figure 3.3.23 shows the rate of TAZ metabolism for female liver and lung 
microsomes.  There is a significant difference between activities of lung and liver 
microsomes isolated from female wild type mice (p<0.005). Lung microsomes are 
more efficient at TAZ metabolism than liver microsomes from female wild type mice.    
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Figure 3.3.20: The effect of Anti-NADPH-dependent Cytcrome P450 reductase 
serum on TAZ metabolism observed for female lung microsomes. Inactivation of 
NADPH-dependent Cytochrome P450 reductase in lung microsomes is described in 
section 2.10.3.3. The rate of TAZ metabolism catalysed by lung microsomes prepared 
from female wild type and Fmo5 (-/-) mice was determined as described in section 
2.10.2.   Data are mean ± standard deviation obtained from two independent 
experiments.  Enzyme assays were carried out in triplicate.   
  
 
* p<0.05 compared to the result obtained from untreated female wild type or  
Fmo5 (-/-) lung microsomes respectively. 
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Figure 3.3.21: The effect of Anti-NADPH-dependent Cytochrome P450 reductase 
serum on TAZ metabolism by male lung microsomes.  Inactivation of P450s in 
lung microsomes is described in section 2.10.3.3. The rate of TAZ metabolism 
catalysed by lung microsomes prepared from male wild type and Fmo5 (-/-) mice was 
determined as described in section 2.10.2.   Data are mean ± standard deviation 
obtained from two independent experiments.  Enzyme assays were carried out in 
triplicate.   
  
 
* p<0.05 compared to the result obtained from untreated male wild type or Fmo5 (-/-) 
lung microsomes respectively. 
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Figure 3.3.22: Comparison of the effects of pre-heat treatment and Anti-NADPH 
Cytochrome P450 reductase antibody incubation on the rate of TAZ metabolism 
observed for male and female lung microsomes.  Pre-heat treatment and incubation 
with anti-NADPH-dependent Cytochrome P450-Reductse antibody of liver 
microsomes is described in section 2.10.3.2 and 2.10.3.3. The rate of TAZ metabolism 
catalysed by lung microsomes prepared from male and female wild type and Fmo5  
(-/-) mice was determined as described in section 2.10.2.   Data are mean ± standard 
deviation obtained from two independent experiments.  Enzyme assays were carried 
out in triplicate.   
 
 
 
 
 
 
 
 
  237However, there is no significant difference in TAZ metabolism by male lung and liver 
microsomes isolated from wild type mice.    This indicates a sex-dependant difference 
within the capacity to metabolise TAZ in mouse lung and liver.  
In summary, experiments carried out in this section describe the relative 
contribution of FMOs and CYPs to the metabolism of TAZ in microsomes prepared 
from lung and liver of mouse.  The data confirms a role for both FMOs and CYPs in 
the  in vitro metabolism of TAZ.  Sex- and tissue-specific differences in TAZ 
metabolism have been identified. 
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Figure 3.3.23: Comparison of the rate of TAZ metabolism by lung and liver 
microsomes prepared from male and female wild type mice.  The rate of TAZ 
metabolism catalysed by lung and liver microsomes prepared from male and female 
wild type mice was determined as described in section 2.10.2.   Data are mean ± 
standard deviation obtained from two independent experiments.  Enzyme assays were 
carried out in triplicate.   
 
**p<0.005  
 
 
 
 
 
 
 
 
  239Discussion - Metabolism of Thiacetazone by Mouse Tissue Microsomes 
 
Studies of drug metabolism traditionally examine the role of Cytochrome P450s 
(CYPs) in this process.  CYPs are a large family of enzymes and considered to be the 
most important group in Phase I metabolism.   Members of this family exhibit broad 
and overlapping substrate specificities towards therapeutic compounds and other 
xenobiotics.   In recent times however, the role of flavin containing monooxygenases 
(FMOs) has become of increasing interest.    
  Numerous substrates of therapeutic importance are metabolised by both CYPs 
and FMOs, these include the estrogen receptor modulator, Tamoxifen prescribed in 
the treatment of breast cancer (Parte et al. 2005), the anti-depressant imipramine (Kim 
et al. 2000; Hernandez et al. 2004) and Triclabendazole a compound used to treat 
fascioliasis (Virkel et al. 2006).  
  In this section, microsomes prepared from mouse liver and lung were 
employed to represent the pool of CYPs and FMOs expressed in a tissue in vivo.  The 
relative contribution of CYPs and FMOs was investigated with reference to TAZ 
using a combination of approaches; inhibition of CYPs with an antiserum directed 
against NADPH-dependent Cytochrome P450 reductase, inactivation and chemical 
inhibition of FMOs, and distinguishing between different FMOs using our knowledge 
of their sex- and tissue-specific expression.  Microsomes prepared from two Fmo 
knockout lines were used to gain further understanding of the contribution of specific 
FMO isoforms to TAZ metabolism. 
  Inhibition experiments performed on microsomes prepared from wild type 
female liver suggests that FMOs and CYPs are responsible for TAZ metabolism in 
vitro and that the contribution of FMOs and CYPs is similar.  The metabolism of TAZ 
  240by male liver microsomes prepared from wild type mice catalysed the reaction to a 
similar extent to female wild type microsomal samples. Inhibition studies however 
unmasked significant differences between the contribution of FMOs and CYPs to this 
reaction by the two sexes.    In males, CYP contribution was determined to be greater 
than that of FMOs with the latter enzymatic contribution being insignificant.  Analysis 
of data obtained from both sexes and the two knockout mouse lines and between both 
sexes implicated FMO1 to be important in the metabolism of TAZ in females but not 
in males.  A survey of literature describing the sexual dimorphic expression of FMOs 
and CYPs was undertaken to try to explain this finding.  Examples of sex-specific 
expression of CYPs and FMOs in the liver are documented. In the mouse, CYP2D9 is 
highly expressed in the liver of males but is repressed in the female (Sakuma et al. 
2004), whereas hepatic expression of CYP2A4 and CYP2B9 is predominant in the 
liver of females (reviewed by Waxman et al. 2009).  Studies of FMO mRNA 
expression have reported FMO1 transcript levels to be significantly higher in the liver 
of female mouse (Janmohamed et al. 2004) whereas FMO3 is not expressed in the 
liver of adult males (Cherrington et al. 1998).  Given that liver microsomes obtained 
from male Fmo1(-/-), 2 (-/-), 4 (-/-) mice showed significantly higher levels of TAZ 
metabolism than female liver microsomes and the insignificant effect of  heat 
inactivation on these samples, suggests that FMOs (and FMO1 in particular) are not 
responsible for the metabolism of TAZ observed in male microsomal samples. 
Therefore it is likely that the sex-specific expression of a CYP isoform was 
responsible for the difference in TAZ metabolism observed in between male and 
female liver microsomes.  It was beyond the scope of this investigation to determine 
the exact CYP isoform responsible for the sex-specific difference.   
  241After CYP and FMO inactivation in male liver microsomal samples, enzyme 
activity representing approximately a third of the control was still observed, indicating 
the contribution of a third enzyme present in male liver but not female liver 
microsomal samples. 
  Lung microsomal samples prepared from female wild type and Fmo5 (-/-) 
mice were significantly more efficient at TAZ metabolism than male microsomal 
samples of this tissue. The contribution of FMOs to TAZ metabolism by male lung 
microsomes was identified but this was about half of that determined for female lung 
microsomes.  This finding, like that observed in the liver microsomes suggests a sex-
specific difference in TAZ metabolism in the lung microsomes of male mice.  A 
literature survey of sex-specific expression of FMO and CYP abundance in lung 
reports significantly higher levels of FMO1 in the female mouse than in males 
(Janmohamed et al. 2004).  Gene expression studies have identified 24 CYP forms 
expressed in mouse lung, among these Cyp 2g1 is specific to this tissue and Cyp 2f2 is 
the most highly expressed (Choudhary et al. 2005), however literature relating to sex-
specific expression of CYPs in the lung was not found. After both FMO and CYP 
inactivation in male lung microsomes significant activity towards TAZ is observed.  
This was not the case for female lung microsomes whose activity towards TAZ was 
abolished when both FMO and CYP activity were inhibited.  The findings illustrate a 
sex-specific difference in both lung and liver microsomes of male mice and implicate 
a third enzyme in TAZ metabolism.   
  Lung microsomes from male and female Fmo1 (-/-), Fmo2 (-/-), Fmo4 (-/-) 
mice showed no activity towards TAZ.  The microsomes demonstrated the ability to 
reduce cytochrome c and therefore were ‘active’ with respect to CYP activity.  From 
this finding it was expected that one or all of the deleted Fmos (expressing FMO1, 
  242FMO2 and FMO4) would be responsible for the total amount of TAZ metabolism 
observed in wild type lung microsomes.  But as described above, metabolism of TAZ 
was still observed after FMO inactivation by heat or methimazole treatment.   This 
result is perplexing, it cannot be explained why microsomes of the knockout line did 
not show CYP-mediated TAZ metabolism when this enzyme group is contributing to 
the reaction in wild type microsomes.     
  In the lung of mouse, FMO1 and FMO2 are considered the major pulmonary 
isoforms (Janmohamed et al. 2004; Siddens et al. 2008).  In this investigation it was 
not possible to distinguish the relative contribution of these isoforms in microsomes 
of this tissue, the reason being the lack of an appropriate probe substrate to distinguish 
between FMO1 and FMO2 activity.  Some reports have claimed that mouse FMO2 is 
considerably more resistant to heat inactivation than other members of this family and 
that this property can be used to distinguish FMO2 activity (Siddens et al. 2008). This 
was not observed in experiments carried out as part of this investigation as 
microsomes were tested for their ability to oxygenate methimazole before and after 
heat treatment.  TNB oxidation was completely abolished after heat treatment and 
suggests that all FMOs were inactivated. 
  Lung and liver microsomes prepared from wild type female mice displayed a 
hyperbolic relationship between enzyme activity and TAZ concentration, indicating 
Michaelis-Menten kinetics.  Given that FMOs and CYPs were contributing to TAZ 
metabolism in these samples, may suggest that the affinity of this substrate for the two 
enzymes is similar at the tested concentrations.           
  In summary, this section has described the in vitro metabolism of TAZ by 
liver and lung microsomes prepared from mouse.  The relative contribution of CYPs 
and FMOs has been determined and an insight into the possible FMO isoform 
  243involved in this reaction has been gained.  Further studies are required to identify 
CYP isoforms involved in this reaction and also to identify other enzymes which are 
likely to be involved in TAZ metabolism.  Additional studies are required to identify 
the products generated by CYP-mediated metabolism of TAZ. 
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  2454.1 Summary 
TAZ and ETA are anti-tubercular drugs prescribed to treat TB in the poorest parts of 
the world and in industrialised countries respectively.  With TB announced as a 
pandemic by the WHO and the dramatic increase in MDR- and X-MDR- TB cases, 
development of new and effective drugs is a race against time.  Some researchers and 
medical professionals alike have resorted to the re-introduction of TAZ to 
chemotherapy regimens in an attempt to use whatever is at hand.   There are two main 
obstacles in the way of ‘reinstating’ this cheap and effective drug, first the toxicity 
that TAZ exerts in a significant proportion of individuals and secondly the scarce 
amount of information regarding its metabolism in man and bacteria.  The metabolism 
of TAZ in the latter has provided the focus of recent literature that has subsequently 
determined the nature of TAZ as a prodrug (Alahari et al. 2007), the enzyme 
responsible for its activation (Baulard et al. 2000; DeBarber et al. 2000; Qian et al. 
2006; Dover et al. 2007; Alahari et al. 2009), the bacterial target of TAZ action 
(Alahari et al. 2007) and the mechanism by which it debilitates Mycobacteria (Alahari 
et al. 2007; Dover et al. 2007).  Though essential pieces of information, they do not 
explain why or how TAZ induces derma- and hepatic toxicity.  This will become clear 
once the in vivo metabolism of TAZ in man is determined and understood.  
A pharmacogenetic investigation was undertaken to assess the effect of a 
recently identified genetic variation in FMOs in individuals of African-decent.  A 
SNP in the human FMO2 gene that occurs at a frequency of 100% of Asians and 
Europeans results in the production of a non-functional enzyme (Dolphin et al. 1998).  
Interestingly, a significant proportion of Africans and Hispanics of African-decent 
encode the ancestral form of the gene and consequently express functionally active 
FMO2 in the lungs (Dolphin et al. 1998; Krueger et al. 2002; Krueger et al. 2005; 
  246Veeramah et al. 2008).   The pharmacological implications of human FMO2.1 are yet 
to be identified, but given that FMOs are important in drug metabolism it is plausible 
to assume that individuals expressing this enzyme in the lung will display an altered 
metabolic profile with regard to xenobiotics in this tissue.  Experiments in this 
investigation were used to assess the pharmacological consequences that this enzyme 
might have on the metabolism of TAZ and ETA. 
Human FMO2.1, at least in vitro can catalyse the oxidation of both TAZ and 
ETA.  In the case of ETA, FMO2.1 forms one of the products that has been identified 
for EtaA, that is the S-oxide.  Given the non-toxic nature of such a metabolite, it is 
likely that FMO2.1 may catalyse the detoxification of this drug and in effect mediate 
the ‘inactivation’ of ETA thus decreasing the effective concentration of ETA available 
to the bacteria.  This would result in reduced drug efficacy in such individuals and 
therefore may represent a genetic disadvantage.  Conversely, FMO2.1 can catalyse 
two independent oxidation steps of TAZ to generate the same products as EtaA.   Data 
presented in this thesis has for the first time identified the intermediate of this reaction 
as the sulphenic acid of TAZ.  The potential implications of our findings are that, 
those patients given TAZ as part of TB treatment and that also express the FMO2.1 
enzyme in their lung will have two activation events taking place; one by EtaA in the 
Mycobacteria and the other by FMO2.1 in healthy lung cells.   The net effect will be 
the production of toxic, highly reactive electrophilic species and the concurrent 
decrease in TAZ available to Mycobacteria.  Thus it is feasible to assume that 
individuals expressing FMO2.1 in the lung are likely to be at a therapeutic 
disadvantage if prescribed TAZ.  To provide a direct link between FMO2.1 
expression and drug toxicity, analysis of lung injury would be required.  Although this 
would be important to establish, the finding will be complicated because it would be 
  247difficult to distinguish between lung injury caused by Mycobacterial infection and 
that caused by drug toxicity as a result of TAZ-activation by FMO2.1.     
Mycobacterial infections cause lesions in the lung and further injury is caused by the 
oxidative activation of macrophages. 
    This study also assayed variant forms of the major human hepatic FMO, 
FMO3 for their capacity to catalyse TAZ oxygenation.   The results demonstrate that 
some polymorphic variants of FMO3 displayed reduced catalytic activity whereas 
others displayed an increase in catalytic efficiency.   The importance of this finding to 
human health is two-fold.  First, in the case of the double variant K158/G308, 
individuals may be protected from TAZ toxicity as the enzyme has significantly 
reduced capacity at oxidising this compound and so more TAZ reaches the site of 
infection.  In the second scenario those expressing the ‘hyper-active’ variant P360 
might be predisposed to hepato- and dermatological toxicity and may require higher 
doses of TAZ to treat the infection.  The effect of polymorphic FMO3 variants on 
sulindac and benzydamine metabolism has been discussed in section 3.2 and 
demonstrates how the outcome of a therapeutic regime may be affected by the 
catalytic efficiency of an FMO3 variant.  Data provided in this thesis supports and 
strengthens this knowledge.   
Although products of the reaction were not analysed, both CYPs and FMOs 
were found to contribute to TAZ metabolism by microsomes isolated from mouse 
lung and liver.  There is no evidence to date that demonstrates a role for CYPs in the 
meabolism of TAZ in humans.   Inferences from microsomes prepared from male and 
female mice of FMO knockout lines suggested that in the mouse, FMO1 is the major 
FMO involved in TAZ metabolism.  However, it should be noted that species 
differences exist with respect to the tissue distribution of FMOs in humans and 
  248mouse. The most notable difference being that the FMO1 gene is switched off in 
human liver at birth. Thus in humans, FMO3 is the enzyme expected to produce 
hepatic toxicity as a result of TAZ metabolism. 
Though not detailed in this thesis, preliminary in vivo studies of TAZ 
metabolism in mouse identified, for the first time, TAZ-sulphinic acid, TAZ-
carbodiimide and TAZ-sulphenic acid in the kidney. This indicated a role for FMOs 
in the extra-hepatic metabolism of this drug.  Though unexpected, this finding 
supports the role of FMO1 as the predominant TAZ metaboliser in mouse.       
Extrapolation of mouse data to humans should always be done with caution especially 
in the case of FMOs because of the difference in the tissue-specific expression of 
these enzymes stated above.  In mouse and all other mammals, FMO1 is the major 
hepatic FMO isoform whereas humans express FMO3 in the liver and FMO1 
expression is largely restricted to the kidney and skin.   
It is increasingly being acknowledged that FMOs, though a small family of 
enzymes are still important players in the metabolism of xenobiotics and endogenous 
compounds when compared to the vast family of CYPs.  The high expression in 
tissues that are vital for drug metabolism and the unique mechanism by which FMOs 
catalyse the oxidation of a plethora of foreign compounds provides a remarkably wide 
substrate palette for these enzymes. Experiments undertaken as part of this 
investigation have attempted to broaden the understanding of FMO catalysed 
reactions and to delineate the contribution of individual FMO enzymes. 
Clearly the data presented in this thesis can be considered as the tip of the 
iceberg; nevertheless it is envisaged that the basic biochemical details regarding the 
metabolism of TAZ and ETA given here will provide a foundation for future work in 
this field.  The knowledge gained of the contribution and inter-play of different FMO 
  249genetic variants to the metabolism of a therapeutic drug may help to rationalise drug 
treatment regimes and we hope contribute to better health care especially in the poorer 
areas of the world. 
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  269Table 1: Primer sequences used in standard PCR. 
 
 
Name of primer  Orientation   Sequence (5’ – 3’)  Source of sequence 
M13F Forward  TCCCAGTCACGACGTCGT 
 
pUC 
M13R Reverse  GGAAACAGCTATGACCATG pUC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  270Gene  Orientation  Primer Sequence  
(5’-3’) 
Amplicon size 
(bp) 
Source 
Fmo1  Forward 
Reverse 
TGTCTCTGGACAGTGGGAAGT 
CATTCCAACTACAAGGACTCG 
166 (Janmohamed et al. 2001) 
Fmo2  Forward 
Reverse 
AGGCTCCATCTTCCCAACCGTA 
CCGGGTCTTTAAGGGTTTCAGG 
382 (Siddens et al. 2008) 
Fmo3  Forward 
Reverse 
ACAACTTACCCACCGCCATCTC 
GGCATAACCATAGCCTGTGGCAAA 
269 (Hernandez et al. 2009) 
GAPDH  Forward 
Reverse 
TTCACCACCATGGAGAAGGC 
GGCATGGACTGTGGTCATGA 
237  Bioline Reference Gene Panel 
18S rRNA  Forward 
Reverse 
TTGACGGAAGGGCACCACCAG 
GCACCACCACCCACGGAATCG 
130  Bioline Reference Gene Panel 
G-Actin  Forward 
Reverse 
AGGAGATCACAGCCCTAGCA 
ACATCTGCTGGAAGGTGGAC 
189  Bioline Reference Gene Panel 
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ABSTRACT:
The second-line antitubercular drugs thiacetazone (TAZ) and ethi-
onamide (ETA) are bioactivated by the mycobacterial enzyme EtaA.
We report here that human flavin-containing monooxygenase 2.1
(FMO2.1), which is expressed predominantly in the lung, catalyzes
oxygenation of TAZ. The metabolites generated, the sulfenic acid,
sulfinic acid, and carbodiimide derivatives, are the same as those
produced by EtaA and human FMO1 and FMO3. Two of the me-
tabolites, the sulfenic acid and carbodiimide, are known to be
harmful to mammalian cells. FMO2.1 also catalyzes oxygenation of
ETA, producing the S-oxide. We have developed a novel spectro-
photometric assay for TAZ oxygenation. The assay was used to
determine kinetic parameters for TAZ oxygenation catalyzed by
human FMO1, FMO2.1, and FMO3 and by EtaA. Although the KM
values for the four enzyme-catalyzed reactions are similar, kcat
and, consequently, kcat/KM (the specificity constant) for FMO2.1-
catalyzed TAZ oxygenation are much higher than those of FMO1,
FMO3, or EtaA. This indicates that FMO2.1 is more effective in
catalyzing TAZ oxygenation than are the other three enzymes and
thus is likely to contribute substantially to the metabolism of TAZ,
decreasing the availability of the prodrug to mycobacteria and
producing toxic metabolites. Because of a genetic polymorphism,
Europeans and Asians lack FMO2.1. However, in sub-Saharan
Africa, a region in which tuberculosis is a major health problem, a
substantial proportion of individuals express FMO2.1. Thus, our
results may explain some of the observed interindividual differ-
ences in response to TAZ and ETA and have implications for the
treatment of tuberculosis in sub-Saharan Africa.
Pulmonary tuberculosis (TB) is a serious respiratory disease caused
by the opportunistic bacterium Mycobacterium tuberculosis. The
World Health Organization estimated 9.2 million new cases of TB
infection worldwide in 2006, of which 31% were in Africa. The
appearance of strains of M. tuberculosis that are resistant to more than
one first-line antitubercular drug has required the use of second-line
drugs (Peloquin, 1993), such as the thiourea thiacetazone (TAZ;
4-formylacetanilide thiosemicarbazone) and the thioamide ethionamide
(ETA; 2-ethylpyridine-4-carbothioamide). TAZ has been widely used
in the developing world (Brown, 1992). Although an effective treat-
ment for multidrug-resistant TB, it can produce adverse effects such
as liver toxicity, gastrointestinal disturbances, and life-threatening
skin reactions, particularly in human immunodeficiency virus patients
(Teklu, 1976; Brown, 1992; Peloquin, 1993; Ipuge et al., 1995), and,
consequently, its use has been discontinued in several countries
(Brown, 1992). ETA continues to be prescribed in both developed and
developing countries.
Both TAZ and ETA are prodrugs that are converted to their active
forms by the mycobacterial enzyme EtaA (Baulard et al., 2000;
DeBarber et al., 2000; Qian and Ortiz de Montellano, 2006), a
flavin-containing monooxygenase (FMO) (Vannelli et al., 2002).
EtaA activates TAZ by two sequential oxidation steps to form a
sulfinic acid and a carbodiimide via a postulated sulfenic acid inter-
mediate (Qian and Ortiz de Montellano, 2006). TAZ treatment affects
mycolic acid biogenesis in mycobacteria (Alahari et al., 2007; Dover
et al., 2007), and this may be the mechanism by which the drug exerts
its antimicrobial effect.
The FMOs (EC 1.14.13.8) of mammals catalyze the oxidative
metabolism of numerous xenobiotics, including pesticides, fertilizers,
and therapeutic drugs (Krueger and Williams, 2005; Cashman and
Zhang, 2006; Phillips et al., 2007; Phillips and Shephard, 2008).
Humans express five functional FMOs, FMOs 1 through 5 (Phillips et
al., 1995; Hernandez et al., 2004). FMO1, FMO2, and FMO3 can
The work in San Francisco was supported by National Institutes of Health
[Grant AI074824].
Article, publication date, and citation information can be found at
http://dmd.aspetjournals.org.
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 bioactivate thiourea-based drugs (Smith and Crespi, 2002; Henderson
et al., 2004; Onderwater et al., 2006), and FMO1 and FMO3 have
been shown to catalyze oxygenation of TAZ in vitro, forming the
same products as EtaA (Qian and Ortiz de Montellano, 2006).
A genetic polymorphism of the FMO2 gene, g.23238CT
(Q472X), gives rise to an allele, FMO2*2, which encodes a truncated,
nonfunctional protein (FMO2.2) (Dolphin et al., 1998). Essentially all
Europeans and Asians are homozygous for FMO2*2 and thus do not
express functional FMO2 (Dolphin et al., 1998; Whetstine et al.,
2000). However, in sub-Saharan Africa, and in populations recently
descended from this region, a substantial proportion of individuals
possess at least one copy of the ancestral FMO2*1 allele, which
encodes a full-length functional protein (FMO2.1) (Dolphin et al.,
1998; Whetstine et al., 2000; Veeramah et al., 2008). In contrast to
FMO1 and FMO3, which in the adult human are expressed primarily
in kidney and liver, respectively (Dolphin et al., 1996; Yeung et al.,
2000; Hernandez et al., 2004; Cashman and Zhang, 2006), the main
site of expression of FMO2 is the lung (Dolphin et al., 1998; Krueger
et al., 2002; Hernandez et al., 2004; Cashman and Zhang, 2006).
Expression of functional FMO2.1 has been confirmed in lung micro-
somes from an individual heterozygous for the FMO2*1 allele
(Krueger et al., 2002).
Because TAZ and ETA act against mycobacteria in the lung, we
investigated the ability of human FMO2.1 to catalyze the oxygenation
of these antitubercular drugs. In this article, we show that the protein
encoded by the FMO2*1 allele, FMO2.1, catalyzes oxygenation of
both TAZ and ETA, forming the same metabolites as those produced
by human FMO1 and FMO3 and by the mycobacterial enzyme EtaA.
Furthermore, we show that the specificity constant of FMO2.1 for
TAZ is higher than that of any of the other three enzymes. Our results
provide a potential explanation for some of the observed interindi-
vidual differences in the efficacy of and response to TAZ and ETA
and have implications for the treatment of TB in sub-Saharan Africa
and in individuals of recent African descent.
Materials and Methods
Materials. Chemical reagents, enzymes, and antibiotics were obtained from
Sigma-Aldrich (St. Louis, MO) unless stated otherwise. Plasticware for insect
cell culture was obtained from VWR (West Chester, PA). Reagents for
high-performance liquid chromatography (HPLC) were obtained from Fisher
Scientific (Waltham, MA) and were of HPLC grade.
Protein Expression. Recombinant bacmids encoding full-length human
FMO2 (FMO2Q472; FMO2.1) and FMO3 were as described previously (Dol-
phin et al., 1997, 1998). A recombinant bacmid encoding human FMO1 was
prepared from an FMO1 cDNA (Dolphin et al., 1991) (accession number
Q01740) via site-specific transposition in Escherichia coli, through the use of
the Bac-to-Bac system (Invitrogen, Carlsbad, CA) as described previously
(Janmohamed et al., 2006). Bacmid DNAs were isolated using a modified
alkaline lysis method. Production of baculovirus and expression of FMOs in
Spodoptera frugiperda (Sf) 9 cells were as described previously (Janmohamed
et al., 2006), except that after infection with recombinant baculovirus, cells
were cultured for 96 h before harvesting. EtaA was expressed and purified as
described previously (Vannelli et al., 2002).
Isolation of Microsomal Membranes. Sf9 cells were harvested and resus-
pended in HEPES buffer [0.154 M KCl, 10 mM HEPES, pH 7.4, 1 mM EDTA,
20% (v/v) glycerol]. Cells were lysed by three 12-s bursts of sonication on ice.
Cell lysates were centrifuged at 1000g for 10 min at 4°C. The resulting
supernatant was centrifuged at 100,000g f o r1ha t4°C. The pellet was
resuspended in HEPES buffer by hand, using a glass-glass homogenizer placed
on ice, and stored in aliquots at 80°C. Protein concentration was determined
using the method of Lowry (DC Protein Assay kit; Bio-Rad, Hercules, CA) and
bovine serum albumin (Bio-Rad) as a standard.
Quantification of FMOs. Antibodies to FMO1, FMO2, and FMO3 were a
gift from Dr. R. Philpot. Heterologously expressed FMOs were quantified by
Western blotting essentially as described previously (Dolphin et al., 1997,
1998). Blots were incubated with goat anti-(rabbit FMO1), goat anti-(rabbit
FMO2), or goat anti-(rabbit FMO3) serum (1 in 3000 dilution), then with a
rabbit anti-(goat IgG)-alkaline phosphatase conjugate (1 in 30,000 dilution).
Antigen was visualized through the use of a color development kit (AP
Conjugate Substrate Kit; Bio-Rad). The concentration of each expressed FMO
was determined by scanning densitometry and Image Gauge software, version
4.2.1 (Science Lab, FujiFilm, Tokyo, Japan) using a standard curve of authen-
tic rabbit FMO1 and FMO2 or human FMO3 (which were gifts from Dr.
R. Philpot). As a comparison, the relative abundance of heterologously ex-
pressed FMOs was estimated from scans of Coomassie Blue-stained SDS-
polyacrylamide gels of a range of amounts of microsomal protein isolated from
Sf9 cells infected with recombinant baculoviruses (data not shown). The results
corresponded well with those obtained by Western blotting, indicating that
there was no appreciable difference in cross-reactivity among the antibodies.
Enzyme Incubations with TAZ or ETA. Sf9 insect cell microsomes
containing heterologously expressed human FMO1, FMO2.1, or FMO3 (at a
final concentration of 500 nM) or purified EtaA (1 M final concentration)
were incubated with TAZ (100 M final concentration) at 37°C for 90 min in
the buffer described previously (Qian and Ortiz de Montellano, 2006). Reac-
tions were initiated by the addition of enzyme. Reactions were stopped by
addition of an equal volume of ice-cold CH3CN. Mixtures were centrifuged at
10,000g for 5 min at 4°C and analyzed by HPLC as described below.
Sf9 insect cell microsomes containing heterologously expressed human
FMO2.1 were incubated with ETA (final concentration 100 M) for 60 min as
described previously (Qian and Ortiz de Montellano, 2006). Reactions were
analyzed by liquid chromatography/mass spectroscopy (LC/MS) as described
below.
HPLC. The supernatants were diluted to a final concentration of 5%
CH3CN and then analyzed by HPLC on a reverse-phase C18 column (3.5-m
particle size, 4.6 mm i.d.  150 mm, Symmetry; Waters, Milford, MA) using
two buffers: A, H2O and 0.1% formic acid (FA) and B, CH3CN and 0.1% FA.
The solvent flow rate was 0.2 ml/min, and the eluent was spectrophotometri-
cally monitored using two bandwidths (330  60 and 260  4 nm). The
column was eluted from 0 to 25 min with a linear gradient from 5 to 20%
buffer B. For spectral analysis of metabolites, eluent peaks were monitored
between 200 and 500 nm.
LC/MS Analyses. For analysis of TAZ metabolites, LC/MS was performed
as described previously (Qian and Ortiz de Montellano, 2006), with the
exception of the following modifications. The reverse-phase column was
eluted with a flow rate of 0.2 ml/min (buffer A, H2O and 0.1% FA; buffer B,
CH3CN and 0.1% FA) with the following protocol: 0 to 16 min, 5 to 30%
buffer B (linear gradient). The eluent was monitored at 310 nm. The mass
spectrometer settings were as described previously (Qian and Ortiz de Mon-
tellano, 2006).
LC/MS analysis of ETA metabolites produced by FMO2.1 was performed
as described above, with the following modifications. The column was eluted
at a flow rate of 0.2 ml/min (buffer A, H2O and 0.1% FA; buffer B, CH3CN
and 0.1% FA) with the following protocol: 0 to 15 min with 1% buffer B
(isocratic). The eluent was monitored at 350 nm.
Determination of Kinetic Parameters by Spectrophotometric Analysis.
The molar extinction coefficient of TAZ was determined as follows. Two
cuvettes containing 1 ml of Tris-HCl, pH 8.5, 1 mM EDTA were placed in a
Varian Cary 100 dual-beam spectrophotometer (Varian, Inc., Palo Alto, CA).
The spectrophotometer was set to blank correction mode. TAZ [in dimethyl
sulfoxide (DMSO)] was added to the sample cuvette, and DMSO was added to
the reference cuvette. The final organic solvent concentration in each cuvette
was held at 0.1% (v/v). Using the Varian Scan application, samples were
scanned from 200 to 500 nm over a range of TAZ concentrations between 1
and 20 M. These measurements were carried out in triplicate using three
independently prepared stock solutions of TAZ (20 M) that were diluted
accordingly in DMSO. The absorbance of TAZ, measured at its max (328 nm),
was plotted against concentration. The molar extinction coefficient of TAZ in
DMSO was determined from the gradient of this graph and the Beer-Lambert
equation.
Enzyme-catalyzed oxidation of TAZ was monitored by measuring the rate
of decrease in the absorbance of TAZ at 328 nm using a dual-beam spectro-
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 photometer (Varian Cary 100, kinetics module). The pH optima for human
FMOs and EtaA were determined using the following reaction buffers: 0.1 mM
potassium phosphate, pH 7.5, 1 mM EDTA; 0.1 M Tris-HCl, pH 8.5, 1 mM
EDTA; and 0.1 M Tricine-OH, pH 9.5, 1 mM EDTA. Immediately before use
buffers were aerated at 37°C for 30 min in a shaking water bath. Assays were
performed in a volume of 1 ml in reaction buffer containing 0.1 mM NADPH
and either Sf9 cell microsomes containing human FMO1 (320 nM), FMO2.1
(5 nM), or FMO3 (230 nM) or purified EtaA (1 M). Reaction mixtures were
allowed to equilibrate for 1 min at 37°C. Reactions were initiated by the
addition of TAZ in DMSO (to a final TAZ concentration of 10 M) to the
sample cuvette and DMSO to the reference cuvette. Initial rates were recorded
between 1 and 5 min.
For determination of kinetic parameters, assays were performed on triplicate
preparations of enzymes at concentrations of TAZ ranging from 1 to 20 M.
The final organic solvent concentration was held at 0.1% (v/v). Assays were
carried out in triplicate as described above in the optimum pH buffer for each
enzyme: pH 8.5 for FMO1 and FMO3 and pH 9.5 for FMO2.1 and EtaA.
KM and Vmax values were determined from vi versus [S]o data using
nonlinear regression and the kinetics module 3.1 of Sigma Plot version 10
(SPSS Inc., Chicago, IL). For calculation of kcat values, enzyme concentration
was determined as described above.
Determination of Kinetic Parameters by HPLC Analysis. Sf9 cell mi-
crosomes containing heterologously expressed human FMO2.1 were incubated
in 0.1 M Tricine-OH, pH 9.5, 1 mM EDTA, 0.1 mM NADPH, and TAZ
(concentrations ranged from 1–50 M in DMSO). A duplicate set of samples
was prepared but without the addition of enzyme. The final organic solvent
concentration was held at 0.1% (v/v). Mixtures were incubated at 37°C for 5
min, and reactions were quenched with an equal volume of ice-cold CH3CN.
ETA was added as an internal standard at a final concentration of 100 M (in
DMSO), and mixtures were prepared for HPLC analysis as described above. A
standard curve was generated by plotting the ratio of the integrated HPLC peak
areas of TAZ and ETA (from the sample set without added enzyme) against the
range of TAZ concentrations used. The ratio of the integrated HPLC peak areas
of TAZ and ETA, in the sample set with added enzyme, was calculated, and
the amount of unmetabolized TAZ was determined from the standard curve.
This value was subtracted from the input concentration of TAZ to calculate the
amount of TAZ metabolized by the enzyme. Vmax, KM, and kcat were deter-
mined as above.
Enzyme Incubations with Methimazole. Sf9 insect cell microsomes con-
taining heterologously expressed human FMO1, FMO2.1, or FMO3 were
assayed for activity toward methimazole by the method of Dixit and Roche
(1984) as described previously (Dolphin et al., 1998). Assays for FMO1 and
FMO3 activity were carried out at pH 8.5, and those for FMO2.1 were done at
pH 9.5.
Results
Catalytic Oxidation of TAZ by Human FMO2.1. Incubation of
TAZ with Sf9 insect cell microsomes containing heterologously ex-
pressed human FMO2.1, in the presence of NADPH, resulted in the
formation of three major metabolites with reverse-phase retention
times of 7.5 min (M1), 11.4 min (M2), and 14.6 min (M3) (Fig. 1).
No products were observed when TAZ was incubated with micro-
somes isolated from noninfected Sf9 cells or when NADPH was
omitted (results not shown). UV spectral analysis of the metabolites
(Fig. 2) showed that M1 had a maximal absorption peak at 325 nm
and a smaller peak at approximately 230 nm. M2 had a similar
spectrum, with peaks at 320 and 220 nm. The absorption spectrum of
M3 exhibited a main peak at 295 nm and a secondary peak at 220 nm.
To identify the three metabolites, M1, M2, and M3, formed from TAZ
by the action of human FMO2.1, they were analyzed by LC/MS. The
mass spectrum of M1 had a molecular ion [M  H]
 at m/z 269.07, with
fragment ions at m/z 205.14 and 163.12 (Fig. 3A). The mass of the
molecular ion of M1 is 32 atomic mass units more than that of the
molecular ion of TAZ (237), suggesting a structure in which TAZ has
incorporated two oxygen atoms (Fig. 3A) and hence supports identifica-
tion of the metabolite as the sulfinic acid derivative. The mass spectrum
FIG. 1. UV-HPLC chromatogram of the products from incubations of TAZ with
Sf9 insect cell microsomes containing heterologously expressed human FMO2.1
in the presence of NADPH. Reactions were carried out at pH 9.5 for 90 min at 37°C.
FIG. 2. UV-absorption spectra of the three metabolites produced from the incuba-
tion of TAZ with heterologously expressed human FMO2.1 and NADPH. Dotted
line, M1; solid line, M2; and dashed line, M3.
180 FRANCOIS ET AL.
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 FIG. 3. Mass spectra and structures of the products from incubations of TAZ with Sf9 insect cell microsomes containing heterologously expressed human FMO2.1 in the
presence of NADPH in 100 mM tricine buffer, pH 9.5, for 90 min at 37°C. A, M1, identified as the sulfinic acid, has a molecular ion [M  H]
  m/z 269.07, with fragment
ions at m/z 205.14 and 163.12. B, M2, identified as the sulfenic acid, has a molecular ion [M  H]
  m/z 253, with fragment ions at m/z 235 and 193. C, M3, identified
as the carbodiimide, has a molecular ion [M  H]
  m/z 203.13, with a fragment ion at m/z 161.11.
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 of M2 had a molecular ion [M  H]
 at m/z 253, with fragment ions at
m/z 235 and 193 (Fig. 3B). The mass of the molecular ion of M2 is in
accord with a structure in which TAZ has incorporated a single oxygen
atom, and thus supports identification of M2 as the monooxygenated,
sulfenic acid derivative. The metabolite M3 has a molecular ion [M 
H]
 at m/z 203.13, which suggests that it is the carbodiimide generated
by elimination from M2 of the oxidized sulfur atom (Fig. 3C). Previously
synthesized authentic standards of TAZ-sulfinic acid and TAZ-
carbodiimide (Qian and Ortiz de Montellano, 2006) were used to confirm
the identity of M1 and M3. Comparison of their HPLC elution times, UV
spectra, and MS spectra with those of the synthetic standards unambig-
uously identified the metabolites M1 and M3 as the sulfinic acid and
carbodiimide derivatives of TAZ, respectively.
The same three metabolites (the sulfinic acid, sulfenic acid, and
carbodiimide derivatives) were also produced when TAZ was incu-
bated with purified EtaA or Sf9 cell microsomes containing heterolo-
gously expressed human FMO1 or FMO3 (data not shown). Previous
work identified M1 and M3 as products formed by the action of these
enzymes on TAZ (Qian and Ortiz de Montellano, 2006). Although the
sulfenic acid derivative (M2) was not detected, it was postulated as an
intermediate in the enzyme-catalyzed metabolism of TAZ (Qian and
Ortiz de Montellano, 2006). To confirm this, incubations of TAZ with
heterologously expressed human FMO2.1 were quenched at different
time points (Fig. 4). It is clear from the results that formation and
accumulation of M2 precede that of M1 and M3, indicating that M2
is an intermediate in the formation of the latter two metabolites.
Catalytic Oxidation of ETA by Human FMO2.1. Incubation of
ETA with Sf9 microsomes containing heterologously expressed hu-
man FMO2.1, in the presence of NADPH, resulted in the formation of
a major product, P1, with LC retention time of 6.2 min (Fig. 5A). The
mass spectrum of P1 had a molecular ion [M  H]
 at m/z 183, with
fragment ions at m/z 151 and 133 (Fig. 5B). The mass of the molecular
ion of P1 is 16 atomic mass units more than that of the molecular ion
of ETA (166), suggesting a structure in which ETA has incorporated
one oxygen atom (Fig. 5B). This supports identification of P1 as the
S-oxide of ETA. The retention time and mass spectrum of P1 are
identical to those of authentic ETA S-oxide (Vannelli et al., 2002),
therefore unambiguously identifying this metabolite as the S-oxide of
ETA. A mass spectrum of the broad peak with an LC retention time
of approximately 4 min (Fig. 5A) could not be obtained.
Development of a Spectrophotometric Assay of TAZ Oxidation.
A UV absorption spectrum of TAZ revealed an absorption maximum
at 328 nm and a smaller peak at approximately 220 nm (data not
shown). The absorbance of TAZ at 328 nm was linear between 1 and
20 M (data not shown), and at this wavelength the molar extinction
coefficient of TAZ in DMSO was determined as 38,300  2320
M
1cm
1. Incubation of TAZ, in the presence of NADPH, with Sf9
cell microsomes containing heterologously expressed human FMO1,
FMO2.1, or FMO3, or with purified EtaA resulted in a decrease in
TAZ absorbance at 328 nm that was linear over time (Fig. 6 and data
not shown) and with respect to enzyme concentration. No decrease in
TAZ absorbance was observed in the absence of EtaA or human
FMOs or when microsomes prepared from noninfected Sf9 cells
were used. Omission of NADPH from reaction mixtures containing
heterologously expressed human FMOs resulted in a very small (1%
of that observed in the presence of NADPH) and short-lived (2 min)
decrease in TAZ absorbance. This is because of the presence of
endogenous NADPH in the insect cell microsomes. This spectropho-
tometric assay was used to determine the pH optima and kinetic
parameters of enzyme-catalyzed oxidation of TAZ.
Effect of pH on TAZ Oxidation Catalyzed by Human FMOs and
EtaA. TAZ was incubated with purified EtaA or with heterologously
expressed human FMO1, FMO2.1, or FMO3 in buffers of pH 7.5, 8.5, or
9.5. Oxidation of TAZ was measured spectrophotometrically. The pH op-
timum for the oxidation of TAZ at a concentration of 10 M was 8.5 for
human FMO1 and FMO3 and 9.5 for human FMO2.1 and EtaA (Fig. 7).
Kinetics of TAZ Oxidation by Human FMOs and EtaA. The
kinetics of TAZ oxidation catalyzed by EtaA or heterologously ex-
pressed human FMO1, FMO2.1, or FMO3 was evaluated by deter-
mining the initial rates of TAZ oxidation, measured spectrophoto-
metrically, over a range of TAZ concentrations (Fig. 8 and data not
shown). Assays were performed at the optimum pH determined for
each enzyme as described above. Steady-state kinetic parameters were
determined from vi versus [S] data by nonlinear regression.
The KM values for TAZ oxidation catalyzed by human FMO1,
FMO2.1, and FMO3 are very similar to each other and slightly lower
than that of the EtaA-catalyzed reaction (Table 1). The kcat of the
FMO2.1-catalyzed reaction is much higher than that of reactions
catalyzed by human FMO1, FMO3, or EtaA (Table 1). Consequently,
kcat/KM (the specificity constant) for TAZ is much higher for human
FMO2.1 than for the other three enzymes (Table 1). Very similar
kinetic parameters for FMO2.1-catalyzed TAZ oxygenation were
obtained through the use of an HPLC-based assay, thus validating the
spectrophotometric assay (data not shown).
As a comparison, we determined kinetic parameters for FMO1-,
FMO2.1-, and FMO3-catalyzed oxygenation of methimazole, a pro-
totypic substrate for FMOs (Table 1). The kcat of each enzyme was
similar for TAZ and methimazole. However, for FMO2.1 the KM for
FIG. 4. UV-HPLC chromatograms of the products from incubations of TAZ with
Sf9 insect cell microsomes containing heterologously expressed human FMO2.1
in the presence of NADPH. Reactions were carried out at pH 9.5 and 37°C for 0 min
(A), 10 min (B), or 20 min (C).
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 methimazole was 100-fold greater than that for TAZ. Consequently,
for methimazole oxygenation, the kcat/KM of FMO2.1 is considerably
less than that of FMO1 and slightly less than that of FMO3.
Discussion
Our results show that full-length, functional FMO2 of human
(FMO2.1) catalyzes oxygenation of the second-line thiourea antitu-
bercular drug TAZ in vitro. The metabolites generated, the sulfenic
acid, sulfinic acid, and carbodiimide derivatives, are the same as those
produced by the action of human FMO1, human FMO3, or the
mycobacterial enzyme EtaA. The sulfinic acid and carbodiimide de-
rivatives have been identified previously as products of TAZ oxygen-
ation catalyzed by FMO1, FMO3, or EtaA (Qian and Ortiz de Mon-
tellano, 2006). Although these authors did not detect the sulfenic acid
derivative, it was postulated to be an intermediate. Our results confirm
that in reactions catalyzed by all three human FMOs and by EtaA,
TAZ sulfenic acid is indeed an intermediate in the formation of the
sulfinic acid and carbodiimide metabolites.
FIG. 5. Analysis of the products from incubation of ETA with Sf9 insect cell microsomes containing heterologously expressed human FMO2.1 and NADPH in 100 mM
potassium phosphate buffer, pH 7.5, for 60 min at 37°C. A, LC chromatogram (350 nm). B, the mass spectrum and structure of the product P1. P1 has a molecular ion
[M  H]
 at m/z 183, with fragment ions at m/z 151 and 133.
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 Human FMO2.1 also catalyzes the oxygenation of ETA, a thioamide
second-line antitubercular. The single metabolite identified, the S-
oxide, has been shown to be the product of EtaA-catalyzed metabo-
lism of the drug (Vannelli et al., 2002). However, the second product
identified by these authors, the amide of ETA, was not detected in our
study.
Our kinetic analyses reveal that kcat/KM (the specificity constant)
for FMO2.1-catalyzed TAZ oxygenation is much higher than that of
FMO1, FMO3, or the mycobacterial enzyme EtaA, indicating that
FMO2.1 is more effective in catalyzing TAZ oxygenation than are the
other three enzymes. In contrast, FMO2.1 is less effective than FMO1
or FMO3 in catalyzing the oxygenation of methimazole. Although
kinetic analyses were done at the pH optimum for each enzyme, even
at a more physiological pH, 7.5, as shown in Fig. 7, FMO2.1 is the
most effective of the enzymes studied in catalyzing TAZ oxygenation.
The higher value of the specificity constant of FMO2.1 for TAZ is a
consequence of the higher kcat value rather than a lower KM value,
which is similar to those of the other enzymes with lower kcat values
(Table 1). Similar high kcat values have been reported for human
FMO2.1-catalyzed oxygenation of other thioureas, including thiourea
and ethylene-thiourea (Henderson et al., 2004). The relatively low kcat
values determined for TAZ oxygenation catalyzed by FMO1 and
FMO3 are comparable to those reported for oxygenation of a panel of
thioureas by these enzymes (Onderwater et al., 2006). The high values
of KM and kcat determined for FMO2.1-catalyzed oxygenation of
methimazole are similar to the values reported for purified or heter-
ologously expressed FMO2 of rabbit (Lawton et al., 1991).
Spectrophotometric and kinetic studies indicate that the rate-limit-
ing step for FMO-catalyzed reactions occurs after substrate oxygen-
ation (reviewed in Ziegler, 2002) and thus is independent of oxidiz-
able substrate. Consequently, for a particular FMO, the value of kcat
would be expected to be similar for all its substrates. Although our
results conform to this expectation, they indicate that the kcat of
human FMO2.1 is higher than that of FMO1 or FMO3, suggesting
that FMO2.1 is more effective in catalyzing the rate-limiting step of
the reaction, the elimination of H2O, than is either of the other two
FMOs investigated.
Substrate oxygenation by FMOs is usually a detoxification process.
However, in the case of thioureas, the products of FMO-catalyzed
oxygenation are typically more toxic than the parent compound
(Smith and Crespi, 2002; Henderson et al., 2004; Onderwater et al.,
2004, 2006). TAZ sulfenic acid is an electrophile that can react with
glutathione (GSH) (Qian and Ortiz de Montellano, 2006) to regenerate
the parent compound and convert GSH to its oxidized form (GSSG).
In the presence of GSH reductase, a redox cycle may be established
that depletes GSH, thus causing oxidative stress and cellular injury
(Krieter et al., 1984; Henderson et al., 2004; Onderwater et al., 2004).
Sulfenic acid metabolites of thioureas can react covalently with other
thiol-containing molecules, such as cysteine residues in proteins, and
thus directly perturb protein function (Decker and Doerge, 1992). The
TAZ carbodiimide also has the potential to form covalent products
with cysteine residues in proteins. Thus, each of the human FMOs that
we have investigated—FMO1, FMO2.1, and FMO3—is able to cat-
alyze oxygenation of TAZ, producing metabolites that are known to
be harmful to mammalian cells.
The FMO-catalyzed production of TAZ metabolites that are known
to be harmful to mammalian cells may be the basis for the adverse
clinical reactions associated with this drug (Teklu, 1976; Brown,
1992; Peloquin, 1993; Ipuge et al., 1995). This is supported by the fact
that all the adverse effects associated with TAZ occur in tissues in
which FMOs are expressed: hepatotoxicity, FMO3 in the liver (Dol-
phin et al., 1996; Hernandez et al., 2004); gastrointestinal problems,
FMO1 in the small intestine (Yeung et al., 2000); and skin rashes,
FMO1 and FMO3 in skin (Janmohamed et al., 2001).
Human FMO1 and FMO3 are expressed primarily in the kidney and
liver, respectively, and thus may contribute to the extrapulmonary
metabolism of TAZ. FMO1 displays interindividual variation in its
expression (Yeung et al., 2000; Koukouritaki et al., 2002), and several
nonsynonymous polymorphic variants of FMO3 have been identified
FIG. 6. Linearity of FMO2.1- and NADPH-dependent decrease in TAZ absorbance
over time. TAZ (20 M) was incubated with Sf9 insect cell microsomes containing
heterologously expressed human FMO2.1 and NADPH in tricine buffer, pH 9.5, at
37°C, and absorbance at 328 nm was monitored over time.
FIG. 7. Effect of pH on the rate of TAZ oxygenation catalyzed by purified EtaA or
by heterologously expressed human FMO1, FMO2.1, or FMO3. The initial con-
centration of TAZ was 10 M. The decrease in TAZ concentration over time was
measured at 328 nm in the presence of NADPH in buffers at pH 7.5, 8.5, or 9.5.
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 (reviewed in Phillips et al., 2007; Phillips and Shephard, 2008), one of
which, L360P, increases enzyme activity (Lattard et al., 2003),
whereas others, such as E158K and E308G, when present together in
cis, decrease enzyme activity (reviewed in Phillips et al., 2007;
Phillips and Shephard, 2008). Promoter variants that affect transcrip-
tion have also been identified (Koukouritaki et al., 2005). Therefore,
individuals who have lower expression or activity of FMO1 or FMO3
would be less able to metabolize TAZ in extrapulmonary tissues,
FIG. 8. A, Michaelis-Menten plot of TAZ
oxygenation catalyzed by heterologously
expressed human FMO2.1 in the presence
of NADPH at pH 9.5. B, linear transform of
Michaelis-Menten data using Hanes-Woolf
regression (r
2  0.961).
TABLE 1
Kinetic parameters of enzyme-catalyzed oxygenation of TAZ and methimazole
TAZ assays were performed in triplicate on batches of microsomes isolated from three independent infections of Sf9 cells (i.e., nine measurements per FMO). Methimazole assays were
performed in triplicate on a single batch of microsomes for each heterologously expressed human FMO. EtaA assays were performed in triplicate on purified protein. Kinetic parameters are
reported as mean  S.E.
Enzyme
Thiacetazone Methimazole
KM kcat kcat/KM KM kcat kcat/KM
M min
1 min
1M
1 (10
5) M min
1 min
1M
1 (10
4)
FMO1 6.30  0.80 5.08  0.46 7.94  1.99 8.08  2.35 2.27  0.30 28.11  7.95
FMO2.1 5.80  0.55 80.10  4.42 142.56  18.30 575.75  60.02 31.50  2.11 5.48  0.68
FMO3 7.01  0.53 1.37  0.20 1.96  0.39 29.30  4.06 2.60  0.38 8.97  1.81
EtaA 9.05  0.57 3.02  0.30 3.29  0.81 N.D. N.D. N.D.
N.D., not determined.
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 whereas those with higher expression or activity would metabolize
TAZ more effectively, thus reducing the amount of prodrug reaching
the lung and increasing the amounts of metabolites toxic to the host.
Polymorphic variants in FMO3 have been shown to influence the
metabolism and therapeutic outcomes of drugs such as benzydamine
and sulindac (Sto ¨rmer et al., 2000; Hisamuddin et al., 2005).
TAZ and ETA are prodrugs that are converted to their active forms
in mycobacteria. Therefore, for treatment to be effective, a sufficient
amount of unmetabolized drug must reach mycobacteria in the lung.
Although Europeans and Asians lack functional FMO2, a substantial
proportion of sub-Saharan Africans and individuals of recent African
descent possess an ancestral FMO2*1 allele (Whetstine et al., 2000;
Veeramah et al., 2008) and thus would be expected to express func-
tional FMO2 in the lung (Krueger et al., 2002). The relatively high
specificity constant for FMO2.1-catalyzed TAZ oxygenation suggests
that, when present in lung, FMO2.1 is likely to contribute substan-
tially to the metabolism of TAZ in this tissue, thus decreasing the
availability of the prodrug to mycobacteria and producing metabolites
toxic to the host. Therefore, patients with multidrug-resistant TB who
express FMO2.1 may respond less well to treatment with second-line
antitubercular drugs such as TAZ and ETA and may be more prone to
adverse clinical reactions to these drugs. The relatively high frequency
of the FMO2*1 allele in sub-Saharan Africa, a region in which TB is
a major health problem, has implications for the efficacy of and
response to antitubercular drugs, such as TAZ and ETA, that are
substrates for FMO2.1.
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Abstract: Flavin-containing monoooxygenases (FMOs) are a family of enzymes involved in the metabolism of foreign 
chemicals, including many therapeutic drugs. In this review we focus on the functional FMOs of humans (FMOs 1, 2, 3, 4 
and 5). For each FMO we describe its gene organization, developmental- and tissue-specific pattern of expression, sub-
strate specificity and the identity, frequency and functional effect of polymorphic variants. We also review the conse-
quences of genetic variation in the FMOs for the metabolism of therapeutic drugs and the implications of this for drug ef-
ficacy and response. Some key points are: the majority of humans are homozygous for an allele (FMO2*2) that encodes a 
truncated, non-functional polypeptide, but a substantial proportion of individuals of African descent possess a copy of the 
functional ancestral (FMO2*1) allele and thus are predicted to respond differently to drugs and other foreign chemicals 
that are substrates for FMO2; FMO3 polymorphisms that decrease catalytic activity have been linked to increased drug ef-
ficacy; rare mutations in FMO3 are causative of the disorder trimethylaminuria; and the role of FMO1 and FMO3 in the 
oxidation of the antiestrogen tamoxifen and the antitubercular drug thiacetazone are discussed.  
INTRODUCTION 
  Flavin-containing monooxygenases (FMOs; EC 1.14.13. 
8) of eukaryotes are located in the membranes of the endo-
plasmic reticulum. The enzymes contain flavin adenine dinu-
cleotide (FAD), as a prosthetic group, and require NADPH 
and molecular oxygen to catalyze the oxidative metabolism 
of numerous foreign chemicals, including therapeutic drugs, 
dietary-derived compounds and pesticides [Ziegler 1993; 
Krueger  and Williams, 2005; Cashman  and Zhang, 2006]. 
Preferred substrates contain, as the site of oxidative attack by 
the enzyme, a soft nucleophile, typically a nitrogen, sulfur, 
phosphorus or selenium atom, and include chemicals as di-
verse as hydrazines [Prough et al. 1981], phosphines [Smy-
ser and Hodgson, 1985], iodide boron-containing compounds 
[Jones  and Ballou,1986], sulfides [Hamman et al. 2000], 
selenides [Ziegler et al. 1992] and many secondary and terti-
ary amines [Ziegler 1980]. The products of FMO-catalyzed 
reactions are relatively polar, readily excretable and gener-
ally less toxic or pharmacologically active than the parent 
compounds. However, compounds such as N-alkylarylamines 
are converted into more reactive, carcinogenic products 
[Ziegler 1991]. FMOs thus have an important pharmacologi-
cal and toxicological relevance. A limited number of en-
dogenous compounds, including methionine [Duescher et al. 
1994], cysteamine and cysteine- and homocysteine-S-conju-
gates, may function as substrates for FMOs [Ziegler 1993]. 
  FMOs differ from other monooxygenases because activa-
tion of oxygen, in the form of the C(4a) hydroperoxide de-
rivative of FAD, does not require binding of the substrate 
capable of being oxygenated [Ziegler 1993]. Consequently, 
the enzyme is present within the cell in its activated form and  
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has been likened to a “loaded, cocked gun,” capable of oxi-
dizing any soft nucleophile able to gain access to the active 
site. The unique mechanism of FMOs thus accounts for their 
extremely broad range of substrates.  
 In humans, five functional FMO genes, designated FMO1-
FMO5, have been identified [Lawton et al. 1994; Phillips et 
al. 1995; Hernandez et al. 2004]. FMO1 to FMO4 are lo-
cated within a cluster spanning ~245 kb on chromosome 1, 
in the region q24.3 [Hernandez et al. 2004]. The cluster con-
tains an additional FMO gene, FMO6P, which is classified 
as a pseudogene because it is unable to produce a correctly 
spliced mRNA [Hines et al. 2002]. The order of the genes 
within the cluster is cen-FMO3-FMO6P-FMO2-FMO1-
FMO4-tel, with no other genes being present. The gene en-
coding FMO5 is located ~26 Mb closer to the centromere, in 
the region 1q21.1 [Hernandez et al. 2004]. A second cluster 
of five FMO genes has been identified in the region 1q24.2, 
approximately 4 Mb to the centromeric side of the q24.3 
cluster. This cluster, however, consists entirely of pseu-
dogenes, designated FMO7P-FMO11P [Hernandez et al. 
2004]. The human genome therefore contains 11 FMO 
genes, five of which are functional. This review will focus 
on the five functional FMO genes, FMO1 to FMO5, and the 
proteins which they encode. Functional FMO genes contain 
eight coding exons and either one or two 5’ non-coding ex-
ons. In each case, the mature mRNA is produced by splicing 
the coding exons to a single non-coding exon. 
  FMOs 1, 2, 3, 4 and 5 have 51 to 57% amino acid se-
quence identity, whereas FMO6 is 72% identical to FMO3. 
FMOs of other mammalian species have >80% sequence 
identity to their human orthologues. Two GXGXXG motifs, 
characteristic of FAD- and NADPH-pyrophosphate-binding 
sites are present at identical positions (residues 9-14 and 
191-196, respectively) in each human FMO. The FAD-
binding site is contained within a “fingerprint” sequence that 
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known to be involved in binding dinucleotides [Wierenga et 
al. 1985]. A hydrophobic motif, F(A/T)TGY, characteristic 
of FMOs, is present at about residue 330. For more informa-
tion on the structural features of FMOs, see the review by 
Krueger and Williams [2005]. Recently, a three-dimensional 
structure of a FMO from Schizosaccharomyces pombe has 
been determined [Eswaramoorthy et al. 2006]. In contrast to 
mammalian FMOs, the yeast enzyme is cytosolic and about 
85 residues shorter.  
  Phylogenetic analysis suggests that the five functional 
FMO genes arose from a common ancestral gene via a series 
of gene duplications, estimated to have occurred between 
210 and 275 million years ago [Hernandez et al. 2004]. This 
is much earlier than the divergence of mammals, some 85 
million years ago, and therefore it is predicted that all mam-
mals possess the functional FMO genes FMO1 to FMO5.  
  Each member of the FMO gene family exhibits a differ-
ent developmental stage- and tissue-specific pattern of ex-
pression, which accounts for the marked qualitative and 
quantitative differences in FMO activities in tissues such as 
liver, lung and kidney. In addition, there are species differ-
ences in FMO gene expression (see below), which have im-
plications for the extrapolation of drug metabolism data from 
experimental animals to humans.  
  In this review we focus on the functional FMOs of hu-
mans. For each FMO we describe gene organization, devel-
opmental- and tissue-specific pattern of expression (and how 
this may differ from that in other mammals) and substrate 
specificity. We also describe genetic variants that have been 
identified, focusing on validated coding-region variants, but 
including promoter variants that have been shown to have an 
effect on gene expression, the frequency with which the 
variants occur in the world’s major population groups and 
their effect on enzyme function. We then discuss conse-
quences of genetic variation in the FMOs for the metabolism 
of therapeutic drugs and the implications of this for drug 
efficacy and response. 
FMO1  
  In 1971 Ziegler identified a mixed-function amine oxi-
dase in porcine liver microsomes whose substrates included 
nitrogen- and sulphur-containing compounds [Ziegler et al. 
1971]. A cDNA for the corresponding protein of humans 
was isolated in 1991 [Dolphin et al. 1991], and the enzyme is 
now known as FMO1 [Lawton et al. 1994]. The FMO1 gene, 
which was mapped to the long arm of chromosome 1 
[Shephard et al. 1993], encodes a polypeptide of 532 amino-
acid residues of molecular mass 60,306. 
Tissue Distribution 
  There is a distinct species difference in the hepatic ex-
pression of FMO1. In humans, neither FMO1 mRNA [Dol-
phin et al. 1991; Phillips et al. 1995; Dolphin et al. 1996] 
nor protein [Yeung et al. 2000; Koukouritaki et al. 2002] is 
present in adult liver. This is in marked contrast to all other 
mammals investigated, in which FMO1 constitutes a major 
form of the enzyme in adult liver [Lawton et al. 1990; Gas-
ser et al. 1990; Cherrington et al. 1998a; Lattard et al. 
2002a; Stevens et al. 2003]. However, the FMO1 gene is 
expressed in fetal human liver [Dolphin et al. 1991, 1996; 
Phillips et al. 1995; Yeung et al. 2000; Koukouritaki et al. 
2002]. Expression is highest in the first trimester (7.8 ± 5.3 
pmol/mg microsomal protein), then declines during fetal 
development and by 3 days after birth is completely extin-
guished [Koukouritaki et al. 2002]. FMO1 is also expressed 
in fetal human kidney, but in this tissue expression is in-
creased after birth, not switched off as in the liver [Dolphin 
et al. 1991, 1996; Phillips et al. 1995; Yeung et al. 2000; 
Krause et al. 2003].  
  In adult human the main site of expression of FMO1 is 
the kidney [Dolphin et al. 1991, 1996; Phillips et al. 1995; 
Yeung et al. 2000]. The gene is also expressed in the small 
intestine [Yeung et al. 2000] and stomach, and in a number 
of endocrine tissues, including pancreas, adrenal cortex and 
medulla, thyroid, thymus and testis [Hernandez et al. 2004]. 
The amount of FMO1 in adult human kidney (47 ± 9 pmol/ 
mg microsomal protein) [Yeung et al. 2000] is not much 
lower than that observed in liver for the major hepatic cyto-
chrome P450 (CYP), CYP3A4 (96 ± 51 pmol/mg microso-
mal protein) [Shimada et al. 1994], and is greater than that of 
the total content of CYPs in adult human kidney [Jakobsson 
and Cintig, 1973]. Thus, in adult human, FMO1 is likely to 
be a major contributor to the renal metabolism and clearance 
of therapeutic drugs. Another study reported lower amounts 
of FMO1 in adult kidney (3.2 – 11.5 pmol/mg microsomal 
protein) [Krause et al. 2003]. It has been suggested that dif-
ferences in the amounts of FMO1 detected in these two stud-
ies may have been due to the use of different antibodies 
[Krause et al. 2003]. Krause et al. [2003] report also that 
FMO1 amounts are greater in individuals of African descent 
(African Americans) than in Caucasians. However, it should 
be noted that the Caucasian kidney samples were obtained 
from cadavers, whereas the African-American samples were 
from biopsies.  
  Interindividual differences in the expression of FMO1 
have been reported. Variations in expression in fetal liver of 
10- to 20-fold (n=92), depending on gestational age, were 
observed [Koukouritaki et al. 2002]. Studies of adult human 
kidney samples found little variation (n=4) [Yeung et al. 
2000], less than 4-fold variation (n=26) [Krause et al. 2003], 
or less than 5-fold variation (n=13) [Hamman et al. 2000], 
whereas amounts in small intestine varied by up to 5-fold 
(n=7) [Yeung et al. 2000].  
Organization of The Human FMO1 Gene  
 The  human  FMO1 gene has 10 exons. The translation 
initiation codon is located in exon 2 and the protein-coding 
sequence is contained within exons 2 to 9. Exons 0 and 1 are 
upstream non-coding exons. In fetal liver, transcription is 
initiated from the most 5’ exon (exon 0), via the P0 pro-
moter. To produce the mature FMO1 mRNA sequences de-
rived from exon 0 are spliced to those derived from exon 2 
[Hernandez et al. 2004]. Analysis of a cDNA isolated from 
the small intestine (accession no. AK097039) indicates that 
in this tissue transcription starts from exon 1, via the P1 
promoter, and sequences derived from exon 1 are spliced to 
those derived from exon 2. In the kidney transcription can 
begin from a site within intron 1, via the P2 promoter 
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three alternative promoters, P0, P1 and P2. In fetal liver only 
the most upstream, P0, is used [Shephard et al. 2007]. Irre-
spective of the promoter used the FMO1 protein, encoded by 
alternatively spliced mRNAs, is identical as both exon 0 and 
1 are untranslated.  
  The reasons for the silencing of the FMO1 gene in adult 
human liver are not understood. However, a recent study 
[Shephard et al. 2007] using reporter gene assays has shown 
that sequences upstream of the core liver promoter (upstream 
of exon 0) act as a powerful transcriptional repressor in 
transfected HepG2 cells. The repressor sequences contain 
repetitive elements that are absent from species in which the 
gene is expressed in adult liver
 [Shephard et al. 2007]. Con-
tinued expression of the gene in adult human extra-hepatic 
tissues can be explained in part by the use of alternative 
promoters to direct expression in the intestine and kidney 
[Hernandez et al. 2004]. 
Genetic Variants  
Protein-Coding Variants 
 Fig.  (1) shows the polymorphic variants identified in the 
coding region of FMO1. Analysis of the FMO1 gene from 50 
unrelated African Americans identified four single-nucleotide 
polymorphisms (SNPs) that change the amino-acid sequence 
of the protein [Furnes et al. 2003]: g.9614C>G(H97Q), 
g.23970A>G (I303V), g.23971T>C (I303T) and g.27362C> 
T(R502X), (Fig. (1)) and (Table 1). Each of the variants was 
found in only one or two of the 100 chromosomes surveyed. 
I303V, which is also reported in dbSNP126, has been found 
in African Americans and Yorubans at frequencies of 10-
15%, but is absent from Europeans and Asians. The catalytic 
activity of each of these variants for N- and S-oxygenation 
was assessed in a heterologous expression system using four 
known substrates for FMO1: methimazole, imipramine, fen-
thion and methyl p-tolyl sulphide [Furnes  and Schlenk, 
2004]. Three of the variants, H97Q, I303V and I303T, had 
little if any effect on enzyme activity with any of the sub-
strates. Although R502X was missing 31 residues from the 
C-terminus, this had only a modest if any effect on activity 
towards imipramine, fenthion and methyl p-tolyl sulphide. 
However, the variant was completely inactive towards me-
thimazole. The results of this study show that, depending on 
the substrate, the same SNP can have a markedly different 
effect on FMO1 activity. R502X was identified in only one 
of the 100 chromosomes surveyed and thus may represent a 
rare variant that would have little consequence for the gen-
eral population.  
  A further nonsynonymous SNP, g.22739G>A(R223Q), is 
reported in dbSNP126 (rs16864310), (Fig. (1) and Table 1). 
The effect of this polymorphism on enzyme activity is not 
known. However, it is apparently specific to Chinese, in 
which it occurs at very low frequency (2%). Thus, only five 
nonsynonymous SNPs have been identified in FMO1, each 
of which is apparently confined to a single population group, 
in which it occurs at low, or very low frequency.  
  Three coding variants that do not alter the amino- 
acid sequence, g.22818C>T(T249T), g.25061A>G(V396V) 
[Furnes et al. 2003] and g.27258A>G(P467P) (dbSNP126, 
rs28360432) have also been identified in FMO1, (Fig. (1) 
and Table 1). These synonymous SNPs will not affect pro-
tein activity; however, it is not known whether such exonic 
changes will affect the amount of protein produced by influ-
encing the rate of splicing or efficiency of translation of the 
FMO1 mRNA.  
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Genetic variants of FMO1, FMO2, FMO4 and FMO5. 
Horizontal bars represent the polypeptide chains. Alternating grey and white boxes represent regions encoded by exons 2 to 9. Black boxes 
indicate, from left to right, the FAD and NADPH binding sites and the conserved F(A/T)TGY sequence. Nonsynonymous variants are shown 
in black and synonymous variants in grey. The Flavin-Containing Monoooxygenases (FMOs)  Current Pharmacogenomics, 2007, Vol. 5, No. 4    295 
Table 1.  Protein-coding SNPs for FMOs 1, 2, 4 and 5 
Gene Variant Exon  Amino  Acid 
Change 
Functional Consequence  Reference 
FMO1  g.9614C>G 3  H97Q  no  effect  Furnes et al. 2003;  
Furnes and Schlenk, 2004 
FMO1 g.22739G>A  6  R223Q  n.d.  dbSNP126 
FMO1 g.22818C>T  6  T249T  -  Furnes et al. 2003; dbSNP126 
FMO1 g.23970A>G  7  I303V  no  effect  Furnes et al. 2003;  
Furnes and Schlenk, 2004; dbSNP126 
FMO1 g.23971T>C  7  I303T  no  effect  Furnes et al. 2003;  
Furnes and Schlenk, 2004; dbSNP126 
FMO1 g.25061A>G  8  V396V  -  Furnes et al. 2003; dbSNP126 
FMO1 g.27258A>G  9  P467P  -  dbSNP126 
FMO1 g.27362C>T  9  R502X  substrate-dependent  decrease  Furnes et al. 2003;  
Furnes and Schlenk, 2004 
FMO2 g.107A>G  2  D36G  n.d.  Furnes et al. 2003 
FMO2 g.7661G>A  3  V59I  n.d.  Furnes et al. 2003 
FMO2  g.7695T>A 3  F69Y  n.d.  dbSNP126 
FMO2 g.7700_7702dupGAC  3  D71dup  loss  of  function  Furnes et al. 2003;  
Krueger et al. 2005 
FMO2  g.7731T>C 3  F81S  n.d.  dbSNP126 
FMO2 g.10951delG  4  V113fsX  loss  of  function  Furnes et al. 2003;  
Krueger et al. 2005 
FMO2 g.13693T>C  5  F182S  n.d.  Furnes et al. 2003 
FMO2 g.13732C>T  5  S195L  loss  of  function  Furnes et al. 2003;  
Krueger et al. 2005 
FMO2 g.13733A>G  5  S195S  -  Furnes et al. 2003 
FMO2 g.18237G>A  6  R238Q  n.d.  Furnes et al. 2003 
FMO2  g.18269C>T  6  R249X  n.d. (but likely loss of function)  dbSNP126 
FMO2 g.19679A>G  7  E314G  n.d.  dbSNP126 
FMO2 g.19839G>A  7  A367A  -  Furnes et al. 2003 
FMO2 g.19898_19899ins 
TCAAGCTC 
7  R387RfsX5  n.d. (but likely loss of function)  Furnes et al. 2003 
FMO2 g.19910G>C  7  R391T  n.d.  Furnes et al. 2003 
FMO2 g.22027G>A  8  E402E  -  Furnes et al. 2003 
FMO2 g.22060T>G  8  N413K  no  effect  Furnes et al. 2003;  
Krueger et al. 2005 
FMO2 g.23238C>T  9  Q472X  loss  of  function  Dolphin et al. 1998;  
Whetstine et al. 2000 
FMO2 g.23300A>G  9  K492K  -  Furnes et al. 2003 
FMO2 g.23405_23406insT  9  F528FfsX32  n.d.  dbSNP126 
FMO2 g.23412_23413insT  9  C530LfsX30  n.d.  Whetstine et al. 2000 296    Current Pharmacogenomics, 2007, Vol. 5, No. 4  Phillips et al. 
(Table 1. Contd….) 
Gene  Variant  Exon  Amino Acid Change  Functional Consequence  Reference 
FMO4 g.110T>C  2  I37T  n.d.  Furnes et al. 2003 
FMO4 g.14601C>T  7  F281F  n.d.  dbSNP126 
FMO4 g.14680A>T  7  T308S  n.d.  dbSNP126 
FMO4 g.14724T>C  7  D322D  n.d.  Furnes et al. 2003 
FMO4 g.14726T>C  7  V323A  n.d.  Furnes et al. 2003 
FMO4 g.14770G>C  7  E339Q  n.d.  Furnes et al. 2003 
FMO5 g.23716G>A  7  P337P  n.d.  dbSNP126 
FMO5 g.  23806A>G  7  A367A  n.d.  Furnes et al. 2003 
FMO5 g.37917C>T  9  P457L  n.d.  Furnes et al. 2003 
FMO5  g.38059G>T 9  R506S  n.d.  dbSNP126 
Mutation nomenclature follows that recommended by the Human Genome Organization (http://www.hgvs.org/mutnomen/). n.d., not determined. 
 
Untranslated Coding Variants 
  Four verified SNPs have been identified in the 3’ un-
translated region (UTR) of the FMO1 mRNA: g.27568C>T 
(rs12954) [Hines et al. 2003], g.27578 G>A (dbSNP126, 
rs28360434), g.27590 G>A(dbSNP126, rs28360435;) and 
g.27664C>T(rs7877) [Hines et al. 2003] (Table 1). Two of 
these, g.27568C>T and g.27664C>T, are discussed below in 
the section on FMO1 and disease.  
Promoter Variants 
  A limited number of reports indicate that in rat expres-
sion of FMO1 can be modulated in response to 3-methyl-
cholanthrene [Chung et al. 1997], indoles [Katchamart et al. 
2000] and corticosterone [Chen et al. 2005]. However, two 
of these studies are of liver [Chung et al. 1997; Katchamart 
et al. 2000], a tissue in which FMO1 is not expressed in 
adult human. Consequently, the relevance of these findings 
for humans is not clear. The evidence available to date sug-
gests that in humans FMO1 expression, in contrast to that of 
CYP genes, is not greatly influenced by foreign chemicals. 
Thus the observed interindividual variations in amounts of 
FMO1 (see above) are more likely due to genetic rather than 
environmental factors.  
  To identify nucleotide changes that might affect the ex-
pression of FMO1, Hines and co-workers analysed the FMO1 
gene from 177 unrelated individuals representing the world’s 
ethnic diversity: northern Europeans, Africans, Mexican- and 
native-Americans, and east- and south-Asians [Hines et al. 
2003]. A region extending about 1 kb upstream of exon 0 
[Hernandez et al. 2004], exons 0, 2-9 and the immediate 
flanking intronic sequences were examined for SNPs. This 
study assessed the novel SNPs identified, together with pre-
viously reported SNPs, for any that were likely to influence 
the expression of FMO1. None of the four SNPs in the 5’ 
sequence of FMO1, g.-10361T>A, g.-10330C>T, g.-10046A 
>G and g.-9782C>A, were located in regulatory elements 
previously identified and implicated in the regulation of tran-
scription of the gene [Luo et al. 2001]. However, the SNP g.-
9536C>A (in exon 0) was located in a YY1 element previ-
ously shown to be involved in regulation of rabbit FMO1 
[Luo et al. 2001]. Electrophoretic mobility shift assays using 
extracts from HepG2 cells revealed a complex set of DNA-
protein interactions when 24-bp sequences containing either 
of the g.-9536C>A SNP variants were used as probes [Hines 
et al. 2003]. The CA transversion prevented YY1 binding 
to DNA, but increased the affinity for the transcription fac-
tors Oct1, HNF1 and HNF1. Transfection of HepG2 cells 
with reporter gene constructs under the control of either the 
g.-9536C (FMO1*1) or g.-9536A (FMO1*6 ) alleles showed 
no difference when the plasmid contained the FMO1 mini-
mal promoter. However, constructs containing longer sec-
tions of either of the two alleles showed a 2- to 3-fold de-
crease in reporter gene activity when the g.-9536A was pre-
sent.  
 The  FMO1*6 allele is present in African Americans at a 
frequency of 13%, in northern-European Americans at 11% 
and in Hispanic Americans at 30%. The effect of this rela-
tively common variant (g.-9536C>A) on FMO1 gene expres-
sion in vivo is not clear. Two fetal liver samples, homozy-
gous for the FMO1*6 allele, showed FMO1 expression lev-
els in the upper quartile range for their age bracket rather 
than the lower range [Koukouritaki et al. 2002] that would 
be predicted from the results of the transfection experiments 
described above. It is possible that other transcription factors 
compensate for the loss of YY1 binding in FMO1*6 indi-
viduals. Therefore at present little is known about SNPs that 
might influence the amount of FMO1 protein produced.  
  Two SNPs, g.-11T>C and g.17248T>C, are located 
within polypyrimidine splice donor sites. However, such 
pyrimidine for pyrimidine changes are unlikely to affect 
splicing of the FMO1 transcript and hence would not be ex-
pected to influence the amount or type of protein produced.  
Therapeutic Drug Substrates For FMO1: Detoxification 
Versus Bioactivation 
  Among all FMO isoforms, FMO1 has the broadest range 
of substrates. A wide range of xenobiotics and foreign com- 
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pounds are among its substrates, which include therapeutic 
drugs, pesticides and endogenous compounds. A list of sub-
strates for human FMO1 that are of therapeutic importance is 
given in Tables 2 and 3.  
  A detailed discussion of the activity of FMO1 towards 
each of these drugs is beyond the scope of this review. For 
more information on this topic the reader is referred to the 
review by Krueger and Williams [2005]. However, we have 
selected two drugs, tamoxifen and thiacetazone, for special 
mention because of their widespread use in the treatment, 
respectively, of breast cancer and tuberculosis, and the po-
tential conflict between bioactivation and detoxification with 
respect to drug metabolism and therapeutic outcome.  
  Recent work has highlighted interesting results concern-
ing the relationship between FMOs and CYPs with regard to 
tamoxifen metabolism [Parte and Kupfer, 2005]. Tamoxifen 
is converted to its N-oxide by FMO1 and, less effectively, by 
FMO3 (see below). N-oxygenation of a drug by a FMO is 
generally considered as a detoxification pathway, with the N-
oxide being a non-toxic product. In contrast to FMO1-
mediated detoxification of tamoxifen, the drug can be bioac-
tivated by CYP-mediated hydroxylation, a reaction catalyzed 
mainly by CYP3A4, the major hepatic CYP (reviewed in 
[Krueger et al. 2006]). The products of this reaction can bind 
covalently to DNA and proteins, causing macromolecular 
damage and potential health risks. Because FMO1 is not 
present in adult human liver, the ratio of the CYP-bio-
activated tamoxifen products to the N-oxide detoxification 
product is expected to be high. However, in tissues in which 
FMO1 is expressed, for example, the kidney, in which the 
amounts of FMO1 more closely resemble that of CYP3A4, 
tamoxifen-related DNA adducts would be expected to be 
low. This has been shown to be the case in a study of tissues 
of monkey treated with tamoxifen [Shibutani et al. 2003]. 
Tamoxifen and its metabolites are widely distributed through-
out the body in patients treated with the drug for short or 
long periods [Lien et al. 1991]. The study of Parte and 
Kupfer [2005] has raised some interesting possibilities with 
regard to the interplay between CYP and FMO1 metabolism 
in different tissues. The N-oxide of tamoxifen, formed by 
FMO-mediated action, can be reduced to tamoxifen by CYPs 
Table 2.  Nitrogen-containing Drugs Oxygenated by Human FMO1 
Substrate  Type of Drug and Health Condition  Product  Reference 
Benzydamine nonsteroidal  antiinflammatory   N-oxide Lang and Rettie, 2000;  
Stormer et al. 2000 
Chlorpromazine  dopamine D2 antagonist  
(antipsychotic) 
-  Kim et al. 2000 
Deprenyl   monoamine oxidase type B inhibitor (Parkinson’s disease)  hydroxylamine  Cashman et al. 1999;  
Szoko et al. 2004 
Imipramine  5HT/noradrenalin re-uptake inhibitor (antidepressant)  N-oxide  Kim and Ziegler, 2000 
Itopride  dopamine D2 antagonist  
(gastroprokinetic)  
N-oxide  Mushiroda et al. 2000 
Methamphetamine psychostimulant  hydroxylamine  Cashman et al. 1999;  
Szoko et al. 2004 
N-deacetyl ketoconazole*  antifungal agent  N-hydroxyl  Rodriguez and Miranda, 2000 
Olopatadine antihistamine    N-oxide Kajita et al. 2002 
Orphenadrine anticholinergic   
(Parkinson’s disease) 
-  Kim and Ziegler, 2000 
SNI-2011  muscarinic receptor agonist  
(Sjogren's Syndrome) 
N-oxide  Washio et al. 2003 
Tamoxifen  estrogen receptor modulator  
(Breast Cancer Therapy) 
N-oxide  Parte and Kupfer, 2005 
Xanomeline  muscarinic receptor agonist  
(Alzheimer’s Disease) 
N-oxide  Ring et al. 1999 
*Major metabolite of the antifungal agent ketoconazole; - Products not identified/unpublished. 
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and other heme proteins. Thus, depending on the ratio of 
FMO1 to CYPs in a particular tissue, reduction of tamoxifen 
N-oxide back to tamoxifen could provide an additional 
source of the drug for bioactivation by CYPs, or, by acting as 
a potential store of tamoxifen, the N-oxide might increase the 
amount of available drug and thus lead to greater drug effi-
cacy.  
  The anti-tubercular drug thiacetazone is a thiocarbamide 
prodrug, which is activated in Mycobacterium tuberculosis 
by the FMO enzyme EtaA to form a sulfenic acid intermedi-
ate [Qian  and Ortiz de Montellano, 2006]. This is further 
oxidized to two metabolites, a sulfinic acid and a carbodi-
imide. The mechanism of cytotoxicity within the bacterial 
cell is not known, but it is suggested that metabolites of 
thiacetazone may lower the concentration of mycothiol (a 
bacterial antioxidant that has a role similar to that of glu-
tathione in eukaryotic cells), eventually resulting in cell 
death. Thiacetazone is a substrate in vitro for both human 
FMO1 and FMO3 (see below), the products being the same 
as those of the reaction catalyzed by the bacterial FMO 
[Qian and Ortiz de Montellano, 2006]. There is evidence to 
suggest bioactivation of thiocarbamide drugs by mammalian 
monooxygenases in both humans and rats [Ruse and Waring, 
1991 a, b]. The in vivo detoxification routes for thiacetazone 
are unclear, but FMOs may well play a role in both detoxifi-
cation and bioactivation pathways. This poses a question 
concerning the response of individuals to the drug. Will po-
lymorphic variants in FMO1 that affect the amount or activ-
ity of the protein influence the distribution of the drug in 
extra-hepatic tissues and thus the amount of drug ultimately 
delivered to the bacterium? 
  The examples of bioactivation versus detoxification dis-
cussed above pose important questions regarding an individ-
ual’s response to drug therapy. In the case of tamoxifen, tis-
sue distribution of the drug and its metabolites, and hence the 
balance between drug efficacy and harmful side effects, is 
likely to be influenced by the combined effects of FMO1 and 
CYP genetic variants. In the case of thiacetazone, the inter-
play between the bacterial EtaA protein and FMO1- (or 
FMO3-) mediated metabolism is predicted to play a role in 
drug efficacy. However, adverse drug reactions are expected 
to be due to host FMO-mediated effects.  
FMO1 And Disease 
  Gene expression profiling of human myocardial tissue 
from patients diagnosed with atrial fibrillation (AF) showed 
a significant increase in the expression of FMO1 mRNA and 
of several other mRNAs encoding proteins thought to be 
involved in oxidative stress [Kim et al. 2003]. The role, if 
any, of specific FMO1 SNPs in AF is not known. Other 
DNA profiling experiments have indicated that FMO1 mRNA 
is under-represented in the spinal cord of patients with 
amyotrophic lateral sclerosis (ALS) [Malaspina et al. 2001]. 
A recent study [Cereda et al. 2006] examined the allelic fre-
quency of two FMO1 SNPs, g.27568C>T (rs12954) and 
g.27664C>T (rs7877), located within the 3’ UTR of the 
mRNA, in a group of sporadic ALS patients and a control 
group. Both SNPs were found to be over-represented in fe-
male, but not male, ALS patients. The short distance (97 bp) 
between the SNPs explains the strong linkage disequilibrium 
between these two polymorphisms. It is not known whether 
the two SNPs affect the stability of the mRNA, but this is 
thought to be unlikely [Hines et al. 2003]. The authors sug-
gest that the expression of FMO1 may be down-regulated in 
males compared with females and thus the role of FMO1 in 
neurometabolism may be less important in males than in 
females. In contrast to the situation in mouse [Cherrington et 
al. 1998b], no significant gender differences in the expres-
sion of FMO1 have been reported for human.  
FMO2 
  The main site of FMO2 expression is the lung, where in 
most mammals it constitutes the major form of the enzyme 
present [Lawton et al. 1990; Nikbakht et al. 1992; Yueh et 
al. 1997]. In humans the gene is also expressed in skeletal 
muscle, kidney, prostate gland and blood vessels [Hernandez 
et al. 2004]. In contrast to other FMOs, FMO2 can mediate 
the  N-oxygenation of some primary alkylamines to their 
oximes, via an N-hydroxylamine intermediate [Tynes et al. 
1986; Poulsen et al. 1986], but is unable to catalyze the oxy-
genation of certain tertiary amines, such as imipramine and 
Table 3.  Sulphur-containing Drugs Oxygenated by Human FMO1 
Substrate  Type of Drug or Health Condition  Product  Reference 
Ethionamide antibiotic  (tuberculosis)  -  Krueger and Williams, 2005 
Methimazole thyroperoxidase  inhibitor 
(hyperthyroidism) 
S-oxide Furnes et al. 2004 
S-methyl esonarimod*   cytokine production inhibitor 
(rheumatism) 
S-oxide Ohmi et al. 2003 
Tazarotenic acid**  retinoic acid receptor modulator 
(acne/psoriasis) 
S-oxide  Attar et al. 2003 
Thiacetazone  antibiotic (tuberculosis)  sulfinic acid/carbodiimide  Qian and Ortiz de Montellano 2006 
Products not identified/unpublished; * active metabolite of parent compound esonarimod; ** active metabolite of parent compound tazarotene  
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chlorpromazine [Ohmiya and Mehendale, 1982; Williams et 
al. 1984], that are good substrates for FMO1. In comparison 
with other FMOs, FMO2 exhibits a greater restriction in the 
size of its substrates, displaying a marked preference for sub-
strates with a long side chain. This suggests that the active 
site of FMO2 is located further from the surface of the en-
zyme than that of other FMOs and is accessed by a relatively 
narrow channel. In addition, FMO2 is less sensitive to inac-
tivation by elevated temperature and anionic detergents. The 
gene for FMO2, which was mapped to the long arm of hu-
man chromosome 1 [M
cCombie et al. 1996] comprises 9 
exons, the first of which is non-coding.  
Genetic Variants 
  Analysis of cDNAs for human FMO2 revealed that they 
encoded a polypeptide that, in comparison with FMO2 of 
rabbit [Lawton et al. 1990], guinea pig [Nikbakht et al. 
1992] and rhesus macaque [Yueh et al. 1997], lacks 64 resi-
dues from its carboxy terminus [Dolphin et al. 1998]. This 
was the result of CT mutation that changed a glutamine 
codon at position 472 to a stop codon. The presence of the 
premature stop codon in the human FMO2 gene was con-
firmed by sequencing genomic DNA from several individu-
als [Dolphin et al. 1998]. The nonsense mutation, g.23238C 
>T (Q472X), that gave rise to the truncated polypeptide is 
not present in non-human primates such as chimpanzee (Pan-
troglodytes) and gorilla (Gorilla gorilla) [Dolphin et al. 
1998] and must therefore have arisen in the human lineage 
some time after the divergence of the Homo and Pan clades 
took place some 6 million years ago.  
  Analysis of individuals of different racial and ethnic 
backgrounds, namely European Caucasians, Orientals (Japa-
nese and Chinese), Africans (including African Americans 
and UK Afro-Caribbeans), New-Guinea Aboriginals, Indians 
and Maoris, revealed that the allele encoding the truncated 
FMO2, g.23238T (FMO2*2A), occurred at a frequency of 
100% in all groups investigated, with the exception of indi-
viduals of African descent, in which the ancestral g.23238C 
allele (FMO2*1), which encodes a full-length polypeptide 
(FMO2.1), was present at a frequency of 4% [Dolphin et al. 
1998]. These results were confirmed and extended by a 
larger population study [Whetstine et al. 2000]. All Europe-
ans (n=79) and Asians (n=120) investigated to date are ho-
mozygous for the FMO2*2A allele, whereas in African 
Americans (n=180) the FMO2*1 allele is present at a fre-
quency of 13%. FMO2*1 has also been identified in Hispan-
ics [Krueger et al. 2002a], and a subsequent study [Krueger 
et al. 2004] found that it is present in Hispanics of Puerto 
Rican (n=327) and Mexican (n=280) descent at frequencies 
of 3.5 and 1%, respectively.  
  Analysis of products of heterologously expressed cDNAs 
revealed that the truncated protein (X472) encoded by the 
major allele (FMO2*2A) is inactive, whereas the full-length 
protein (Q472) encoded by the minor allele (FMO2*1) is 
catalytically active [Dolphin et al. 1998]. The presence of 
full-length, active FMO2 in lung microsomes isolated from 
an individual heterozygous for FMO2*1/FMO2*2A was sub-
sequently confirmed [Krueger et al. 2002b].  
  A frame-shift mutation, g.23412_23413insT, has been 
observed at frequencies of 7 and 13% in African Americans 
and Caucasians, respectively [Whetstine et al. 2000]. This 
mutation would change the last six amino-acid residues and 
add 23 residues to the C-terminus of the protein. However, 
the frame-shift mutation was found to segregate with the 
g.23238T allele encoding the premature stop codon and thus 
would have no functional consequence.  
  A survey of 50 African Americans [Furnes et al. 2003] 
identified an additional 14 coding-region variants in FMO2. 
Four were synonymous; the other ten (seven nonsynony-
mous, two frame-shifts and one in-frame 3-bp duplication) 
would result in a change in amino acid sequence. Four of  
the latter, g.7700_7702dupGAC(D71dup), g.10951delG 
(V113fsX), g.13732C>T(S195L) and g.22060T>G(N413K), 
occurred at high frequency (>25%) in this population. The 
effect on FMO2 activity of these four mutations has been 
investigated [Krueger et al. 2005]. The frame-shift mutation 
(g.10951delG) results in the replacement of valine at position 
113 with a stop codon and thus produces a severely truncated 
protein. When expressed in a baculovirus-insect cell system 
the truncated protein was not detected and thus may have 
been targeted for degradation. The D71dup protein failed to 
bind FAD and was thus catalytically inactive. Although 
S195L bound FAD it retained only 2% of the activity of 
FMO2.1. In contrast, the activity of N413K was similar to 
that of FMO2.1.  
  With the exception of g13732C>T(S195L), which is pre-
sent at high frequency in Africans (35-60%), Asians (45-
55%) and Europeans (15-30%), the other mutations are ei-
ther absent or present in much lower frequency in non-
African populations. Of particular importance is whether 
variants that affect the function of FMO2 occur on the 
FMO2*1 allele, which encodes a full-length protein, or on 
the FMO2*2A allele, which encodes a truncated non-func-
tional protein. Haplotype analysis of g.10951delG(V113fsX), 
g.13732C>T(S195L) and g.22060T>G(N413K) indicated 
that all three variants segregated with the g.23238T(Q472X) 
variant and would thus be associated with a protein that is 
already inactive [Krueger et al. 2005]. This implies that indi-
viduals who possess a FMO2*1 allele are likely to express a 
protein that is catalytically active.  
  The other coding-region variants identified by Furnes et 
al. [Furnes et al. 2003] plus additional ones reported in 
dbSNP126 are shown in Fig. (1) and Table 1. The functional 
effect of the nonsynonymous SNPs has not been established. 
Of the nonsynonymous SNPs, three, g.7695T>A(F69Y), 
g.18237G>C(R238Q) and g.19910G>C(R391T) are appar-
ently restricted to African populations, where they occur at 
low frequency (4 to 7%). G.19679A>G(E314G) is particu-
larly common (25-35%) in Asians, whereas g.7731T>C 
(F81S) is absent from Asians, but relatively common (12-
30%) in Africans. Of the synonymous SNPs, g.13733A>G 
(S195S) occurs at high frequency (25-60%) in all popula-
tions, whereas g.19839G>A(A367A) and g.22027G>A(E402E) 
are restricted to Africans (15-23%).  
  A large study
1 (more than 1800 individuals from 25 dif-
ferent populations) demonstrated that the FMO2*1 allele is 
widely distributed throughout Africa. The allele occurs at 
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relatively low frequency (2-6%) in north Africa, but is more 
common in sub-Saharan Africa, in some regions reaching 
frequencies as high as 26%, with almost 50% of individuals 
having at least one FMO2*1 allele.  
FMO2 Substrates 
  Substrates of FMO2 include the thioether-containing 
organophosphate insecticides phorate and disulfoton [Hen-
derson et al. 2004a]. Organophosphates are bioactivated by 
CYP-mediated desulfuration to produce the oxon, which is a 
far more potent inhibitor of acetylcholinesterase than is the 
parent compound [Kulkarni and Hodgson, 1984]. In contrast, 
FMO2 catalyzes the S-oxygenation of organophosphates 
[Henderson et al. 2004a], which represents a detoxification 
pathway. Thus, individuals who express functional FMO2 
may have a reduced risk of toxicity if exposed to organo-
phosphates. 
  Of particular concern is the role of FMO2 in bioactiva-
tion. FMO2 has been shown to catalyze the S-oxygenation of 
thioureas, including thiourea, 1-phenylthiourea and ethylene 
thiourea, which are known or suspected lung toxicants, to 
produce the more toxic sulfenic and/or sulfinic acid metabo-
lites [Henderson et al. 2004b]. The sulfenic acid derivatives 
can combine with glutathione and undergo redox cycling, 
leading to oxidative stress and toxicity. Thus, individuals 
who express functional FMO2 would be predicted to be at 
increased risk of pulmonary toxicity following exposure to 
thiourea or its derivatives.  
  Little is known about the role of FMO2 in the metabo-
lism of drugs. However, prochloperazine and trifluoperazine 
have been shown to be substrates for FMO2 of rabbit [Lomri 
et al. 1993]. Of particular interest is the recent finding that 
the anti-tubercular drug thiacetazone is a good substrate for 
human FMO2
2, which has implications for the efficacy and 
toxicity of this drug in African populations.  
Potential Animal Model  
  A gene encoding a truncated, non-functional FMO2 is 
present in strains of laboratory rats (Sprague-Dawley and 
Wistar) and in the species, Rattus norvegicus, from which 
they were derived, but not in the closely related species Rat-
tus rattus [Lattard et al. 2002b]. However, the mutation that 
gives rise to the truncated protein, a 2-bp deletion in codon 
421, which results in a premature stop codon at position 433, 
is different from that present in humans, and must have oc-
curred independently after the divergence of Rattus nor-
vegicus and Rattus rattus. Interestingly, the mutation is po-
lymorphic in wild Rattus norvegicus and thus this species 
may represent a good model for investigating the metabolic 
and toxicological consequences of the human FMO2 poly-
morphism [Hugonnard et al. 2004]. 
Conclusions 
  Evidence to date indicates that in most of the world’s 
population groups essentially all individuals are homozygous 
for the FMO2*2 allele (g.23238C>T[Q472X]) and thus pro-
duce no functional FMO2. However, in sub-Saharan Africa 
and in populations recently descended from this region, a 
                                                 
2 Francois, A., Phillips, I.R. and Shephard, E. A. (unpublished). 
substantial proportion of individuals (almost 50% in some 
regions) possess at least one copy of the ancestral FMO2*1 
allele and thus express functional FMO2. This has implica-
tions for inter-ethnic and, in African populations, interindi-
vidual variations in response to drugs, and in susceptibility to 
toxic chemicals, that are substrates of FMO2, particularly 
those for which the lung is the target organ or route of entry.  
FMO3 
  A cDNA for human FMO3 was identified in 1992 by 
Lomri  et al. [Lomri et al. 1992]. The FMO3 gene was 
mapped to the long arm of chromosome 1 [Shephard et al. 
1993]. It comprises 9 exons, of which exon 1 is non-coding 
[Dolphin et al. 1997a], and encodes a polypeptide of 532 
amino-acid residues and molecular mass 60,047 [Phillips et 
al. 1995].  
Tissue Distribution 
  FMO3 is the predominant FMO isoform expressed in the 
liver of the human adult [Lomri et al. 1992; Phillips et al. 
1995; Dolphin et al. 1996]. FMO3 mRNA has been detected 
also in lung, kidney, adrenal medulla and cortex, pancreas, 
thyroid, gut and brain [Hernandez et al. 2004]. FMO3 ex-
pression is switched on after birth in humans [Koukouritaki 
et al. 2002] and in other species such as mouse [Janmo-
hamed et al. 2004]. However, small amounts of FMO3 pro-
tein have been detected in the human embryonic, but not 
fetal, liver [Koukouritaki et al. 2002]. The mRNA for FMO3 
is also not detectable in fetal liver [Dolphin et al. 1996]. The 
mechanisms and factors required to express the FMO3 gene 
in the embryo, to silence its expression during fetal devel-
opment and then to re-activate expression of the gene after 
birth are unknown. A comprehensive, immunochemical study 
[Koukouritaki et al. 2002] of human liver samples from 240 
individuals, ranging in age from 8 weeks gestation to 18 
years old, detected small amounts of FMO3 as early as 8 
weeks (the embryonic stage), but not in the fetus, 15-40 
weeks gestation. Analysis of postnatal samples showed that, 
during the first 3 weeks postpartum, in most individuals 
FMO3 was undetectable or present in only small amounts. 
Three subsequent developmental phases of FMO3 expres-
sion were apparent. In the first phase, between 3 weeks and 
10 months of age, amounts of FMO3 increased 5-fold, to 4.7 
± 5.9 pmol/mg microsomal protein. Between 10 months and 
11 years of age another 3-fold increase in expression was 
observed (to 12.7 ± 8.0 pmol/mg microsomal protein). In the 
third phase, between 11 and 18 years of age, there was a fur-
ther 2-fold increase (to 26.9 ± 8.6 pmol/mg microsomal pro-
tein). The amount of FMO3 produced was not influenced by 
gender.  
  The data indicate that birth is necessary, but not suffi-
cient, for the onset of FMO3 expression in human liver. The 
age at which FMO3 expression is switched on varies from 
birth to up to 2 years old. However, by ten months of age, 
the majority of individuals are expressing FMO3. This con-
trasts with the extinction of FMO1 expression in human 
liver, which is tightly linked to the process of birth, being 
switched off within a few days of birth, irrespective of gesta-
tional age [Koukouritaki et al. 2002] (see above). Conse-
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have no, or very small amounts of drug-metabolizing FMOs 
in their liver, which has important implications for their abil-
ity to metabolize therapeutic drugs that are substrates for 
these enzymes.  
  Interindividual variations of 10- to 20-fold in the expres-
sion of FMO3 have been reported [Overby et al. 1997; 
Koukouritaki et al. 2002; Cashman and Zhang, 2002]. The 
amounts of hepatic FMO3 reported by Overby et al., 
[Overby et al. 1997] (60 ± 43 pmol/mg microsomal protein) 
were higher than those reported by Koukouritaki et al. 
[2002] (see above). However, the samples analysed in the 
former study were from adult liver, whereas those in the lat-
ter study were from livers of 11 to 18 year olds. Therefore, it 
is possible that the differences reflect a further increase in 
FMO3 expression from the teenage years to adulthood. The 
amounts of FMO3 present in adult liver are therefore similar 
to those of the most abundant hepatic CYPs, CYP3A4, 
CYP2C and CYP1A2, with reported specific contents of 96 
± 51, 60 ± 27 and 42 ± 23 pmol/mg microsomal protein, re-
spectively [Shimada et al. 1994]. FMO3 expression has been 
found to be inducible by dioxin in male mouse liver [Tijet et 
al. 2006] and, in humans, may be influenced by physiologi-
cal factors, e.g., FMO3 declines during menstruation [Zhang 
et al. 1996; Shimizu et al. 2007a]. However, the majority of 
the observed interindividual variation in FMO3 expression is 
likely to be due to genetic factors.  
Genetic Variants 
Trimethylaminuria 
  Loss-of-function mutations in the FMO3 gene (MIM 
136132) cause the inherited disorder trimethylaminuria 
(TMAuria) (MIM 60279), also known as fish-odor syn-
drome. Affected individuals are unable to metabolize die-
tary-derived trimethylamine (TMA) to its non-odorous N-
oxide, a reaction catalyzed by FMO3 [Lang et al. 1998]. 
Consequently, they secrete the smelly free amine in their 
breath, sweat and urine, which imparts a bodily odor remi-
niscent of rotting fish [Mitchell and Smith, 2001]. Sufferers 
often display a variety of psychological and antisocial reac-
tions to their condition, including anxiety, chronic depres-
sion, and attempted suicide [Mitchell and Smith, 2001]. The 
disorder is inherited in a recessive manner [Al-Waiz et al. 
1988]. 
  The incidence of heterozygotes in British Caucasians is 
estimated to be about 1%, but may be higher in other popula-
tion groups [Hadidi et al. 1995; Mitchell et al. 1997; 
Mitchell  and Smith, 2001]. The first report identifying a 
causative mutation for this disorder, g.15153C>T(P153L), 
was in 1997 [Dolphin et al. 1997b]. The mutant protein, ex-
pressed in a baculovirus-insect cell system, was unable to 
catalyze the N-oxygenation of TMA. Subsequently, more 
than 30 mutations have been identified that cause TMAuria 
[Mitchell and Smith, 2001; Hernandez et al. 2003; Cashman 
and Zhang, 2006; Phillips and Shephard, 2007], (Fig. (2) and 
Table 4). The resultant mutant enzymes are unable to cata-
lyze TMA N-oxygenation and, with one exception, N61S, 
are also inactive towards other substrates tested, such as 10-
(N,N-dimethylaminopentyl)-2-(trifluoromethyl) phenothiaz-
ine (5’-DPT), tyramine and methimazole. Although N61S is 
incapable of catalyzing N-oxygenation of TMA, its ability to 
catalyze S-oxygenation of methimazole is unaffected [Dol-
phin et al. 2000].  
  Individuals displaying symptoms of TMAuria are re-
ferred to in the ancient Indian epic the Mahabharata and in 
Shakespeare’s the Tempest [Mitchell and Smith, 2001]. Al-
though we now understand the genetic basis of TMAuria, 
there has been little improvement in the lives of those af-
fected by this distressing disorder. Antibiotics are sometimes 
prescribed in an attempt to kill gut flora that produce TMA 
from dietary precursors such as choline and lecithin. The 
dietary supplements copper chlorophyllin and charcoal are 
reported to decrease the amount of TMA in the urine [Yama-
zaki et al. 2004]. However, patients report variable effec-
tiveness of these treatments. Strict diets that limit the intake 
of foodstuffs rich in precursors of TMA, such as meat, eggs, 
soya and marine fish, have been reported to help control the 
condition.  
Polymorphic Variants  
  In the course of studies on the genetic causes of TMAu-
ria, several polymorphic variants of FMO3 have been dis-
covered, (Fig. (2) and Table 5). Common variants that affect 
enzyme function are of particular interest because of their 
potential effect on the metabolism of therapeutic drugs and 
other foreign chemicals by the general population. The first 
such variant identified was g.15167G>A(E158K) [Brunelle 
et al. 1997; Dolphin et al. 1997b]. Although initially identi-
fied in TMAuria kindreds, the variant did not segregate with 
the disorder and was found to be common in the general 
population. Subsequently, it was found to be present at high 
frequency in all populations (dbSNP126): 40-45% in Afri-
cans, 35-45% in Europeans and 20-25% in Asians. Many 
studies have investigated the effect of this common variant 
on catalytic activity, both in vitro and in vivo (reviewed in 
[Cashman 2004; Krueger and Williams 2005; Koukouritaki 
and Hines, 2005 and Cashman and Zhang, 2006); Shimizu et 
al. 2007b]. The results are conflicting. Some reports indicate 
that the 158K variant has a lower catalytic activity towards 
some substrates, whereas others indicate no effect, or sub-
strate-dependent effects.  
  Another variant, g.21443A>G(E308G) [Treacy et al. 
1998], is relatively common in Asians and Europeans (at 
allele frequencies of 15-25%), but is rare in Africans (fre-
quency of 1 to 2%) (dbSNP126). As is the case for E158K 
(see above), studies on the effect of E308G on enzyme activ-
ity report conflicting results [Cashman 2004; Krueger  and 
Williams 2005; Koukouritaki and Hines, 2005; Cashman and 
Zhang, 2006]. In Asians and Europeans, the E158K and 
E308G variants are often linked, occurring on the same 
haplotype [Sachse et al. 1999; Kang et al. 2000; Cashman et 
al. 2001; Park et al. 2002]. Evidence from several studies 
indicates that the effect on enzyme activity is greater when 
both mutations are present than when either is present alone 
[Lattard et al. 2003; Cashman 2004; Krueger et al. 2005; 
Koukouritaki and Hines, 2005; Cashman and Zhang, 2006; 
Shimizu et al. 2007b]. Individuals homozygous for the 
linked E158K/E308G variants may exhibit symptoms of 
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1998; Zschocke et al. 1999]. However, many of the cases 
reported are of young children, in whom low expression of 
FMO3 [Koukouritaki et al. 2002] (see above) may contribute 
to symptoms. 
  A third variant, g.18281G>A(V257M) [Treacy et al. 
1998], is relatively common in Asian (allele frequency of 16 
to 28%), but less so in African (0 to 4%) or European (4 to 
7%) populations (dbSNP126). V257M has little effect on 
enzyme activity [Dolphin et al. 2000; Cashman 2004; 
Table 4.  Rare FMO3 Mutations Causative of TMAuria or Implicated in the Disorder  
Mutation  Exon  Amino Acid Change  Reference 
g.-2092 to 10145del      Forrest et al. 2001 
g.94G>A 2  E32K  Zhang et al. 2003 
g.110T>C 2  I37T  Teresa et al. 2006  
g.11145A>G 3  R51G  Mazon  Ramos et al. 2003  
g.11148G>T 3  A52T  Akerman et al. 1999a 
g.11166G>A 3  V58I  Kubota et al. 2002 
g.11177A>G 3  N61S  Dolphin et al. 2000 
g. 11185delA  3  K64KfsX2  Zhang et al. 2003  
g.11192G>T 3  M66I 
Cashman et al. 1997;  
Akerman et al. 1999b; 
Forrest et al. 2001 
g.11239T>C 3  M82T  Murphy et al. 2000 
g.15036A>G  4          N114S  Shimizu et al. 2007c 
g.15123T>A 4  V143E  Basarab et al. 1999 
g.15137G>T 4  G148X  Park et al. 1999 
g.15153C>T 
4 
P153L  Dolphin et al. 1997b;  
Cashman et al. 1997 
g.15526_15527delTG 5  C197fsX Yamazaki et al. 2007 
g.15531T>A 5  D198E  Fujieda et al. 2003 
g.15533T>C 5  I199T  Zschocke et al. 1999 
g.15539C>A 5  T201K  Shimizu et al. 2006 
g.18177G>A 6  R223Q  Preti et al. 2002 
g.18225G>C 6  R238P  Teresa et al. 2006 
g.21429G>T 7  E305X  Treacy et al. 1998; Akerman et al. 1999a 
g.21460G>T 7  E314X  Akerman et al. 1999a 
g.21680G>T 7  R387L  Akerman et al. 1999a 
g.21684G>A 7  W388X  Shimizu  et al. 2007c 
g.21702delG 7 K394KfsX11  Teresa et al. 2006 
g.23580delG 8  M405IfsX  Teresa et al. 2006 
g.24486G>A 9  M434I  Dolphin et al. 2000 
g.24592C>T 9  Q470X  Shimizu  et al. 2007c 
g.24608G>A 9  G475D  Zschocke et al. 1999 
g.24658C>T 9  R492W  Akerman et al. 1999b; Dolphin, 2000 
g.24682C>T 9  R500X  Shimizu et al. 2006 
K64KfsX2 has also been referred to as M66X  
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Krueger and Williams 2005; Koukouritaki and Hines, 2005; 
Cashman and Zhang, 2006; Shimizu et al. 2007b].  
  A further 20 coding-region SNPs, 8 synonymous and 12 
nonsynonymous, have been identified in FMO3 [Dolphin et 
al. 2000; Cashman 2002; Furnes et al. 2003; Fujieda et al. 
2003; Koukouritaki et al. 2005b; and dbSNP126], (Fig. (2) 
and Table 5). Of the nonsynonymous SNPs only g.21350T> 
C(V277A) is relatively common, occurring at a frequency of 
13% in Africans and ~20% in Asians, but it is absent from 
Europeans. Another, g.11177C>A(N61K), is present in Afri-
cans and Europeans at frequencies of 3.5 and 5%, respec-
Table 5.  Polymorphic Variants of FMO3 
Variant Exon 
Amino Acid 
Change 
Functional Consequence 
Reference 
g.72G>T 2  E24D  limited  Koukouritaki et al. 2007 
g.11177C>A 3  N61K*  reduced  or  abolished  Koukouritaki et al. 2007 
g.15089G>C 4  D132H  substrate-dependent  decrease  Kobayashi et al. 2001; Furnes et al. 2003;  
Lattard et al. 2003 
g.15167G>A 4  E158K moderate, substrate- dependent 
decrease 
Dolphin et al. 1997b; Brunelle et al. 1997;  
Treacy et al. 1998; Zschocke et al. 1999; Furnes et al. 2003 
g.15475G>T 5  G180V  no  effect  Dolphin et al. 2000 
g.15550C>T 5  R205C  moderate  decrease  Fujieda et al. 2003 
g.18281G>A 6  V257M  no effect or limited substrate de-
pendent decrease 
Treacy et al. 1998; Dolphin et al. 2000; Furnes et al. 2003 
g.18290A>G 6  M260V  n.d.  Shimizu et al. 2006 
g.21350T>C  7  V277A  n.d.   Cashman 2002 
g.21443A>G 7  E308G  moderate 
substrate dependent decrease 
Treacy et al. 1998; Zschocke et al. 1999 
g.21599T>C 7  L360P  increased  activity  Furnes et al. 2003; Lattard et al. 2003 
g.21604G>C  7  E362Q  n.d.  Cashman 2002; Furnes et al. 2003 
g.23613G>T 8  K416N  limited  Koukouritaki et al. 2007 
g.24642G>A 9  I486M  n.d.  Cashman  2002 
g.24691G>C 9  G503R  n.d.  Furnes et al. 2003 
*likely to be causative for TMAuria 
 
 
 
 
 
 
 
Fig. (2). Genetic variants of FMO3. 
Horizontal bars represent the polypeptide chains. Alternating grey and white boxes represent regions encoded by exons 2 to 9. Black boxes 
indicate, from left to right, the FAD and NADPH binding sites and the conserved FATGY sequence. The upper bar shows the identity and 
position of rare mutations that are causative of TMAuria, or implicated in the disorder. The lower bar shows the identity and position of non-
synonymous polymorphic variants. *SNP likely to be causative for TMAuria. 304    Current Pharmacogenomics, 2007, Vol. 5, No. 4  Phillips et al. 
tively. The remaining SNPs occur at low frequency (<4%, in 
some cases <1%) and are confined to a single population 
group.  
 G180V  [Dolphin et al. 2000], K416N and E24D [Kouk-
ouritaki et al. 2007] have little or no effect on catalytic activ-
ity. The effect of D132H appears to be substrate-dependent, 
decreasing  N-oxygenation of TMA and S-oxygenation of 
methimazole, but not N-oxygenation of 5’DPT [Koukouri-
taki et al. 2007]. R205C has a moderate effect on enzyme 
activity and, interestingly, exhibits substrate-inhibition of 
sulindac sulfide S-oxygenation [Shimizu et al. 2007b]. N61K 
either abolished or dramatically reduced enzyme activity 
towards four different substrates [Koukouritaki et al. 2007]. 
In contrast, L360P causes a 2- to 5-fold increase in catalytic 
activity [Lattard et al. 2003], and is the only genetic variant 
of FMO3 known to substantially increase enzyme activity. 
As such, it could increase the rate of drug metabolism, with a 
consequent decrease in efficacy. However, it has been de-
tected only in African populations and then at low frequency 
(2 to 4%). Consequently, it is of limited significance for the 
general population. The functional consequence of V277A, 
which is relatively common in Asian and African popula-
tions, but absent from Europeans, has not been investigated. 
However, valine is not conserved in FMOs at this position 
and thus the substitution, which represents a conservative 
change, is not expected to affect activity.  
Polymorphisms in Upstream Regulatory Region 
  Resequencing of 24 DNA samples from the Coriell Poly-
morphism Discovery Resource [Koukouritaki et al. 2005b] 
identified seven variants in the FMO3 5’-flanking sequence: 
g.-2650C>A, g.-2589C>T, g.-2543T>A, g.-2177G>C,   
g.-2106G>A, g.-2099A>G and g.-1961T>C. Based on the 
frequencies of individual alleles in northern-European 
Whites, African Americans or Hispanic Americans of Mexi-
can descent, 15 haplotypes were inferred. Seven haplotypes 
were considered common (frequency >1%) and were found 
in one or more of the ethnic groups at significantly different 
frequencies. The effect of individual haplotypes on gene ex-
pression was measured in HepG2 cells transfected with dif-
ferent FMO3-reporter constructs [Koukouritaki et al. 2005b]. 
Haplotype 2, (g.-2650C>A, g.-2543T>A, g.-2177G>C) 
caused an 8-fold increase in reporter gene activity compared 
with haplotype 1 (the reference sequence). Haplotype 2 was 
present at frequencies of 29, 11 and 6%, respectively, in the 
Hispanic, African-American and White groups. Two haplo-
types, 8 (g.-2589C>T, g.-2106G>A) and 15 (g.-2106G>A, 
g.-1961T>C), resulted in very low reporter gene activity. 
Haplotype 8 (-2589C>T, -2106G>A) is present only in the 
White group, at a frequency of 4%, whereas haplotype 15  
(-2106G>A, -1961T>C) was found only in the African-
American group (frequency 1.5%). The effects on reporter 
gene activity of haplotypes 3 (-2650C>G), 4 (-2650C>G,   
-2543T>A) and 11 (-2543T>A) were similar to those of the 
reference haplotype 1. 
   Individuals with haplotype 2, particularly homozygotes, 
would be expected to metabolize FMO3 substrates more 
rapidly if the increased promoter activity observed in vitro 
[Koukouritaki et al. 2005b] translates into increased produc-
tion of FMO3 protein in the liver. Similarly, those individu-
als homozygous for haplotypes 8 or 15 are predicted to pro-
duce lower amounts of the protein. If the relative promoter 
activities seen in the HepG2 cell transfection experiments are 
similar to those in vivo then individuals homozygous for 
haplotypes 8 or 15 would be expected to suffer some of the 
symptoms of TMAuria, due to the low amount of FMO3 
protein produced in their liver. Individuals who are com-
pound heterozygotes for haplotypes 2 and 15 (African 
American) or haplotypes 2 and 8 (White) would be expected 
to have amounts of the protein closer to that produced under 
the influence of haplotype 1.  
  This study was extended over a longer region of the 
FMO3 gene to examine linkage between the promoter SNP 
clusters (see above) and downstream coding variants, in 404 
Hispanic (Mexican), 400 Latino White and 402 African 
Americans [Koukouritaki et al. 2007]. Haplotype 2 [Kouk-
ouritaki et al. 2005b], which caused an 8-fold increase in 
reporter gene activity (see above) was found to be associated 
with E158K, E308G or the linked variant E158K/E308G. 
The combination of a high activity promoter with a coding 
variant that causes substrate-dependent reduction in enzyme 
activity may balance out and result in the production of suf-
ficient protein to compensate for an enzyme with lower ac-
tivity. The haplotype analysis undertaken by Koukouritaki et 
al. [Koukouritaki et al. 2007] underlines the importance, and 
the difficulties we face, in understanding the complete rela-
tionship between genotype and phenotype in vivo. 
Human FMO3 Variation And Clinical Implications 
  TMAuria sufferers lack functional FMO3 and, conse-
quently, are expected to have impaired ability to metabolize 
therapeutic drugs that are substrates for FMO3. Owing to the 
relatively small number of patients identified to date, little 
systematic investigation of this has been undertaken. How-
ever, one study (Mayatepek et al. 2004) found that TMAuria 
sufferers have a markedly reduced capacity for N-oxyge-
nation of benzydamine, a non-steroidal anti-inflammatory, 
and there are numerous anecdotal accounts of patients expe-
riencing poor responses to other drugs. Tables 6 and 7 sum-
marize the known drug substrates for FMO3.  
  In this section we highlight some recent studies of the 
effect of polymorphic FMO3 variants on drug metabolism. 
The first study to show that FMO3 variants influence clinical 
outcomes was in a group of patients treated with sulindac 
[Hisamuddin et al. 2004], a nonsteroidal anti-inflammatory 
drug prescribed to patients with familial adenomatous poly-
posis (FAP) or to individuals who are perceived to be pre-
disposed to this condition, judged by mutations in the APC 
gene. Sulindac is a prodrug and is converted by gut flora to 
its active metabolite, sulindac sulfide, which is then absorbed 
[Duggan et al. 1977; Etienne et al. 2003].  Human FMO3 
catalyzes the oxygenation of sulindac sulfide to its sulfoxide 
[Hamman et al. 2000], which is virtually inactive [Duggan et 
al. 1977]. Forty one individuals who were known to have 
mutations in the APC gene, but had not developed polyps at 
the start of the study, were divided into two groups. One 
group was given sulindac for 4 years, while the other re-
ceived a placebo. At the end of the trial 57% of the sulindac-The Flavin-Containing Monoooxygenases (FMOs)  Current Pharmacogenomics, 2007, Vol. 5, No. 4    305 
treated group were polyp-free compared with 45% of the 
placebo-treated group. When the individuals were genotyped 
for common FMO3 polymorphic variants, those homozygous 
for E158K (33%) or E308G (17%), and who had received 
sulindac, had not developed polyps. Individuals who had 
developed polyps were not homozygous for either of the 
FMO3 variant alleles [Hisamuddin et al. 2004]. A follow-on 
study with 19 individuals already suffering from FAP as-
sessed whether FMO3  genotype correlated with polyp re-
gression following sulindac treatment [Hisamuddin et al. 
2005]. All individuals homozygous or heterozygous for the 
E158K allele or heterozygous for both E158K and E308G 
alleles showed a reduction in polyp number. No individuals 
homozygous for E308G were included in this study.  
  The reasons for the increased sulindac efficacy in patients 
with E158K and E308G variants might be due to the reduc-
tion in the conversion by FMO3 of sulindac sulfide to inac-
tive metabolites. Thus the amount of sulindac sulfide avail-
able to the patient’s circulation would be expected to in-
crease and the longer duration of the active drug may con-
tribute to the regression of polyps and/or more effectively 
prevent their formation. 
  This study raises an important question with respect to 
sulindac efficacy and other FMO3 polymorphisms. Recently, 
the N61K variant was shown to have a 30-fold decrease in 
catalytic activity towards sulindac [Koukouritaki et al. 
2007]. It remains to be seen whether sulindac will be a less 
effective treatment against FAP in individuals with FMO3 
variants that increase promoter activity [Koukouritaki et al. 
2005b] or enzyme activity (L360P) [Lattard et al. 2003] (see 
above). 
  Clozapine, an antipsychotic, is metabolized to its N-oxide 
by both FMO3 [Tugnait et al. 1997] and CYP3A4 [Fang et 
al. 1998]. A study of 396 individuals of German ethnicity 
found no correspondence between serum N-oxide concentra-
tions and FMO3 haplotypes [Sachse et al. 1999]. 
  Most studies on the effect of FMO3 polymorphisms have 
been carried out in vitro. An interesting example of the effect 
of the E158K polymorphism in vitro is with respect to   
 
Table 6.  Nitrogen-containing Drugs Oxygenated by Human FMO3 
Substrate  Type of Drug or Health Condition  Product(s)  Reference 
Amphetamine  dopamine transporter ligand (antipsychotic)  hydroxylamine  Cashman et al. 1999;  
Szoko et al. 2004 
Benzydamine   nonsteroidal antiinflammatory (rheumatism)  N-oxide  Lang and Rettie, 2000;  
Stormer et al. 2000 
Clozapine   antipsychotic agent  N-oxide  Tugnait et al. 1997 
Deprenyl  monoamine oxidase type B inhibitor (Parkin-
son’s disease) 
hydroxylamine Szoko et al. 2004 
Itopride   dopamine D2 antagonist 
(gastroprokinetic agent) 
N-oxide  Mushiroda et al. 2000 
K11777  cysteine protease inhibitor 
agent against Trypanosoma cruzi 
N-oxide  Jacobsen et al. 2000 
Methamphetamine psychostimulant hydroxylamine  Cashman et al. 1999;  
Szoko et al. 2004 
N-deacetyl ketoconazole*   antifungal   N-hydroxy/nitrone  Rodriguez and Miranda, 2000 
Nicotine stimulant  Trans  N-oxide Park  et al. 1993 
Olopatadine   antihistamine  N-oxide  Kajita et al. 2002 
Pyrazolacridine   antitumour   N-oxide  Reid et al. 2004 
Ranitidine   Antihistamine 
(stomach ulcers/ Zollinger Ellison syndrome) 
N-oxide  Overby et al. 1997;  
Chung et al. 2000 
S16020   topoisomerase II inhibitor (antitumour)  N-oxide  Pichard-Garcia et al. 2004 
Tamoxifen  estrogen receptor modulator (breast cancer 
therapy) 
N-oxide  Parte and Kupfer, 2005 
Xanomeline   muscarinic receptor agonist 
(Alzheimer’s Disease) 
N-oxide  Ring et al. 1999 
*Major metabolite of antifungal agent ketoconazole. 
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tamoxifen  N-oxidation: when catalyzed by baculovirus-
expressed  FMO3  variants this was 5-fold greater with 
FMO3(K158) than with FMO3(E158) [Krueger et al. 2006]. 
Therefore the K158 variant would be expected to increase 
the amount of tamoxifen N-oxide in the liver, which may be 
important in the therapeutic response  (see FMO1 section 
above). 
  Benzydamine, an anti-rheumatic drug is metabolized by 
FMO3 to its N-oxide [Lang and Rettie, 2000]. A study in-
volving human liver microsomes from individuals genotyped 
for FMO3 variants, found that microsomes from individuals 
homozygous for the K158 variant showed significantly re-
duced activity compared with those from individuals with at 
least one copy of the E158 variant [Stormer et al. 2000]. 
However, a study using recombinantly expressed E158 and 
K158 variants found no difference in oxygenation of benzy-
damine [Shimizu et al. 2007b]. The different results obtained 
by different groups when studying the effect of FMO3 vari-
ants on enzyme activity indicates the need for the validation 
of methods used to express the recombinant proteins and to 
assay their activity. 
  FMO3, like FMO1 (see above), metabolizes thiaceta-
zone, an anti-tubercular drug prescribed in certain parts of 
Africa because it is cheap. Thiacetazone is a thiocarbamide 
prodrug and is a substrate for human FMO3. The main prod-
ucts of the reaction are the sulfinic and sulfenic acids of   
the drug [Qian and Ortiz de Montellano, 2006], which have 
been shown to be genotoxic in mammalian cells [Ziegler-
Skylakakis et al. 1998] and are thought to affect the redox 
state [Qian and Ortiz de Montellano, 2006]. The use of this 
drug in areas of the world other than Africa is limited, due to 
severe hepatotoxic effects. It would be of interest to know 
whether polymorphic variants of FMO3 contribute to this 
toxicity. Although the large-scale genotyping of individuals 
in developing countries may not be realistic on economic 
grounds, it may be worth considering in cases where a com-
mon polymorphism has been identified that has a significant 
effect on response to a commonly prescribed drug. 
FMO4 
  When cDNA clones for human FMO4 were first isolated 
[Dolphin et al. 1992] the isoform was designated FMO2. 
The nomenclature was subsequently changed to FMO4 
[Lawton et al. 1994]. FMO4 is 558 amino-acid residues long 
and has a molecular mass of 63,338. Other members of the 
FMO family, with the exception of the truncated form of 
FMO2, encoded by the FMO2*2A allele (see above), contain 
between 532 and 535 residues [Phillips et al. 1995]. From 
sequence comparisons, it is apparent that the additional resi-
dues in FMO4 are contained in a single block located at the 
C-terminus of the polypeptide [Dolphin et al. 1992]. Inspec-
tion of the nucleotide sequence of the FMO4 cDNA lead 
these authors to suggest that the extension may have been the 
result of a single point mutation in the termination codon of 
the ancestral FMO4 gene. A similar extension is present in 
FMO4s of other mammals and thus the predicted mutation 
would have occurred before the radiation of mammals. 
 The  FMO4 gene was mapped to the long arm of human 
chromosome 1 [Shephard et al. 1993]. It contains ten exons, 
of which eight are coding [Hernandez et al. 2004]. In con-
trast to other FMO mRNAs the mRNA for FMO4 contains 
sequences derived from 10, not 9 exons, the first two of 
which are entirely non-coding. FMO4 is expressed in rela-
tively low amounts in several tissues, the main sites of ex-
pression being liver and kidney [Dolphin et al. 1996; Her-
nandez et al. 2004; Zhang and Cashman, 2006; Cashman and 
Table 7.  Sulfur-containing 
Drugs Oxygenated by Human 
FMO3ubstrate  Type of Drug Or Health Condition  Product(s)  Reference 
Ethionamide antibiotic  (tuberculosis)  -  Krueger and Williams, 2005 
MK-0767 methyl sulfide  peroxisome proliferator receptor activator 
(diabetes) 
S-oxide  Karanam et al. 2004 
Methimazole  thyroperoxidase inhibitor 
(hyperthyroidism) 
S-oxide Overby et al. 1997 
Ranitidine   Antihistamine 
(stomach ulcers/ Zollinger Ellison syndrome) 
S-oxide  Chung et al. 2000 
S-methyl esonarimod *  cytokine production inhibitor 
(rheumatism) 
S-oxide  Ohmi et al. 2003 
Sulindac sulfide**  nonsteroidal anti-inflammatory  
(colorectal cancer) 
S-oxide  Hamman et al. 2000 
Tazarotenic Acid***  retinoic acid receptor  modulator 
(acne/psoriasis) 
S-oxide  Attar et al. 2003 
Thiacetazone  antibiotic  (tuberculosis)  sulfinic acid/ 
carbodiimide 
Qian and Ortiz de Montellano,  2006 
- Products not identified/unpublished; * active metabolite of parent drug esonarimod; **active metabolite of parent drug sulindac; *** active metabolite of parent drug tazarotene. 
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Zhang, 2006]. Alternative splice variants of FMO4 have 
been reported [Lattard et al. 2004]. However, the relevance 
of this for the metabolism of foreign chemicals is not known. 
Polymorphic Variants  
  A survey of 50 African Americans identified four cod-
ing-region SNPs, Fig. (1) and Table 1 [Furnes et al. 2004]. 
One was synonymous. The other three, g.110T>C(I37T), 
g.14726T>C(V323A) and g.14770G>C(E339Q), were non-
synonymous. Of these, I37T and E339Q each occurred only 
once in the 100 chromosomes surveyed and thus may repre-
sent rare mutations. However, V323A, which is also reported 
in dbSNP126, is common in Africans (20-33%), but is ab-
sent from Europeans and Asians. Although the functional 
consequence of this SNP has not been investigated, valine at 
position 323 is not conserved among FMOs and the change 
of amino acid (valala) is conservative. This SNP is there-
fore unlikely to have a significant effect on protein function. 
A further two SNPs are reported in dbSNP126. One of these 
is a synonymous SNP, g.14601C>T(F281F), which is pre-
sent at low frequency (4 to 7%) in Asians, but is absent from 
Africans and Europeans. The other, which is nonsynony-
mous, g.14680A>T(T308S), is present in Japanese, at fre-
quency ~1%, but has not been detected in Africans or Euro-
peans. 
 Although  FMO4 is expressed in many tissues, in each 
case expression is low [Dolphin et al. 1996]. Furthermore, 
expression of the protein in a stable form in heterologous 
systems has proved difficult [Itagaki et al. 1996] and, conse-
quently, little is known about the substrate specificity of 
FMO4. Nevertheless, it has been shown that FMO4 is capa-
ble of oxidizing methimazole [Itagaki et al. 1996], L-
methionine and S-allyl-L-cysteine [Ripp et al. 1999].  
FMO5 
  A cDNA for FMO5 of human was isolated in 1995 
[Overby et al. 1995; Phillips et al. 1995]. The FMO5 gene is 
not part of the FMO gene cluster on human chromosome 
1q24.3, but is located ~26Mb closer to the centromere, at 
1q21.1 [Hernandez et al. 2004]. However, the internal orga-
nization of the gene is similar to that of other FMO genes: it 
comprises nine exons, the first of which is non-coding, and 
encodes a polypeptide of 533 amino-acid residues and has a 
molecular mass of 60,225. FMO5 is expressed in many fetal 
and adult tissues, but in human its main site of expression is 
adult liver [Janmohamed et al. 2001; Hernandez et al. 2004; 
Cashman  and Zhang, 2006; Zhang  and Cashman, 2006], 
where, along with FMO3, it is a major form of the enzyme 
present [Overby et al. 1997; Cashman  and Zhang, 2006; 
Zhang and Cashman, 2006]. It is also the most abundantly 
expressed FMO in the small intestine [Cashman and Zhang, 
2006; Zhang and Cashman, 2006] and skin [Janmohamed et 
al. 2001].  
 FMO5 exhibits little catalytic activity towards compounds, 
such as methimazole, that are good substrates for other 
FMOs [Rettie et al. 1994; Overby et al. 1995; Cherrington et 
al. 1998a; Krueger and Williams, 2005], but does catalyze 
the  N-oxygenation of short-chain aliphatic primary amines 
such as N-octylamine [Overby et al. 1995]. Aliphatic pri-
mary amines are substrates of FMO2, but this enzyme has a 
marked preference for molecules with longer chains (see 
above). More recently, FMO5 has been reported to catalyze 
the oxygenation of other compounds, for instance, thioethers 
with proximal carboxylic acids that are not utilized as sub-
strates for other FMOs. For example, esonarimod, an anti-
rheumatic drug is converted to the active metabolite S-
methyl esonarimod by FMO5 [Ohmi et al. 2003]. 
  Thus, with respect to substrate specificity, FMO5 is re-
garded as an atypical FMO and, despite its high level of ex-
pression in adult human liver, the enzyme is not thought to 
play a significant role in the metabolism of drugs, with the 
possible exception of esonarimod. 
Polymorphic Variations  
  In a survey of 50 African Americans [Furnes et al. 2003] 
only two coding-region mutations were identified, of which 
only one, g.37917C>T(P457L), results in a change in amino-
acid sequence, Fig. (1) and Table 1. Although the effect of 
this change on protein function has not been investigated, a 
proline at this position is conserved in all mammalian FMOs 
sequenced to date. However, the variant was identified in 
only one of the 100 chromosomes surveyed and thus may 
represent a rare mutation that would have little consequence 
for the general population. The other mutation detected in 
this study, g.23806A>G(A367A), was synonymous. Two 
additional coding-region SNPs are reported in dbSNP126. 
One is a synonymous SNP, g.23716G>A(P337P). The other, 
g.38059G>T(R506S), is nonsynonymous, but is found only 
in Yorubans, at a frequency of 9%. 
Physiological And Xenobiotic Factors Influence FMO5 
Expression 
  Interindividual variations of 10-fold in the amount of 
FMO5 in adult human liver (3.5 to 34 pmol/mg microsomal 
protein) have been reported [Overby et al. 1997]. Although 
no polymorphisms have been identified that affect FMO5 
catalytic activity, it is possible that promoter variants exist 
that influence the amount of FMO5 produced. Unlike other 
human FMOs, FMO5 is inducible and interindividual varia-
tions in amounts of the protein may be due in part to physio-
logical effects or to exposure to xenobiotics. The synthetic 
progestin R5020 increased FMO5 expression in a breast can-
cer cell line stably expressing the progesterone B-receptor 
[Miller et al. 1997]. The authors suggested that increased 
expression of FMO5 might lead to increased carcinogenicity 
of tamoxifen in target tissues that overexpress progesterone 
B-receptors. However, FMO5, unlike FMO1 and FMO3, 
does not metabolize tamoxifen [Hodgson et al. 2000]. A 
recent profiling study of primary breast tumours showed that 
FMO5 expression may be up-regulated by estrogen receptor 
 (ER) [Bieche et al. 2004]. FMO5 mRNA was increased 
in ER-positive tumours, but was not detected in ER-
negative tumours. There was a strong correlation in this 
study between FMO5 over-expression and N-acetyl trans-
ferase 1 (NAT-1) over-expression, with regard to relapse-free 
survival. However, statistical analysis found that only NAT-1 
expression was of prognostic value [Bieche et al. 2004]. 
FMO5 is increased by the xenobiotic hyperforin [Krusekopf 
and Roots, 2005], a component of St. John’s Wort, and the 
antibiotic rifampicin [Rae et al. 2001]. Both compounds are 
known to increase CYP3A4 through the action of the preg-308    Current Pharmacogenomics, 2007, Vol. 5, No. 4  Phillips et al. 
nane X receptor (PXR) [Kliewer et al. 1999; Moore et al. 
2000]. No study on the mechanism of action of FMO5 gene 
activation, by any of the compounds mentioned, has been 
published.  
  Extensive expression profiling of human liver samples 
found that FMO5 mRNA was markedly down-regulated in 
individuals with type-2 diabetes compared with unaffected 
individuals [Takamura et al. 2004]. As knowledge of the role 
of FMO5 in both endogenous and xenobiotic metabolism is 
limited, the significance, if any, for drug treatment of those 
with type-2 diabetes is unknown.  
CONCLUDING REMARKS 
  Five functional FMOs, FMO1, 2, 3, 4 and 5, are present 
in humans. Based on substrate-specificity and site and 
amount of expression, FMO1 and FMO3 are the most impor-
tant for the metabolism of therapeutic drugs. For both of 
these FMOs the pattern of expression in humans is markedly 
different from that in other mammals, particularly rodents 
used as animal models for the investigation of drug metabo-
lism. In humans, the expression of the FMO1 gene is 
switched off after birth and FMO1 is undetectable in adult 
liver. This is in contrast to other mammals, in which FMO1 
represents the major form of the enzyme present in adult 
liver. FMO3 is the major drug-metabolizing FMO in adult 
human liver. These species differences in the tissue-specific 
pattern of expression of FMO1 and FMO3 have important 
consequences for the extrapolation of drug metabolism data 
from experimental animals to humans. 
  Essentially all individuals of European or Asian origin 
express no functional FMO2, which in most other mammals 
is the major form of the enzyme present in the lung. How-
ever, in sub-Saharan Africa, and in populations recently de-
scended from this region, a substantial proportion of indi-
viduals do express functional FMO2 in the lung. This has 
implications for inter-ethnic and, in African populations, 
interindividual variations in response to drugs and toxic 
chemicals that are substrates for FMO2. 
  There are very few examples of induction or inhibition of 
FMOs by endogenous or foreign chemicals, suggesting that 
drug-drug interactions would not be an important feature of 
therapeutic agents that are metabolized predominantly by 
FMOs. Variations in the expression and activity of FMOs are 
thus mainly due to genetic factors. An understanding of the 
pharmacogenetics of FMOs would help identify individuals 
who would respond favourably to a particular drug and those 
who would be at risk of experiencing harmful side effects, 
and thereby contribute significantly to drug development by 
decreasing the failure rate of new candidate drugs and reduc-
ing the time taken for approval of a drug by regulatory 
authorities. 
  The number of validated nonsynonymous SNPs identi-
fied in FMO2 and FMO3 is considerably more than in 
FMO1, FMO4 or FMO5 (see Tables 1 and 5). In the case of 
FMO2 and FMO3, several variants are present in high fre-
quency in some, or all, major population groups and are 
known to affect enzyme activity. In FMO1,  FMO4 and 
FMO5, however, all variants are confined to only one popu-
lation group and, with the exception of V323A in FMO4, 
which is unlikely to affect enzyme function, are present at 
low or very low frequency. The differences in the number of 
nonsynonomous variants identified in various members of 
the FMO family may reflect greater interest in FMO3, as a 
consequence of its role in the inherited disorder TMAuria, 
and in FMO2, as a result of the discovery of the common 
Q472X polymorphism. This seems unlikely, however, be-
cause the total number of genetic variants, i.e., coding and 
noncoding, reported in dbSNP126 for FMO1 and FMO5 is 
greater than for FMO3 and is comparable with that for 
FMO2.  
  The relatively high number and frequency of nonsynono-
mous SNPs in FMO2 may be the result of an accumulation 
of potentially deleterious mutations in an allele, FMO2*2, 
which is already defective. In FMO3, the ratio of non-
synonomous to synonomous polymorphisms is significantly 
more than expected under a neutral model of evolution, pro-
viding evidence that the gene has been the subject of balanc-
ing natural selection (Allerston et al. 2007). In the case of 
FMO1 and FMO5, the relative paucity and low frequency of 
nonsynonymous SNPs may be indicative of an important 
physiological role for the proteins encoded by these genes.  
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ABBREVIATIONS 
ALS  =  Amyotrophic lateral sclerosis 
AF =  Atrial  fibrillation 
CYP =  Cytochrome  P450 
5’-DPT = 10-(N,N-dimethylaminopentyl)-2-
(trifluoromethyl) phenothiazine 
ER =  Estrogen  receptor   
FAD  =  Flavin adenine dinucleotide 
FAP =  Familial  adenomatous  polyposis 
FMO =  Flavin-containing  monooxygenase 
NAT-1 = N-acetyl transferase 1 
SNP =  Single-nucleotide  polymorphism 
TMA =  Trimethylamine 
TMAuria =  Trimethylaminuria 
UTR =  untranslated  region 
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